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 Chapter 1
introduction 
Ageing and 
Neuropsychiatric Disease: 
A General Overview of 
prevalence and Trends
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Aging of the population is a global phenomenon: it is accelerating and becoming a significant de-
mographic, societal and economic challenge (Oeppen & Vaupel, 2002). Many societies, especially 
in Western countries, already have a population that is older than has ever been seen in the past 
and low, and middle-income countries are also progressing toward a similar population structure 
(Salomon et al., 2012). Globally, there are more than 900 million people aged 60 or more years, and 
their number is projected to grow to 1.4 billion by 2030, and to 2.1 billion by 2050 (United Nations 
Population Fund (UNFPA), 2015). Further, within elderly populations, there is a large subgroup of 
“very old aged people” comprising of individuals between the age of 80-85 years (Forman, Berman, 
McCabe, Baim, & Wei, 1992). Far-reaching economic and social adjustments will be required in most 
countries, as well as understanding the impact of this transformation on health and everyday living 
(Colchero et al., 2016). 
The brain undergoes morphological changes associated with aging so many elderly people are 
affected by neuropsychiatric diseases (Taneri et al., 2016). Depression is amongst the most common 
psychiatric disorders, affecting elderly people, while Alzheimer’s Disease (AD) and Parkinson’s 
disease (PD) are the most common neurodegenerative diseases among the elderly (Djernes, 2006; 
United Nations Population Fund (UNFPA), 2015). Recent systematic reviews have shown that the 
prevalence of major depression in late life ranged from 4.6% to 9.3%, and that of depressive disorders 
ranged from 4.5% to 37.4%. Pooled prevalence was 7.2% (95% CI 4.4–10.6%) for major depression 
and 17.1% (95% CI 9.7–26.1%) for depressive disorders (Luppa et al., 2012). Further, worldwide, the 
global prevalence of dementia is estimated to be 3.9 % in people aged 60+ years, most of whom suffer 
from AD (Qiu, Kivipelto, & von Strauss, 2009). PD is the second most common neurodegenerative 
disorder after AD and is expected to impose an increasing social and economic burden on societies as 
populations age (de Lau & Breteler, 2006). The prevalence of PD in industrialised countries is gener-
ally estimated at 0.3% of the entire population and about 1% in people over 60 years of age (Nussbaum 
& Ellis, 2003). Due to ageing population, this number is expected to double every 20 years (Qiu et al., 
2009). Neuropsychiatric diseases pose a high economic burden to societies. Currently they account 
for 6.6% of all disability adjusted life years (DALYs) and 17.4% of Years Lived with Disability (YLDs), 
and these numbers will increase in the future (WHO, 2016). 
The impact of neuropsychiatric diseases in the elderly can further increase as a result of alcohol 
misuse and the consequences of traumatic life events. Emerging evidence indicates that in the coming 
years, there will be an increase in the absolute number of elderly people with alcohol misuse disorders 
and, thus, with notable impairment in physiological and cognitive health (Briggs, Magnus, Lassiter, 
Patterson, & Smith, 2011; Connell, Chin, Cunningham, & Lawlor, 2003; Han, Gfroerer, Colliver, & 
Penne, 2009). Moreover, death of someone close, like family or friends, is generally accepted as among 
the most common and traumatic life event in late life. In late life most frequent loss event is of a 
spouse (Rozenzweig, Prigerson, Miller, & Reynolds, 1997) Depression (along with suicide), anxiety, 
substance abuse, and symptoms of “complicated” grief are among the most important psychiatric 
conditions associated with spousal bereavement and the challenges of adaption to becoming wid-
owed. (Rozenzweig et al., 1997) Widowhood occurs more frequently in older women than older men, 
with estimates nearing 42.2% for widows and 13.1% for widowers among U.S. community dwelling 
older adults (Federal Interagency Forum on Age-Related Statistics, 2008).
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Epigenetic, an Emerging factor in Development of Neurodegenerative 
Diseases
The last decade broadened our knowledge about the etiology of AD and PD (Bertram, McQueen, 
Mullin, Blacker, & Tanzi, 2007; Farrer, 2006; Gusella & MacDonald 1993, Karch & Goate, 2015). It is 
now widely accepted that there is a strong genetic component in the development of AD and PD, in-
cluding chromosomal aberrations and gene mutations (Ghani et al., 2015; Karch & Goate, 2015). One 
of the factors that has enhanced the understanding of genetic modifications is epigenetics. (Jakovcev-
ski & Akbarian, 2012). Epigenetics literally means “above” or “on top of ” genetics. It refers to external 
modifications to DNA that turn the expression of genes “on” or “off.” Epigenetic modifications do 
not change the DNA sequence, but instead, they affect how cells “read” genes by altering the physical 
structure of DNA. Epigenetic mechanisms are known to alter gene expression in a heritable manner 
mainly via modifications to DNA methylation and histone proteins (Henikoff & Matzke, 1997). Sev-
eral epidemiological studies suggest an epigenetic contribution to the etiology of AD and PD (Bollati 
et al., 2011; Mogi et al., 1996; Urdinguio, Sanchez-Mut, & Esteller, 2009). Furthermore, DNA meth-
ylation and histone acetylation have recently been implicated in the development of depression (Sun, 
Kennedy, & Nestler, 2013). Depression is an important correlate of neuropsychiatric diseases and it 
includes some neurodegenerative processes (Rickards, 2005). Despite this evidence, there has not 
yet been a comprehensive assessment and understanding of the role of epigenetic mechanisms, such 
as DNA methylation or histone modifications, in the development of neurodegenerative disorders.
Neuropsychiatric Disorders in Women: role of Menopause Transition and 
Estrogen 
The majority of the common neurological diagnoses, including depression, AD, and PD, are more 
common in women than in men, and among women, more prevalent in postmenopausal women 
(Mary, 1997). Furthermore, some other neurological diseases such as stroke tend to present more 
severely in women than in men (Hofman, de Jong, van Duijn, & Breteler, 2006). Females have longer 
lifespan predisposing them to psycho-neurological disease (O’Neal, 2013). Furthermore, women are 
more prone to neuropsychiatric disorders due to unique risk factors such as hypercoagulable states 
caused by pregnancy and hormonal contraceptives (Katz & Beilin, 2015; Thornton & Douglas, 2010; 
Wolski, 2014). Once women reach menopause, hormonal changes cause women to lose the protec-
tive anti-inflammatory effects previously conferred by estrogen, and hormonal replacement therapy 
replenishment seems to be insufficient to compensate for the state of hypoestrogenia (O’Neal, 2013). 
Estrogen has many physiological roles in the body and brain, all of which are mediated by its 
main receptors α and β (ERβ). The newly discovered ERβ is widely distributed in the brain. It is 
unclear whether ERβ has favourable functions in the female brain and whether it could be considered 
as a novel target therapy for prevention and treatment of neuropsychiatric diseases in menopausal 
women. 
Also, data indicate that estrogenic signalling can change with menopausal status and age. As 
women age and live through menopause, alcohol misuse and dependence also become more preva-
lent (Epstein, Fischer-Elber, & Al-Otaiba, 2007). Due to sex-differences in metabolism of alcohol, 
women are more vulnerable to alcohol’s harmful effects, and tend to develop alcohol-related diseases 
and other consequences of drinking earlier in life than men (Epstein et al., 2007). Moreover, elderly 
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people, especially older women, are particularly vulnerable to the adverse effects of alcohol, and alco-
hol use disorders in this subgroup are often overlooked or misdiagnosed (Bratberg et al., 2016). Also, 
women have more difficulty gaining access to treatment and recovering from alcohol dependence 
(Epstein et al., 2007).
bereavement in the Elderly population: impact on health and Quality of Life
Experiencing the loss of a close person is a traumatic event that is likely to be experienced during a 
person’s life span (Boelen & Hoijtink, 2009; Monk, Germain, & Reynolds, 2008; Shear, 2015). With 
aging, death and loss might occur once or several times. Even though it is a traumatic event, most 
people recover within six to twelve months after the loss (Kacel, Gao, & Prigerson, 2011). However, an 
estimated 10-20% of bereaved people continue to grieve for a prolonged period, imprisoned by memo-
ries, regrets and a sense of guilt (Prigerson et al., 1997; Prigerson et al., 2009). This complex condition 
is termed as Prolonged Grief Disorder (PGD), also referred to as ‘complicated grief ’(Prigerson et al., 
1997; Prigerson et al., 2009). Noticeably, the grieving process is distinct from depression, anxiety, 
and can lead to impairment in social and interpersonal daily functioning, leading to impairment of 
overall well-being (Newson, Boelen, Hek, Hofman, & Tiemeier, 2011). Emerging evidence shows that 
acute grief and complicated grief can induce changes of the circadian rhythm (Monk, Begley, et al., 
2008), eating patterns (Hall et al., 2014), cognition (Hall et al., 2014) and sleep patterns (Milic et al., 
2017). Since all these aspects of daily functioning are subject to change, grief can severely influence 
the quality of life. 
As the loss of a loved one is a highly upsetting event, intense emotional stress might be triggered. 
Under intense emotional stress, the hypothalamic-pituitary-adrenocortical (HPA) axis is stimulated 
and activates the secretion of cortisol into the bloodstream as an adaptation to the stressor. Dysregu-
lation of cortisol is associated with problematic alcohol use and dependence, memory loss, physical 
and psychological impairment and, thus, reduced quality of life and higher risk of mortality (Kumari, 
Shipley, Stafford, & Kivimaki, 2011; Mura et al., 2014; Stephens & Wand, 2012). Few studies have fo-
cused on the effect of grief on the neuroendocrine system, in particular on cortisol secretion patterns 
(Saavedra Perez et al., 2017). Further, previous studies suggest that grief and complicated grief are 
associated with significant sleep impairment (Hall et al., 1997; Kowalski & Bondmass, 2008; Monk, 
Begley, et al., 2008) Schwartz and Sprangers have explored how changes in general health status af-
fect the quality of life of a grieving person (QoL) (Schwartz & Sprangers, 1999). Other authors have 
found that in the phase of grief, an individual’s diminished capacity to preserve desirable physical, 
psychological and social responses can reduce an individual’s level of satisfaction and sense of self-
worth (Cousson-Gelie, de Chalvron, Zozaya, & Lafaye, 2013; Ozer, Firat, & Bektas, 2009; Schwartz 
& Sprangers, 1999). 
Despite on-going research, our collective knowledge of the associations of grief and health 
outcomes is limited. Research in this field tends to include studies with a small sample size and cross-
sectional design (Boelen & Lancee, 2013; Germain, Caroff, Buysse, & Shear, 2005; Maytal et al., 2007; 
Monk, Begley, et al., 2008; Purebl, Pilling, Konkoly, Bodizs, & Kopp, 2012; Spira, Stone, Beaudreau, 
Ancoli-Israel, & Yaffe, 2009). Likewise, the association between grief, complicated grief, and the do-
mains of QoL remains unclear. The available evidence examining the association between grief and 
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quality of life has yet to be rigorously reviewed in order to help us to understand how bereavement 
might impair quality of life and everyday life. 
Grief Cessation and its Determinants 
For some bereaved individuals, the adaptation to life without their loved one might be complicated, 
slowed, or halted, leading to incessant grief (Boelen & van den Bout, 2008; Shear et al., 2007). Lasting 
grief impairs daily functioning and sleep, and may increase the risk of cancer and cardiovascular 
disease (Simon et al., 2005; Simon et al., 2007). The severity of grief relates to severity of impair-
ment. Therefore, identifying the determinants and predictors of grief severity and its persistence is of 
crucial importance in identifying bereaved individuals at high risk for long-term dysfunction. After 
individuals at high risk of prolonged grief are identified, novel interventions for the disorder may be 
developed and implemented (Currier, Neimeyer, & Berman, 2008). 
Several factors have been suggested to influence the duration and severity of grief, including gen-
der. After loss of a spouse, males suffer more severe health consequences and decrease in overall qual-
ity of life (Stroebe & Schut, 2001). Mortality rates of persons are higher for both males and females 
compared to non-bereaved people, but the relative increase in mortality is higher for males (Stroebe 
& Schut, 2001). Previous studies have suggested that the explanation for this discrepancy might be 
related to the weaker social support common among bereaved men. Also, woman have better overall 
coping abilities and capacities for self-empowerment (Neimeyer, 2006). In addition, age may also 
play a significant role in how well people can recover during the bereavement period. According to 
Stroebe and Schut, younger bereaved persons encounter more complications after a loss, including 
more serious health consequences, both psychological and physical (Stroebe & Schut, 2001). Younger 
grievers might experience more unexpected and sudden losses, which could lead to more severe grief. 
Older grievers may have better coping strategies due to life experiences or because as people age they 
become less susceptible to dramatic emotional shifts (Onrust, Cuijpers, Smit, & Bohlmeijer, 2007). 
Even though younger grievers may experience more health-related complications during the acute 
phase of grieving, previous studies suggest that they recover more quickly. They may recover more 
quickly because they have greater access to various types of social support (Stroebe & Schut, 2001). 
Beyond the role of age and gender in grief severity, studies have aimed to understand other 
determinants and predictors of grief severity and persistence such as ethnicity (Fitzpatrick & Tran, 
2002), education level (Boelen, Van Den Bout, De Keijser, & Hoijtink, 2003) and previous depressive 
symptoms. (Tsai et al., 2016; Tsuboya et al., 2016) However, most studies on these topics have been 
cross-sectional and limited in sample size. The few longitudinal studies that investigated determinants 
of grief severity and persistence had a short follow-up period of less than 24 months (Bonanno et al., 
2002; Prigerson et al., 2009; Tsai et al., 2016)). Furthermore, none of the previous studies have utilized 
a population-based cohort study with sufficient power to explore determinants of grief related to 
long-term bereavement and other types of loss. (Bonanno et al., 2002; Prigerson et al., 2009; Tsai 
et al.,2016; Zisook, Paulus, Shuchter, & Judd, 1997; Zisook & Shuchter, 1991; Zisook et al., 1994). 
Further studies are necessary to identify the factors associated with grief severity. 
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General Aim of the Thesis
The overall aim of the thesis was to identify factors associated with neuropsychiatric disorders among 
the elderly. The first objective of the thesis was to identify epigenetic and women-specific factors 
and that can play a role in the development of neuropsychiatric outcomes. A second objective was 
to identify the impact of grief and complicated grief on cortisol secretion, sleep pattern, and overall 
quality of life, as well as to identify factors associated with grief persistence. 
Study Design
Systematic reviews 
To meet the aims of the thesis, some of the chapters are comprised of systematic reviews of the 
literature. The reviews were conducted using a predefined protocol in accordance with the PRISMA 
(Moher, Liberati, Tetzlaff, Altman, & The PRISMA Group, 2009) and MOOSE (Stroup et al., 2000) 
guidelines. By searching numerous electronic databases as specified in detail in each chapter, we 
found relevant citations for further screening. Our search was performed without any language or 
study design restriction, with the help of an experienced medical information specialist. Two in-
dependent reviewers screened the titles and abstracts of all studies initially identified, according to 
the selection criteria, and any disagreement was resolved through consensus or consultation with a 
third independent reviewer. Full texts were retrieved from studies that satisfied all selection criteria. 
Additionally, reference lists of the included studies were screened to identify further studies. Two 
independent reviewers extracted the data using a pre-designed data collection form. The Newcastle-
Ottawa Scale was used to assess the risk of bias in observational studies.(Wells et al., 2011) Where 
possible, the inverse variance weighted method was used to combine the reported estimates from 
each study to produce a pooled estimate using random- effects meta-analysis models to allow for 
between study heterogeneity. Heterogeneity was assessed using the Cochrane χ2 statistic and the I2 
statistic. Publication bias was evaluated through a funnel plot and Egger’s test. Further details on the 
methods can be found in the specific chapters. 
rotterdam Study
The studies presented in chapters 3 and 4 of the thesis were carried out within the framework of the 
Rotterdam Study, a population-based prospective cohort study started in 1990 in the Ommoord dis-
trict in the city of Rotterdam, the Netherlands. Details regarding the design, objectives, and methods 
of the Rotterdam Study have been described in details elsewhere (Hofman et al., 2015). In brief, in 
1990, all inhabitants of a well-defined district of Rotterdam were invited to participate in the study, of 
whom 7983 agreed (78,1%). In 2000, an additional 3011 participants were enrolled (RS-II), consisting 
of all persons living in the study district who had turned at least 55 years of age between 1991 and 
2000). The third cohort was established in 2006 and included 3932 participants 45 years and older 
(RS-III). Follow up examinations were performed approximately every 3 to 5 years (Hofman et al., 
2015). There were no eligibility criteria to enter the Rotterdam Study cohort except the minimum age 
requirement and that the individual resided in the Ommoord residential area, defined based on zip 
codes. 
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Grief and complicated grief as used in this thesis was assessed and diagnosed at the fourth (RS –I-4 
and RS-II-2) round (2002-2005) and fifth round (2009-2012) of the Rotterdam Study using a Dutch 
version of the 17-item Inventory of Complicated Grief (ICG) originally constructed by Prigerson 
et al. (which contains 19 items) (Prigerson et al., 2009). First, participants were asked if they were 
currently grieving, if a positive answer was received they were classified as grievers and the ICG 
was administered, if not, they were categorized as non-grievers. The Dutch version of the Inven-
tory of Complicated grief contains 17 items and has been previously validated (Boelen, 2003). These 
seventeen questions were asked and responses were provided on a 5-point scale to reflect an increase 
in severity (0-never, 1-seldom, 2-sometimes, 3-often, 4-always). We divided all interview participants 
into groups of non-grievers, normal grievers, and complicated grievers. Complicated grief symptoms 
were assessed in participants who scored equal to or greater than 22 on the ICG score and who 
indicated they had grieved for longer than 6 months (Newson et al., 2011; Saavedra Perez et al., 2015). 
Sleep duration and sleep quality were measured with the Pittsburgh Sleep Quality Index (PSQI), a 
self-reported questionnaire (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). The PSQI consists 
of 19 self-rated items. Questions are grouped into seven component scores, each weighted equally 
on a 0-3 scale. The seven component scores are then summed to yield a global PSQI score, which is 
used in all further analyses. This score has a range of 0-21. Higher scores indicate worse sleep quality. 
In the current study we use total sleep time in hours to indicate sleep duration, and total score of 
PSQI to indicate sleep quality. Salivary cortisol was obtained by saliva samples that were collected on 
awakening (T1), 30 min after awakening (T2), at 1700 h (T3), and at bedtime (T4). Salivary cortisol 
concentrations were measured using a commercial immunoassay with chemiluminescence detection 
(CLIA; IBL Hamburg, Hamburg, Germany). 
Outline of this Thesis
Following this general introduction, the aims of this thesis will be addressed in six chapters. In the 
second chapter I use systematic reviews to explore the epigenetic mechanisms that play a role in 
neurodegenerative disorders. I searched the existing published literature on the topic of epigenetics, 
with a focus on the role of DNA methylation and histone modifications on AD and PD. 
The third chapter is dedicated to the specific risk factors related to female gender in the process 
of neurodegeneration and neuropsychiatric disorders. In chapter 3.1 I present a systematic review 
in which we explore the functions of estrogen receptor beta in the female brain. In Chapter 3.2 I 
critically appraise the literature on the impact of the menopausal transition on alcohol misuse and 
dependence in women. 
In chapter 4 I present the results of studies on the psychiatric aspects of healthy aging with a focus 
on bereavement. For chapter 4 I conducted original research within the population-based Rotterdam 
cohort, along with systematic reviews. In chapter 4.1 I explore the impact of complicated grief on di-
urnal cortisol levels. In chapter 4.2 I assess the prospective association between grief and complicated 
grief with sleep duration and in chapter 4.3 I investigate the association between grief and quality of 
life by conducting a systematic review. 
In chapter 5 I prospectively examine the determinants and predictors of grief cessation. 
Lastly, chapter 6 provides an overview of the main findings of this thesis, including methodologi-
cal considerations, clinical implications and future directions for research.
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AbSTrACT
Objective: To systematically review studies investigating epigenetic marks in AD or PD. 
Methods: Eleven bibliographic databases (Embase.com, Medline (Ovid), Web-of-Science, Scopus, 
PubMed, Cinahl (EBSCOhost), Cochrane Central, ProQuest, Lilacs, Scielo and Google Scholar) were 
searched until July 11th 2016 to identify relevant articles. We included all randomized controlled tri-
als, cohort, case-control and cross-sectional studies in humans that examined associations between 
epigenetic marks and ND. Two independent reviewers, with a third reviewer available for disagree-
ments, performed the abstract and full text selection. Data was extracted using a pre-designed data 
collection form. 
Results: Of 6927 searched references, 73 unique case-control studies met our inclusion criteria. Over-
all, 11,453 individuals were included in this systematic review (2640 AD and 2368 PD outcomes). 
There was no consistent association between global DNA methylation pattern and any ND. Studies 
reported epigenetic regulation of 31 genes (including cell communication, apoptosis, and neurogen-
esis genes in blood and brain tissue) in relation to AD and PD. Methylation at the BDNF, SORBS3 and 
APP genes in AD were the most consistently reported associations. Methylation of α-synuclein gene 
(SNCA) was also found to be associated with PD. Seven studies reported histone protein alterations 
in AD and PD. 
Conclusion: Many studies have investigated epigenetics and ND. Further research should include 
larger cohort or longitudinal studies, in order to identify clinically significant epigenetic changes. 
Identifying relevant epigenetic changes could lead to interventional strategies in ND. 
The role of DNA Methylation and Histone Modifications in Neurodegenerative Diseases
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iNTrODuCTiON
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most common neurodegenerative 
disorders and are a major cause of disability and premature death among older people worldwide 
(Bird et al., 2003; de Lau & Breteler, 2006; Savica et al., 2013). Due to global population ageing, 
prevalence of AD and PD is expected to increase, imposing a social and economic burden on society 
(Hebert, Scherr, Bienias, Bennett, & Evans, 2003; Kowal, Dall, Chakrabarti, Storm, & Jain, 2013). The 
causes of most cases of neurodegenerative diseases remain largely unknown. However, in the last 
decade great advances have been made in our understanding of the pathogenetic mechanisms that 
lead to AD and PD (Bertram, McQueen, Mullin, Blacker, & Tanzi, 2007; Farrer, 2006; Karch & Goate, 
2015). It has been accepted that there are several genetic causes that play a role in the development 
of these disorders, including chromosome aberrations and gene mutations (Ghani et al., 2015; Karch 
& Goate, 2015). Additionally, environmental exposures have been suggested to play a crucial role in 
the etiological process of neurodegenerative diseases. Both AD and PD are thought to be caused by 
complicated interactions between genetic and environmental factors (Cannon & Greenamyre, 2011). 
Despite improvements in knowledge and understanding, there are currently no disease-modifying 
therapies for these diseases. A large amount of the variance in the risk of developing neurodegenera-
tive diseases remains to be explained. 
The epigenome is responsible for the molding and the three-dimensional structure of the genomic 
material in the cell nucleus. It provides a bridge between genes and environment and may help to im-
prove our understanding on the etiology of complex diseases, AD, and PD (Jakovcevski & Akbarian, 
2012). Epigenetic mechanisms are known to alter gene expression or cellular phenotype in a heritable 
manner (Henikoff & Matzke, 1997). DNA methylation and modifications of histone proteins are the 
most intensively studied among the major epigenetic modifications. DNA methylation occurs when a 
methyl group is added at a cytosine nucleotide that precede guanines (so-called CpG dinucleotides). 
It further influences the function of DNA by activating or repressing the transcriptional activity of 
a gene (Henikoff & Matzke, 1997). Posttranslational histone modifications, such as methylation and 
acetylation of lysine residues on histone tails, are another type of epigenetic modification. Histone 
modifcations affect gene expression mainly by altering chromatin structure (Henikoff & Matzke, 
1997; Shen & Casaccia-Bonnefil, 2008). 
Clinical features of neurological disorders and results from epidemiological studies suggest an epi-
genetic contribution to etiology of these diseases. Epigenetic modulation has been well documented in 
brain development, plastic changes, and in brain diseases including AD and PD. The most compelling 
evidence on the role of epigenetics on AD comes from the results of treatment of AD patients with 
inhibitors of histone deacetylases (HDAC). HDAC is a key enzyme involved in histone acetylation 
(Graff et al., 2012). Also, in animal models of PD, HDAC inhibitor inhibits α-synuclein toxicity in the 
dopamine neuron, a common neuropathological feature of PD (Outeiro et al., 2007). Dysregulation 
of DNA methylation in AD and PD patients is also well documented. Recent evidence shows that AD 
patients have an elevated DNA methylation state of repetitive elements (Bollati et al., 2011). Hypo-
methylation of the tumor necrosis factor (TNF) gene in cortex and higher levels of TNF-α cytokine 
in the cerebrospinal fluid has been reported in patients with PD (Mogi et al., 1996). TNF-α is one of 
the main proinflammatory cytokines that play a central role in the inflammatory response. TNF-α is 
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also upregulated in AD patients and is involved in the pathogenesis of AD (Perry, Collins, Wiener, 
Acton, & Go, 2001). In dopaminergic regions of post-mortem brains, decreased methylation of the 
α-synuclein gene (SNCA) has been observed. The decreased methylation might be responsible for the 
accumulation of the protein α-synuclein, and thus the progression of PD (Jowaed, Schmitt, Kaut, & 
Wullner, 2010; Matsumoto et al., 2010b). Moreover, DNA methylation and histone acetylation have 
recently been identified as playing a role in depression (Sun, Kennedy, & Nestler, 2013), an important 
feature of neurodegenerative diseases (Rickards, 2005). Emerging evidence shows that epigenetic 
mechanisms contribute to the process of learning and memory formation (Jarome, Thomas, & Lubin, 
2014; Levenson & Sweatt, 2005). Despite this evidence, to date, a comprehensive assessment of the 
role of epigenetic mechanisms in the development of AD and PD has not yet been done. 
Therefore, we aimed to systematically review all available evidence in humans to assess the as-
sociation of DNA methylation and histone modifications with the neurodegenerative disorders AD 
and PD. 
MATEriAL AND METhODS
Literature Search 
This review was conducted using a predefined protocol in accordance with the PRISMA (Moher, 
Liberati, Tetzlaff, Altman, & Group, 2009b) and MOOSE (Stroup et al., 2000) guidelines (eAppendix 
1 and 2). Eleven bibliographic databases (Embase.com, Medline (Ovid), Web-of-Science, Scopus, 
PubMed, Cinahl (EBSCOhost), Cochrane Central, ProQuest, Lilacs, Scielo and Google Scholar) were 
searched until July 11th 2016 (date last searched) without any language restrictions, with the help of 
an experienced medical information specialist (WMB). The search strategy combined terms related 
to exposure (e.g., epigenetics, DNA methylation, histone, CpG) and outcomes (e.g., neurological 
disorders, dementia, Alzheimer, Parkinson). In databases where a thesaurus was available (Embase, 
Medline and Cinahl) articles were searched by thesaurus terms, title and/or abstract; other databases 
were searched only by title and/or abstract. We restricted the search to studies on human adults. The 
full search strategies of all databases are provided in eAppendix 3. After eliminating duplications, we 
identified a total of 6927 potentially relevant citations. We retrieved reference lists of the studies and 
sought contact with experts to find further relevant publications.
Study Selection and inclusion Criteria
Included studies either described an association between epigenetic marks (global, site specific or 
genome-wide methylation of DNA) or histone modifications (methylation, phosphorylation, acety-
lation, ubiquitylation, and sumoylation) and neurodegenerative outcomes defined as AD and PD. 
There was no restriction based on the tissue type examined for epigenetic marks, and therefore, 
epigenetic marks assessed in any tissue (e.g. brain, blood) were included. We included cross-sectional, 
prospective, case-cohort and nested case control studies. Studies were excluded if they (i) examined 
epigenetic marks other than DNA methylation and histone modifications, such as noncoding RNAs; 
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(ii) examined neurodegerative diseases other than AD and PD, such as Huntington’s disease, Prion 
disease, Motor neurone diseases, Spinocerebellar ataxia, Spinal muscular atrophy; (iii) were case stud-
ies or letters to the editor. Two independent reviewers (KW/JM and KD/JN/TP/BK/AZ) screened the 
retrieved titles and abstracts and selected eligible studies. In cases of disagreement, decision was made 
through consensus or consultation with a third independent reviewer (TM). Full texts were retrieved 
for studies that satisfied all selection criteria. 
Data Extraction
A predesigned data collection form was prepared to extract the relevant information from the se-
lected studies, including study design, study population, location, age range, duration of follow up 
(for longitudinal studies), confounders, tissue sample, method used to assess epigenetic marks, type 
and numbers of neurodegenerative outcomes and reported measures of associations (e.g., correlation 
analysis, odds ratio, relative risks, confidence intervals). Two independent authors (KW and JM/TM) 
extracted the data. 
Assessing the risk of bias
Bias within each individual study was evaluated by two independent reviewers (KW and JM) using 
the validated Newcastle-Ottawa Scale, a semi-quantitative scale designed to evaluate the quality of 
nonrandomized studies (Stang, 2010). The scores are provided in eAppendix 4. Study quality was 
judged based on the selection criteria of participants, comparability of cases and controls, and expo-
sure and outcome assessment. Studies that received a score of 9 stars were judged to be at low risk of 
bias; studies that scored 7 or 8 stars were considered to be at medium risk; those that scored 6 or less 
were considered to be at high risk of bias.
Outcome Assessment and Statistical Methods
For each study, we defined whether an association was reported and whether direction and effect 
sizes were reported, when applicable. Heterogeneity permitting, we sought to pool the results using a 
random effects meta-analysis model. If pooled, results were expressed as the pooled estimate and the 
corresponding 95% confidence intervals.
rESuLTS
We identified 6927 potentially relevant publications (Figure 1) after removal of duplicate citations. 
Based on the title and abstracts, 107 articles were selected for detailed evaluation of their full texts. 
Of those, 32 articles were excluded for either having the wrong exposure or outcome (n=28), report-
ing results from animal models (n=3), or unavailable full texts (n= 1) (Figure 1 and eAppendix 4). 
Seventy-five articles, based on 73 unique case-control studies, met our eligibility criteria and were 
included in this review. 
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Summary of included Studies
Overall, 11453 individuals were included within the systematic review, with a total of 2640 for AD 
and 2368 for PD outcomes. Of the 73 unique studies included, 13 studies assessed global DNA-meth-
ylation, 45 studies assessed DNA methylation in specific candidate genes, 8 studies used genome-
wide approaches, 1 study assessed both global DNA methylation, histone modifications and DNA 
methylation in specific candidate genes, and 6 studies examined histone modifications in relation 
to ND (Tables 1-3). Twenty-nine studies assessed DNA methylation and/or histone modifications 
only in blood, 35 in the brain tissue, 8 studies in both blood and brain tissue and 1 study assessed 
methylation in skin fibroblasts. Fifty-seven studies examined AD as an outcome while 18 studies 
examined PD. Twenty-four studies included participants from USA, 11 studies from China, 4 stud-
ies included participants from more than 1 country and the rest included participants solely from 
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Figure 1. Flowchart of studies investigating epigenetic marks in relation to Alzheimer’s 
disease and Parkinson’s disease 
 
  
Records identified through 
database searching 
(n=6927) 
Records screened  
(n=6927) 
Records given full text detailed 
assessment 
(n=107) 
Studies included 
(n=75, based on 73 unique studies) 
Records excluded based on title 
and abstract  
(n=6820) 
Full-text articles excluded  
(n=32) 
 
 Not the appropriate 
exposure or outcome 
(n=28) 
 Not human tissue (n=3) 
 Full texts not found 
(n=1) 
figure 1. Flowchart of studies investigating epigenetic marks in relation to Alzheimer’s disease 
and Parkinson’s disease
The role of DNA Methylation and Histone Modifications in Neurodegenerative Diseases
33
Ch
ap
te
r 2
.1
Canada, Germany, United Kingdom, Italy, Spain, Japan, Sweden, Columbia, Australia, New Zealand, 
Serbia or Brazil (Table 1-3). Three studies were judged at low risk of bias whereas the rest were at 
medium and high risk of bias (eAppendix 5).
Global DNA Methylation 
Global methylation refers to the overall level of methylcytosine in the genome, expressed as percentage 
of total cytosine. Many of the methylation sites within the genome are found in repeat sequences and 
transposable elements, such as Alu and long-interspersed nuclear element (LINE-1). They correlate 
with the total genomic methylation content. Measurements of methylation of the repetitive elements 
in the genome are used as a surrogate measurement for the overall methylation of the genome. Some 
studies quantified global DNA methylation by calculating the amount of methylated cytosines in 
the sample (5 mc) relative to global cytidine (5mC + dC) in a positive control. Other methods to 
assess global genomic DNA methylation (e.g., Luminometric Methylation Assay (LUMA) and the 
[3H]-methyl acceptance based method) are primarily based on the digestion of genomic DNA by 
restriction enzymes HpaII, MspI and Dpn I. 
(i) Alzheimer’s Disease
Thirteen studies examined the association between global DNA methylation and AD (Table 1). Eight 
studies assessed DNA methylation in brain tissue and the rest of the studies assessed it in blood 
cells. Seven studies assessed global DNA methylation as a percentage of 5-methylcytosine in samples 
from brain. Of these seven studies, three studies (Chouliaras et al., 2013; Condliffe et al., 2014; 
Mastroeni et al., 2010) found lower levels of methylation in AD cases compared to controls, two 
studies (Bednarska-Makaruk et al., 2016; Lashley et al., 2014) found no difference, and two other 
studies (Coppieters et al., 2014; Rao, Keleshian, Klein, & Rapoport, 2012) reported higher levels of 
methylation in AD subjects. One study (Mastroeni et al., 2016) reported an increase in DNA 5-hy-
droxymethylation levels in AD compared to age-matched controls. One study (Hernandez, Mahecha, 
Mejia, Arboleda, & Forero, 2014) assessed global DNA methylation in LINE-1 elements in blood 
and showed no difference between AD patients and healthy controls. One study (Bollati et al., 2011) 
examined global DNA methylation in both LINE-1 and Alu elements. It reported no difference in 
global DNA methylation levels in Alu elements, and reported higher levels of methylation in LINE-1 
elements in blood cells of AD compared to healthy controls. Three studies used other methods to 
assess global DNA methylation: two studies (Basile, Colacicco, Venezia, Kanduc, & Capurso, 1997; 
Di Francesco et al., 2015) reported DNA hypermethylation in AD individuals whereas one study 
(Schwob, Nalbantoglu, Hastings, Mikkelsen, & Cashman, 1990) showed no difference in global DNA 
methylation between AD cases and controls. 
(ii) Parkinson’s disease 
There was only one study that examined the association between global DNA methylation at LINE-1 
elements in blood and PD. The study showed no association (Nielsen et al., 2012) (Table 1). 
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Chapter 2.1
Gene Specific DNA Methylation 
DNA methylation, the addition of a methyl group to the 5’ position of cytosine in a dinucleotide CpG 
site, is an important mechanism in gene expression regulation. The direction of association between 
DNA methylation and gene expression depends on where within the gene sequence the methylation 
occurs. DNA methylation in the promoter region of the gene down-regulates its expression whereas 
higher methylation in the gene body may promote the expression of the gene (Jones, 2012). However, 
in most instances DNA methylation represses gene expression. It is thought that methylation of DNA 
either directly prevents binding of DNA transcription factors, or it recruits proteins that bind to 
methylated DNA. Recruiting proteins may prevent transcription by influencing chromatin structure 
by histone modification (Curradi, Izzo, Badaracco, & Landsberger, 2002; Jones, 2012). The effects of 
DNA methylation allow for the evaluation of gene function by comparing individuals who have the 
methylated or unmethylated versions of a gene. These methylation patterns can be studied both in a 
candidate gene approach or a genome-wide approach. 
Candidate Gene Studies
(i) Alzheimer’s disease 
Thirty-four studies examined methylation sites in or near known candidate genes for AD susceptibil-
ity in relation to AD (Table 2). The 34 studies showed that AD cases, compared to controls, have a 
higher degree of methylation of OPRK1, UQCRC1, AR, BDNF and HTERT in blood cells, BDNF, 
synaptophysin gene, CREB promoters, APOE, TREM 2, TBX2AR, SORBS3 and SPTBN4 in the brain, 
and lower methylation levels of 2-5a-synthetase gene in skin fibroblasts, PIN1, FAAH, ALOX5 and 
DR4 gene in blood cells, TNFA, COX-2, NF-kβ gene and S100A2 and CRTC1 in the brain tissue. 
The most consistently reported epigenetic associations with AD were that of methylation at BDNF 
(Chang et al., 2014; Nagata et al., 2015; Rao et al., 2012) in both blood and brain tissue, and at SORBS3 
(Sanchez-Mut et al., 2013; Siegmund et al., 2007) in the frontal cortex, which were reported in three 
and two studies respectively. However, one study (Siegmund et al., 2007) did not find a difference 
in DNA methylation of BDNF gene in AD brain compared to healthy controls. The most studied 
epigenetic mark in relation to AD was the methylation pattern of the APP gene. The APP gene was 
investigated in five studies: three studies (two studies using brain samples (Iwata et al., 2014; West, 
Lee, & Maroun, 1995) and one study using blood cells (Hou et al., 2013)) showed hypomethylation 
of APP in AD cases compared to controls. Alternatively, two studies (Barrachina & Ferrer, 2009; 
Brohede, Rinde, Winblad, & Graff, 2010) showed no difference in DNA methylation of APP in brain 
tissue between AD and healthy controls. Fourteen studies found no difference or clear pattern in 
methylation of the following genes: 12-LOX (Rao et al., 2012), debrin-like protein gene (Rao et al., 
2012), p450 epoxygenase gene (Rao et al., 2012), MAPT, PSEN1, UCHL1, SST (Grosser, Neumann, 
Horsthemke, Zeschnigk, & Van de Nes, 2014), SSTR4 (Grosser et al., 2014), F2RL2 (Sanchez-Mut et 
al., 2013), SOD-1 (West et al., 1995) and GRN (Banzhaf-Strathmann et al., 2013) in brain tissue; PS1 
(Hou et al., 2013), PS2 (Hou et al., 2013) and tau1 (Hou et al., 2013), SMARCA 5 (P. N. O. Silva et al., 
2008), CHD1 (P. N. O. Silva et al., 2008), BDNF (Carboni et al., 2015), SIRT1 (Carboni et al., 2015), 
PSEN1 (Carboni et al., 2015{Tannorella, 2015 #2823), genes involved in DNA repair (Coppedè et al., 
2016), genes involved in homocysteine pathway (Tannorella et al., 2015), CTSB (Ma, Tang, & Lam, 
2016), CTSD (Ma et al., 2016), DDT (Ma et al., 2016), TSC1 (Ma et al., 2016), NRD1 (Ma et al., 2016) 
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and NDUFA6 (Ma et al., 2016) in blood cells; HSPA8 (P. N. Silva et al., 2014), HSPA9 (P. N. Silva et 
al., 2014), ApoE4 (Hou et al., 2013; Iwata et al., 2014), SNAP25 (Furuya et al., 2012), SORL 1, SIRT1 
and SIRT3 (Furuya et al., 2012; Hou et al., 2013; P. N. O. Silva et al., 2008) in both blood cells and 
brain tissue (Table 2). However, 7 studies showed differences in methylation patterns of CpG sites 
(within same gene some CpG sites were hypomethylated and some others were hypermethylated, in 
AD cases) examined at the following genes: SORL1 (Yu et al., 2015), ABCA7 (Yu et al., 2015), SLC2A4 
(Yu et al., 2015), BIN1 (Yu et al., 2015), HSPA8 (P. N. Silva et al., 2014), HSPA9 (P. N. Silva et al., 2014), 
DR4 gene (Ai et al., 2014), BDNF4 (Chang et al., 2014; Nagata et al., 2015), SIRT1 (Hou et al., 2013), 
APP (Iwata et al., 2014), MAPT (Iwata et al., 2014) and GSK3B (Iwata et al., 2014). 
(ii) Parkinson’s disease
There were 13 studies that examined methylation sites in or near known candidate genes for PD sus-
ceptibility (Table 3). Overall the studies looking at PD found lower levels of methylation of NAPS2 and 
NOS2 in blood cells and of ADORA2A in the brain tissue of PD cases, and higher levels of methyla-
tion of PGC−1α gene in brain tissue of PD patients. Six studies examined the methylation pattern of 
α-synuclein gene (SNCA) in blood and brain tissue in relation to PD: 5 studies (Ai et al., 2014; Jowaed 
et al., 2010; Matsumoto et al., 2010a; I. Schmitt et al., 2015; Y. Y. Tan et al., 2014) showed significantly 
decreased levels of methylation in PD patients compared to controls whereas 1 study (Y. Song et al., 
2014) found a non-significant decrease in PD subjects. Four studies (Banzhaf-Strathmann et al., 2013; 
Cai, Tian, Zhao, Luo, & Zhang, 2011; Lin et al., 2012; Y. Tan et al., 2016) did not show any difference 
in DNA methylation of the following genes: Parkin gene, DJ-1, PER1, PER2, CRY1, CRY2, CLOCK and 
BMAL1 in blood cells and of GRN in brain tissue. One study (Coupland et al., 2014) examined DNA 
methylation of the MAPT gene in blood cells and different areas of the brain and showed that the as-
sociation between DNA methylation of MAPT and presence of PD differ by the tissue examined. 
Genome-wide analysis
(i) Alzheimer’s disease
Six studies looked for differentially methylated sites associated with AD in brain tissue; 1 study also 
looked in both brain tissue and blood cells (Table 2). Up to 1106 CpG sites were reported to be 
differentially methylated in the brains of AD cases compared to individuals without AD. One study 
(Bakulski et al., 2012) found 948 CpGs representing 918 unique genes in the frontal cortex were as-
sociated with late onset-AD status. In AD cases, there was mainly hypermethylation of genes related 
to molecular and biological processes involved in transcription, and hypomethylation of genes related 
to membrane transport and protein metabolism (e.g. TMEM59). One study reported that out of 137 
CpGs in cortical brain tissue found to relate with the burden of natriuretic amyloid plaques (NP), 
22 were also associated with the presence of AD (De Jager et al., 2014). Another study (Humphries 
et al., 2015) reported 1106 CpGs to be differentially methylated in late onset-AD subjects compared 
to healthy controls and that 87,3% of the CpG sites were hypomethylated. Among the CpGs found 
to differ in methylation frequency between AD patients and healthy controls in the initial analysis, 
only the hypermethylation of DUSP22 gene in AD cases could be confirmed in the replication set 
(Sanchez-Mut et al., 2014). Two other studies (Bernstein et al., 2016; Watson et al., 2016) reported 
that differentially methylated regions in the brain tissue of AD patients were related to genes involved 
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Table 2. Specific gene methylation in Alzheimer’s disease: gene and genome-wide approaches. 
Author Study design population/Age range/
follow-up
Cases Tissue type Methylation sites/methods Adjustments Main finding
Candidate gene approach
An S et al. 1994(An, 
Khanna, & Wu, 1994)
CCS/ Comparison of skin fibroblasts of 
AD and age/sex-matched controls
N=4* 
Age and sex unspecified
N=2 Skin fibroblasts 2-5A synthetase gene/
Methylation-sensitive restriction enzymes (HpaII).
Hypo-methylation 
Arosio B et al. 
2012(D’Addario et al., 2012)
CCS/Comparison of subjects with late 
onset AD (LOAD) and age-matched 
controls
Italy, n=60, 79.7 ± 6.3 years, M 
and W
N=32 PBMCs PIN1 gene promoter region
/ bisulphite labelled RT-PCR
Hypo-methylation
Bajic V et. al 2014(Bajic et 
al., 2014)
 CCS/ Comparison of female AD 
patients and healthy age-matched 
controls
Serbia, n=20, 68.1 ± 6.5 years, W N=10 PBMCs Androgen receptor promoter (as a measure of 
X-inactivation pattern)/ MethySYBR Assay
Hyper-methylation
Banzhaf-Strathmann J et al. 
2013(Banzhaf-Strathmann et 
al., 2013)
CCS/ Comparison between 
AD patients and age-matched 
neurologically healthy controls. 
Multiple countries, n=51, 70.5 ± 
7.7 years, M and W.
N=8 Human post-mortem 
brain tissue (frontal 
cortex)
GRN promoter/ Sequenom MassARRAY platform No difference
Barrachina et. al, 
2009(Barrachina & Ferrer, 
2009)
CCS/ Comparison of AD (different 
stages) and controls.
European Brain Bank network 
(BrainNet Europe II, N=70, 73.1 
± 10.1 years
N=44 Human post-mortem 
brain tissue
CpG methylation in MAPT, PSEN1, APP, 
UCHL1/ SEQUENOM (Hamburg, Germany) 
MassArray System.
Other: evaluation of effect of post-mortem delay 
on methylation analysis; comparison to other 
pathologies (FTD, PD etc.)
No difference
Brohede J et al, 
2010(Brohede et al., 2010)
CCS Sweden, n=6, Five men, one 
woman.
N=6 Brain tissue (cortical 
and cerebellar).
12 CpG sites in the amyloid precursor protein 
gene (APP)/ bisulphite-PCR sequencing by 3100 
Genetic analyzer 
No difference
Chang L Et al, 
2014(Chang et al., 2014)
CCS/ comparison of AD patients and 
age- and gender matched controls
China, n=106, Men and women. N=44 PB BDNF promoter (4 CpG islands) / Pyromark 
Gold Q24 Reagents (Qiagen)
Age and gender 
matched
Hyper-methylation
D’addario C 
et al, 
2012(D’Addario et al., 2012)
CCS/ comparison of LOAD cases and 
age-matched controls
Italy, n=66, 79.73 ± 7.77 years, 
Men and women
N=33 PBMCs Methylation at fatty acid amide hydrolase (FAAH) 
gene promotor (18 CpG sites)/ methylation-
specific primer real-time PCR. 
Age matched Hypo-methylation
DiFrancesco
A et al.,
2013(Di Francesco et al., 
2013)
CCS/ comparison of LOAD subjects 
with age-matched controls
Italy, n=55, 79.7 ± 6.34 years N=27 PBMCs DNA methylation of ALOX5 promoter Age-matched 
controls
Hypo-methylation
Furuya T. et. al, 
2012(Furuya et al., 2012)
CCS/ AD cases compared to healthy 
elderly and healthy young controls
Canada, Brain (n=22), PB (n=84)/ 
62.9 ± 3.4 years, M and W
Brain: N=12 
Blood: N=36
Brain (entorhinal 
cortex, auditory 
cortex, hippocampus) 
and PBMCs
SORL1 and SIRT1 gene methylation/ Sequenom 
EpiTYPER
No difference
Furuya T. et al, 2012
(Furuya et al., 2012) 
CCS/ AD cases compared to healthy 
elderly and healthy young controls
Canada, Brain (n=20), PB (n=79), 
63.5 ± 5.1 years, M and W
Brain: N=10 
Blood: N=34
Brain (entorhinal 
cortex, auditory 
cortex, hippocampus) 
and PBMCs
SNAP25 gene methylation/ Sequenom EpiTYPER ApoE4 status No differences
Grosser C, 
et al, 2014
(Grosser et al., 2014)
CCS/ AD cases compared to controls Netherlands, n=10), 77.5 ± 13.3 
years, M and W
N=5 Brain tissue (middle 
temporal and superior 
frontal gyrus)
Methylation of SST and SSTR4 promoter CpG 
islands (27 and 44 CpGs)/ Bisulphite RT-PCR 
sequencing
Age matched No difference
Hou Y. et al,
2013(Hou et al., 2013)
CCS/ AD cases compared to controls China, n=135, 
78.4 ± 13.3 years, M and W
N=63 PBMCs CpG islands of SIRT1 (SI and SII1/SII2) and 
amplifiable regions of APP, ApoE4, PS1, PS2 
and Tau / Bisulphite pyrosequencing (EZ DNA 
methylation Gold Kit)
Age, sex, 
scholarity and 
vascular disease 
matched
SIRT1: Hyper-methylation
APP: Hypo-methylation
Apoe4, PS1, PS2 and Tau: No 
difference
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Table 2. Specific gene methylation in Alzheimer’s disease: gene and genome-wide approaches. 
Author Study design population/Age range/
follow-up
Cases Tissue type Methylation sites/methods Adjustments Main finding
Candidate gene approach
An S et al. 1994(An, 
Khanna, & Wu, 1994)
CCS/ Comparison of skin fibroblasts of 
AD and age/sex-matched controls
N=4* 
Age and sex unspecified
N=2 Skin fibroblasts 2-5A synthetase gene/
Methylation-sensitive restriction enzymes (HpaII).
Hypo-methylation 
Arosio B et al. 
2012(D’Addario et al., 2012)
CCS/Comparison of subjects with late 
onset AD (LOAD) and age-matched 
controls
Italy, n=60, 79.7 ± 6.3 years, M 
and W
N=32 PBMCs PIN1 gene promoter region
/ bisulphite labelled RT-PCR
Hypo-methylation
Bajic V et. al 2014(Bajic et 
al., 2014)
 CCS/ Comparison of female AD 
patients and healthy age-matched 
controls
Serbia, n=20, 68.1 ± 6.5 years, W N=10 PBMCs Androgen receptor promoter (as a measure of 
X-inactivation pattern)/ MethySYBR Assay
Hyper-methylation
Banzhaf-Strathmann J et al. 
2013(Banzhaf-Strathmann et 
al., 2013)
CCS/ Comparison between 
AD patients and age-matched 
neurologically healthy controls. 
Multiple countries, n=51, 70.5 ± 
7.7 years, M and W.
N=8 Human post-mortem 
brain tissue (frontal 
cortex)
GRN promoter/ Sequenom MassARRAY platform No difference
Barrachina et. al, 
2009(Barrachina & Ferrer, 
2009)
CCS/ Comparison of AD (different 
stages) and controls.
European Brain Bank network 
(BrainNet Europe II, N=70, 73.1 
± 10.1 years
N=44 Human post-mortem 
brain tissue
CpG methylation in MAPT, PSEN1, APP, 
UCHL1/ SEQUENOM (Hamburg, Germany) 
MassArray System.
Other: evaluation of effect of post-mortem delay 
on methylation analysis; comparison to other 
pathologies (FTD, PD etc.)
No difference
Brohede J et al, 
2010(Brohede et al., 2010)
CCS Sweden, n=6, Five men, one 
woman.
N=6 Brain tissue (cortical 
and cerebellar).
12 CpG sites in the amyloid precursor protein 
gene (APP)/ bisulphite-PCR sequencing by 3100 
Genetic analyzer 
No difference
Chang L Et al, 
2014(Chang et al., 2014)
CCS/ comparison of AD patients and 
age- and gender matched controls
China, n=106, Men and women. N=44 PB BDNF promoter (4 CpG islands) / Pyromark 
Gold Q24 Reagents (Qiagen)
Age and gender 
matched
Hyper-methylation
D’addario C 
et al, 
2012(D’Addario et al., 2012)
CCS/ comparison of LOAD cases and 
age-matched controls
Italy, n=66, 79.73 ± 7.77 years, 
Men and women
N=33 PBMCs Methylation at fatty acid amide hydrolase (FAAH) 
gene promotor (18 CpG sites)/ methylation-
specific primer real-time PCR. 
Age matched Hypo-methylation
DiFrancesco
A et al.,
2013(Di Francesco et al., 
2013)
CCS/ comparison of LOAD subjects 
with age-matched controls
Italy, n=55, 79.7 ± 6.34 years N=27 PBMCs DNA methylation of ALOX5 promoter Age-matched 
controls
Hypo-methylation
Furuya T. et. al, 
2012(Furuya et al., 2012)
CCS/ AD cases compared to healthy 
elderly and healthy young controls
Canada, Brain (n=22), PB (n=84)/ 
62.9 ± 3.4 years, M and W
Brain: N=12 
Blood: N=36
Brain (entorhinal 
cortex, auditory 
cortex, hippocampus) 
and PBMCs
SORL1 and SIRT1 gene methylation/ Sequenom 
EpiTYPER
No difference
Furuya T. et al, 2012
(Furuya et al., 2012) 
CCS/ AD cases compared to healthy 
elderly and healthy young controls
Canada, Brain (n=20), PB (n=79), 
63.5 ± 5.1 years, M and W
Brain: N=10 
Blood: N=34
Brain (entorhinal 
cortex, auditory 
cortex, hippocampus) 
and PBMCs
SNAP25 gene methylation/ Sequenom EpiTYPER ApoE4 status No differences
Grosser C, 
et al, 2014
(Grosser et al., 2014)
CCS/ AD cases compared to controls Netherlands, n=10), 77.5 ± 13.3 
years, M and W
N=5 Brain tissue (middle 
temporal and superior 
frontal gyrus)
Methylation of SST and SSTR4 promoter CpG 
islands (27 and 44 CpGs)/ Bisulphite RT-PCR 
sequencing
Age matched No difference
Hou Y. et al,
2013(Hou et al., 2013)
CCS/ AD cases compared to controls China, n=135, 
78.4 ± 13.3 years, M and W
N=63 PBMCs CpG islands of SIRT1 (SI and SII1/SII2) and 
amplifiable regions of APP, ApoE4, PS1, PS2 
and Tau / Bisulphite pyrosequencing (EZ DNA 
methylation Gold Kit)
Age, sex, 
scholarity and 
vascular disease 
matched
SIRT1: Hyper-methylation
APP: Hypo-methylation
Apoe4, PS1, PS2 and Tau: No 
difference
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Table 2. Specific gene methylation in Alzheimer’s disease: gene and genome-wide approaches. (continued)
Author Study design population/Age range/
follow-up
Cases Tissue type Methylation sites/methods Adjustments Main finding
Iwata A et al, 2014(Iwata et 
al., 2014)
CCS/ AD cases compared to controls Japan, n=158, 77.4 ± 6.1 years N=62 Brain tissue 
(cerebellum, anterior 
parietal lobe and 
inferior temporal lobe)
203 CpGs for ACE, APOE, APP, BACE1, GSK3B, 
MAPT, PSEN1/ Bisulphite pyrosequencing by 
Pyromark Q24 analyzer (Qiagen)
Age-matched 
samples
Kaut O et al, 2014(Kaut et 
al., 2014)
CCS/ AD cases compared to controls Germany, PB, n=105, 
69.7 ± 7.6 years
Cortical tissue, n=8, 77.15 ± 10.0 
years 
M and W
N=55 and 
n=4
PBMCs and cortical 
tissue
TNF-α promoter. 10 CpGs analyzed by bisulphite 
sequencing PCR
Cortex: Hypo-methylation
PBMC: No difference
Nagata T et al, 2015(Nagata 
et al., 2015)
CCS/ Comparison of AD patients with 
age-matched controls.
Japan, n=40, 66.5 ± 5.09, M and 
W
N=20 PBMCs BDNF promoter 20 CpGs/ bisulfite sequencing Hyper-methylation
Sanchez-Mut JV et al. 
2013(Sanchez-Mut et al., 
2013)
CCS/ Comparison of AD patients 
with age and gender matched non-AD 
subjects.
eBrainNet Europe Bank / n=40, 
76,5 ± 2,5
N=20 Human post-mortem 
brain tissue (grey 
matter of frontal 
cortex)
F2RL2, SORB3, SPNB4 and TBX2AR/ bisulfite 
pyrosequencing
TBX2AR, SORBS3 and 
SPTBN4: Hyper-methylation
F2RL2: No difference
Siegmund KD et al. 
2007(Siegmund et al., 2007)
CCS/ Comparison of AD patients 
with controls (including schizophrenic 
subjects).
USA, N=58,60-104.3, M and W N=18 Human post-mortem 
brain tissue (temporal 
and frontal cortex)
50 loci related to central nervous system growth 
and development (SORBS3, S100A2, LDLR, 
MYOD1, MGMT, LZTS1, GDNF, PYCARD, 
STK11, UIR, CRABP1, PLAGL1, DIRAS3, 
PGR, SERPINB5, NEUROD2, GAD1, RNR1, 
ALU, TFAP2A, MINT1, CDKN2A, NTF3, 
SASH1, PAX8, SYK, NEUROD1, PSEN1, ALU, 
GABRA2, DRD2, LTBR4, ALU, HOXA1, CALCA, 
DNAJC15, SMAD3, CDX1, SCGB3A1, MT1A, 
TNFRSF25, MTHFR, MGMT, FAM127A, 
AR, LPHN2, ALU, RASSF1, BDNF)/ bisulfite 
pyrosequencing. 
SORB3: Hyper-methylation
S100A2: Hypo-methylation
Other genes: No difference
Silva PN et al. 2014(P. N. 
Silva et al., 2014)
CCS/ Comparison of AD patients with 
non-AD controls.
Canada, n=79, 75,7 ± 8.2 years, 
M and W
N=46 PB and human post-
mortem brain tissue
HSPA8 and HSPA9, 22 and 34 CpGs respectively/ 
Sequenom EpiTyper MassARRAY
No difference overall, but 
differentially methylated CpG 
sites
Silva PNO et al 2008(P. N. 
O. Silva et al., 2008)
CCS/ Comparison of AD patients with 
age matched non-AD controls and 
young controls.
Brazil, n=145,, 55.32 ± 49 years, 
M and W
N=45 PB SIRT3, SMARCA5, HTERT and CHD1 gene/ 
bisulfite pyrosequencing 
HTERT: Hyper-methylation
SIRT3, SMARCA5 and CHD1: 
No difference
Wang SC et al. 2008(S. 
C. Wang, Oeize, & 
Schumacher, 2008)
CCS/ Comparison of late onset-AD 
patients with geographical location, 
ethnicity, age and sex matched non-AD 
controls
Germany, n=34, , 80,6 ± 9,4 years, 
M and W
N=24 Human post-mortem 
brain tissue (prefrontal 
gyrus frontalis 
superior) and Blood 
lymphocytes
12 AD’s susceptibility loci (HTATIP, MTHRF, 
DNMT1, TFAM, SIN3A, NCSTN, BACE1, 
APP, PSEN1 APH1B and APOE/ bisulfite 
pyrosequencing (MALDI-TOF mass spectrometry 
analysis) 
Wang Y et al. 2014(Ai et al., 
2014)
CCS/ Comparison of AD patients with 
age and sex matched non-AD controls.
China, n=50, 75.44 ± 9.1 (60-90) 
years.
M and W
N=25 Blood lymphocytes. DR4 gene promoter, 2 CpG islands (9 and 13 
CpG sites each)/ Bisulfite sequencing 
Hypo-methylation
West RL et al. 1995(West et 
al., 1995)
CCS/ Comparison of female AD 
patients with age-matched controls. 
USA, n=3, 83, 74 and 81 years, w N=12 Human post-
mortem brain tissue 
(Brodmann’s area 38)
Amyolid precursor protein (APP) and superoxide 
dismutase (SOD-1) genes/ Methylation-sensitive 
restriction enzymes (HpaII).
APP: Hypo-methylation
SOD-1: No difference
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Table 2. Specific gene methylation in Alzheimer’s disease: gene and genome-wide approaches. (continued)
Author Study design population/Age range/
follow-up
Cases Tissue type Methylation sites/methods Adjustments Main finding
Iwata A et al, 2014(Iwata et 
al., 2014)
CCS/ AD cases compared to controls Japan, n=158, 77.4 ± 6.1 years N=62 Brain tissue 
(cerebellum, anterior 
parietal lobe and 
inferior temporal lobe)
203 CpGs for ACE, APOE, APP, BACE1, GSK3B, 
MAPT, PSEN1/ Bisulphite pyrosequencing by 
Pyromark Q24 analyzer (Qiagen)
Age-matched 
samples
Kaut O et al, 2014(Kaut et 
al., 2014)
CCS/ AD cases compared to controls Germany, PB, n=105, 
69.7 ± 7.6 years
Cortical tissue, n=8, 77.15 ± 10.0 
years 
M and W
N=55 and 
n=4
PBMCs and cortical 
tissue
TNF-α promoter. 10 CpGs analyzed by bisulphite 
sequencing PCR
Cortex: Hypo-methylation
PBMC: No difference
Nagata T et al, 2015(Nagata 
et al., 2015)
CCS/ Comparison of AD patients with 
age-matched controls.
Japan, n=40, 66.5 ± 5.09, M and 
W
N=20 PBMCs BDNF promoter 20 CpGs/ bisulfite sequencing Hyper-methylation
Sanchez-Mut JV et al. 
2013(Sanchez-Mut et al., 
2013)
CCS/ Comparison of AD patients 
with age and gender matched non-AD 
subjects.
eBrainNet Europe Bank / n=40, 
76,5 ± 2,5
N=20 Human post-mortem 
brain tissue (grey 
matter of frontal 
cortex)
F2RL2, SORB3, SPNB4 and TBX2AR/ bisulfite 
pyrosequencing
TBX2AR, SORBS3 and 
SPTBN4: Hyper-methylation
F2RL2: No difference
Siegmund KD et al. 
2007(Siegmund et al., 2007)
CCS/ Comparison of AD patients 
with controls (including schizophrenic 
subjects).
USA, N=58,60-104.3, M and W N=18 Human post-mortem 
brain tissue (temporal 
and frontal cortex)
50 loci related to central nervous system growth 
and development (SORBS3, S100A2, LDLR, 
MYOD1, MGMT, LZTS1, GDNF, PYCARD, 
STK11, UIR, CRABP1, PLAGL1, DIRAS3, 
PGR, SERPINB5, NEUROD2, GAD1, RNR1, 
ALU, TFAP2A, MINT1, CDKN2A, NTF3, 
SASH1, PAX8, SYK, NEUROD1, PSEN1, ALU, 
GABRA2, DRD2, LTBR4, ALU, HOXA1, CALCA, 
DNAJC15, SMAD3, CDX1, SCGB3A1, MT1A, 
TNFRSF25, MTHFR, MGMT, FAM127A, 
AR, LPHN2, ALU, RASSF1, BDNF)/ bisulfite 
pyrosequencing. 
SORB3: Hyper-methylation
S100A2: Hypo-methylation
Other genes: No difference
Silva PN et al. 2014(P. N. 
Silva et al., 2014)
CCS/ Comparison of AD patients with 
non-AD controls.
Canada, n=79, 75,7 ± 8.2 years, 
M and W
N=46 PB and human post-
mortem brain tissue
HSPA8 and HSPA9, 22 and 34 CpGs respectively/ 
Sequenom EpiTyper MassARRAY
No difference overall, but 
differentially methylated CpG 
sites
Silva PNO et al 2008(P. N. 
O. Silva et al., 2008)
CCS/ Comparison of AD patients with 
age matched non-AD controls and 
young controls.
Brazil, n=145,, 55.32 ± 49 years, 
M and W
N=45 PB SIRT3, SMARCA5, HTERT and CHD1 gene/ 
bisulfite pyrosequencing 
HTERT: Hyper-methylation
SIRT3, SMARCA5 and CHD1: 
No difference
Wang SC et al. 2008(S. 
C. Wang, Oeize, & 
Schumacher, 2008)
CCS/ Comparison of late onset-AD 
patients with geographical location, 
ethnicity, age and sex matched non-AD 
controls
Germany, n=34, , 80,6 ± 9,4 years, 
M and W
N=24 Human post-mortem 
brain tissue (prefrontal 
gyrus frontalis 
superior) and Blood 
lymphocytes
12 AD’s susceptibility loci (HTATIP, MTHRF, 
DNMT1, TFAM, SIN3A, NCSTN, BACE1, 
APP, PSEN1 APH1B and APOE/ bisulfite 
pyrosequencing (MALDI-TOF mass spectrometry 
analysis) 
Wang Y et al. 2014(Ai et al., 
2014)
CCS/ Comparison of AD patients with 
age and sex matched non-AD controls.
China, n=50, 75.44 ± 9.1 (60-90) 
years.
M and W
N=25 Blood lymphocytes. DR4 gene promoter, 2 CpG islands (9 and 13 
CpG sites each)/ Bisulfite sequencing 
Hypo-methylation
West RL et al. 1995(West et 
al., 1995)
CCS/ Comparison of female AD 
patients with age-matched controls. 
USA, n=3, 83, 74 and 81 years, w N=12 Human post-
mortem brain tissue 
(Brodmann’s area 38)
Amyolid precursor protein (APP) and superoxide 
dismutase (SOD-1) genes/ Methylation-sensitive 
restriction enzymes (HpaII).
APP: Hypo-methylation
SOD-1: No difference
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Table 2. Specific gene methylation in Alzheimer’s disease: gene and genome-wide approaches. (continued)
Author Study design population/Age range/
follow-up
Cases Tissue type Methylation sites/methods Adjustments Main finding
Rao JS et al. 2012(Rao et 
al., 2012)
CCS/ Comparison of AD patients with 
age-matched controls.
USA, n=20, 70.4 ± 2.4 years, 
Gender not specified
N=10 Human post-
mortem brain tissue 
(Brodmann’s area 9)
Promoter of COX-2, BDNF, NF-kβ, CREB, 12-
LOX, p450
 epoxygenase, synaptophysin and debrin-like 
genes/ Methylation-sensitive restriction enzymes
COX-2 and NF-kβ: Hypo-
methylation
BDNF, synaptophysin and 
CREB: Hyper-methylation
12-LOX, debrin-like protein or 
p450 epoxygenase: No difference
Yu L et al. 2015(Yu et al., 
2015)
CCS/ Comparison of AD patients with 
non-AD controls.
USA, n=740, 88 ± 6.7 years, M 
and W
N=447 Human post-mortem 
brain tissue (gray 
matter) 
28 reported AD loci/ Infinum HumanMethylation 
450: Illumina) 
Age, sex, 
batch, bisulfite 
conversion 
efficacy, 
macroscopic 
and 
microscopic 
infarcts and 
cortical Lewy 
bodies
Results vary per CpG sites
Carboni L et al. 
2015(Carboni et al., 2015)
CCS/ Comparison of AD patients with 
non-AD controls.
Italy, n=39, 75 ± 7, M N=20 Peripheral blood Promoter of Bdnf, Sirtuin 1 (Sirt1) and and 
Presenilin 1 (Psen1)/ Bisulfite sequencing
No difference
Celarain N et al. 
2016(Celarain et al., 2016)
CCS/ Comparison of AD patients with 
non-AD controls.
Spain, n=42, 19 to 98 years, M 
and W
N=30 Frozen postmortem 
hippocampus
samples
TREM2 transcription start site (TSS)-associated 
region / Bisulfite sequencing
Hypermethylation
Coppedè F et al. 
2016(Coppedè et al., 2016)
CCS/ Comparison of late onset-
AD (LOAD) patients with non-AD 
controls.
Italy, n=111, 77.1 ± 8.8, M and W N=56 PB Genes involved in major DNA repair pathways: 
OGG1, PARP1, MRE11A, BRCA1, MLH1,and 
MGMT/ effectivePCR based methylation-
sensitive high-resolution melting (MS-HRM) 
technique
Age, gender 
and multiple 
comparison
No difference
Ferri E et al. 2016(Ferri et 
al., 2016)
CCS/ Comparison of AD patients with 
non-AD controls.
Italy, n=283, 79.4 ± 0.5, M and W N=176 Peripheral blood
mononuclear cells
Pin1 gene promoter, 5 CpG sites / Bisulfite 
sequencing
Age and gender No difference
Foraker J et al. 2015(Foraker 
et al., 2015)
CCS/ Comparison of AD patients with 
non-AD controls.
USA, n=25, 83.6 ± 9, M and W N=15 Postmortem 
brain, cerebellum, 
hippocampus, frontal 
lobe
APOE, 76 CpG sites/ Bisulfite sequencing Age, sex, 
disease status, 
APOE
genotype, CpG 
site, and tissue 
type, as well 
as all
second-order 
interactions 
involving tissue
Hypermethylated
Ji H et al. 2015(Ji et al., 
2015)
CCS/ Comparison of sporadic AD 
patients with non-AD controls.
China, n=106, 80.4 ± 8.4, M 
and W
N=48 PB Promoter OPRK1, 3 CpG sites/ Bisulphite 
pyrosequencing
History of 
smoking, 
diabetes and 
hypertension
Hypermethylated
Ma SL, et al. 2016(Ma et 
al., 2016)
CCS/ Comparison of AD patients with 
non-AD controls.
China, n=260, 81.3 ± 7.0, W N=80 PB CTSB, CTSD, DDT, TSC1, NRD1, UQCRC1 
and NDUFA6 / Bisulphite pyrosequencing
Hypermethylated and no 
difference
Tannorella P et al. 
2015(Tannorella et al., 2015)
CCS/ Comparison of sporadic AD 
patients with non-AD controls.
Italy, n=223, 76.6 ± 8.2, M and W N=120 PB The promoter/5-UTR regions of PSEN1, BACE1, 
MTHFR, DNMT1, DNMT3A, and DNMT3B / 
Bisulphite pyrosequencing
Age at 
sampling, 
gender, 
homocysteine, 
folate, vitamin 
B12 and batch
No difference
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Table 2. Specific gene methylation in Alzheimer’s disease: gene and genome-wide approaches. (continued)
Author Study design population/Age range/
follow-up
Cases Tissue type Methylation sites/methods Adjustments Main finding
Rao JS et al. 2012(Rao et 
al., 2012)
CCS/ Comparison of AD patients with 
age-matched controls.
USA, n=20, 70.4 ± 2.4 years, 
Gender not specified
N=10 Human post-
mortem brain tissue 
(Brodmann’s area 9)
Promoter of COX-2, BDNF, NF-kβ, CREB, 12-
LOX, p450
 epoxygenase, synaptophysin and debrin-like 
genes/ Methylation-sensitive restriction enzymes
COX-2 and NF-kβ: Hypo-
methylation
BDNF, synaptophysin and 
CREB: Hyper-methylation
12-LOX, debrin-like protein or 
p450 epoxygenase: No difference
Yu L et al. 2015(Yu et al., 
2015)
CCS/ Comparison of AD patients with 
non-AD controls.
USA, n=740, 88 ± 6.7 years, M 
and W
N=447 Human post-mortem 
brain tissue (gray 
matter) 
28 reported AD loci/ Infinum HumanMethylation 
450: Illumina) 
Age, sex, 
batch, bisulfite 
conversion 
efficacy, 
macroscopic 
and 
microscopic 
infarcts and 
cortical Lewy 
bodies
Results vary per CpG sites
Carboni L et al. 
2015(Carboni et al., 2015)
CCS/ Comparison of AD patients with 
non-AD controls.
Italy, n=39, 75 ± 7, M N=20 Peripheral blood Promoter of Bdnf, Sirtuin 1 (Sirt1) and and 
Presenilin 1 (Psen1)/ Bisulfite sequencing
No difference
Celarain N et al. 
2016(Celarain et al., 2016)
CCS/ Comparison of AD patients with 
non-AD controls.
Spain, n=42, 19 to 98 years, M 
and W
N=30 Frozen postmortem 
hippocampus
samples
TREM2 transcription start site (TSS)-associated 
region / Bisulfite sequencing
Hypermethylation
Coppedè F et al. 
2016(Coppedè et al., 2016)
CCS/ Comparison of late onset-
AD (LOAD) patients with non-AD 
controls.
Italy, n=111, 77.1 ± 8.8, M and W N=56 PB Genes involved in major DNA repair pathways: 
OGG1, PARP1, MRE11A, BRCA1, MLH1,and 
MGMT/ effectivePCR based methylation-
sensitive high-resolution melting (MS-HRM) 
technique
Age, gender 
and multiple 
comparison
No difference
Ferri E et al. 2016(Ferri et 
al., 2016)
CCS/ Comparison of AD patients with 
non-AD controls.
Italy, n=283, 79.4 ± 0.5, M and W N=176 Peripheral blood
mononuclear cells
Pin1 gene promoter, 5 CpG sites / Bisulfite 
sequencing
Age and gender No difference
Foraker J et al. 2015(Foraker 
et al., 2015)
CCS/ Comparison of AD patients with 
non-AD controls.
USA, n=25, 83.6 ± 9, M and W N=15 Postmortem 
brain, cerebellum, 
hippocampus, frontal 
lobe
APOE, 76 CpG sites/ Bisulfite sequencing Age, sex, 
disease status, 
APOE
genotype, CpG 
site, and tissue 
type, as well 
as all
second-order 
interactions 
involving tissue
Hypermethylated
Ji H et al. 2015(Ji et al., 
2015)
CCS/ Comparison of sporadic AD 
patients with non-AD controls.
China, n=106, 80.4 ± 8.4, M 
and W
N=48 PB Promoter OPRK1, 3 CpG sites/ Bisulphite 
pyrosequencing
History of 
smoking, 
diabetes and 
hypertension
Hypermethylated
Ma SL, et al. 2016(Ma et 
al., 2016)
CCS/ Comparison of AD patients with 
non-AD controls.
China, n=260, 81.3 ± 7.0, W N=80 PB CTSB, CTSD, DDT, TSC1, NRD1, UQCRC1 
and NDUFA6 / Bisulphite pyrosequencing
Hypermethylated and no 
difference
Tannorella P et al. 
2015(Tannorella et al., 2015)
CCS/ Comparison of sporadic AD 
patients with non-AD controls.
Italy, n=223, 76.6 ± 8.2, M and W N=120 PB The promoter/5-UTR regions of PSEN1, BACE1, 
MTHFR, DNMT1, DNMT3A, and DNMT3B / 
Bisulphite pyrosequencing
Age at 
sampling, 
gender, 
homocysteine, 
folate, vitamin 
B12 and batch
No difference
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Table 2. Specific gene methylation in Alzheimer’s disease: gene and genome-wide approaches. (continued)
Author Study design population/Age range/
follow-up
Cases Tissue type Methylation sites/methods Adjustments Main finding
Mendioroz M et al. 
2016(Mendioroz et al., 
2016)
CCS/ Comparison of AD patients with 
non-AD controls.
Spain, n=42, age and sex not 
defined
N=30 Hippocampus CRTC1 gene / Bisulphite pyrosequencing Hypomethylation
Genome-wide approach
Bakulski K et al. 
2012(Bakulski et al., 2012)
CCS/Comparison of subjects with 
LOAD and age- and gender-matched 
controls
USA, n=24, 79.8 years (range 
69-95)
 
(13 additional matched pairs for 
the population validation phase, 
78.2 years (range 61-95)
M and W
N=12/
N=13
Human post-mortem 
frontal cortex tissue
Genome-wide DNA methylation profile. 27,578 
CpG sites spanning 14,475 genes/ Infinium 
HumanMethylation27 BeadArray (Illumina)
Gene-specific DNA methylation/bisulfite-
pyrosequencing on the Qiagen Pyromark MD 
(Valencia, CA).
Other: gene expression, protein quantification 
Age and gender 948 CpG sites representing 
918 unique genes potentially 
associated with LOAD disease 
status (p<0.05). Across these sites 
the mean methylation difference 
between cases and controls is 
2.9%.
Hypermethylation in AD cases 
of molecular function and 
biological processes associated 
with transcription (e.g. RNA 
polymerase II transcription 
factor activity).
Hypomethylation in AD 
cases of functions relating to 
membrane transport and protein 
metabolism.
The CpG site in the promoter 
of the Transmembrane Protein 
59 (TMEM59) gene is 7.3% 
hypomethylated in AD cases.
De Jager et al, 2014(De Jager 
et al., 2014)
CCS/ comparison of participants in 
a prospective cohort study, with post-
mortem diagnosis of AD.
USA, n=708, M and W 60.8% 
(N=430) of 
subjects met 
a pathological 
diagnosis of 
AD.
Cortical brain tissue Methylation at 425,848 discrete CpG 
dinucleotides in 708 subjects (Illumina 
HumanMethylation beadset)
Other: Identification of genes near the associated 
CpGs. 
137 CpGs were found to be 
associated with the burden 
of neuritic amyloid plaques 
(NP) (p<1.20x 10^-7). When 
corrected for the proportion 
of neurons and possible 
measurement artifacts, 71 CpG 
associations remained.
22 of the NP-associated CpG 
s were also associated with 
AD at a genome-wide level of 
significance, and all displayed at 
least (p<0.001) some evidence of 
association with AD. 
Associated methylated regions 
included ABCA7 and BIN1 
genes, which are known AD 
susceptibility regions.
Fernandez AF. et al, 
2012(Fernandez, Assenov, & 
Martin-Subero, 2012)
CS/ whole genome methylation 
“fingerprint” including normal tissues, 
oncogenic tissues, and non-cancerous 
disease tissues (such as AD and DLB)
Europe, Asia and North America, 
n=1628
Men and women
N=11 Brain tissue and 
PBMCs
1322 CpG sites/ Golden Gate DNA methylation 
BeadArray (Illumina), Pyromark Q24 (Qiagen)
No significant difference was 
found between brain samples 
from AD patients and normal 
tissues. 
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Table 2. Specific gene methylation in Alzheimer’s disease: gene and genome-wide approaches. (continued)
Author Study design population/Age range/
follow-up
Cases Tissue type Methylation sites/methods Adjustments Main finding
Mendioroz M et al. 
2016(Mendioroz et al., 
2016)
CCS/ Comparison of AD patients with 
non-AD controls.
Spain, n=42, age and sex not 
defined
N=30 Hippocampus CRTC1 gene / Bisulphite pyrosequencing Hypomethylation
Genome-wide approach
Bakulski K et al. 
2012(Bakulski et al., 2012)
CCS/Comparison of subjects with 
LOAD and age- and gender-matched 
controls
USA, n=24, 79.8 years (range 
69-95)
 
(13 additional matched pairs for 
the population validation phase, 
78.2 years (range 61-95)
M and W
N=12/
N=13
Human post-mortem 
frontal cortex tissue
Genome-wide DNA methylation profile. 27,578 
CpG sites spanning 14,475 genes/ Infinium 
HumanMethylation27 BeadArray (Illumina)
Gene-specific DNA methylation/bisulfite-
pyrosequencing on the Qiagen Pyromark MD 
(Valencia, CA).
Other: gene expression, protein quantification 
Age and gender 948 CpG sites representing 
918 unique genes potentially 
associated with LOAD disease 
status (p<0.05). Across these sites 
the mean methylation difference 
between cases and controls is 
2.9%.
Hypermethylation in AD cases 
of molecular function and 
biological processes associated 
with transcription (e.g. RNA 
polymerase II transcription 
factor activity).
Hypomethylation in AD 
cases of functions relating to 
membrane transport and protein 
metabolism.
The CpG site in the promoter 
of the Transmembrane Protein 
59 (TMEM59) gene is 7.3% 
hypomethylated in AD cases.
De Jager et al, 2014(De Jager 
et al., 2014)
CCS/ comparison of participants in 
a prospective cohort study, with post-
mortem diagnosis of AD.
USA, n=708, M and W 60.8% 
(N=430) of 
subjects met 
a pathological 
diagnosis of 
AD.
Cortical brain tissue Methylation at 425,848 discrete CpG 
dinucleotides in 708 subjects (Illumina 
HumanMethylation beadset)
Other: Identification of genes near the associated 
CpGs. 
137 CpGs were found to be 
associated with the burden 
of neuritic amyloid plaques 
(NP) (p<1.20x 10^-7). When 
corrected for the proportion 
of neurons and possible 
measurement artifacts, 71 CpG 
associations remained.
22 of the NP-associated CpG 
s were also associated with 
AD at a genome-wide level of 
significance, and all displayed at 
least (p<0.001) some evidence of 
association with AD. 
Associated methylated regions 
included ABCA7 and BIN1 
genes, which are known AD 
susceptibility regions.
Fernandez AF. et al, 
2012(Fernandez, Assenov, & 
Martin-Subero, 2012)
CS/ whole genome methylation 
“fingerprint” including normal tissues, 
oncogenic tissues, and non-cancerous 
disease tissues (such as AD and DLB)
Europe, Asia and North America, 
n=1628
Men and women
N=11 Brain tissue and 
PBMCs
1322 CpG sites/ Golden Gate DNA methylation 
BeadArray (Illumina), Pyromark Q24 (Qiagen)
No significant difference was 
found between brain samples 
from AD patients and normal 
tissues. 
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Table 2. Specific gene methylation in Alzheimer’s disease: gene and genome-wide approaches. (continued)
Author Study design population/Age range/
follow-up
Cases Tissue type Methylation sites/methods Adjustments Main finding
Humphries C et. al 
2015(Humphries et al., 
2015)
CCS/ AD cases compared to healthy 
controls and diseased controls (DLB)
USA, n=30, 77.0 ± 4.5 years N=8 Brain tissue DNA methylation analysis including 5,147 
CpG sites on 465 genes/ Illumina Infinium 
HumanMethylation 450 beadchip
1,106 CpG sites differed in 
LOAD-associated methylation 
network genes between LOAD 
and control subjects (p<0.05). 
Hypomethylation was observed 
in LOAD subjects in 87.3% of 
these CpG sites. 
Sanchez-Mut JV et al. 
2014(Sanchez-Mut et al., 
2014)
CCS/ Comparison of AD patients with 
non-AD subjects.
Spain
Discovery set: n=20, 79.7 ± 1.9
Replication set: n=50, 71,7 ± 2,1.
M and W
Discover set, 
n=15
Replication 
set, n=25
Human post-mortem 
brain tissue (grey 
matter, Brodmann 
area 9)
Illumina 27K array assay and bisulfite 
pyrosequencing 
In the discovery set, four 
CpG methylation probes 
corresponding to 3 individual 
genes showed a significant 
difference between AD-cases 
and controls (P<0.05); two 
hypermethylated CpGs in 
dual specificity phosphatase 22 
(DUSP22), 1 CpG in claudin 15 
(CLDN15) and and 1 CpG in 
quiescin Q66 sulfhydryl oxidase 
1 (QSCN6). In the replication 
set, the hypermethylation of 
DUSP22 was confirmed. 
Bernstein AI et al. 
2016(Bernstein et al., 2016)
Comparison of AD with control cases USA, n=11, 78-91, M and W 
(both discovery and replication set)
N=6 Human post-mortem 
brain tissue (frontal 
cortex)
5-methylcytosine and 5-hydroxymethylcytosine 
(5hmC)
There were 325 genes containing 
differentially hydroxymethylated 
loci (DhMLs) in both
discovery and replication 
datasets. These are enriched for 
pathways involved in neuron 
projection development and
neurogenesis.
Watson CT et al. 
2016(Watson et al., 2016)
CCS/ Comparison of AD patients with 
non-AD subjects.
USA, n=68, 66-95, M and W N=34 Bulk tissue samples 
from the superior 
temporal gyrus
461,272 autosomal CpGs / 
HumanMethylation450 platform
AOD,
gender, race, 
array/batch, 
and neuronal/
glial cell 
composition.
There were 479 differentially 
methylated regions (DMR) ( 
(increased in AD; hyper-DMRs 
= 321, hypo-DMRs = 158), with 
relevant roles in neuron function 
and development, as well as 
cellular metabolism. Top DMRs 
were close to following genes: 
MOV10L1, B3GALT4, DUSP6, 
TBX15, HLA-J, ZNRD1-AS1, 
PRDM16, ELOVL1, RIBC2, 
SMC1B, KLK7, TRIM6, 
FBRSL1, VAX2, CDH23, 
KIF25, NRG2, RNF39, 
CMYA5, TNXB, NAV2, TAP2, 
ZNF177, FLOT1
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Table 2. Specific gene methylation in Alzheimer’s disease: gene and genome-wide approaches. (continued)
Author Study design population/Age range/
follow-up
Cases Tissue type Methylation sites/methods Adjustments Main finding
Humphries C et. al 
2015(Humphries et al., 
2015)
CCS/ AD cases compared to healthy 
controls and diseased controls (DLB)
USA, n=30, 77.0 ± 4.5 years N=8 Brain tissue DNA methylation analysis including 5,147 
CpG sites on 465 genes/ Illumina Infinium 
HumanMethylation 450 beadchip
1,106 CpG sites differed in 
LOAD-associated methylation 
network genes between LOAD 
and control subjects (p<0.05). 
Hypomethylation was observed 
in LOAD subjects in 87.3% of 
these CpG sites. 
Sanchez-Mut JV et al. 
2014(Sanchez-Mut et al., 
2014)
CCS/ Comparison of AD patients with 
non-AD subjects.
Spain
Discovery set: n=20, 79.7 ± 1.9
Replication set: n=50, 71,7 ± 2,1.
M and W
Discover set, 
n=15
Replication 
set, n=25
Human post-mortem 
brain tissue (grey 
matter, Brodmann 
area 9)
Illumina 27K array assay and bisulfite 
pyrosequencing 
In the discovery set, four 
CpG methylation probes 
corresponding to 3 individual 
genes showed a significant 
difference between AD-cases 
and controls (P<0.05); two 
hypermethylated CpGs in 
dual specificity phosphatase 22 
(DUSP22), 1 CpG in claudin 15 
(CLDN15) and and 1 CpG in 
quiescin Q66 sulfhydryl oxidase 
1 (QSCN6). In the replication 
set, the hypermethylation of 
DUSP22 was confirmed. 
Bernstein AI et al. 
2016(Bernstein et al., 2016)
Comparison of AD with control cases USA, n=11, 78-91, M and W 
(both discovery and replication set)
N=6 Human post-mortem 
brain tissue (frontal 
cortex)
5-methylcytosine and 5-hydroxymethylcytosine 
(5hmC)
There were 325 genes containing 
differentially hydroxymethylated 
loci (DhMLs) in both
discovery and replication 
datasets. These are enriched for 
pathways involved in neuron 
projection development and
neurogenesis.
Watson CT et al. 
2016(Watson et al., 2016)
CCS/ Comparison of AD patients with 
non-AD subjects.
USA, n=68, 66-95, M and W N=34 Bulk tissue samples 
from the superior 
temporal gyrus
461,272 autosomal CpGs / 
HumanMethylation450 platform
AOD,
gender, race, 
array/batch, 
and neuronal/
glial cell 
composition.
There were 479 differentially 
methylated regions (DMR) ( 
(increased in AD; hyper-DMRs 
= 321, hypo-DMRs = 158), with 
relevant roles in neuron function 
and development, as well as 
cellular metabolism. Top DMRs 
were close to following genes: 
MOV10L1, B3GALT4, DUSP6, 
TBX15, HLA-J, ZNRD1-AS1, 
PRDM16, ELOVL1, RIBC2, 
SMC1B, KLK7, TRIM6, 
FBRSL1, VAX2, CDH23, 
KIF25, NRG2, RNF39, 
CMYA5, TNXB, NAV2, TAP2, 
ZNF177, FLOT1
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Table 3. Specific gene methylation in Parkinson’s disease: gene and genome-wide approaches. 
Author Study design population/Age 
range/
follow-up
Cases Tissue type Methylation sites/
methods
Adjustments Main finding
Candidate gene approach
Ai SX. et al, 2014(Ai 
et al., 2014)
CCS/ Comparison between PD patients 
and neurologically healthy controls
China, n=195, 
61.8 ± 9.7 years, M 
and W
N=100 PBMCs 23 CpG sites in the SNCA gene/ Bisulphite 
pyrosequencing (Epitect Bisulfite Kite, 
Qiagen)
Other: genotyping of Rep1 (polymorphic 
dinucleotide repeat upstream of SNCA), 
rt-PCR of SNCA 
Age, gender 
and origin 
matched
Hypo-methylation
Banzhaf-Strathmann 
J et al. 2013(Banzhaf-
Strathmann et al., 
2013)
CCS/ Comparison between PD patients 
and age-matched neurologically healthy 
controls. 
Multiple countries, 
n=51, 70.5 ± 7.7 
years, M and W.
N=8 Human post-
mortem brain 
tissue (frontal 
cortex)
GRN promoter/ Sequenom MassARRAY 
platform
No difference
Cai M. et al, 2011(Cai 
et al., 2011)
CCS/ Comparison between PD patients 
(with and without heterozygous Parkin 
gene mutations) and neurologically 
healthy controls
China, n=44
Men and women
N=34 
(17 with 
heterozygous 
Parkin gene 
mutations and 
17 without)
PBMCs 33 CpG sites in the Parkin gene promoter 
region/ Bisulphite sequencing (EZ DNA 
Methylation Kit, Zymo Research). 
Age, gender 
and ethnicity 
matched
No difference
Coupland K.G. et al, 
2014(Coupland et al., 
2014)
CS Australia (n = 1442 
leukocyte samples + 
109 PD brain tissue 
DNA samples)
N=386 Leukocyte 
DNA and brain 
tissue DNA
Six CpGs in the MAPT gene. Methylation 
assessed by bisulphite pyrosequencing 
(PyroMark Q24, Qiagen)
Other: in vitro MAPT promoter 
methylation assay and Vitamin E assay
In leukocytes, 
adjustment 
for (amongst 
others) 
smoking, 
L-dopa 
medication, 
gender, 
age, MAPT 
diplotype
In brain tissue 
(cerebellum), 
adjustment 
for age, sex 
and MAPT 
diplotype
Hyper-methylation in the cerebellum. Hypo-
methylation in the putamen.
Jowaed A et. al, 
2010(Jowaed et al., 
2010)
CCS/ Comparison between PD patients 
and neurologically healthy controls
Germany, n=26, 
77,5 ± 3,8 years, M 
and W
N=12 Brain tissue 
(substantia 
nigra pars 
compacta 
(SNpc) and 
cortex and 
putamen)
Bisulphite sequencing of 23 CpG sites in the 
SNCA gene
Hypo-methylation
Song Y et al. 2014(Y. 
Song et al., 2014)
CCS/ Comparison of PD patients 
with age, gender, ethnicity and area of 
residence matched controls. 
China, n=100, 
72.26 ± 7.6 years, M 
and W
N=50 Blood 
leucocytes 
α-synuclein gene (SNCA), 13 CpGs/ 
bisulfite pyrosequencing 
No difference 
Lin Q et al. 2012(Lin 
et al., 2012)
CCS/ Comparison of PD patients with 
age and gender non-PD controls.
China, n=386, 
66.2 ± 3.4 years, M 
and W
N=206 Blood 
leucocytes
Clock genes (PER1, PER2, CRY1, CRY2, 
CLOCK, NPAS2 and BMAL1)/ bisulfite 
pyrosequencing
NAPS2: Hypo-methylation
Other genes: No difference 
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Table 3. Specific gene methylation in Parkinson’s disease: gene and genome-wide approaches. 
Author Study design population/Age 
range/
follow-up
Cases Tissue type Methylation sites/
methods
Adjustments Main finding
Candidate gene approach
Ai SX. et al, 2014(Ai 
et al., 2014)
CCS/ Comparison between PD patients 
and neurologically healthy controls
China, n=195, 
61.8 ± 9.7 years, M 
and W
N=100 PBMCs 23 CpG sites in the SNCA gene/ Bisulphite 
pyrosequencing (Epitect Bisulfite Kite, 
Qiagen)
Other: genotyping of Rep1 (polymorphic 
dinucleotide repeat upstream of SNCA), 
rt-PCR of SNCA 
Age, gender 
and origin 
matched
Hypo-methylation
Banzhaf-Strathmann 
J et al. 2013(Banzhaf-
Strathmann et al., 
2013)
CCS/ Comparison between PD patients 
and age-matched neurologically healthy 
controls. 
Multiple countries, 
n=51, 70.5 ± 7.7 
years, M and W.
N=8 Human post-
mortem brain 
tissue (frontal 
cortex)
GRN promoter/ Sequenom MassARRAY 
platform
No difference
Cai M. et al, 2011(Cai 
et al., 2011)
CCS/ Comparison between PD patients 
(with and without heterozygous Parkin 
gene mutations) and neurologically 
healthy controls
China, n=44
Men and women
N=34 
(17 with 
heterozygous 
Parkin gene 
mutations and 
17 without)
PBMCs 33 CpG sites in the Parkin gene promoter 
region/ Bisulphite sequencing (EZ DNA 
Methylation Kit, Zymo Research). 
Age, gender 
and ethnicity 
matched
No difference
Coupland K.G. et al, 
2014(Coupland et al., 
2014)
CS Australia (n = 1442 
leukocyte samples + 
109 PD brain tissue 
DNA samples)
N=386 Leukocyte 
DNA and brain 
tissue DNA
Six CpGs in the MAPT gene. Methylation 
assessed by bisulphite pyrosequencing 
(PyroMark Q24, Qiagen)
Other: in vitro MAPT promoter 
methylation assay and Vitamin E assay
In leukocytes, 
adjustment 
for (amongst 
others) 
smoking, 
L-dopa 
medication, 
gender, 
age, MAPT 
diplotype
In brain tissue 
(cerebellum), 
adjustment 
for age, sex 
and MAPT 
diplotype
Hyper-methylation in the cerebellum. Hypo-
methylation in the putamen.
Jowaed A et. al, 
2010(Jowaed et al., 
2010)
CCS/ Comparison between PD patients 
and neurologically healthy controls
Germany, n=26, 
77,5 ± 3,8 years, M 
and W
N=12 Brain tissue 
(substantia 
nigra pars 
compacta 
(SNpc) and 
cortex and 
putamen)
Bisulphite sequencing of 23 CpG sites in the 
SNCA gene
Hypo-methylation
Song Y et al. 2014(Y. 
Song et al., 2014)
CCS/ Comparison of PD patients 
with age, gender, ethnicity and area of 
residence matched controls. 
China, n=100, 
72.26 ± 7.6 years, M 
and W
N=50 Blood 
leucocytes 
α-synuclein gene (SNCA), 13 CpGs/ 
bisulfite pyrosequencing 
No difference 
Lin Q et al. 2012(Lin 
et al., 2012)
CCS/ Comparison of PD patients with 
age and gender non-PD controls.
China, n=386, 
66.2 ± 3.4 years, M 
and W
N=206 Blood 
leucocytes
Clock genes (PER1, PER2, CRY1, CRY2, 
CLOCK, NPAS2 and BMAL1)/ bisulfite 
pyrosequencing
NAPS2: Hypo-methylation
Other genes: No difference 
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Table 3. Specific gene methylation in Parkinson’s disease: gene and genome-wide approaches. (continued)
Author Study design population/Age 
range/
follow-up
Cases Tissue type Methylation sites/
methods
Adjustments Main finding
Tan Y et al. 2014(Y. Y. 
Tan et al., 2014)
CCS/ Comparison of PD patients 
with age and gender matched non-PD 
controls.
China, n=200, 65.23 
± 0.12 years, M 
and W
N=100 Blood 
leucocytes
α-synuclein gene (SNCA) (2CpGs islands, 
30 CpGs) and LRRK2 (1 CpG island, 34 
CpGs) promoter/ bisulfite Specific PCR-
based and bisulfite Specific Cloning-based
Hypo-methylation
Villar-Menendez I 
et al. 2014(Villar-
Menendez et al., 
2014)
CCS/ Comparison of PD patients with 
age matched non-PD controls.
Spain, n=19, 24-85 
years, M and W
N=7 Human 
post-mortem 
brain tissue 
(putamen)
ADORA2A, 3 CpG island, 108 CpG sites/ 
Sequenom EpiTyper MassARRAY
Hypo-methylation
Nielsen SS et al. 
2015(Searles Nielsen 
et al., 2015)
CCS/ Comparison of PD cases with 
non-PD controls.
USA, n=201, 25-65 
years, M
N=49 WB NOS2, 3CpGs/ bisulfite pyrosequencing Age, 
examiner and 
experimental 
plate
Hypo-methylation
Matsumoto L et al. 
2010(Matsumoto et 
al., 2010a)
CCS/ Comparison of PD cases with 
non-PD controls.
Japan, n=20, 57-87 
years, M and W
N=11 Human post-
mortem brain 
tissue (anterior 
cingulate, 
putamen and 
substantia 
nigra) 
α-synuclein gene (SNCA), CpG-2 / bisulfite 
sequencing
Hypo-methylation
Tan Y et al. 2016(Y. 
Tan et al., 2016)
CCS/ Comparison of PD cases with 
non-PD controls.
China, n=80, 62.5 ± 
7.8, M and W
N=40 Peripheral 
blood
leukocytes
DJ-1, 2 CpGs / bisulfite sequencing Age No difference
Su X et al. 2015(Su et 
al., 2015)
CCS/ Comparison of PD cases with 
non-PD controls.
USA, n=20, 78.3 ± 
8.1, M and W
N=10 Substantia nigra Peroxisome proliferator-activated receptor 
gamma coactivator−1 α (PGC−1α)/ bisulfite 
sequencing
Age Hypermethylated 
Schmitt I et al. 2015(I. 
Schmitt et al., 2015)
CCS/ Comparison of PD cases with 
non-PD controls.
Germany, n=975, 
64.6 ± 9.6, M and W
N=490 PB α-synuclein Not clear Hypomethylated
Genome-wide approach
Kaut O. et al, 
2012(Kaut et al., 
2012)
Case control study/ Comparison 
between PD patients and neurologically 
healthy controls
Germany, n=18, 
78,6 ± 10,1 years, M 
and W 
N=6 Brain tissue 
(cortex and 
putamen)
Genome-wide methylation. 17,500 
individual CpG sites from 14,495 genes
(EZ DNA Methylation Gold Kit 
(Zymo Research) and Illumina Human-
Methylation27 BeadChip). 
In both cortex and putamen of PD patients, CYP2E1 
was hypomethylated (Mean β-value: 0.37 ±0.27 
(control) vs. 0.07±0.06 (PD), p=0.04 and 0.48±0.17 
(control) vs 0.07±0.01 (PD), p=0.0005 respectively). 
This difference remained when the analysis was 
stratified by gender.
In the cortex of PD patients, the gene PPP4R2 was 
hypomethylated (0.50±0.30 (control) vs. 0.32±0.05 
(PD), p=0.02) in comparison to controls. In the 
putamen of PD patients, the gene MGC 3207 was 
hypomethylated when compare to controls(0.47 ±0.22 
(control) vs. 0.16±0.13 (PD), p=0.02)..
In the putamen of PD patients, DEFA1 and CHFR 
were hypermethylated. 
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Table 3. Specific gene methylation in Parkinson’s disease: gene and genome-wide approaches. (continued)
Author Study design population/Age 
range/
follow-up
Cases Tissue type Methylation sites/
methods
Adjustments Main finding
Tan Y et al. 2014(Y. Y. 
Tan et al., 2014)
CCS/ Comparison of PD patients 
with age and gender matched non-PD 
controls.
China, n=200, 65.23 
± 0.12 years, M 
and W
N=100 Blood 
leucocytes
α-synuclein gene (SNCA) (2CpGs islands, 
30 CpGs) and LRRK2 (1 CpG island, 34 
CpGs) promoter/ bisulfite Specific PCR-
based and bisulfite Specific Cloning-based
Hypo-methylation
Villar-Menendez I 
et al. 2014(Villar-
Menendez et al., 
2014)
CCS/ Comparison of PD patients with 
age matched non-PD controls.
Spain, n=19, 24-85 
years, M and W
N=7 Human 
post-mortem 
brain tissue 
(putamen)
ADORA2A, 3 CpG island, 108 CpG sites/ 
Sequenom EpiTyper MassARRAY
Hypo-methylation
Nielsen SS et al. 
2015(Searles Nielsen 
et al., 2015)
CCS/ Comparison of PD cases with 
non-PD controls.
USA, n=201, 25-65 
years, M
N=49 WB NOS2, 3CpGs/ bisulfite pyrosequencing Age, 
examiner and 
experimental 
plate
Hypo-methylation
Matsumoto L et al. 
2010(Matsumoto et 
al., 2010a)
CCS/ Comparison of PD cases with 
non-PD controls.
Japan, n=20, 57-87 
years, M and W
N=11 Human post-
mortem brain 
tissue (anterior 
cingulate, 
putamen and 
substantia 
nigra) 
α-synuclein gene (SNCA), CpG-2 / bisulfite 
sequencing
Hypo-methylation
Tan Y et al. 2016(Y. 
Tan et al., 2016)
CCS/ Comparison of PD cases with 
non-PD controls.
China, n=80, 62.5 ± 
7.8, M and W
N=40 Peripheral 
blood
leukocytes
DJ-1, 2 CpGs / bisulfite sequencing Age No difference
Su X et al. 2015(Su et 
al., 2015)
CCS/ Comparison of PD cases with 
non-PD controls.
USA, n=20, 78.3 ± 
8.1, M and W
N=10 Substantia nigra Peroxisome proliferator-activated receptor 
gamma coactivator−1 α (PGC−1α)/ bisulfite 
sequencing
Age Hypermethylated 
Schmitt I et al. 2015(I. 
Schmitt et al., 2015)
CCS/ Comparison of PD cases with 
non-PD controls.
Germany, n=975, 
64.6 ± 9.6, M and W
N=490 PB α-synuclein Not clear Hypomethylated
Genome-wide approach
Kaut O. et al, 
2012(Kaut et al., 
2012)
Case control study/ Comparison 
between PD patients and neurologically 
healthy controls
Germany, n=18, 
78,6 ± 10,1 years, M 
and W 
N=6 Brain tissue 
(cortex and 
putamen)
Genome-wide methylation. 17,500 
individual CpG sites from 14,495 genes
(EZ DNA Methylation Gold Kit 
(Zymo Research) and Illumina Human-
Methylation27 BeadChip). 
In both cortex and putamen of PD patients, CYP2E1 
was hypomethylated (Mean β-value: 0.37 ±0.27 
(control) vs. 0.07±0.06 (PD), p=0.04 and 0.48±0.17 
(control) vs 0.07±0.01 (PD), p=0.0005 respectively). 
This difference remained when the analysis was 
stratified by gender.
In the cortex of PD patients, the gene PPP4R2 was 
hypomethylated (0.50±0.30 (control) vs. 0.32±0.05 
(PD), p=0.02) in comparison to controls. In the 
putamen of PD patients, the gene MGC 3207 was 
hypomethylated when compare to controls(0.47 ±0.22 
(control) vs. 0.16±0.13 (PD), p=0.02)..
In the putamen of PD patients, DEFA1 and CHFR 
were hypermethylated. 
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Table 3. Specific gene methylation in Parkinson’s disease: gene and genome-wide approaches. (continued)
Author Study design population/Age 
range/
follow-up
Cases Tissue type Methylation sites/
methods
Adjustments Main finding
Masliah E et al. 
2013(Masliah et al., 
2013)
Genome-wide DNA methylation 
Case control study/ Comparison of PD 
cases with age matched non-PD controls.
USA (n=11) ND
Men and women
N=5 Human post-
mortem brain 
tissue (frontal 
cortex) and 
PBL
485386 CpG/ HumanMethylation 450k 
BeadChip (Illumina # WG-314-1003)
2908 CpG - 174 genes (317 hypermethylated-84 
genes and 2591 – 233 genes hypomethylated-90 
genes) in the brain and 3897 CpG (476 
hypermethylated-127 genes and 3421 
hypomethylated-106 genes) in the blood of PD cases 
were differentially methylated compared to controls. 
30% (124/407) of the total autosomal annotated 
genes differentially methylated presented concordant 
changes in methylation between blood and brain 
(63 loci with increased methylation and 61 with 
decreased methylation), suggesting that a number of 
methylation changes in PD is shared between brain 
and blood, positioning these 124 genes that co-varied 
among tissues as candidates for biomarker discovery. 
Top 30 loci: hypermethylated in PD: KCTD5, VAV2, 
MOG, TRIM10, HLA-DQA1, ARHGEF10, GFPT2, 
HLA-DRB5, TMEM9, MRI1, MAPT, HLA-DRB6, 
MAPT, HLA-DRB6, LASS3, GSTTP2 and GSTTP1; 
Hypomethylated in PD: DNAJA3, JAKMIP3, FRK, 
LRRC27, DMBX1, LGALS7, FOXK1, APBA1, 
MAG12, APBA1, SLC25A24, GSTT1, MYOM2, 
MIR886, TUBA3E and TMCO3. Gene ontology 
analysis showed that same functional groups were 
affected in brain and blood, with cell communication 
and cellular and metabolic processes being the more 
populated clusters, and including genes related to 
apoptosis, a molecular pathway largely implicated in 
PD. 
Overall methylation patterns of the brain and blood 
were similar, with more than 80% of the sites reported 
as differentially methylated being hypomethylated. 
While there were no differences between brain and 
blood in CpGs clustering in low-methylated fraction, 
there were more CpGs in the high-methylated fraction 
in PD blood in comparison to control subject’s blood 
and also to PD brains (P<0.001). 
CpG neighbourhood context analysis and genomic 
location distribution was comparable between 
brain and blood samples and showed that loci with 
decreased methylation were more likely to locate at 
CG islands and associated with promoter regions 
including TSS1500, TSS200 and 1st exon sites; while 
CpG sites located further away from islands (open 
sea) and at the gene bodies were more likely to present 
increased methylation.
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Table 3. Specific gene methylation in Parkinson’s disease: gene and genome-wide approaches. (continued)
Author Study design population/Age 
range/
follow-up
Cases Tissue type Methylation sites/
methods
Adjustments Main finding
Masliah E et al. 
2013(Masliah et al., 
2013)
Genome-wide DNA methylation 
Case control study/ Comparison of PD 
cases with age matched non-PD controls.
USA (n=11) ND
Men and women
N=5 Human post-
mortem brain 
tissue (frontal 
cortex) and 
PBL
485386 CpG/ HumanMethylation 450k 
BeadChip (Illumina # WG-314-1003)
2908 CpG - 174 genes (317 hypermethylated-84 
genes and 2591 – 233 genes hypomethylated-90 
genes) in the brain and 3897 CpG (476 
hypermethylated-127 genes and 3421 
hypomethylated-106 genes) in the blood of PD cases 
were differentially methylated compared to controls. 
30% (124/407) of the total autosomal annotated 
genes differentially methylated presented concordant 
changes in methylation between blood and brain 
(63 loci with increased methylation and 61 with 
decreased methylation), suggesting that a number of 
methylation changes in PD is shared between brain 
and blood, positioning these 124 genes that co-varied 
among tissues as candidates for biomarker discovery. 
Top 30 loci: hypermethylated in PD: KCTD5, VAV2, 
MOG, TRIM10, HLA-DQA1, ARHGEF10, GFPT2, 
HLA-DRB5, TMEM9, MRI1, MAPT, HLA-DRB6, 
MAPT, HLA-DRB6, LASS3, GSTTP2 and GSTTP1; 
Hypomethylated in PD: DNAJA3, JAKMIP3, FRK, 
LRRC27, DMBX1, LGALS7, FOXK1, APBA1, 
MAG12, APBA1, SLC25A24, GSTT1, MYOM2, 
MIR886, TUBA3E and TMCO3. Gene ontology 
analysis showed that same functional groups were 
affected in brain and blood, with cell communication 
and cellular and metabolic processes being the more 
populated clusters, and including genes related to 
apoptosis, a molecular pathway largely implicated in 
PD. 
Overall methylation patterns of the brain and blood 
were similar, with more than 80% of the sites reported 
as differentially methylated being hypomethylated. 
While there were no differences between brain and 
blood in CpGs clustering in low-methylated fraction, 
there were more CpGs in the high-methylated fraction 
in PD blood in comparison to control subject’s blood 
and also to PD brains (P<0.001). 
CpG neighbourhood context analysis and genomic 
location distribution was comparable between 
brain and blood samples and showed that loci with 
decreased methylation were more likely to locate at 
CG islands and associated with promoter regions 
including TSS1500, TSS200 and 1st exon sites; while 
CpG sites located further away from islands (open 
sea) and at the gene bodies were more likely to present 
increased methylation.
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in neurogenesis, neuronal projection development and regulation of neuron differentiation, as well as 
β-amyloid and tau metabolism.
(ii) Parkinson’s disease
Two studies conducted an epigenome-wide association study approach for PD. One study reported 
hypomethylation of CYP2E1, PPP4R2 and MGC3207 and hypermethylation of DEFA1 and CHFR in 
the putamen and cortex of PD cases compared to controls (Kaut, Schmitt, & Wullner, 2012). Another 
study (Masliah, Dumaop, Galasko, & Desplats, 2013) found 2908 CpGs (317 hypermethylated and 
2591 hypomethylated) in the brain tissue and 2897 CpGs (476 hypermethylated and 3421 hypometh-
ylated) in the blood cells of PD patients to be differentially methylated compared to controls. The study 
found that 30% of the differentially methylated sites presented concordant changes in methylation 
between blood and brain. The identified genes were enriched for genes (known from genome-wide 
association studies) with epigenetic changes in biological pathways relevant to PD-development, such 
as cell communication and apoptosis (Table 3). 
histone Modifications and Neurodegenerative disorders
(i) Alzheimer’s disease
Five studies (Anderson & Turko, 2015; Narayan, Lill, Faull, Curtis, & Dragunow, 2015; Plagg, Ehrlich, 
Kniewallner, Marksteiner, & Humpel, 2015; Rao et al., 2012; Zhang et al., 2012) examined histone 
modification in relation to AD. There were no consistent findings on the role of H3 or H4 acetylation 
in AD (Table 1). However, one of the studies (Rao et al., 2012) showed increased H3 phosphorylation 
in AD brains compared to age-matched controls (Table 1). 
(ii) Parkinson’s disease
There were two studies (Gebremedhin & Rademacher, 2016; Park et al., 2016) examining the role of 
histone modifications in PD. They mainly showed an increase in levels of histone acetylation in PD 
patients. 
DiSCuSSiON 
We have systematically reviewed the current knowledge about epigenetic associations with Al-
zheimer’s disease (AD) and Parkinson’s disease (PD). There is some evidence that DNA methylation 
may be related to the risk of neurological disease. Among gene-specific studies, DNA methylation 
at 24 genes was found to be associated with AD, while 7 genes were differentially methylated in PD.
The present review finds inconsistent associations between global DNA methylation and AD. 
These results are in line with previous studies showing contradictory results when studying the 
relationship between global DNA methylation and other health outcomes, including cardiovascular 
disease and diabetes (M. Kim et al., 2010; Luttmer et al., 2013; Muka, Koromani, et al., 2016; Muka, 
Nano, et al., 2016; Ribel-Madsen et al., 2012; P. Sharma et al., 2008; Wei et al., 2014). The use of dif-
ferent methods for assessing global DNA methylation, including the 5-methylcytosine ratio and the 
methylation of LINE-1 and Alu repeat elements, may account for some of these differences. LINE-1 
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and Alu repeat elements are used as a measure of global DNA methylation due to their ubiquitous 
presence in the genome. However, as they may have different functions, the resulting differences in 
methylation may explain some of the conflicting results (Nelson, Marsit, & Kelsey, 2011). DNA meth-
ylation at Alu is about one-third to one-fourth of methylation at LINE-1. The difference may suggest 
that epigenetic changes at LINE-1 and Alu measure different traits (Nelson et al., 2011). Global DNA 
methylation assessed by LUMA modestly correlates with LINE-1 methylation, suggesting that the 
differences in the reported results may come from the assay used to assess global DNA methylation 
(Terry, Delgado-Cruzata, Vin-Raviv, Wu, & Santella, 2011). Furthermore, as different tissue types 
(brain tissue or peripheral blood samples) are assessed between studies, tissue-specific DNA methyla-
tion patterns may partially explain the heterogeneous findings. Even within studies performed on 
brain tissue, samples are obtained from different areas of the brain, including cortical, cerebellar, and 
hippocampal tissue. This difference may limit comparability of the results as specific brain regions 
comprise different cell populations (astrocytes, neurons, microglia, oligodendrocytes). Furthermore, 
the same methylation pattern, depending on its position toward coding gene, can have different ef-
fects (Aran, Toperoff, Rosenberg, & Hellman, 2011; Jones, 2012). Therefore, global DNA methylation 
provides an oversimplified assessment of epigenetic dysregulation, as it neither quantitatively nor 
qualitatively acknowledges the co-existence of hypo- and hypermethylation within a gene or distinct 
genes within the same cell. 
In our review, several genes were found to be differentially methylated in brain tissue or peripheral 
blood of AD patients when compared to controls. In particular, brain derived neurotrophic factor 
(BDNF) and SORBS3 were each found in two different studies to be significantly more methylated in 
AD patients than in controls. These results parallel previous studies showing an association between 
BDNF hypermethylation in blood and depression, depressive symptoms and antidepressants response 
(Januar, Saffery, & Ryan, 2015). Similarly, previous studies have reported hypermethylation of BDNF 
and of its receptor (Tropomyosin-Related Kinase B) in brains of individuals who have committed 
suicide (Ernst et al., 2009; Keller et al., 2010). BDNF is a secretory protein with neuroprotective ef-
fects (Nagahara et al., 2009) which has been shown to be associated with neurodegenerative diseases, 
including AD, PD and Huntington’s disease (Zuccato & Cattaneo, 2009). BDNF was shown to be 
hypermethylated in the peripheral blood of AD patients compared to controls, indicative of decreased 
expression of BDNF. This is consistent with findings in brain tissue of patients diagnosed postmortem 
with AD (Rao et al., 2012) and with other studies showing that BDNF promoter methylation is related 
to BDNF mRNA expression (Keller et al., 2010). As BDNF is able to cross the blood-brain barrier (Pan, 
Banks, Fasold, Bluth, & Kastin, 1998), DNA methylation in the peripheral tissue may exert effects on 
neuronal tissue and vice versa, highlighting the potential utility of peripheral BDNF methylation as 
a biomarker for AD. This is supported by the overlap of epigenetic changes in both AD-brain tissue 
and peripheral blood reported in this review. SORBS3 is involved in neuronal signaling (Ito et al., 
2007) and regulation of gene expression (Matsuyama et al., 2005), and was found in two studies to be 
hypermethylated in the frontal cortex of AD patients. However, its role in the pathogenesis of AD and 
whether methylation of SORBS3 is consistent across tissue types remains to be investigated. 
Also, genes of proteins implicated in AD pathogenesis, such as CREB, were differentially meth-
ylated in PD, but the evidence is too limited to draw a firm conclusion. AD is associated with a 
reduction of CREB activation. CREB is a histone acetyltransferase that functions as a co-activator 
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that catalyzes histone acetylation, causing a decrease in the transcription of memory-associated 
genes, and therefore, leading to memory impairment (Teich et al., 2015). Treatment targeting the 
transcription machinery interacting with CREB during memory formation has been suggested to 
be a useful strategy for treating AD (Teich et al., 2015). Furthermore, genes of proteins such as death 
receptor 4 (DR4) and NF-ĸB are involved in processes that may play a role in the pathogenesis of AD 
such as apopotosis and/or inflammation. DR4 and NF-ĸB genes were reported to be differentially 
methylated in AD cases (Edgunlu, Ozge, Yalin, Kul, & Erdal, 2013; Granic, Dolga, Nijholt, van Dijk, 
& Eisel, 2009). DR4 might impair the apoptotic signal transduction and may cause apoptosis of brain 
cells(Edgunlu et al., 2013). Polymorphisms of the DR4 gene have been shown to influence susceptibil-
ity to AD (Edgunlu et al., 2013). NF-ĸB activation is a common feature of many neurodegenerative 
diseases, particularly of AD (Granic et al., 2009). Activation of NF-ĸB leads to the expression of a 
large variety of pro-inflammatory molecules such as cytokines and chemokines, which could be in 
part responsible for the neurotoxicity seen in AD (Granic et al., 2009). The interaction of methylation 
of these genes with molecular pathways and how this affects risk of AD remains to be elucidated. 
In PD patients, SNCA was consistently found to be hypomethylated in both peripheral blood 
cells and brain tissue. Known to be a causative gene of familial PD (Shulman, De Jager, & Feany, 
2011), the overexpression of SNCA in sporadic PD cases (Chiba-Falek, Lopez, & Nussbaum, 2006; 
Grundemann, Schlaudraff, Haeckel, & Liss, 2008; Grundemann, Schlaudraff, & Liss, 2011) suggests 
a role in the pathogenesis of sporadic PD as well. The finding that SNCA is similarly hypomethylated 
in both peripheral blood and in brain tissues is in line with previous studies and indicates it may be 
useful as a biomarker in sporadic PD. 
Also, several other genes involved in the pathogenesis of PD were reported to be differentially 
methylated in PD cases, including NOS2 (hypomethylated), ADORA2A (hypomethylated), and 
CYP2E1 (hypomethylated). NOS2, the gene coding for inducible nitric oxide synthase (iNOS) is 
primarily regulated at the transcriptional level, at least partially via DNA methylation (Chan et al., 
2005). Hypomethylation of CpG sites in the 5′ promoter region of the gene might increase iNOS 
expression (Chan et al., 2005). Increased iNOS expression in turn promotes inflammation and may 
lead to PD (Aquilano, Baldelli, Rotilio, & Ciriolo, 2008). In line with this evidence, a selective iNOS 
inhibitor, GW274150 ([2-[(1-iminoethyl) amino] ethyl]-L-homocysteine) has been reported to have 
a neuroprotective effect in a model of PD (Broom et al., 2011). ADORA2A is the gene coding for 
adenosine A2A receptor (A2AR), which is highly expressed in the striatum. ADORA2A polymor-
phisms have been inversely associated with PD risk (Popat et al., 2011). Also, A2AR antagonists are 
effective in relieving parkinsonian motor symptoms and have been suggested as potential new drugs 
for PD treatment (Armentero et al., 2011). CYP2E1 codes for Cytochrome P450 2E1, a member of 
the Cytochrome P450 enzyme family, which represent a major part of the cellular defense against 
xenobiotic exposure and have been implicated in PD pathophysiology since the mid-1980s (Riedl, 
Watts, Jenner, & Marsden, 1998). Decreased methylation of CYP2E1 is related to increased expression 
of CYP2E1 messenger RNA in PD patients (Kaut et al., 2012). Enhanced CYP2E1 activity has been 
suggested to contribute to dopaminergic neurodegeneration in PD (Riedl et al., 1998; Viaggi, Vaglini, 
Pardini, Caramelli, & Corsini, 2009). 
This review demonstrated that while epigenetic changes in AD and PD patients have been inves-
tigated via global methylation and gene-specific methylation studies, findings are lacking regarding 
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histone modification. Histone modifications are another epigenetic mark that play a pivotal role in 
the epigenetic regulation of transcription and other functions in cells, including neurons (Graff, Kim, 
Dobbin, & Tsai, 2011). Posttranslational histone modifications interfere with the transcriptional pro-
gram inducing long-lasting phenotypic changes in neural plasticity including learning and memory 
(Peleg et al., 2010; M. Schmitt & Matthies, 1979). Many enzymes are involved in the regulation of 
histones including processes such as acetylation, methylation, phosphorylation, sumoylation and 
ubiquitination, which may play important roles in the pathogenesis of ND (C. Song, Kanthasamy, 
Anantharam, Sun, & Kanthasamy, 2010). Histone deacetylases (HDACs) has been reported to be ac-
tive in these processes. Valproic acid, an inhibitor of HDACs, demonstrates neuroprotection against 
rotenone in a rat model of PD (Monti et al., 2010). Also in AD and PD animal models, histone 
acetylation has been linked to neurodegeneration (Francis et al., 2009; C. Song et al., 2010). One 
study in Huntington’s disease patients found that most of the identified histone modifications in the 
brain are associated with genes that have known roles in neuronal signaling (Bai et al., 2015). Those 
findings suggest that histone modifications may be a relevant form of epigenetic change in patients 
of neurological diseases. Therefore, much information may still be gained from histone modification 
studies in AD or PD patients. 
The strengths and limitations of the findings from this review merit careful consideration. The 
present report involves data from nearly 11,453 individuals. It is the first systematic review on the 
subject that has critically appraised the literature following an a priori designed protocol with clearly 
defined inclusion and exclusion criteria. Using a systemic search in medical databases, few reviews 
evaluating the role of epigenetics marks in AD and PD were found (Coppede, 2014; Lardenoije et al., 
2015; Wullner, Kaut, deBoni, Piston, & Schmitt, 2016). Existing reviews were all narrative reviews 
(not performed systematically). Narrative reviews do not involve a systemic search and they are 
often focused on a subset of studies in the chosen area based on availability of the author selection. 
Therefore, they are more likely to experience selection bias. A number of limitations, however, need 
to be considered. The majority of studies included in our systematic review are cross-sectional as-
sessments, making it difficult to draw conclusions on causality. Also, studies investigating epigenetic 
dysregulation in neurological diseases suffer from small sample size, the consequences of which 
include reduced statistical power and increased false discovery rates. In addition, although most of 
the epigenetic studies included in this review adjusted for age and sex and sampled from an ethnically 
homogenous population, a number of analyses are lacking adjustment for lifestyle and environmental 
factors. Factors including smoking and alcohol consumption are important risk factors for neurologi-
cal disorders and can alter epigenetic mechanisms. Furthermore, when assessing epigenetic modifica-
tions, studies used different techniques, which may produce heterogeneous results. Also, genetically, 
AD and PD are usually divided into familial cases with Mendelian inheritance and sporadic cases 
with no familial aggregation (Piaceri, Nacmias, & Sorbi, 2013). The sporadic form is more complex 
and likely results from a combination of genetic and environmental influences. Therefore, examin-
ing whether epigenetic marks may have different role in the etiology of AD and PD types would 
be interesting (Piaceri et al., 2013). Most of the studies included in this review used post-mortem 
brain tissue, which can help to provide several insights about the nature of epigenetic medications in 
relation to neurodegenerative diseases, but can also present several limitations. Using post-mortem 
brain is problematic with respect to temporality between exposure and outcome(Harrison, 2011). 
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Second, untangling real effects from confounders (such as medications) can be challenging. Lastly, 
death often involves acidosis, which can alter genetic material, increasing the likelihood of misclas-
sifying epigenetic modification and increasing the chances of spurious findings (Tomita et al., 2004; 
Vawter et al., 2006). 
CONCLuSiON 
Overall, the findings from this review indicate that there are significant epigenetic differences be-
tween patients with neurodegenerative diseases and healthy individuals. Furthermore, candidate 
gene studies have shown that some genes known to play a role in maintenance and function of 
neurological tissues are differentially methylated in diseased individuals. In addition, a number of 
these genes, such as BDNF in AD patients and SNCA in PD patients, are similarly methylated in blood 
and brain tissue. Along the same lines, Epigenetic Wide Association Studies show that differentially 
methylated sites in neurological disorders present concordant changes in methylation between blood 
and brain. These data suggest that studies in peripheral blood can provide valuable information on 
the neuronal epigenetic changes and their consequences on cell function. Therefore, methylation 
profiling in peripheral blood to identify neurological disorders-related methylated regions has a high 
potential clinical utility. It may allow clinicians to identify high-risk individuals who may benefit 
from preventive and therapeutic interventions. However, due to the mostly cross-sectional design 
of included studies and lack of replication in the case of new findings, there remain many questions 
about the temporal relation between epigenetic modifications and neurological diseases, as well as 
the significance of the findings in disease pathology. Also, given the reversible nature of epigenetic 
aberrations, targeting the epigenome can be a novel preventive strategy and treatment for AD and 
PD. There is evidence showing that methyl donors such as folate and vitamin B12 may affect DNA 
methylation and the risk for several neurodegenerative conditions, including AD and PD (Clarke 
et al., 1998; Luchsinger, Tang, Miller, Green, & Mayeux, 2007). Studies from animal studies show 
that histone deacetylase inhibitors lowers Aβ levels and improves learning and memory in a mouse 
model of Alzheimer’s disease. Those findings provide support that histone deacetylase inhibitors may 
serve as a novel therapeutic strategy for AD (Sung et al., 2013). Epigenetic therapy has been shown 
to successfully reverse several epigenetics marks and disease symptoms and have been approved by 
the FDA for use in cancer (S. Sharma, Kelly, & Jones, 2010). Therefore, studies in larger cohorts with 
longitudinal design may help to close the gap on identifying epigenetic changes that have clinical 
significance and could lead to strategies for intervention in neurological diseases. 
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AbSTrACT 
Females have unique and additional risk factors for neurological disorders. Among classical estrogen 
receptors, estrogen receptor beta (ERβ) has been suggested as a therapeutic target. However, little is 
known about the role of ERβ in the female brain. Six electronic databases were searched for articles 
evaluating the role of ERβ in the female brain and the influence of age and menopause on ERβ func-
tion. After screening 3186 titles and abstracts, 49 articles were included in the review, all of which 
were animal studies. Of these, 19 focused on cellular signalling, 7 on neuroendocrine pathways, 8 
on neurological disorders, 4 on neuroprotection and 19 on psychological and psychiatric outcomes 
(6 studies evaluated two or more outcomes). Our findings showed that ERβ phosphorylated and 
activated intracellular second messenger proteins and regulated protein expression of genes involved 
in neurological functions. It also promoted neurogenesis, modulated the neuroendocrine regulation 
of stress response, conferred neuroprotection against ischemia and inflammation, and reduced anxi-
ety- and depression-like behaviours. Targeting ERβ may constitute a novel treatment for menopausal 
symptoms, including anxiety, depression, and neurological diseases. However, to establish potential 
therapeutic and preventive strategies targeting ERβ, future studies should be conducted in humans to 
further our understanding of the importance of ERβ in women’s mental and cognitive health.
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iNTrODuCTiON
Non-communicable diseases including neurological disorders constitute a significant and increasing 
public health problem (Epstein, Fischer-Elber, & Al-Otaiba, 2007). The global burden of disease due 
to neurological disorders, measured in disability-adjusted life years, is expected to increase to 103 
million DALYs in the next fifteen years; an approximate 10% increase from today’s values (Epstein 
et al., 2007). The highest prevalence of many of the most common neurological disorders, including 
stroke, dementia, Parkinson’s disease, and depression are found in the female population (Hofman, de 
Jong, van Duijn, & Breteler, 2006). Women are more prone to neurological disorders due to additional 
and unique risk factors: hypercoagulable states in relation to pregnancy and hormonal contracep-
tives, as well as longer lifespan predispose women to Alzheimer’s disease (AD) and stroke (O’Neal, 
2013). In addition, postmenopausal women lose the protective anti-inflammatory effects previously 
conferred by estrogen, and replenishment of the hypoestrogenic state through hormonal replacement 
therapy seems to be insufficient.(O’Neal, 2013) Estrogen, including estradiol, has many physiological 
roles in the body and brain, all of which are mediated by its receptors. A newly-discovered estrogen 
receptor beta (ERβ) has been found to be widely distributed throughout the brain (Sugiyama, Barros, 
Warner, & Gustafsson, 2010). Consequently, high expression of ERβ in certain regions such as the 
hippocampus, amygdala, and dorsal raphe nucleus has raised the question of whether these estrogenic 
receptors could be used as novel therapeutic agents against common neurological and behavioral 
disorders (Sugiyama et al., 2010). However, the definitive role of ERβ and its mechanism of action in 
estradiol-regulated brain areas remain to be further elucidated. 
We conducted a systematic review of all the available evidence evaluating the function of ERβ in 
the female brain and the role of age and menopause on ERβ actions. 
METhODS
2.1 Literature Search 
This review was conducted using a predefined protocol and was conducted in accordance with the 
PRISMA and MOOSE guidelines (eAppendix 1 and 2). Six electronic databases (Medline, Embase, 
Web of Science, PubMed, Cochrane and Google Scholar) were searched until September 17th 2015 
(date last searched) without any language or study design restriction, with the help of an experienced 
medical information specialist (WMB). The search strategy combined terms related to exposure (e.g., 
estrogen receptor beta) and outcome (e.g., nervous system, mental function, depression, AD, Parkin-
son’s disease, cognition). In databases where a thesaurus was available (Embase and Medline), articles 
were searched by thesaurus terms and in title and / or abstract. In other databases, they were searched 
only by title and / or abstract. The full search strategies of all databases are provided in eAppendix 3. 
In total, we identified 3186 potentially relevant citations.
2.2 Study Selection and inclusion Criteria
We included studies that evaluated the function of ERβ in the female brain on at least one of the 
following outcomes: 1) cellular signaling, including metabolic regulation, regulation of gene expres-
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sion in the brain, posttranslational modification, and neurogenesis; 2) neuroendocrine pathways, 
i.e., hypothalamic-pituitary-adrenal axis; 3) neurological outcomes, such as hippocampal-dependent 
learning tasks or memory; 4) neuroprotection, including protection against neuroinflammation, 
and finally; 5) psychological and psychiatric disorders including cognitive function, anxiety-related 
behavior, aggression, pain, emotions and sexual dysfunction, depression, AD and Parkinson’s disease. 
We considered studies that assessed the function of ERβ via its gene deletion, use of ERβ ligand, for 
example, diarylpropionitrile (DPN), antibodies/vectors or its expression levels. Studies performed 
either in female animals or adult humans were also included. We excluded conference abstracts, nar-
rative reviews, studies evaluating the localization of ERβ only, as well as studies that assessed ERβ 
function in tissues other than the brain. Furthermore, we excluded studies that did not report the sex 
of participants or that did not show sex-specific results when both males and females were included.
Two independent reviewers screened the retrieved titles and abstracts and selected eligible stud-
ies. Any disagreements were discussed and resolved by consensus with the participation of a third 
investigator. Full texts were retrieved for studies that satisfied all selection criteria. 
2.3 Data Extraction
Two reviewers (KGV and AZ) independently performed the extraction of the data. A predesigned 
extraction form was used to collect relevant information from the selected full-text articles, including 
lead author, year of publication, sample type, sex, age, and number of participants, menopausal status, 
brain region involved, method used to assess ERβ function, outcome measures, and results of each 
study. In case of disagreement, a decision was made through consensus or consultation with a third 
independent reviewer (TM). 
2.4 Outcome Assessment
For each animal study, we defined whether a positive (enhanced), negative (decreased), or null ef-
fect was reported. For population-based studies, we reported the effect magnitude, direction and 
significance.
rESuLTS
A total of 3186 potentially relevant citations were identified (Figure 1). After removing duplicates and 
excluding studies by titles and abstracts, 141 articles were retrieved for detailed assessment. Of these, 
92 did not meet our selection criteria. Thus, 49 were included in our analysis. 
3.1 General Characteristics of the included Studies
General characteristics of the included studies are reported in Table 1. All studies were performed 
in animal models (24 used tissues from mice, 24 from rats and 1 used combined tissue from both 
mice and rats). Of the included studies, 19 focused on the function of ERß on cellular signaling, 7 
focused on the neuroendocrine pathway, 4 studied whether neuroprotection was conferred, 8 dealt 
with neurological outcomes and 19 with psychological and psychiatric outcomes. Six studies evalu-
ated and reported results on two or more major outcomes (Benmansour, Adeniji, Privratsky, & Frazer, 
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2015; Clark et al., 2012; Kudwa, McGivern, & Handa, 2014; Liu et al., 2008; Raval, Borges-Garcia, 
Javier Moreno, Perez-Pinzon, & Bramlett, 2013; Rossi et al., 2010). 
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figure 1 Flowchart of studies investigating the function of estrogen receptor beta in the female brain
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Table 1. General Characteristics of the Animal Studies Included in this Review
No. Author Animal Type N Age Assessment of Erβ function Tissue Outcome
1 (Abraham et 
al., 2003)
Mice ND 40–54 days Gene deletion,
estradiol (E2)
GnRH neurons in medial septum , rostral preoptic area, 
and anterior hypothalamus
Cellular signaling 
2 (Abraham et 
al., 2004)
Mice ND ND Gene deletion; 
17-ß-estradiol
Medial preoptic nucleus; medial septum;; caudate-
putamen; the retrosplenial granulate
cortex
Cellular signaling: phosphorylation; rapid intracellular 
signaling
3 (Bansal & 
Chopra, 2015)
Rats (Sprague-
Dawley)
8-12 ND DPN NA Psychological and psychiatric (depression-like and 
memory impairment)
4 (Bastos et al., 
2015)
C57BL/6 mice ND 8-12 weeks DPN, E2 Hippocampus Psychological and psychiatric (depression-like and non-
spatial memory)
5 (Benmansour 
et al., 2014)
Sprague–Dawley 
rats
ND ND DPN,
E2
CA3 region of the hippocampus Psychological outcomes (mood)
6 (Benmansour 
et al., 2015)
Sprague–Dawley 
rats
12-28 4 months DPN Hippocampus Cellular signaling: 
Psychological and psychiatric outcomes (depression-like)
7 (Bosch et al., 
2009)
Mice ND ND Gene deletion,
E2
Hypothalamic nuclei and pituitary calcium channel 
subunit: Cav3.1
Neuroendocrine pathway: excitability of hypothalamic 
neurons and modulation of pituitary
secretion
8 (Boulware et 
al., 2005) 
Rat pups ND 1- to 2-days-
old rat pups 
DPN,
17 E- 1 
CA3–CA1 Hippocampal pyramidal neurons Cellular signaling: CREB phosphorylation 
9 (Boulware et 
al., 2013)
C57BL/6 mice ND 8–12 weeks 
of age 
DPN,
E2,
novel object recognition and object placement 
behavioral tests 
Dorsal hippocampus Neurological outcomes: (hippocampal memory 
consolidation)
 
10 (C. M. Brown 
et al., 2010)
Mice ND 10–15 weeks 
of age
Gene deletion, E2, cytokine/chemokine 
quantification.
Cortex and
striatum
Neuroprotection: anti-inflammatory effects (mediation of 
neuroinflammatory response) 
11 (Carswell et al., 
2004)
 C57BL/6J mice 44 3 months of 
age
DPN Caudate nucleus and dorsal
hippocampus
Neuroprotection 
12 (Cheong et al., 
2012)
Mice ND 2–3 months Gene deletion,
17-ß-estradiol
GnRH neurons from medial septum (MS) to the anterior
hypothalamic area
Cellular signaling 
13 (Choleris et al., 
2003)
Mice 89 3–5 months 
old
Gene deletion,
social recognition paradigm (tests) and 
behavioral analysis.
NA Psychological outcomes: social recognition and anxiety 
14 (Choleris et al., 
2006)
Mice 88 3–4 months Gene deletion, social recognition paradigm 
(tests) and behavioral analysis.
NA Psychological outcomes: binary social discrimination
15 (Chu et al., 
2009)
Mice ND 2–3 months 
of age 
DPN
Estradiol 
Preoptic area (POA) and hypothalamus Neuroendocrine pathway: GnRH release
16 (Clark et al., 
2012)
Mice ND ND SERM-beta1,
SERM-beta2, E2,
gene deletion, forced swim test (FST)
Dorsal
raphe nuclei, dentate gyrus in hippocampus
·	 Psychological outcomes: mood, antidepressive effect. ·	 Neurogenesis
17 (Donner & 
Handa, 2009)
Sprague–Dawley 
rats
ND ND DPN and behavioral testing Brainstem (dorsal
raphe nuclei)
Psychological outcomes: stress and anxiety-related 
behaviors
18 (Galvin & 
Ninan, 2014)
C57/BL6 mice ND 3-5 months 
old
DPN Infralimbic medial prefrontal cortex Psychological outcomes: fear extinction
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Table 1. General Characteristics of the Animal Studies Included in this Review
No. Author Animal Type N Age Assessment of Erβ function Tissue Outcome
1 (Abraham et 
al., 2003)
Mice ND 40–54 days Gene deletion,
estradiol (E2)
GnRH neurons in medial septum , rostral preoptic area, 
and anterior hypothalamus
Cellular signaling 
2 (Abraham et 
al., 2004)
Mice ND ND Gene deletion; 
17-ß-estradiol
Medial preoptic nucleus; medial septum;; caudate-
putamen; the retrosplenial granulate
cortex
Cellular signaling: phosphorylation; rapid intracellular 
signaling
3 (Bansal & 
Chopra, 2015)
Rats (Sprague-
Dawley)
8-12 ND DPN NA Psychological and psychiatric (depression-like and 
memory impairment)
4 (Bastos et al., 
2015)
C57BL/6 mice ND 8-12 weeks DPN, E2 Hippocampus Psychological and psychiatric (depression-like and non-
spatial memory)
5 (Benmansour 
et al., 2014)
Sprague–Dawley 
rats
ND ND DPN,
E2
CA3 region of the hippocampus Psychological outcomes (mood)
6 (Benmansour 
et al., 2015)
Sprague–Dawley 
rats
12-28 4 months DPN Hippocampus Cellular signaling: 
Psychological and psychiatric outcomes (depression-like)
7 (Bosch et al., 
2009)
Mice ND ND Gene deletion,
E2
Hypothalamic nuclei and pituitary calcium channel 
subunit: Cav3.1
Neuroendocrine pathway: excitability of hypothalamic 
neurons and modulation of pituitary
secretion
8 (Boulware et 
al., 2005) 
Rat pups ND 1- to 2-days-
old rat pups 
DPN,
17 E- 1 
CA3–CA1 Hippocampal pyramidal neurons Cellular signaling: CREB phosphorylation 
9 (Boulware et 
al., 2013)
C57BL/6 mice ND 8–12 weeks 
of age 
DPN,
E2,
novel object recognition and object placement 
behavioral tests 
Dorsal hippocampus Neurological outcomes: (hippocampal memory 
consolidation)
 
10 (C. M. Brown 
et al., 2010)
Mice ND 10–15 weeks 
of age
Gene deletion, E2, cytokine/chemokine 
quantification.
Cortex and
striatum
Neuroprotection: anti-inflammatory effects (mediation of 
neuroinflammatory response) 
11 (Carswell et al., 
2004)
 C57BL/6J mice 44 3 months of 
age
DPN Caudate nucleus and dorsal
hippocampus
Neuroprotection 
12 (Cheong et al., 
2012)
Mice ND 2–3 months Gene deletion,
17-ß-estradiol
GnRH neurons from medial septum (MS) to the anterior
hypothalamic area
Cellular signaling 
13 (Choleris et al., 
2003)
Mice 89 3–5 months 
old
Gene deletion,
social recognition paradigm (tests) and 
behavioral analysis.
NA Psychological outcomes: social recognition and anxiety 
14 (Choleris et al., 
2006)
Mice 88 3–4 months Gene deletion, social recognition paradigm 
(tests) and behavioral analysis.
NA Psychological outcomes: binary social discrimination
15 (Chu et al., 
2009)
Mice ND 2–3 months 
of age 
DPN
Estradiol 
Preoptic area (POA) and hypothalamus Neuroendocrine pathway: GnRH release
16 (Clark et al., 
2012)
Mice ND ND SERM-beta1,
SERM-beta2, E2,
gene deletion, forced swim test (FST)
Dorsal
raphe nuclei, dentate gyrus in hippocampus
·	 Psychological outcomes: mood, antidepressive effect. ·	 Neurogenesis
17 (Donner & 
Handa, 2009)
Sprague–Dawley 
rats
ND ND DPN and behavioral testing Brainstem (dorsal
raphe nuclei)
Psychological outcomes: stress and anxiety-related 
behaviors
18 (Galvin & 
Ninan, 2014)
C57/BL6 mice ND 3-5 months 
old
DPN Infralimbic medial prefrontal cortex Psychological outcomes: fear extinction
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Table 1. General Characteristics of the Animal Studies Included in this Review (continued)
No. Author Animal Type N Age Assessment of Erβ function Tissue Outcome
19 (Grove-
Strawser et al., 
2010)
Rat pups ND 1–2 day old 
rat pups
DPN Striatal neurons culture Cellular signaling: CREB phosphorylation
20 (Gundlah et 
al., 2005)
Mice ND 14 weeks Gene deletion,
estradiol
Dorsal raphe nucleus (DRN) in midbrain. Psychological outcomes: serotonin 
21 (Han et al., 
2013)
Mice 163 4 months 
and 13–14 
months
Gene deletion; 
Estradiol (17 ß-estradiol benzoate);
Behavioral studies 
Hippocampus Neurological outcomes: maintenance of hippocampal-
dependent
memory. 
22 (Imwalle et al., 
2005)
Mice 80 10 week Gene deletion;E2; 
behavioral testing (the elevated plus-maze 
test),
monoamine HPLC
Cingulate cortex, caudate putamen, nucleus accumbens, 
medial
septum, stria
terminalis, hippocampus; posterodorsal amygdale; 
substantia nigra; dorsal raphe, locus
coeruleus
Psychological outcomes: modulation of estrogen effects on 
anxiety and catecholamine concentrations 
23 (Irwin et al., 
2012)
Sprague–Dawley 
rats
ND 4–6 months 
old
DPN,
E2
Isolated brain mitochondria (of forebrain) Cellular signaling: modulation of mitochondrial function 
in the brain 
24 (Jacome et al., 
2010)
Sprague–Dawley 
rats
32–34 2 months old DPN; 
estradiol benzoate;
behavioral tests (object recognition / 
placement memory tasks)
NA Neurological outcomes: mediation of sub-chronic and 
acute effects
of estrogens on recognition memory 
25 (Krezel et al., 
2001)
Mice ND 8-month-old Gene deletion; behavioral testing;
electrophysiological evaluation of amygdala 
functions 
Amygdala Psychological outcomes: emotional
behavior
26 (Kudwa et al., 
2014)
Sprague–Dawley 
rats
118 ND DPN, behavioral and restraint testing NA ·	 Neuroendocrine pathway: HPA reactivity.·	 Psychological outcomes (anxiety-like behaviors).
27 (Le & Belcher, 
2010)
Neonatal Rats
(Sprague Dawley) 
ND ND Xenoestrogens, DPN Immature cerebellar granule cell cultures Cellular signaling: rapid intracellular signaling
28 (Liu et al., 
2008)
Mice ND ND Gene deletion; WAY-200070 or WAY-202779; 
behavioral tests
Hippocampus Neurological outcomes: hippocampal-dependent memory 
+ hippocampal synaptic plasticity 
29 (Lynch et al., 
2014)
Long-Evans rats 146 90 days old DPN; behavioral test NA Psychological outcomes:
fear generalization
30 (Mazzucco et 
al., 2006)
Sprague-Dawley 
rats
69 Adults DPN Hippocampus
(Dentate gyrus) 
Cellular signaling (cellular proliferation)
31 (W. J. Miller et 
al., 2004)
Sprague-Dawley 
rats
5 Adults Transfected ER beta 1 Hypothalamus Neuroendocrine pathway
32 (N. R. Miller 
et al., 2005)
Sprague-Dawley 
rats
8 21 days WAY 200070-2 Hippocampus Neuroprotection
33 (Morissette et 
al., 2008)
Sprague-Dawley 
rats
10 Adults DPN Prefrontal cortex and hippocampal regions Cellular signaling(NMDA receptor modulation)
34 (Oyola et al., 
2012)
Mice ND 3-4 months Gene deletion, S-DPN NA Psychological and psychiatric (anxiety-like behaviors)
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Table 1. General Characteristics of the Animal Studies Included in this Review (continued)
No. Author Animal Type N Age Assessment of Erβ function Tissue Outcome
19 (Grove-
Strawser et al., 
2010)
Rat pups ND 1–2 day old 
rat pups
DPN Striatal neurons culture Cellular signaling: CREB phosphorylation
20 (Gundlah et 
al., 2005)
Mice ND 14 weeks Gene deletion,
estradiol
Dorsal raphe nucleus (DRN) in midbrain. Psychological outcomes: serotonin 
21 (Han et al., 
2013)
Mice 163 4 months 
and 13–14 
months
Gene deletion; 
Estradiol (17 ß-estradiol benzoate);
Behavioral studies 
Hippocampus Neurological outcomes: maintenance of hippocampal-
dependent
memory. 
22 (Imwalle et al., 
2005)
Mice 80 10 week Gene deletion;E2; 
behavioral testing (the elevated plus-maze 
test),
monoamine HPLC
Cingulate cortex, caudate putamen, nucleus accumbens, 
medial
septum, stria
terminalis, hippocampus; posterodorsal amygdale; 
substantia nigra; dorsal raphe, locus
coeruleus
Psychological outcomes: modulation of estrogen effects on 
anxiety and catecholamine concentrations 
23 (Irwin et al., 
2012)
Sprague–Dawley 
rats
ND 4–6 months 
old
DPN,
E2
Isolated brain mitochondria (of forebrain) Cellular signaling: modulation of mitochondrial function 
in the brain 
24 (Jacome et al., 
2010)
Sprague–Dawley 
rats
32–34 2 months old DPN; 
estradiol benzoate;
behavioral tests (object recognition / 
placement memory tasks)
NA Neurological outcomes: mediation of sub-chronic and 
acute effects
of estrogens on recognition memory 
25 (Krezel et al., 
2001)
Mice ND 8-month-old Gene deletion; behavioral testing;
electrophysiological evaluation of amygdala 
functions 
Amygdala Psychological outcomes: emotional
behavior
26 (Kudwa et al., 
2014)
Sprague–Dawley 
rats
118 ND DPN, behavioral and restraint testing NA ·	 Neuroendocrine pathway: HPA reactivity.·	 Psychological outcomes (anxiety-like behaviors).
27 (Le & Belcher, 
2010)
Neonatal Rats
(Sprague Dawley) 
ND ND Xenoestrogens, DPN Immature cerebellar granule cell cultures Cellular signaling: rapid intracellular signaling
28 (Liu et al., 
2008)
Mice ND ND Gene deletion; WAY-200070 or WAY-202779; 
behavioral tests
Hippocampus Neurological outcomes: hippocampal-dependent memory 
+ hippocampal synaptic plasticity 
29 (Lynch et al., 
2014)
Long-Evans rats 146 90 days old DPN; behavioral test NA Psychological outcomes:
fear generalization
30 (Mazzucco et 
al., 2006)
Sprague-Dawley 
rats
69 Adults DPN Hippocampus
(Dentate gyrus) 
Cellular signaling (cellular proliferation)
31 (W. J. Miller et 
al., 2004)
Sprague-Dawley 
rats
5 Adults Transfected ER beta 1 Hypothalamus Neuroendocrine pathway
32 (N. R. Miller 
et al., 2005)
Sprague-Dawley 
rats
8 21 days WAY 200070-2 Hippocampus Neuroprotection
33 (Morissette et 
al., 2008)
Sprague-Dawley 
rats
10 Adults DPN Prefrontal cortex and hippocampal regions Cellular signaling(NMDA receptor modulation)
34 (Oyola et al., 
2012)
Mice ND 3-4 months Gene deletion, S-DPN NA Psychological and psychiatric (anxiety-like behaviors)
84
Chapter 3.1
Table 1. General Characteristics of the Animal Studies Included in this Review (continued)
No. Author Animal Type N Age Assessment of Erβ function Tissue Outcome
35 (Raval et al., 
2013)
Sprague-Dawley 
rats
ND 9-11 
days
DPN, 17β-Estradiol (E2) Hippocampus ·	 Neuroprotection (against cerebral ischemia)·	 Neurological (learning and memory)
36 (Rocha et al., 
2005)
Mice 24 ND Gene deletion; 17β-Estradiol (E2) NA Psychological and psychiatric (antidepressant-like effect)
37 (Rossi et al., 
2010)
Sprague-Dawley 
rats
ND Adults DPN Hypothalamic paraventricular nucleus ·	 Cellular signaling ·	 Psychological and psychiatric 
38 (Sa et al., 
2013)
Wistar rats 34 10 weeks DPN, EB Hypothalamic ventromedial nucleus Neuroendocrine pathway
39 (Sarvari et al., 
2011)
Wistar rats ND Middle-aged DPN, E2 Frontal cortex Cellular signaling (neuroinflammatory genes regulation)
40 (Sarvari et al., 
2014)
Harlan-Wistar rats 13 13months DPN, E2 Hippocampus Cellular signaling
41 (Spencer-Segal 
et al., 2012)
Mice 63 9-20 weeks Gene deletion, estradiol benzoate (EB) Hippocampus (dorsal) Cellular signaling (synaptic plasticity)
42 (S. Suzuki et 
al., 2007)
Mice 120 11 weeks Gene deletion, E2 Subventricular zone Cellular signaling (neurogenesis)
43 (H. Suzuki et 
al., 2013)
Mice 10 6 months Gene deletion Dorsal raphe nucleus Psychological and psychiatric
44 (Walf & Frye, 
2007)
Long-Evans rats 84 55+ days DPN; E2 Hippocampus Psychological and psychiatric 
45 (J. M. Wang et 
al., 2006)
Sprague-Dawley 
rats
9 4-6 months DPN Hippocampus Neurological (ApoE protein expression)
46 (Waters et al., 
2009)
Sprague-Dawley 
rats
ND Adults DPN, estradiol benzoate Hippocampus (dorsal region) Cellular signaling (postsynaptic protein expression)
47 (Zeidan et al., 
2011)
Sprague-Dawley 
rats 
35 Adults DPN Ventromedial prefrontal cortex and amygdala Psychological and psychiatric 
48 (Zhao et al., 
2011)
Sprague-Dawley 
rats
3xTg-AD mice
ND 14-16 weeks
12 months
DPN; 17β-Estradiol Hippocampus Neurological 
49 (Zhao et al., 
2013)
OVX
Triple transgenic 
AD (3xTg-AD) 
mice
(3 months old)
ND 3 months old Phytoestrogenic ER-ß selective modulator 
(SERM)
Formulation, Y-Maze cognition-behavioral test 
Hippocampus, cortex, cerebellum Neurological
DPN, diarylpropionitrile; EB, estradiol benzoate; E2, 17β-Estradiol; NA, not available; ND, not defined.
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Table 1. General Characteristics of the Animal Studies Included in this Review (continued)
No. Author Animal Type N Age Assessment of Erβ function Tissue Outcome
35 (Raval et al., 
2013)
Sprague-Dawley 
rats
ND 9-11 
days
DPN, 17β-Estradiol (E2) Hippocampus ·	 Neuroprotection (against cerebral ischemia)·	 Neurological (learning and memory)
36 (Rocha et al., 
2005)
Mice 24 ND Gene deletion; 17β-Estradiol (E2) NA Psychological and psychiatric (antidepressant-like effect)
37 (Rossi et al., 
2010)
Sprague-Dawley 
rats
ND Adults DPN Hypothalamic paraventricular nucleus ·	 Cellular signaling ·	 Psychological and psychiatric 
38 (Sa et al., 
2013)
Wistar rats 34 10 weeks DPN, EB Hypothalamic ventromedial nucleus Neuroendocrine pathway
39 (Sarvari et al., 
2011)
Wistar rats ND Middle-aged DPN, E2 Frontal cortex Cellular signaling (neuroinflammatory genes regulation)
40 (Sarvari et al., 
2014)
Harlan-Wistar rats 13 13months DPN, E2 Hippocampus Cellular signaling
41 (Spencer-Segal 
et al., 2012)
Mice 63 9-20 weeks Gene deletion, estradiol benzoate (EB) Hippocampus (dorsal) Cellular signaling (synaptic plasticity)
42 (S. Suzuki et 
al., 2007)
Mice 120 11 weeks Gene deletion, E2 Subventricular zone Cellular signaling (neurogenesis)
43 (H. Suzuki et 
al., 2013)
Mice 10 6 months Gene deletion Dorsal raphe nucleus Psychological and psychiatric
44 (Walf & Frye, 
2007)
Long-Evans rats 84 55+ days DPN; E2 Hippocampus Psychological and psychiatric 
45 (J. M. Wang et 
al., 2006)
Sprague-Dawley 
rats
9 4-6 months DPN Hippocampus Neurological (ApoE protein expression)
46 (Waters et al., 
2009)
Sprague-Dawley 
rats
ND Adults DPN, estradiol benzoate Hippocampus (dorsal region) Cellular signaling (postsynaptic protein expression)
47 (Zeidan et al., 
2011)
Sprague-Dawley 
rats 
35 Adults DPN Ventromedial prefrontal cortex and amygdala Psychological and psychiatric 
48 (Zhao et al., 
2011)
Sprague-Dawley 
rats
3xTg-AD mice
ND 14-16 weeks
12 months
DPN; 17β-Estradiol Hippocampus Neurological 
49 (Zhao et al., 
2013)
OVX
Triple transgenic 
AD (3xTg-AD) 
mice
(3 months old)
ND 3 months old Phytoestrogenic ER-ß selective modulator 
(SERM)
Formulation, Y-Maze cognition-behavioral test 
Hippocampus, cortex, cerebellum Neurological
DPN, diarylpropionitrile; EB, estradiol benzoate; E2, 17β-Estradiol; NA, not available; ND, not defined.
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3.2 Cellular signaling:
Nineteen studies evaluated the function of ERβ on cellular signaling (Table 2A). Of these, nine 
studies assessed the effect of phosphorylation in different subunits (Abraham, Han, Todman, Ko-
rach, & Herbison, 2003; Abraham, Todman, Korach, & Herbison, 2004; Benmansour et al., 2015; 
Boulware et al., 2005; Cheong et al., 2012; Grove-Strawser, Boulware, & Mermelstein, 2010; Le & 
Belcher, 2010; Raval et al., 2013; Spencer-Segal et al., 2012). Within these nine, four studies (Abraham 
et al., 2004; Benmansour et al., 2015; Le & Belcher, 2010; Spencer-Segal et al., 2012) reported that 
activation of ERβ was associated with increased immunoreactivity and expression of phosphorylated 
mitogen-activated protein kinase (MAPK/ERK), protein kinase B (Akt), and tropomyosin receptor 
kinase B (TrKB) receptor. Also, one study (Cheong et al., 2012) found that ERβ was involved in 
the phosphorylation of ERK1/2 in gonadotropin-releasing hormone (GnRH) neurons. Akt and 
TrkB receptors participate in synaptic plasticity involved in spatial memory, cognition, and other 
hippocampal-dependant behaviors (Spencer-Segal et al., 2012). MAPK/ERK signaling regulates a 
variety of cellular activities including proliferation, differentiation, survival, and death and has been 
implicated in the development of AD, Parkinson’s Disease, and amyotrophic lateral sclerosis (E. K. 
Kim & Choi, 2010). Two other studies (Boulware et al., 2005; Grove-Strawser et al., 2010) showed that 
ERβ, via activation of metabotropic glutamate receptor (mGlur) 2 but not mGlur3, dephosphorylates 
L-type calcium channels and, therefore causes a reduction in L-type calcium channel-mediated cAMP 
response element-binding protein (CREB). Furthermore, two studies (Abraham et al., 2003; Cheong 
et al., 2012) reported an involvement of ERβ in CREB phosphorylation in GnRH neurons whereas 
another study (Abraham et al., 2004) found regional actions of ERβ on CREB phosphorylation. In 
the medial preoptic septum, phosphorylation of CREB was found to be dependent solely on ERß, 
whereas no role of this receptor on CREB phosphorylation was found in hypothalamic ventromedial 
nucleus, caudate-putamen, or retrosplenial granulate cortex. Moreover, one study tested periodic 
ERβ-activation on CREB phosphorylation in the hippocampus and showed increased protein ex-
pression of phosphorylated CREB (Raval et al., 2013). CREB has been found to be involved in the 
formation of long-term memories, long-term potentiation, and in the development of drug addiction, 
physiological dependence and Huntington’s Disease (Bourtchuladze et al., 1994; DiRocco, Scheiner, 
Sindreu, Chan, & Storm, 2009; Nazarian et al., 2009; Rouaux, Loeffler, & Boutillier, 2004; Y. Wang, 
Ghezzi, Yin, & Atkinson, 2009).
Three studies assessed the function of ERβ on neurogenesis (Clark et al., 2012; Mazzucco et al., 
2006; S. Suzuki et al., 2007). The first two studies were performed in the hippocampus under normal 
conditions, and the third in the subventricular zone after an induced stroke injury. Their conclusions 
were consistent in that the number of newborn cells was significantly increased with the activation of 
ERβ, and therefore support a role of ERβ in neurogenesis. 
Five studies evaluated gene and protein expression (Irwin et al., 2012; Liu et al., 2008; Sarvari et 
al., 2011; Sarvari, Kallo, Hrabovszky, Solymosi, & Liposits, 2014; Waters et al., 2009). One study found 
that ERβ activation was required in order to potentiate mitochondrial function in the brain (Irwin et 
al., 2012). The second study found that ERβ agonist affected the expression of a specified set of genes 
(Iba1, Cd68, Cd11b and Cd18) that, in turn, affects neuronal control of microglia and complement 
expression (Sarvari et al., 2014). Two studies concluded that ERβ increased the regulation of post-
synaptic PSD-95 and AMPA-type glutamate receptor subunit GluR1 (Liu et al., 2008; Waters et al., 
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2009). One study evaluated the effect of DPN on the modulation of N-methyl-D-aspartate (NMDA) 
receptor specific binding and found no modulating effect (Morissette, Le Saux, & Di Paolo, 2008). 
One other study concluded that DPN upregulated the expression of more than 16 neuroinflammatory 
genes, thus leading to suspicion that ERβ may be a target to supress regulatory functions of glial cells 
in the E2-deprived female brain and inflammatory diseases. (Sarvari et al., 2011)
Finally, one study assessed whether DPN had an effect on the desensitization of serotonin 1A 
(5-HT1A) receptor signaling and on the plasma levels of oxytocin and adrenocorticotropic hormone 
(ACTH) and found no effect.(Rossi et al., 2010)
3.3 Neuroendocrine pathway Outcomes:
Seven studies evaluated the functions of ERβ on neuroendocrine pathway outcomes (Table 2B). Of 
these, one study found that ERß agonist activates GnRH firing and increases gamma-aminobutyric 
acid (GABA) transmission and postsynaptic response in GnRH neurons.(Chu, Andrade, Shupnik, & 
Moenter, 2009) 
Two studies evaluated the involvement of ERβ in modulation of hypothalamus-pituitary-adrenal 
(HPA) axis reactivity.(Kudwa et al., 2014; W. J. Miller, Suzuki, Miller, Handa, & Uht, 2004) The 
first study found that administration of DPN reduced adrenal corticosterone (CORT) and ACTH 
responses to restraint stress. Based on the observed findings, the authors concluded that ERβ may 
modulate HPA/neuroendocrine stress reactivity.(Kudwa et al., 2014) The second study found that 
ERβ isoforms had a positive effect on regulation of corticotropin-releasing hormone (CRH) promoter 
activity; indicating possible involvement of ERβ in the mechanisms of the stress response and HPA 
axis disorders pathogenesis.(W. J. Miller et al., 2004) Furthermore, one study investigated the role of 
ERβ in oxytocin cells in desensitization of 5-HT1A receptor signalling and showed no effect. (30) Thus, 
it was inferred that ERβ might not play a role in central regulation of 5-HT1A-mediated ACTH release.
The role of ERβ in the induction of progesterone receptors (PRs), which are critical for female 
sexual behavior, was assessed in two studies.(Clark et al., 2012; Sa, Pereira, Malikov, & Madeira, 
2013) One study showed that ERβ activation in hypothalamic ventromedial nucleus averts the action 
of ERα in the induction of PRs (Sa et al., 2013), whereas one study reported that the ERβ agonist 
selective estrogen receptor modulator beta 2 (SERM-beta 2) dose-dependently increased PRs in the 
murine dorsal raphe nucleus but not in the hippocampus.(Clark et al., 2012)
Finally, one study assessed the role of ERβ in the expression and function of T-type calcium 
channels (subtype Cav3.2) in the hypothalamus. The authors found that the effect of estradiol on 
Cav3.2 was dependent on ERβ as well as on ERα indicating involvement of ERβ in excitability of 
hypothalamic neurons.(Bosch, Hou, Fang, Kelly, & Ronnekleiv, 2009)
 3.4 Neurological outcomes:
Eight studies evaluated the function of ERβ on neurological outcomes (Table 2C). Of these, four 
investigated memory as their main outcome.(Boulware, Heisler, & Frick, 2013; Jacome et al., 2010; 
Liu et al., 2008; Raval et al., 2013) One study demonstrated that ERβ in dorsal hippocampus, through 
activation of mGluR1 signaling, enhanced novel object recognition and object placement memory.
(Boulware et al., 2013) Another study (Liu et al., 2008) concluded that along with increased protein 
expression of the AMPA receptor (AMPAR) subunit GluR1 and PSD-95, ERβ activation induced 
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morphological changes in hippocampal neurons, including increased dendritic branching and in-
creased density of mushroom-type spines. Furthermore, the same study showed that ERβ improved 
performance in hippocampus-dependent memory tasks. This finding implies that activation of ERβ 
could regulate hippocampal synaptic plasticity and improve hippocampus-dependent cognition.(Liu 
et al., 2008) Jacome at al found that ERβ activation increased recognition memory and altered the 
levels of monoamines (3-methoxy-4-hydroxyphenylglycol (MHPG) or the MHPG/norepinephrine 
(NE) ratio), dopamine’s metabolite (homovanillic acid (HVA)), and serotonin metabolite (5-hydroxy-
indole acetic acid (5-HIAA)) in several areas of the brain, including the prefrontal cortex, ventral 
hippocampus and dentate gyrus, but not in the striatum or medial septum. This finding implies that 
ERβ may enhance recognition memory through alterations in monoaminergic containing systems 
primarily in the prefrontal cortex and hippocampus.(Jacome et al., 2010) One study assessed spatial 
learning, memory, and post-ischemic neuronal survival. It showed improvement in all these out-
comes when ERβ agonist (DPN) was given periodically.(Raval et al., 2013) 
The four other studies evaluated a neurological outcome based on gene regulation and protein 
expression.(Han et al., 2013; J. M. Wang, Irwin, & Brinton, 2006; Zhao, Mao, Chen, Schneider, & 
Brinton, 2013; Zhao et al., 2011) The first investigated the role of ERβ in regulating gene transcription 
and learning in the hippocampus. It found a positive effect and concluded that ERβ might regulate 
transcription involved in maintaining hippocampal function during aging.(Han et al., 2013) The 
second study on gene and protein expression demonstrated a decrease in apolipoprotein E (ApoE) 
mRNA protein expression (detrimental in AD) with the use of DPN.(J. M. Wang et al., 2006) The 
third publication studied whether any changes were produced at the insulin-degrading enzyme 
(IDE) level. IDE is an enzyme involved in the catabolism of amyloid beta (Aβ) protein in the brain 
and has been associated with the etiology and development of AD. The third publication found that 
DPN significantly increased IDE in hippocampal neurons via activation of phosphatidylinositol 
3-kinase (PI3-K).(Zhao et al., 2011) Finally, the fourth study sought to determine the efficacy of a 
SERM formulation in the regulation of early stages of AD. A nine-month dietary supplementation of 
β-SERM formulation was found to promote physical health, prolonged survival and improved spatial 
recognition memory. It also revealed attenuation of both Aβ deposition and plaque formation in AD 
mice.(Zhao et al., 2013)
3.5 Neuroprotection outcomes:
Four studies set out to determine the role of ERβ on neuroprotection (Table 2D). Three of these 
considered whether protection against ischemia was conferred either by way of DPN (Carswell, 
Macrae, Gallagher, Harrop, & Horsburgh, 2004; Raval et al., 2013) or WAY 200070-3.(N. R. Miller, 
Jover, Cohen, Zukin, & Etgen, 2005) Regardless of the ERβ agonist used, their results were all similar 
in that protection of neurons in caudate nucleus and hippocampus against global ischemia-induced 
death was conferred. The fourth study evaluated two outcomes: regulation of cerebral inflammatory 
cytokine and chemokine levels as well as regulation of the blood brain barrier permeability. The 
authors found a positive effect for both and concluded that ERβ may also confer protection against 
neuroinflammation.(C. M. Brown, Mulcahey, Filipek, & Wise, 2010)
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3.6 psychological and psychiatric outcomes:
Nineteen studies assessed the function of ERβ agonists or behavioral testing after gene deletion or 
a combination of both (Table 2E). Of these, three studies considered anxiety-like behavior as their 
main outcome. The first evaluated anxiety-like behavior and measurement of brain serotonin and 
dopamine levels. It found enhanced anxiety and decreased concentrations of these neurotransmitters 
in the absence of functional ERβ.(Imwalle, Gustafsson, & Rissman, 2005) The second studied the 
contribution of estrogen receptors in modulation of anxiety and analyzed the effect of deleting ERβ 
gene in mice. Absence of this receptor was associated with expression of anxiety disorders and with a 
reduced threshold for synaptic plasticity in the amygdala, suggesting a role of ERβ in the processing 
of emotional behavior.(Krezel, Dupont, Krust, Chambon, & Chapman, 2001) The third study showed 
that S-enantiomer of diarylpropionitrile (S-DPN) reduced anxiety-like behavior and attenuated 
stress-induced corticosterone (CORT) and ACTH in wild-type mice, but not in mice lacking the ERβ 
gene, suggesting anxiolytic effects mediated by ERβ.(Oyola et al., 2012)
Seven studies focused on depression-like behavior.(Bansal & Chopra, 2015; Bastos et al., 2015; 
Benmansour et al., 2015; Benmansour, Privratsky, Adeniji, & Frazer, 2014; Clark et al., 2012; Donner 
& Handa, 2009; Rocha, Fleischer, Schaeffer, Rohrer, & Hickey, 2005) The first (Benmansour et al., 
2014) described that activation of ERβ in the CA3 region of hippocampus induced by DPN slowed 
serotonin clearance via MAPK/ERK1/2 signaling and interactions with both TrKB and IGF-1 recep-
tors whereas no role of PI3K/Akt signaling in mediating this effect was shown. These results show an 
antidepressant-like effect of ERβ.(Benmansour et al., 2014) Moreover, the other six studies used the 
widely used behavioural assays/tests, Porsolt test or forced swim test and found an anti-depressant 
effect of ERβ activation.(Bansal & Chopra, 2015; Bastos et al., 2015; Benmansour et al., 2015; Clark et 
al., 2012; Donner & Handa, 2009; Rocha et al., 2005)
Two other studies evaluated both anxiety- and depression-like behaviors simultaneously. They 
reached the same conclusion in that both outcomes were decreased after the use of ERβ agonists 
(Kudwa et al., 2014; Walf & Frye, 2007).
Four studies focused on the role of ERβ in tryptophan hydroxylase (TPH) 1 mRNA expression, 
which is involved in the synthesis of serotonin. Three of these studies found that ERβ was associ-
ated with increased expression of TPH1 (Clark et al., 2012; Donner & Handa, 2009; Gundlah et al., 
2005) A fourth study concluded that high TPH levels could be maintained by using the selective ERβ 
agonist, LY3201) even after ovariectomy.(H. Suzuki et al., 2013) 
Two publications dealt with social recognition.(Choleris et al., 2003; Choleris et al., 2006) Both 
used gene deletion, social recognition paradigm tests, and behavioral analysis. Their results were 
similar: ERβ is necessary for social discrimination and modulation of social behavior.(Choleris et al., 
2003; Choleris et al., 2006) 
Three publications looked to study the role of ERβ on extinction recall, which is the process of 
learning not to fear. Two of these authors concluded that DPN administration facilitated extinction 
memory consolidation.(Galvin & Ninan, 2014; Zeidan et al., 2011) However, one study found that 
fear generalization was increased via an effect on fear memory retrieval mechanisms through activa-
tion of ERβ.(Lynch et al., 2014)
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Table 2A. Estrogen Receptor Beta and Cellular Signaling Outcomes
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
1 (Abraham et al., 2003) Phospho-cAMP response 
element binding protein 
(pCREB) 
CREB phosphorylation 
MAPK phosphorylation
OVX 
KO/WT
Mice 
GnRH neurons in medial 
septum (MS), rPOA, and 
anterior hypothalamus 
Gene deletion, 
estradiol (E2) 
No clear pattern, it depends on brain 
region 
The actions of ERß on CREB phosphorylation 
depends on the brain region: in the medial septum, 
phosphorylation of CREB was found to be dependent 
solely on ERß, whereas no role of this receptor on 
CREB phosphorylation was found in hypothalamic 
ventromedial nucleus, caudate-putamen and 
retrosplenial granulate cortex. ERß plays a role in 
MAPK phosphorylation in the medial preoptic septum 
but not in the retrosplenial granulate cortex.
2 (Abraham et al., 2004) CREB phosphorylation 
MAPK/
ERK1/2 phosphorylation
OVX KO/WT
Mice
Medial preoptic nucleus; 
medial septum; ventrolateral 
VNM; caudate-putamen; 
the retrosplenial granulate
cortex
Gene deletion; 
17-ß-estradiol
No clear pattern, it depends on brain 
region 
The actions of ERß on CREB phosphorylation 
depends on the brain region: in the medial preoptic 
septum, phosphorylation of CREB was found to be 
dependent solely on ERß, whereas no role of this 
receptor on CREB phosphorylation was found in 
hypothalamic ventromedial nucleus, caudate-putamen 
and retrosplenial granulate cortex. ERß plays a role in 
MAPK phosphorylation in the medial preoptic septum 
but not in the retrosplenial granulate cortex. 
3 (Benmansour et al., 
2015)
DPN Phosphorylation of 
both ERK and TrkB
OVX Sprague-Dawley 
rats
Hippocampus DPN Increased DPN did not alter phosphorylation of Akt. All of these 
signaling pathways may mediate neuroprotection and 
cognitive function. 
4 (Boulware et al., 2005) CREB phosphorylation 
L-type calcium channel-
dependent CREB 
phosphorylation
L-type calcium channel 
currents
Intact rat pups of both 
sexes
CA3–CA1 Hippocampal 
pyramidal neurons culture
DPN,
17 E-1
CRCREB phosphorylation: No effect
B)  L-type calcium channel-dependent 
CREB phosphorylation:  reduced 
(attenuated or decreased)
L-type calcium channel currents: 
reduced (attenuated or decreased)
ERβ activates mGlur2 and/or mGlurR3 which leads to 
diminished cAMP concentrations and a reduction in 
PKA activity, ultimately resulting in dephosphorylation  
of L-type calcium channels and a reduction in L-type 
calcium channel-mediated CREB phosphorylation.
5 (Cheong et al., 2012) ERK1/2 and CREB 
phosphorylation in 
GnRH neurons
OVX GnRH 
neuron-specific KO/WT 
Mice
and OVX C57BL/6 Mice
GnRH neurons from medial 
septum (MS) to the anterior
hypothalamic area 
Gene deletion,
17-ß-estradiol 
Direct and indirect positive effect in 
GnRH neurons
E2 acts through calcium/calmodulin-dependent
protein kinase type II and protein kinase A to rapidly 
phosphorylate ERK1/2, which then acts to
phosphorylate CREB in adult female GnRH neurons. 
These effects of E2 are dependent
upon both direct ERß mechanisms as well as indirect 
actions mediated by afferent inputs to GnRH
neurons.
6 (Clark et al., 2012) Neurogenesis in the 
dentate gyrus
KO/WT mice
and OVX C57BL/6 mice
Dorsal
raphe nuclei, dentate gyrus 
in hippocampus
SERM-beta1,
SERM-beta2, E2,
gene deletion, forced 
swim test (FST)
Positive effect
Positive effect
ERß stimulates
neurogenesis in the dentate gyrus.
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Table 2A. Estrogen Receptor Beta and Cellular Signaling Outcomes
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
1 (Abraham et al., 2003) Phospho-cAMP response 
element binding protein 
(pCREB) 
CREB phosphorylation 
MAPK phosphorylation
OVX 
KO/WT
Mice 
GnRH neurons in medial 
septum (MS), rPOA, and 
anterior hypothalamus 
Gene deletion, 
estradiol (E2) 
No clear pattern, it depends on brain 
region 
The actions of ERß on CREB phosphorylation 
depends on the brain region: in the medial septum, 
phosphorylation of CREB was found to be dependent 
solely on ERß, whereas no role of this receptor on 
CREB phosphorylation was found in hypothalamic 
ventromedial nucleus, caudate-putamen and 
retrosplenial granulate cortex. ERß plays a role in 
MAPK phosphorylation in the medial preoptic septum 
but not in the retrosplenial granulate cortex.
2 (Abraham et al., 2004) CREB phosphorylation 
MAPK/
ERK1/2 phosphorylation
OVX KO/WT
Mice
Medial preoptic nucleus; 
medial septum; ventrolateral 
VNM; caudate-putamen; 
the retrosplenial granulate
cortex
Gene deletion; 
17-ß-estradiol
No clear pattern, it depends on brain 
region 
The actions of ERß on CREB phosphorylation 
depends on the brain region: in the medial preoptic 
septum, phosphorylation of CREB was found to be 
dependent solely on ERß, whereas no role of this 
receptor on CREB phosphorylation was found in 
hypothalamic ventromedial nucleus, caudate-putamen 
and retrosplenial granulate cortex. ERß plays a role in 
MAPK phosphorylation in the medial preoptic septum 
but not in the retrosplenial granulate cortex. 
3 (Benmansour et al., 
2015)
DPN Phosphorylation of 
both ERK and TrkB
OVX Sprague-Dawley 
rats
Hippocampus DPN Increased DPN did not alter phosphorylation of Akt. All of these 
signaling pathways may mediate neuroprotection and 
cognitive function. 
4 (Boulware et al., 2005) CREB phosphorylation 
L-type calcium channel-
dependent CREB 
phosphorylation
L-type calcium channel 
currents
Intact rat pups of both 
sexes
CA3–CA1 Hippocampal 
pyramidal neurons culture
DPN,
17 E-1
CRCREB phosphorylation: No effect
B)  L-type calcium channel-dependent 
CREB phosphorylation:  reduced 
(attenuated or decreased)
L-type calcium channel currents: 
reduced (attenuated or decreased)
ERβ activates mGlur2 and/or mGlurR3 which leads to 
diminished cAMP concentrations and a reduction in 
PKA activity, ultimately resulting in dephosphorylation  
of L-type calcium channels and a reduction in L-type 
calcium channel-mediated CREB phosphorylation.
5 (Cheong et al., 2012) ERK1/2 and CREB 
phosphorylation in 
GnRH neurons
OVX GnRH 
neuron-specific KO/WT 
Mice
and OVX C57BL/6 Mice
GnRH neurons from medial 
septum (MS) to the anterior
hypothalamic area 
Gene deletion,
17-ß-estradiol 
Direct and indirect positive effect in 
GnRH neurons
E2 acts through calcium/calmodulin-dependent
protein kinase type II and protein kinase A to rapidly 
phosphorylate ERK1/2, which then acts to
phosphorylate CREB in adult female GnRH neurons. 
These effects of E2 are dependent
upon both direct ERß mechanisms as well as indirect 
actions mediated by afferent inputs to GnRH
neurons.
6 (Clark et al., 2012) Neurogenesis in the 
dentate gyrus
KO/WT mice
and OVX C57BL/6 mice
Dorsal
raphe nuclei, dentate gyrus 
in hippocampus
SERM-beta1,
SERM-beta2, E2,
gene deletion, forced 
swim test (FST)
Positive effect
Positive effect
ERß stimulates
neurogenesis in the dentate gyrus.
92
Chapter 3.1
Table 2A. Estrogen Receptor Beta and Cellular Signaling Outcomes (continued)
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
7 (Grove-Strawser et al., 
2010)
L-type calcium
channel-mediated CREB 
phosphorylation
Mglur2 and Mglu3
Intact female rat pups Striatal neurons culture DPN CRCREB phosphorylation: No effect
B)  
 L-type calcium channel-dependent 
CREB phosphorylation:  reduced 
(attenuated or decreased)
C)   ERβ activates mGlur3 but not 
mGlurR2
ERβ activates mGlur2 and therefore leads to a 
reduction in L-type calcium channel-mediated CREB 
phosphorylation.
8 (Irwin et al., 2012) Mitochondrial DNA-
encoded COX I 
expression;
OVX Sprague–Dawley 
Rats
Isolated brain mitochondria 
from forebrain
DPN
E2
Positive effect Activation of ERß is
differentially required to potentiate mitochondrial 
function in brain.
9 (Le & Belcher, 2010) ERK phosphorylation Intact neonatal female
Sprague Dawley rats
Immature cerebellar granule 
cell cultures
Xenoestrogens;
DPN
Positive effect Rapid intracellular signaling of estrogen is mediated by 
ER beta.
10 (Liu et al., 2008) Protein expression of the 
AMPAR subunit GluR1 
and
PSD-95;
LTP;
Dendritic branching and 
spine number;
Spatial memory
OVX 
KO/WT
Mice
Hippocampus Gene deletion; 
WAY-200070 or 
WAY-202779; 
Behavioral tests Positive effect 
Positive effect
Positive effect
Positive effect
Activation of ERß can regulate hippocampal synaptic 
plasticity and improve hippocampus-dependent 
cognition.
11 (Mazzucco et al., 2006) hippocampal 
neurogenesis 
(hippocampal cell 
proliferation) 
OVX
Sprague–Dawley rats
n=95 
Hippocampus DPN,
E2
Increased Neurogenesis:
(hippocampal cell proliferation)
ERß is involved in
estradiol-enhanced cell proliferation. 
12 (Morissette et al., 2008) Modulation of NMDA 
receptor specific binding
OVX
Sprague–Dawley rats
n=50 
Prefrontal cortex and 
hippocampus
DPN, 
E2
No effect Cellular signaling outcomes: (modulation of NMDA 
receptors)
ERß agonist had no effect on hippocampal NMDA 
receptor-specific binding and NMDAR2B levels. More 
potent ERß agonist and ⁄ or higher concentrations of 
DPN may be effective to modulate hippocampal
NMDA receptors.
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Table 2A. Estrogen Receptor Beta and Cellular Signaling Outcomes (continued)
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
7 (Grove-Strawser et al., 
2010)
L-type calcium
channel-mediated CREB 
phosphorylation
Mglur2 and Mglu3
Intact female rat pups Striatal neurons culture DPN CRCREB phosphorylation: No effect
B)  
 L-type calcium channel-dependent 
CREB phosphorylation:  reduced 
(attenuated or decreased)
C)   ERβ activates mGlur3 but not 
mGlurR2
ERβ activates mGlur2 and therefore leads to a 
reduction in L-type calcium channel-mediated CREB 
phosphorylation.
8 (Irwin et al., 2012) Mitochondrial DNA-
encoded COX I 
expression;
OVX Sprague–Dawley 
Rats
Isolated brain mitochondria 
from forebrain
DPN
E2
Positive effect Activation of ERß is
differentially required to potentiate mitochondrial 
function in brain.
9 (Le & Belcher, 2010) ERK phosphorylation Intact neonatal female
Sprague Dawley rats
Immature cerebellar granule 
cell cultures
Xenoestrogens;
DPN
Positive effect Rapid intracellular signaling of estrogen is mediated by 
ER beta.
10 (Liu et al., 2008) Protein expression of the 
AMPAR subunit GluR1 
and
PSD-95;
LTP;
Dendritic branching and 
spine number;
Spatial memory
OVX 
KO/WT
Mice
Hippocampus Gene deletion; 
WAY-200070 or 
WAY-202779; 
Behavioral tests Positive effect 
Positive effect
Positive effect
Positive effect
Activation of ERß can regulate hippocampal synaptic 
plasticity and improve hippocampus-dependent 
cognition.
11 (Mazzucco et al., 2006) hippocampal 
neurogenesis 
(hippocampal cell 
proliferation) 
OVX
Sprague–Dawley rats
n=95 
Hippocampus DPN,
E2
Increased Neurogenesis:
(hippocampal cell proliferation)
ERß is involved in
estradiol-enhanced cell proliferation. 
12 (Morissette et al., 2008) Modulation of NMDA 
receptor specific binding
OVX
Sprague–Dawley rats
n=50 
Prefrontal cortex and 
hippocampus
DPN, 
E2
No effect Cellular signaling outcomes: (modulation of NMDA 
receptors)
ERß agonist had no effect on hippocampal NMDA 
receptor-specific binding and NMDAR2B levels. More 
potent ERß agonist and ⁄ or higher concentrations of 
DPN may be effective to modulate hippocampal
NMDA receptors.
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Table 2A. Estrogen Receptor Beta and Cellular Signaling Outcomes (continued)
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
13 (Raval et al., 2013) Protection of 
Hippocampal CA1 
Neurons in
Oxygen-Glucose 
Deprivation Model
In vitro: brain 
hippocampal slices from 
Sprague-Dawley female 
rats
(9–11 days old)
In vivo:
OVX
Sprague–Dawley rats
Hippocampus DPN
E2
Behavioral tests
Positive effect Neuroprotection (against cerebral ischemia).
14 (Rossi et al., 2010) Desensitization of HT1A 
receptor signaling.
OVX, rats Hypothalamic 
paraventricular nucleus 
DPN No effect DPN did not alter plasma baseline levels of ACTH or 
oxytocin.
15 (Sarvari et al., 2011) Neuroinflammatory genes 
regulation
OVX Wistar rats Frontal cortex DPN, E2 Positive effect DPN upregulated the expression of more than sixteen 
neuroinflammatory genes. ERß may be a target to 
supress regulatory functions of glial cells in the E2-
deprived female brain and inflammatory diseases.
16 (Sarvari et al., 2014) mRNA expression in the
hippocampus after 
gonadal hormone 
withdrawal
OVX
Harlan-Wistar rats
n=34 
Hippocampus DPN,
E2 
ERß agonist was capable of 
attenuating the expression of 
several macrophage-associated and 
complement genes. 
After ovariectomy, E2 and DPN restore the mRNA 
expression of genes Iba1, Cd68, Cd11b and Cd18. This 
shows that estrogen replacement partly restores neuronal 
control of microglia and modulates complement 
expression.
17 (Spencer-Segal et al., 
2012)
Gene transcription and
protein expression of 
pAkt-ir, PSD-95-ir and 
pTrkBir 
OVX
KO/WT Mice
n=63
9-20 weeks 
Hippocampus Gene deletion,
E2 
ERß mediates increase in pAkt-ir 
expression after E2 treatment lasting 
6 hrs.
Estradiol tended to decrease PSD-95 
in BERKO mice: However, this trend 
was not
statistically significant.
ERß mediates increase in pTrkB-ir 
expression after E2 treatment lasting 
48 hrs.
Cellular signaling outcomes (synaptic plasticity).
ERß mediates effects of estradiol on pathways important 
for synaptic plasticity in the mouse hippocampal 
formation. 
18 (S. Suzuki et al., 2007) Neurogenesis
in animal model of 
ischemic stroke
OVX
C57BL/6J mice
n=90
11 weeks old.
Age-matched OVX
KO/WT Mice
n=30 
Subventricular zone (SVZ) 
of the brain 
Gene deletion, E2 Enhanced Neurogenesis: (in an
animal model of ischemic stroke).
ERß mediates effects of estradiol treatment on increase 
in number of newborn neurons in the dorsal SVZ of the 
adult mouse and on enhancement of neurogenesis in an
animal model of ischemic stroke. 
19 (Waters et al., 2009) Expression of synaptic 
proteins PSD-95 and 
AMPA-type glutamate 
receptor
subunits GluR1, GluR2 
and GluR3.
OVX, rats Hippocampus DPN DPN administration increased 
expression of PSD-95 and AMPA-
type glutamate receptor
subunit GluR1.
DPN administration increased 
expression of AMPA receptor subunits
GluR2 and decreased expression of 
AMPA receptor subunits
GluR3.
Cellular signaling outcomes (expression of synaptic 
proteins in rat hippocampus)
ERβ specific agonists regulate the expression of synaptic 
proteins in rat hippocampus which is important for 
hippocampal-dependent cognitive performance. 
DPN, diarylpropionitrile; EB, estradiol benzoate; E2, 17β-Estradiol; NA, not available; ND, not defined.
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Table 2A. Estrogen Receptor Beta and Cellular Signaling Outcomes (continued)
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
13 (Raval et al., 2013) Protection of 
Hippocampal CA1 
Neurons in
Oxygen-Glucose 
Deprivation Model
In vitro: brain 
hippocampal slices from 
Sprague-Dawley female 
rats
(9–11 days old)
In vivo:
OVX
Sprague–Dawley rats
Hippocampus DPN
E2
Behavioral tests
Positive effect Neuroprotection (against cerebral ischemia).
14 (Rossi et al., 2010) Desensitization of HT1A 
receptor signaling.
OVX, rats Hypothalamic 
paraventricular nucleus 
DPN No effect DPN did not alter plasma baseline levels of ACTH or 
oxytocin.
15 (Sarvari et al., 2011) Neuroinflammatory genes 
regulation
OVX Wistar rats Frontal cortex DPN, E2 Positive effect DPN upregulated the expression of more than sixteen 
neuroinflammatory genes. ERß may be a target to 
supress regulatory functions of glial cells in the E2-
deprived female brain and inflammatory diseases.
16 (Sarvari et al., 2014) mRNA expression in the
hippocampus after 
gonadal hormone 
withdrawal
OVX
Harlan-Wistar rats
n=34 
Hippocampus DPN,
E2 
ERß agonist was capable of 
attenuating the expression of 
several macrophage-associated and 
complement genes. 
After ovariectomy, E2 and DPN restore the mRNA 
expression of genes Iba1, Cd68, Cd11b and Cd18. This 
shows that estrogen replacement partly restores neuronal 
control of microglia and modulates complement 
expression.
17 (Spencer-Segal et al., 
2012)
Gene transcription and
protein expression of 
pAkt-ir, PSD-95-ir and 
pTrkBir 
OVX
KO/WT Mice
n=63
9-20 weeks 
Hippocampus Gene deletion,
E2 
ERß mediates increase in pAkt-ir 
expression after E2 treatment lasting 
6 hrs.
Estradiol tended to decrease PSD-95 
in BERKO mice: However, this trend 
was not
statistically significant.
ERß mediates increase in pTrkB-ir 
expression after E2 treatment lasting 
48 hrs.
Cellular signaling outcomes (synaptic plasticity).
ERß mediates effects of estradiol on pathways important 
for synaptic plasticity in the mouse hippocampal 
formation. 
18 (S. Suzuki et al., 2007) Neurogenesis
in animal model of 
ischemic stroke
OVX
C57BL/6J mice
n=90
11 weeks old.
Age-matched OVX
KO/WT Mice
n=30 
Subventricular zone (SVZ) 
of the brain 
Gene deletion, E2 Enhanced Neurogenesis: (in an
animal model of ischemic stroke).
ERß mediates effects of estradiol treatment on increase 
in number of newborn neurons in the dorsal SVZ of the 
adult mouse and on enhancement of neurogenesis in an
animal model of ischemic stroke. 
19 (Waters et al., 2009) Expression of synaptic 
proteins PSD-95 and 
AMPA-type glutamate 
receptor
subunits GluR1, GluR2 
and GluR3.
OVX, rats Hippocampus DPN DPN administration increased 
expression of PSD-95 and AMPA-
type glutamate receptor
subunit GluR1.
DPN administration increased 
expression of AMPA receptor subunits
GluR2 and decreased expression of 
AMPA receptor subunits
GluR3.
Cellular signaling outcomes (expression of synaptic 
proteins in rat hippocampus)
ERβ specific agonists regulate the expression of synaptic 
proteins in rat hippocampus which is important for 
hippocampal-dependent cognitive performance. 
DPN, diarylpropionitrile; EB, estradiol benzoate; E2, 17β-Estradiol; NA, not available; ND, not defined.
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Table 2b. Estrogen Receptor Beta and Neuroendocrine Pathway Outcomes
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
1 (Bosch et al., 2009) T-type calcium
channel (subtype Cav3.2) 
expression and function
KO/WT Mice
and OVX C57BL/6 mice
Hypothalamic nuclei and 
pituitary calcium channel 
subunit: Cav3.1
Gene deletion, 
Estradiol (E2) 
Positive effect Involvement in excitability of hypothalamic neurons.
2 (Clark et al., 2012) Tryptophan 
hydroxylase-1 (TPH-1) 
mRNA expression;
progesterone receptor
expression
KO/WT Mice
and OVX C57BL/6 Mice
Dorsal
raphe nuclei; dentate gyrus 
in hippocampus 
SERM-beta1,
SERM-beta2, E2,
gene deletion, forced 
swim test (FST)
Positive effect SERM-beta1 and
2 exhibited antidepressant-like effects / ERß may play 
an important role in modulating mood
3 (Chu et al., 2009) Firing of GnRH neurons
GABA transmission 
OVX
Mice expressing enhanced
green fluorescent protein 
under the control of the
GnRH promoter 
Preoptic area (POA) / 
hypothalamus
Estradiol,
DPN
Supporting effect ERß agonist activates GnRH firing, reduces after 
hyperpolarizing potential (AHP) and increased slow 
afterdepolarization amplitudes (ADP), and reduced IAHP 
and enhanced IADP.
Also, ERß agonist increased GABA transmission and 
postsynaptic response in GnRH neuron 
4 (Kudwa et al., 2014) CORT and ACTH 
response to restraint stress 
Sprague–Dawley rats of 
both sexes
(OVX females)
n=118
NA DPN, behavioral 
and restraint testing
DPN reduced CORT and ACTH 
responses in both
males and females.
ERβ may modulate HPA (neuroendocrine stress) 
reactivity.
5 (W. J. Miller et al., 2004) regulation of the 
corticotropin-releasing 
hormone (CRH) 
promoter
OVX
Sprague–Dawley rats
n=5 
Hypothalamus
 
Expression
vectors: ERß 
isoforms 
Enhanced (Increased) (positive effect) Neuroendocrine pathway: (regulation of the 
corticotropin-releasing hormone promoter).
ERß regulates CRH in the PVH (paraventricular 
nucleus) of the hypothalamus.   
6 (Rossi et al., 2010) Desensitization of 
5-HT1A receptor signaling
OVX
Sprague–Dawley rats
Hypothalamic 
paraventricular nucleus
DPN,
recombinant 
adenovirus-
containing ERß 
siRNAs
No effect Desensitization of 5-
HT1A receptor signaling does not appear to be mediated 
by ERß in oxytocin cells. ERß
together with GPR30, may play a complex role in 
central regulation of 5-HT1A -mediated ACTH release.
7 (Sa et al., 2013) estrogen induction of 
progesterone receptors
(PRs) 
OVX
Wistar rats
(10 weeks of age) 
the ventrolateral division of 
the hypothalamic
ventromedial nucleus 
(VMNvl) 
DPN
E2 
No effect Neuroendocrine pathway: (induction of progesterone 
receptors in hypothalamus).
Since PR induction by estradiol is required for the 
display of
female sexual behavior obtained data point to the 
conclusion that activation of the ERß in OVX rats does 
not facilitate the expression of female sexual
behavior. 
DPN, diarylpropionitrile; EB, estradiol benzoate; E2, 17β-Estradiol; NA, not available; ND, not defined.
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Table 2b. Estrogen Receptor Beta and Neuroendocrine Pathway Outcomes
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
1 (Bosch et al., 2009) T-type calcium
channel (subtype Cav3.2) 
expression and function
KO/WT Mice
and OVX C57BL/6 mice
Hypothalamic nuclei and 
pituitary calcium channel 
subunit: Cav3.1
Gene deletion, 
Estradiol (E2) 
Positive effect Involvement in excitability of hypothalamic neurons.
2 (Clark et al., 2012) Tryptophan 
hydroxylase-1 (TPH-1) 
mRNA expression;
progesterone receptor
expression
KO/WT Mice
and OVX C57BL/6 Mice
Dorsal
raphe nuclei; dentate gyrus 
in hippocampus 
SERM-beta1,
SERM-beta2, E2,
gene deletion, forced 
swim test (FST)
Positive effect SERM-beta1 and
2 exhibited antidepressant-like effects / ERß may play 
an important role in modulating mood
3 (Chu et al., 2009) Firing of GnRH neurons
GABA transmission 
OVX
Mice expressing enhanced
green fluorescent protein 
under the control of the
GnRH promoter 
Preoptic area (POA) / 
hypothalamus
Estradiol,
DPN
Supporting effect ERß agonist activates GnRH firing, reduces after 
hyperpolarizing potential (AHP) and increased slow 
afterdepolarization amplitudes (ADP), and reduced IAHP 
and enhanced IADP.
Also, ERß agonist increased GABA transmission and 
postsynaptic response in GnRH neuron 
4 (Kudwa et al., 2014) CORT and ACTH 
response to restraint stress 
Sprague–Dawley rats of 
both sexes
(OVX females)
n=118
NA DPN, behavioral 
and restraint testing
DPN reduced CORT and ACTH 
responses in both
males and females.
ERβ may modulate HPA (neuroendocrine stress) 
reactivity.
5 (W. J. Miller et al., 2004) regulation of the 
corticotropin-releasing 
hormone (CRH) 
promoter
OVX
Sprague–Dawley rats
n=5 
Hypothalamus
 
Expression
vectors: ERß 
isoforms 
Enhanced (Increased) (positive effect) Neuroendocrine pathway: (regulation of the 
corticotropin-releasing hormone promoter).
ERß regulates CRH in the PVH (paraventricular 
nucleus) of the hypothalamus.   
6 (Rossi et al., 2010) Desensitization of 
5-HT1A receptor signaling
OVX
Sprague–Dawley rats
Hypothalamic 
paraventricular nucleus
DPN,
recombinant 
adenovirus-
containing ERß 
siRNAs
No effect Desensitization of 5-
HT1A receptor signaling does not appear to be mediated 
by ERß in oxytocin cells. ERß
together with GPR30, may play a complex role in 
central regulation of 5-HT1A -mediated ACTH release.
7 (Sa et al., 2013) estrogen induction of 
progesterone receptors
(PRs) 
OVX
Wistar rats
(10 weeks of age) 
the ventrolateral division of 
the hypothalamic
ventromedial nucleus 
(VMNvl) 
DPN
E2 
No effect Neuroendocrine pathway: (induction of progesterone 
receptors in hypothalamus).
Since PR induction by estradiol is required for the 
display of
female sexual behavior obtained data point to the 
conclusion that activation of the ERß in OVX rats does 
not facilitate the expression of female sexual
behavior. 
DPN, diarylpropionitrile; EB, estradiol benzoate; E2, 17β-Estradiol; NA, not available; ND, not defined.
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Table 2C. Estrogen Receptor Beta and Neurological Outcomes
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
1 (Boulware et al., 2013) Hippocampal memory 
consolidation
p42 ERK
phosphorylation
OVX
C57BL/6 mice (8–12 
weeks of age) 
dorsal hippocampus DPN,
E2,
novel object 
recognition and 
object placement 
behavioral tests 
Increased 
Increased
Neurological outcomes: (hippocampal memory 
consolidation)
ERß/mGluR signaling can mediate the beneficial effects 
of E2 on hippocampal memory consolidation.
2 (Liu et al., 2008) Protein expression of the 
AMPAR subunit GluR1 
and
PSD-95;
LTP;
Dendritic branching and 
spine number;
Spatial memory
OVX 
KO/WT
Mice
Hippocampus Gene deletion; 
WAY-200070 or 
WAY-202779; 
Behavioral tests
Positive effect 
Positive effect
Positive effect
Positive effect
Activation of ERß can regulate hippocampal synaptic 
plasticity and improve hippocampus-dependent 
cognition.
3 (Han et al., 2013) Regulation of gene 
transcription and learning 
in the hippocampus
OVX 
KO/WT
Mice n=163
Hippocampus Gene deletion, 
estradiol (17 
ß-estradiol 
benzoate);
behavioral studies
Positive effect ERß interacts with estradiol levels to regulate 
transcription involved in
maintaining hippocampal function (hippocampal 
dependent
memory) during aging
4 (Jacome et al., 2010) Recognition memory
Brain monoamines levels
OVX
Sprague Dawley rats
n=32-34
NA DPN, 
estradiol benzoate;
behavioral tests 
(object recognition / 
placement memory 
tasks)
Positive effect
Increased
ERß mediates sub chronic and acute effects
of estrogens on recognition memory. Memory 
enhancements may occur, in part, through
alterations in monoaminergic-containing systems 
primarily in PFC and hippocampus.
5 (Raval et al., 2013) Post-ischemic
Learning and Memory 
In vitro: brain 
hippocampal slices from 
Sprague-Dawley female 
rats
(9–11 days old)
In vivo:
OVX
Sprague–Dawley rats
Hippocampus DPN,
E2,
behavioral tests 
Improved by periodic activation of 
ERß 
Neurological outcome: (learning and memory).
ERß intracellular signaling mediates improvement of 
post-ischemic outcome and cognition induced by long-
term periodic
E2 treatment in the hippocampus of OvX female rats.
99
Ch
ap
te
r 3
.1
The Functions of Estrogen Receptor Beta in the Female Brain
Table 2C. Estrogen Receptor Beta and Neurological Outcomes
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
1 (Boulware et al., 2013) Hippocampal memory 
consolidation
p42 ERK
phosphorylation
OVX
C57BL/6 mice (8–12 
weeks of age) 
dorsal hippocampus DPN,
E2,
novel object 
recognition and 
object placement 
behavioral tests 
Increased 
Increased
Neurological outcomes: (hippocampal memory 
consolidation)
ERß/mGluR signaling can mediate the beneficial effects 
of E2 on hippocampal memory consolidation.
2 (Liu et al., 2008) Protein expression of the 
AMPAR subunit GluR1 
and
PSD-95;
LTP;
Dendritic branching and 
spine number;
Spatial memory
OVX 
KO/WT
Mice
Hippocampus Gene deletion; 
WAY-200070 or 
WAY-202779; 
Behavioral tests
Positive effect 
Positive effect
Positive effect
Positive effect
Activation of ERß can regulate hippocampal synaptic 
plasticity and improve hippocampus-dependent 
cognition.
3 (Han et al., 2013) Regulation of gene 
transcription and learning 
in the hippocampus
OVX 
KO/WT
Mice n=163
Hippocampus Gene deletion, 
estradiol (17 
ß-estradiol 
benzoate);
behavioral studies
Positive effect ERß interacts with estradiol levels to regulate 
transcription involved in
maintaining hippocampal function (hippocampal 
dependent
memory) during aging
4 (Jacome et al., 2010) Recognition memory
Brain monoamines levels
OVX
Sprague Dawley rats
n=32-34
NA DPN, 
estradiol benzoate;
behavioral tests 
(object recognition / 
placement memory 
tasks)
Positive effect
Increased
ERß mediates sub chronic and acute effects
of estrogens on recognition memory. Memory 
enhancements may occur, in part, through
alterations in monoaminergic-containing systems 
primarily in PFC and hippocampus.
5 (Raval et al., 2013) Post-ischemic
Learning and Memory 
In vitro: brain 
hippocampal slices from 
Sprague-Dawley female 
rats
(9–11 days old)
In vivo:
OVX
Sprague–Dawley rats
Hippocampus DPN,
E2,
behavioral tests 
Improved by periodic activation of 
ERß 
Neurological outcome: (learning and memory).
ERß intracellular signaling mediates improvement of 
post-ischemic outcome and cognition induced by long-
term periodic
E2 treatment in the hippocampus of OvX female rats.
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Table 2C. Estrogen Receptor Beta and Neurological Outcomes (continued)
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
6 (J. M. Wang et al., 2006) Apolipoprotein E
expression in 
hippocampus in vitro and 
in vivo 
Rat
Hippocampal Neurons in 
Primary Culture /
OVX
Sprague–Dawley rats
n=9
(4-6 months old)
Hippocampus DPN Decreased /
ERβ selective agonist, DPN, down-
regulated ApoE mRNA and protein 
expression.
Neurological outcome: AD
Use of ER-selective ligands could provide therapeutic 
benefit to reduce the risk of AD by
increasing ApoE expression in ApoE2/3 allele carriers 
and decreasing ApoE expression in ApoE4 allele carriers.
7 (Zhao et al., 2011) Insulin-degrading 
enzyme(IDE) mRNA and 
protein expression 
OVX
Sprague–Dawley rats(14 
to
16-week-old)
A triple transgenic 
AD(3xTg-AD) mice 
Hippocampus, cortex and
cerebellum 
DPN,
E2
Treatment with DPN increased IDE 
protein expression in rat hippocampal 
neurons
Neurological outcome: AD prevention;
ERß/PI3-K pathway modulates effects of 17ß-E2 
on regulation of insulin-degrading enzyme (IDE) 
expression in a brain region-specific manner. Such 
regulatory role in the hippocampus could serve as 
a direct mechanism underlying estrogen-mediated 
preventative effect against AD when initiated at the 
onset of menopause.
8 (Zhao et al., 2013) Regulation of early
stages of physical and 
neurological changes 
associated with AD 
OVX
Triple transgenic AD 
(3xTg-AD) mice
(3 months old) 
Hippocampus, cortex, 
cerebellum
Phytoestrogenic 
ER-ß selective 
modulator (SERM)
formulation 
containing equal 
parts of genistein, 
daidzein, and equol.
Y-Maze cognition-
behavioral test
When initiated prior to the 
appearance of AD pathology, a 
9-month dietary supplementation
with the phyto- ß -SERM formulation 
promoted physical health, prolonged 
survival, improved spatial recognition 
memory, and
attenuated amyloid-ß deposition and 
plaque formation in the brains of 
treated AD mice. 
Neurological outcome: AD
Obtained results support the therapeutic potential 
of the phyto- ß –SERM formulation for prevention 
and/or early intervention of AD, and warrant further 
investigations in human studies.
DPN, diarylpropionitrile; EB, estradiol benzoate; E2, 17β-Estradiol; NA, not available; ND, not defined.
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Table 2C. Estrogen Receptor Beta and Neurological Outcomes (continued)
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
6 (J. M. Wang et al., 2006) Apolipoprotein E
expression in 
hippocampus in vitro and 
in vivo 
Rat
Hippocampal Neurons in 
Primary Culture /
OVX
Sprague–Dawley rats
n=9
(4-6 months old)
Hippocampus DPN Decreased /
ERβ selective agonist, DPN, down-
regulated ApoE mRNA and protein 
expression.
Neurological outcome: AD
Use of ER-selective ligands could provide therapeutic 
benefit to reduce the risk of AD by
increasing ApoE expression in ApoE2/3 allele carriers 
and decreasing ApoE expression in ApoE4 allele carriers.
7 (Zhao et al., 2011) Insulin-degrading 
enzyme(IDE) mRNA and 
protein expression 
OVX
Sprague–Dawley rats(14 
to
16-week-old)
A triple transgenic 
AD(3xTg-AD) mice 
Hippocampus, cortex and
cerebellum 
DPN,
E2
Treatment with DPN increased IDE 
protein expression in rat hippocampal 
neurons
Neurological outcome: AD prevention;
ERß/PI3-K pathway modulates effects of 17ß-E2 
on regulation of insulin-degrading enzyme (IDE) 
expression in a brain region-specific manner. Such 
regulatory role in the hippocampus could serve as 
a direct mechanism underlying estrogen-mediated 
preventative effect against AD when initiated at the 
onset of menopause.
8 (Zhao et al., 2013) Regulation of early
stages of physical and 
neurological changes 
associated with AD 
OVX
Triple transgenic AD 
(3xTg-AD) mice
(3 months old) 
Hippocampus, cortex, 
cerebellum
Phytoestrogenic 
ER-ß selective 
modulator (SERM)
formulation 
containing equal 
parts of genistein, 
daidzein, and equol.
Y-Maze cognition-
behavioral test
When initiated prior to the 
appearance of AD pathology, a 
9-month dietary supplementation
with the phyto- ß -SERM formulation 
promoted physical health, prolonged 
survival, improved spatial recognition 
memory, and
attenuated amyloid-ß deposition and 
plaque formation in the brains of 
treated AD mice. 
Neurological outcome: AD
Obtained results support the therapeutic potential 
of the phyto- ß –SERM formulation for prevention 
and/or early intervention of AD, and warrant further 
investigations in human studies.
DPN, diarylpropionitrile; EB, estradiol benzoate; E2, 17β-Estradiol; NA, not available; ND, not defined.
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Table 2D. Estrogen Receptor Beta and Neuroprotection Outcomes 
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
1 (C. M. Brown et al., 
2010)
Regulation of brain 
cytokine and chemokine
levels;
Regulation of BBB 
permeability
OVX 
KO/WT
Mice
Cortex and
striatum
Gene deletion; 
E2; Cytokine/
chemokine 
quantification.
Positive effect
Positive effect
ERß regulates proinflammatory cytokine and 
chemokine production
through E2-dependent and E2-independent 
mechanisms. 
ERß is essential for E2-mediated
regulation of BBB permeability.
2 (Carswell et al., 2004) Induction of transient 
global ischemia by 
bilateral carotid artery
occlusion
OVX
C57BL/6J mice
n=44
Caudate nucleus and dorsal
hippocampus
DPN DPN significantly reduced ischemic
damage by 70% in the caudate 
nucleus and 55% in the CA1 region
compared with vehicle controls.
ERß activation is neuroprotective 
in global cerebral ischemia mouse model.
3 (N. R. Miller et al., 2005) Protection of 
hippocampal neurons
in a global ischemia 
model
OVX
Sprague–Dawley rats
(21 days old)
Hippocampus WAY 200070-3 ERß-selective agonist
WAY 200070–3 produced nearly 
complete protection
of CA1 neurons in approximately 
50% of the animals.
Neuroprotection: (protection of hippocampal neurons
in global ischemia model)
ERß mediates estradiol protection of CA1 hippocampal 
neurons from global
ischemia-induced cell death. 
4 (Raval et al., 2013) Protection of 
Hippocampal CA1 
Neurons in
Oxygen-Glucose 
Deprivation Model
In vitro: brain 
hippocampal slices from 
Sprague-Dawley female 
rats
(9–11 days old)
In vivo:
OVX
Sprague–Dawley rats
Hippocampus DPN
E2
Behavioral tests 
Positive effect Neuroprotection (against cerebral ischemia).
DPN, diarylpropionitrile; EB, estradiol benzoate; E2, 17β-Estradiol; NA, not available; ND, not defined.
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Table 2D. Estrogen Receptor Beta and Neuroprotection Outcomes 
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
1 (C. M. Brown et al., 
2010)
Regulation of brain 
cytokine and chemokine
levels;
Regulation of BBB 
permeability
OVX 
KO/WT
Mice
Cortex and
striatum
Gene deletion; 
E2; Cytokine/
chemokine 
quantification.
Positive effect
Positive effect
ERß regulates proinflammatory cytokine and 
chemokine production
through E2-dependent and E2-independent 
mechanisms. 
ERß is essential for E2-mediated
regulation of BBB permeability.
2 (Carswell et al., 2004) Induction of transient 
global ischemia by 
bilateral carotid artery
occlusion
OVX
C57BL/6J mice
n=44
Caudate nucleus and dorsal
hippocampus
DPN DPN significantly reduced ischemic
damage by 70% in the caudate 
nucleus and 55% in the CA1 region
compared with vehicle controls.
ERß activation is neuroprotective 
in global cerebral ischemia mouse model.
3 (N. R. Miller et al., 2005) Protection of 
hippocampal neurons
in a global ischemia 
model
OVX
Sprague–Dawley rats
(21 days old)
Hippocampus WAY 200070-3 ERß-selective agonist
WAY 200070–3 produced nearly 
complete protection
of CA1 neurons in approximately 
50% of the animals.
Neuroprotection: (protection of hippocampal neurons
in global ischemia model)
ERß mediates estradiol protection of CA1 hippocampal 
neurons from global
ischemia-induced cell death. 
4 (Raval et al., 2013) Protection of 
Hippocampal CA1 
Neurons in
Oxygen-Glucose 
Deprivation Model
In vitro: brain 
hippocampal slices from 
Sprague-Dawley female 
rats
(9–11 days old)
In vivo:
OVX
Sprague–Dawley rats
Hippocampus DPN
E2
Behavioral tests 
Positive effect Neuroprotection (against cerebral ischemia).
DPN, diarylpropionitrile; EB, estradiol benzoate; E2, 17β-Estradiol; NA, not available; ND, not defined.
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Table 2E. Estrogen Receptor Beta and Psychological/Psychiatric Outcomes
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
1 (Bansal & Chopra, 2015) Depression-like behavior 
Memory impairment
OVX
Sprague–
Dawley rats
NA DPN DPN markedly prevented memory 
impairment and decreased immobility 
time in OVX or diabetic rats
DPN decreased immobility time in the forced swim test 
when compared to controls.
Memory improvement was suggested by DPN 
decreasing the total distance traveled in a water maze. 
2 (Bastos et al., 2015) Depression-like behavior 
Non-spatial memory
OVX C57BL/6 mice Hippocampus DPN, E2 DPN decreased the immobility time; 
the depressive-like behavior of mice in 
the forced swim test. 
DPN rescued object recognition 
memory by acting on early stages of 
memory consolidation. 
These effects were observed up to 12 weeks after 
ovariectomy; demonstrating that 12 weeks of OVX is 
not a sufficient time to abolish the beneficial effects of 
E2. 
3 (Benmansour et al., 
2014)
Assessment of serotonin
clearance
OVX
Sprague–Dawley rats
CA3 region of the 
hippocampus
DPN,
E2
The E2-induced slowing of serotonin
clearance via activation of ERβ 
required MAPK/ERK1/2
signaling pathways and involved 
interactions both
with TrkB and IGF-1R.
Activation of ERβ induced by E2 slows serotonin 
clearance /
Antidepressant-like effect of estradiol is
mediated by ERβ.
4 (Benmansour et al., 
2015)
Depression-like behavior OVX Sprague-Dawley 
rats
NA DPN DPN at 5 or 10 micrograms induced 
antidepressant-like effects during the 
forced swim test.
Higher doses of DPN were not found to produce 
antidepressant-like effects.
5 (Choleris et al., 2003) Social recognition
Social anxiety
KO/WT Mice and OVX 
Swiss Webster mice
n=89
NA Gene deletion,
social recognition 
paradigm (tests) and 
behavioral analysis.
ß-ERKO mice were
selectively impaired in social 
recognition but not in overall activity.
The reduced social anxiety was found 
in the ß-ERKO mice.
Genes for
ERß play a crucial role in oxytocin-dependent social
recognition.
Estrogen modulation of female
psychosocial anxiety depends on ER-ß.
6 (Choleris et al., 2006) Social recognition (binary 
social discrimination
assay)
KO/WT Mice and OVX 
Swiss Webster mice
n=88
NA Gene deletion, 
social recognition 
paradigm (tests) and 
behavioral analysis.
ß-ERKO mice showed partially 
impaired social discrimination.
ERß genes are
necessary for social discrimination
and, thus, for the modulation of social behavior (e.g.,
aggression, affiliation).
7 (Clark et al., 2012) Tryptophan 
hydroxylase-1 (TPH-1) 
mRNA expression;
progesterone receptor
expression
KO/WT Mice
and OVX C57BL/6 Mice 
Dorsal
raphe nuclei; dentate gyrus 
in hippocampus
SERM-beta1,
SERM-beta2, E2,
gene deletion, forced 
swim test (FST)
Positive effect SERM-beta1 and
2 exhibited antidepressant-like effects / ERß may play 
an important role in modulating mood
8 (Donner & Handa, 
2009)
Tryptophan-Hydroxylase 
2 mRNA expression
Anxiety-like behaviors
Despair-like behavior
OVX
Sprague–
Dawley rats
Brainstem (dorsal
raphe nuclei)
Systemic and local 
application of DPN, 
Behavioral testing
Positive effect
Systemic delivery of DPN
decreased anxiety-like behavior, while 
local administration
of DPN failed to have the same effect.
Local DPN 
administration in animals showed 
decreased despair-like
behavior. does not alter anxiety-like
behaviors, but enhances active stress-
coping behavior.
ERß acts at the level of the rat
DRN to modulate tph2 mRNA expression and thereby 
influence
5-HT synthesis in DRN subregions. 
Local activation of ERß neurons in the DRN may be 
sufficient to decrease despair-like behavior, but not
anxiolytic behaviors.
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Table 2E. Estrogen Receptor Beta and Psychological/Psychiatric Outcomes
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
1 (Bansal & Chopra, 2015) Depression-like behavior 
Memory impairment
OVX
Sprague–
Dawley rats
NA DPN DPN markedly prevented memory 
impairment and decreased immobility 
time in OVX or diabetic rats
DPN decreased immobility time in the forced swim test 
when compared to controls.
Memory improvement was suggested by DPN 
decreasing the total distance traveled in a water maze. 
2 (Bastos et al., 2015) Depression-like behavior 
Non-spatial memory
OVX C57BL/6 mice Hippocampus DPN, E2 DPN decreased the immobility time; 
the depressive-like behavior of mice in 
the forced swim test. 
DPN rescued object recognition 
memory by acting on early stages of 
memory consolidation. 
These effects were observed up to 12 weeks after 
ovariectomy; demonstrating that 12 weeks of OVX is 
not a sufficient time to abolish the beneficial effects of 
E2. 
3 (Benmansour et al., 
2014)
Assessment of serotonin
clearance
OVX
Sprague–Dawley rats
CA3 region of the 
hippocampus
DPN,
E2
The E2-induced slowing of serotonin
clearance via activation of ERβ 
required MAPK/ERK1/2
signaling pathways and involved 
interactions both
with TrkB and IGF-1R.
Activation of ERβ induced by E2 slows serotonin 
clearance /
Antidepressant-like effect of estradiol is
mediated by ERβ.
4 (Benmansour et al., 
2015)
Depression-like behavior OVX Sprague-Dawley 
rats
NA DPN DPN at 5 or 10 micrograms induced 
antidepressant-like effects during the 
forced swim test.
Higher doses of DPN were not found to produce 
antidepressant-like effects.
5 (Choleris et al., 2003) Social recognition
Social anxiety
KO/WT Mice and OVX 
Swiss Webster mice
n=89
NA Gene deletion,
social recognition 
paradigm (tests) and 
behavioral analysis.
ß-ERKO mice were
selectively impaired in social 
recognition but not in overall activity.
The reduced social anxiety was found 
in the ß-ERKO mice.
Genes for
ERß play a crucial role in oxytocin-dependent social
recognition.
Estrogen modulation of female
psychosocial anxiety depends on ER-ß.
6 (Choleris et al., 2006) Social recognition (binary 
social discrimination
assay)
KO/WT Mice and OVX 
Swiss Webster mice
n=88
NA Gene deletion, 
social recognition 
paradigm (tests) and 
behavioral analysis.
ß-ERKO mice showed partially 
impaired social discrimination.
ERß genes are
necessary for social discrimination
and, thus, for the modulation of social behavior (e.g.,
aggression, affiliation).
7 (Clark et al., 2012) Tryptophan 
hydroxylase-1 (TPH-1) 
mRNA expression;
progesterone receptor
expression
KO/WT Mice
and OVX C57BL/6 Mice 
Dorsal
raphe nuclei; dentate gyrus 
in hippocampus
SERM-beta1,
SERM-beta2, E2,
gene deletion, forced 
swim test (FST)
Positive effect SERM-beta1 and
2 exhibited antidepressant-like effects / ERß may play 
an important role in modulating mood
8 (Donner & Handa, 
2009)
Tryptophan-Hydroxylase 
2 mRNA expression
Anxiety-like behaviors
Despair-like behavior
OVX
Sprague–
Dawley rats
Brainstem (dorsal
raphe nuclei)
Systemic and local 
application of DPN, 
Behavioral testing
Positive effect
Systemic delivery of DPN
decreased anxiety-like behavior, while 
local administration
of DPN failed to have the same effect.
Local DPN 
administration in animals showed 
decreased despair-like
behavior. does not alter anxiety-like
behaviors, but enhances active stress-
coping behavior.
ERß acts at the level of the rat
DRN to modulate tph2 mRNA expression and thereby 
influence
5-HT synthesis in DRN subregions. 
Local activation of ERß neurons in the DRN may be 
sufficient to decrease despair-like behavior, but not
anxiolytic behaviors.
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Table 2E. Estrogen Receptor Beta and Psychological/Psychiatric Outcomes (continued)
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
9 (Galvin & Ninan, 2014) Fear extinction C57/BL6 mice Infralimbic medial 
prefrontal cortex
DPN Increased ERß activation facilitates the infralimbic medial 
prefrontal cortex to undergo potentiation; necessary for 
the regulation of fear extinction. 
10 (Gundlah et al., 2005) TPH1 mRNA expression KO/WT mice
and OVX C57BL/6
mice 
Dorsal raphe nucleus 
(DRN) in midbrain 
Gene deletion,
estradiol
Positive effect ERß might be responsible for mediating estrogen 
regulated TPH1 expression in the murine DRN. /
ERß might be a key mediator of estrogen
action in serotonergic neurons. 
11 (Imwalle et al., 2005) Anxiety-like behavior
Measurement of brain 
serotonin and dopamine 
levels
OVX 
KO/WT mice
n=80 
Cingulate cortex; caudate 
putamen; nucleus 
accumbens; medial
septum; stria
terminalis; hippocampus; 
posterodorsal amygdale; 
substantia nigra; dorsal 
raphe, locus
coeruleus
Gene deletion, E2, 
behavioral testing 
(the elevated plus-
maze test),
monoamine HPLC 
In the absence of functional ERß 
female mice exhibited enhanced 
anxiety and
decreased concentrations of 5-HT or 
dopamine in several brain regions. 
ERß may modulate estrogen effects on anxiety and 
catecholamine concentrations. 
12 (Krezel et al., 2001) Anxiety-like 
behavior
5-HT1a receptor 
expression in amygdala
Synaptic
plasticity in the amygdala
KO/WT mice
both sexes 
Amygdala Gene deletion, 
behavioral testing;
electrophysiological 
evaluation of 
amygdala functions. 
ERß mutant females showed increased 
anxiety.
Positive effect
Enhanced
anxiety is associated with a reduced 
threshold for synaptic
plasticity in the amygdala, principally 
in female mice.
ERß mediates estrogen signaling in the processing of 
emotional
behavior particularly in females. /
ERß may
be critically involved in the expression of anxiety 
disorders to
which females may be particularly susceptible.
13 (Kudwa et al., 2014) Anxiety and depressive-
like 
behavior
Sprague–Dawley rats of 
both sexes
(OVX females)
n=118
NA DPN, behavioral 
and restraint testing
DPN effectively increased
anxiolytic behaviors more effectively 
in females. Females responded
to DPN with an anti-depressive 
like response whereas males did not 
respond to treatment.
ERβ may reduce anxiety-like
behavior.
14 (Lynch et al., 2014) Fear generalization Long-Evans rats NA DPN, behavioral 
test.
Increased DPN at a 2.5 mg dose increased fear generalization 
through an effect on fear memory retrieval mechanisms 
by activation of ERß.
15 (Oyola et al., 2012) Anxiety-like behaviors OVX
KO/WT Mice
3-4 months of age 
Anterodorsal medial 
amygdala and bed nucleus 
of the stria terminalis
Gene deletion, 
S-DPN,
E2,
behavioral tests
Reduced by DPN administration Psychological outcomes: (mediation of anxiety-like 
behaviors).
ERß mediates anxiolytic actions of estradiol. 
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Table 2E. Estrogen Receptor Beta and Psychological/Psychiatric Outcomes (continued)
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
9 (Galvin & Ninan, 2014) Fear extinction C57/BL6 mice Infralimbic medial 
prefrontal cortex
DPN Increased ERß activation facilitates the infralimbic medial 
prefrontal cortex to undergo potentiation; necessary for 
the regulation of fear extinction. 
10 (Gundlah et al., 2005) TPH1 mRNA expression KO/WT mice
and OVX C57BL/6
mice 
Dorsal raphe nucleus 
(DRN) in midbrain 
Gene deletion,
estradiol
Positive effect ERß might be responsible for mediating estrogen 
regulated TPH1 expression in the murine DRN. /
ERß might be a key mediator of estrogen
action in serotonergic neurons. 
11 (Imwalle et al., 2005) Anxiety-like behavior
Measurement of brain 
serotonin and dopamine 
levels
OVX 
KO/WT mice
n=80 
Cingulate cortex; caudate 
putamen; nucleus 
accumbens; medial
septum; stria
terminalis; hippocampus; 
posterodorsal amygdale; 
substantia nigra; dorsal 
raphe, locus
coeruleus
Gene deletion, E2, 
behavioral testing 
(the elevated plus-
maze test),
monoamine HPLC 
In the absence of functional ERß 
female mice exhibited enhanced 
anxiety and
decreased concentrations of 5-HT or 
dopamine in several brain regions. 
ERß may modulate estrogen effects on anxiety and 
catecholamine concentrations. 
12 (Krezel et al., 2001) Anxiety-like 
behavior
5-HT1a receptor 
expression in amygdala
Synaptic
plasticity in the amygdala
KO/WT mice
both sexes 
Amygdala Gene deletion, 
behavioral testing;
electrophysiological 
evaluation of 
amygdala functions. 
ERß mutant females showed increased 
anxiety.
Positive effect
Enhanced
anxiety is associated with a reduced 
threshold for synaptic
plasticity in the amygdala, principally 
in female mice.
ERß mediates estrogen signaling in the processing of 
emotional
behavior particularly in females. /
ERß may
be critically involved in the expression of anxiety 
disorders to
which females may be particularly susceptible.
13 (Kudwa et al., 2014) Anxiety and depressive-
like 
behavior
Sprague–Dawley rats of 
both sexes
(OVX females)
n=118
NA DPN, behavioral 
and restraint testing
DPN effectively increased
anxiolytic behaviors more effectively 
in females. Females responded
to DPN with an anti-depressive 
like response whereas males did not 
respond to treatment.
ERβ may reduce anxiety-like
behavior.
14 (Lynch et al., 2014) Fear generalization Long-Evans rats NA DPN, behavioral 
test.
Increased DPN at a 2.5 mg dose increased fear generalization 
through an effect on fear memory retrieval mechanisms 
by activation of ERß.
15 (Oyola et al., 2012) Anxiety-like behaviors OVX
KO/WT Mice
3-4 months of age 
Anterodorsal medial 
amygdala and bed nucleus 
of the stria terminalis
Gene deletion, 
S-DPN,
E2,
behavioral tests
Reduced by DPN administration Psychological outcomes: (mediation of anxiety-like 
behaviors).
ERß mediates anxiolytic actions of estradiol. 
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Table 2E. Estrogen Receptor Beta and Psychological/Psychiatric Outcomes (continued)
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
16 (Rocha et al., 2005) Depression-like behavior 
through total duration of 
immobility in the Forced
Swim Test (FST) 
OVX:
CD1 Mice (n=171)
129S6 Mice (n=35) 
KO/WT Mice
(n=24)
NA Gene deletion,
E2, 
behavioral tests 
E2 did not reduce immobility in the
FST in BERKO mice
Psychological outcomes: (antidepressant-like effects). 
ER-β receptors are implicated in the antidepressant-like 
effects
of E2 in mice.
17 (H. Suzuki et al., 2013) Expression of tryptophan 
hydroxylase (TPH) in the 
Dorsal raphe (DR),
Alterations in glucose 
homeostasis. 
OVX
KO/WT Mice
n=45
6 months old
Dorsal raphe nucleus Gene deletion,
LY3201 (selective 
ERß agonist),
E2 
3-day treatment with LY3201 L
has a rapid onset effect on serotonergic 
activity with
increased expression of TPH and ERß.
LY3201 only
restored TPH expression in the DR 
when the duration of estrogen
deprivation was less than 10 weeks.
3-day treatment with LY3201 causes 
only
mild alterations in glucose 
homeostasis but effectively restored
TPH expression in the DR. 
Psychological outcomes: (serotonergic activity).
ERß agonists could be useful pharmaceuticals in 
maintaining
functional DR neurons to treat postmenopausal 
depression. 
18 (Walf & Frye, 2007) Anxiety and depressive 
behavior
OVX 
Long–Evans rats 
(n=84)
(55+ d old) 
Hippocampus Estrogen receptor 
beta-specific 
selective estrogen
Receptor 
modulators (DPN),
behavioral testing 
ERβ-selective SERMs to the 
hippocampus, but not the ventral 
tegmental area,
decreased anxiety and depressive 
behavior. 
Psychological outcomes: (Anxiety and depressive 
behavior) 
Administration of estrogen receptor beta-specific 
selective estrogen
receptor modulators to the hippocampus decrease 
anxiety and
depressive behavior of ovariectomized rats. 
19 (Zeidan et al., 2011) Extinction memory 
expression
during extinction recall 
(learning not to fear). 
Sprague–Dawley 
naturally cycling rats
n=81
Ventromedial prefrontal 
cortex (vmPFC) and 
amygdala 
DPN and behavioral 
tests (extinction 
recall learning trials) 
in animals
 
Administration of the estrogen-
receptor beta agonist facilitated 
extinction recall.
 
Psychological outcomes: (fear extinction recall)
ERß modulates effects of estradiol on facilitation of 
extinction memory consolidation in a time-dependent 
manner in rodents. 
DPN, diarylpropionitrile; EB, estradiol benzoate; E2, 17β-Estradiol; NA, not available; ND, not defined
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Table 2E. Estrogen Receptor Beta and Psychological/Psychiatric Outcomes (continued)
No. Author Outcome Study Sample brain Tissue Assessment of Erß 
function 
Conclusion Comment
16 (Rocha et al., 2005) Depression-like behavior 
through total duration of 
immobility in the Forced
Swim Test (FST) 
OVX:
CD1 Mice (n=171)
129S6 Mice (n=35) 
KO/WT Mice
(n=24)
NA Gene deletion,
E2, 
behavioral tests 
E2 did not reduce immobility in the
FST in BERKO mice
Psychological outcomes: (antidepressant-like effects). 
ER-β receptors are implicated in the antidepressant-like 
effects
of E2 in mice.
17 (H. Suzuki et al., 2013) Expression of tryptophan 
hydroxylase (TPH) in the 
Dorsal raphe (DR),
Alterations in glucose 
homeostasis. 
OVX
KO/WT Mice
n=45
6 months old
Dorsal raphe nucleus Gene deletion,
LY3201 (selective 
ERß agonist),
E2 
3-day treatment with LY3201 L
has a rapid onset effect on serotonergic 
activity with
increased expression of TPH and ERß.
LY3201 only
restored TPH expression in the DR 
when the duration of estrogen
deprivation was less than 10 weeks.
3-day treatment with LY3201 causes 
only
mild alterations in glucose 
homeostasis but effectively restored
TPH expression in the DR. 
Psychological outcomes: (serotonergic activity).
ERß agonists could be useful pharmaceuticals in 
maintaining
functional DR neurons to treat postmenopausal 
depression. 
18 (Walf & Frye, 2007) Anxiety and depressive 
behavior
OVX 
Long–Evans rats 
(n=84)
(55+ d old) 
Hippocampus Estrogen receptor 
beta-specific 
selective estrogen
Receptor 
modulators (DPN),
behavioral testing 
ERβ-selective SERMs to the 
hippocampus, but not the ventral 
tegmental area,
decreased anxiety and depressive 
behavior. 
Psychological outcomes: (Anxiety and depressive 
behavior) 
Administration of estrogen receptor beta-specific 
selective estrogen
receptor modulators to the hippocampus decrease 
anxiety and
depressive behavior of ovariectomized rats. 
19 (Zeidan et al., 2011) Extinction memory 
expression
during extinction recall 
(learning not to fear). 
Sprague–Dawley 
naturally cycling rats
n=81
Ventromedial prefrontal 
cortex (vmPFC) and 
amygdala 
DPN and behavioral 
tests (extinction 
recall learning trials) 
in animals
 
Administration of the estrogen-
receptor beta agonist facilitated 
extinction recall.
 
Psychological outcomes: (fear extinction recall)
ERß modulates effects of estradiol on facilitation of 
extinction memory consolidation in a time-dependent 
manner in rodents. 
DPN, diarylpropionitrile; EB, estradiol benzoate; E2, 17β-Estradiol; NA, not available; ND, not defined
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DiSCuSSiON
This review summarizes 49 studies published worldwide that investigate the functions of ERβ in the 
female brain. The studies suggest multiple functions of ERβ in the female brain that might contribute 
in a diversity of normal neurophysiologic functions (Figure 2). Our results support non-genomic 
actions of ERβ on the phosphorylation status and activity of multiple different signaling pathways in 
the brain. ERβ may act in the female brain through MAPK/ERK1/2 and PI3K/Akt signaling pathways 
and interactions of ERβ with TrkB and IGF-1R may facilitate activation of these kinases. Akt and 
TrkB are markers of hippocampal synaptic plasticity.(Nakai et al., 2014) Spenser-Segal et al have 
demonstrated that ERβ mediates the increase in pAkt-ir expression after treatment with estradiol for 
6 hours. The kinase pathways in the brain play a role in cell differentiation, survival, apoptosis, and 
cell proliferation among other functions, all of which might determine the initiation and progression 
of neurodegenerative disorders.(Spencer-Segal et al., 2012) Also, ERβ interacts with metabotropic 
glutamate receptors (mGluRs) signaling, which may depend upon caveolin proteins that are essential 
for the trafficking and clustering of signaling molecules.(Boulware et al., 2005) Among mGluRs, 
ERβ may activate cell membrane-localized mGluRs type 2 and 3. Their activation would lead to 
decreased concentrations of cAMP and a reduction in PKA activity, which would, in turn, result in 
ApoE mRNA: 
•	 Alzheimer’s	disease
75 
 
Figure 2 Potential pathways for ERβ function in the female brain. 
 
 
Potential pathways for ERβ function in the female brain. 
 
Legend:  mRNA, Apolipoprotein E messenger RNA; HPA, hypothalamus-pituitary-adrenal; IDE, insulin-degrading 
enzyme; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; NMDA,  N-Methyl-D-aspartic acid; Akt, 
Protein kinase B; MAPK, Mitogen-activated protein kinase; ERK, extracellular signal-regulated kinases; CREB, c-
AMP response-element binding protein. 
HPA reactivity:
•	 Anxiety
Nepriailyn, IDE:
•	 Alzheimer’s	disease
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figure 2 Potential pathways for ERβ function in the female br in.
Legend: mRNA, Apolipoprotein E messenger RNA; HPA, hypothalamus-pituitary-adrenal; IDE, insulin-
degrading enzyme; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; NMDA, N-Methyl-
D-aspartic acid; Akt, Protein kinase B; MAPK, Mitogen-activated protein kinase; ERK, extracellular 
signal-regulated kinases; CREB, c-AMP response-element binding protein.
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dephosphorylation of L-type calcium ion channels and a reduction of L-type calcium ion channel-
mediated CREB phosphorylation. Phosphorylation of CREB in the medial septum, for example, is 
undoubtedly due to action of ERβ since it is the only estrogen receptor type expressed in that part 
of the brain. Alternatively, other regions devoid of both ERα and ERβ, such as the caudate putamen 
or granulate cortex, do not show signs of CREB phosphorylation. CREB-mediated transcription 
has been described as promoting synapse formation and transmission in long-term memory and 
conferring protection against striatal neuronal death. Both of these attributes may be used as ra-
tionale for potential therapeutic interventions against Huntington’s disease.(Choi et al., 2009; Liu 
et al., 2008) Accordingly, an alteration of CREB functioning has also been associated with major 
depressive disorder, drug addiction and psychological dependence; conditions which may be better 
treated with a more thorough understanding of ERβ’s biological function.(Belmaker & Agam, 2008; 
McPherson & Lawrence, 2007) Similarly, mGluRs act as a second messenger in the signaling pathway 
that modulates synaptic transmission and neuronal excitability, suggesting a potential therapeutic 
utility in AD, Parkinson disease, schizophrenia, anxiety and depression.(Niswender & Conn, 2010; 
Pomierny-Chamiolo et al., 2014) Consequently, further research into these components may prove to 
be potential opportunities for treatment for Huntington’s disease, AD, epilepsy, and trauma.(Boulle et 
al., 2012; Chong, Shang, Wang, & Maiese, 2012)
The selected studies in this review consistently showed that ERβ agonists increased hypothalamic 
proteins PSD-95, synaptophysin and AMPA-receptor subunit GluR1, and dendritic branching and 
mushroom-type spines. Altogether, these effects of ERβ may suggest a role of this receptor in enhanc-
ing synaptic plasticity by persistent strengthening of synapses (long-term potentiation) and improv-
ing hippocampus-dependent memory and cognition (13,21). Further evidence in this systematic 
review demonstrates that mGluR1 from the dorsal hippocampus interacts with other membrane 
components such as p42 ERK and Gq proteins to enhance novel object recognition and object place-
ment memory consolidation (27,29). These may constitute potential targets for treatment of memory 
impairment conditions. The effect of ERβ on object recognition and object placement memory tasks, 
however, may only be exerted in certain regions of the brain and in response to a dose-dependent 
administration of estradiol. In this regard, ERβ and its agonist DPN have been associated with altera-
tion of the monoamines 3-methoxy-4-hydroxyphenylglycol (MHPG) and metabolites of dopamine 
and serotonin: homovanillic acid (HVA) and 5-hydroxyindole acetic acid, respectively. These findings 
were noted only in the prefrontal cortex and dentate gyrus but not in the striatum or medial septum.
(Jacome et al., 2010) Although ERβ is present in many areas of the neocortex, it is highly expressed in 
the hippocampus and frontal cortex, areas that are important for memory.(Mitra et al., 2003) 
ERβ also plays a key role in neurogenesis. Three of the studies included in this systematic review 
show a consistent effect of increased cell formation in the hippocampal dentate gyrus and subven-
tricular zone (Clark et al., 2012; Mazzucco et al., 2006; S. Suzuki et al., 2007), a finding supported 
by results from previous studies in adult animal models.(Ormerod, Lee, & Galea, 2003; Tanapat, 
Hastings, & Gould, 2005) These particular areas of the brain are known to produce a high expression 
of ERβ, which may explain their unique function of producing newborn cells. Neurogenesis in the 
hippocampus promotes the formation of new episodic memories and may even contribute to the 
therapeutic actions of antidepressant treatment.(Malberg, Eisch, Nestler, & Duman, 2000) Similarly, 
newly formed astrocytes from the subventricular zone could stimulate brain repair after ischemic 
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injury and may limit the extension of neurodegenerative changes and traumatic brain injuries.(S. Su-
zuki et al., 2007) However, the functional outcome of cell proliferation may become more important 
if we consider the exclusive presence and potential action of ERβ in other cell types of the brain, such 
as neurons of the paraventricular, suprachiasmatic, and tuberal hypothalamic nuclei, as well as the 
cerebellum and pineal gland.(Weiser, Foradori, & Handa, 2008)
Other mechanisms of ERβ action have been described in the neuroendocrine system. The activa-
tion of the HPA axis normally responds to a stress stimulus and is controlled by neurons in the 
paraventricular nucleus of the hypothalamus, an area of the brain rich in ERβ mRNA. Part of this 
response involves the action of CRH whose promoter activity may be regulated by ERβ isoforms. 
Furthermore, ERβ may also decrease stress-induced HPA activation through oxytocin neurons in 
the hypothalamus. ERβ and oxytocin are highly co-expressed in that part of the brain and both their 
actions may be mediated by CRH. Control of ERβ signaling may be better appreciated in the female 
population given that females are known to secrete higher levels of glucocorticoid in response to 
stress than are their male counterparts. Thus, targeting ERβ may be of benefit in the treatment of 
anorexia nervosa and depression, conditions characterized by dysregulation of the HPA axis.(Kudwa 
et al., 2014; W. J. Miller et al., 2004) ERβ was also found to increase postsynaptic response of GnRH 
neurons and could therefore prove to be important in regulating ovulation, fertility, and maternal 
behavior.(Brooks, Le, Chung, & Tsai, 2012; Chu et al., 2009) However, the display of lordosis, another 
female sexual behavior in mice, could not be attributed to ERβ. Its lack of relationship to ERβ was 
implied from the null effect on the expression of progesterone receptors in the hypothalamic ventro-
medial nucleus.(Sa et al., 2013) The raphe nucleus, on the other hand, may respond to the ERβ agonist 
SERM Beta2 in a dose-dependent manner in order to increase progesterone receptor expression.
(Clark et al., 2012) Another significant contribution of ERβ may be observed in the hypothalamus by 
way of regulation of low voltage-activated (T-type) calcium channels that participate in burst firing 
and neurotransmission. These phenomena, however, may also be dependent on the co-expression of 
other estrogen receptors, including ERα.(Bosch et al., 2009)
ERβ has also gained particular interest in the prevention of AD. Several studies included in this sys-
tematic review have shown that ERβ agonist DPN may induce a significant reduction of hippocampal 
ApoE mRNA and protein expression, an established risk factor for late-onset AD. In an aging study 
sample with low estradiol level, ERβ may compensate to maintain hippocampal function, provided 
that estradiol level is increased.(Han et al., 2013; J. M. Wang et al., 2006; Zhao et al., 2013) Another 
mechanism may involve catabolism of Aβ by insulin-degrading enzyme (IDE). ERβ, in conjunction 
with the activation of PI3-K, may regulate the expression of this protease in normal and early-stage 
AD brains. IDE induction, which is reported also to respond rapidly to estradiol administration, may 
prove to be a target for prevention of AD.(Zhao et al., 2011) Functional significance of ERβ is also 
supported by findings from clinical studies in which genetic variations of ERβ were found to increase 
the risk of AD in women.(Pirskanen et al., 2005) 
Neuroprotection has also been consistently reported in this systematic review. ERβ may reduce 
global ischemia in the caudate nucleus and CA1 pyramidal layer by enhancing expression of estrogen-
regulated genes such as ApoE or bcl-2. Other proposed vehicles for neuroprotection are activation of 
CREB or preservation of mitochondrial function.(Carswell et al., 2004; Raval et al., 2013) As ischemic 
neuronal death is mainly caused by mitochondrial dysfunction disrupting calcium homeostasis and 
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increasing oxidative stress, interest has increased in studying the pathway by which ERβ may potenti-
ate mitochondrial function.(Irwin et al., 2012; Raval et al., 2013) Although the exact mechanism of 
action for this protective effect remains to be further explained, its potential benefits may help prevent 
loss of synaptic transmission after cerebral ischemia as well as age-related decline in cognition. Re-
ducing neuroinflammation may also confer brain protection. A number of cytokines and chemokines 
(interleukins) including IL-1 β, IL-6 and IL-12p40 in the brain may be regulated by ERβ through 
alteration of the blood brain barrier. These findings may contribute to decrease proinflammatory 
cytokines commonly described in postmenopausal females and thought to induce subclinical states 
of neurodegeneration and cognitive decline.(Abu-Taha et al., 2009)
This systematic review also shows consistency in the role of ERβ in modulating estrogen signaling 
in the process of emotional behavior (Imwalle et al., 2005; Krezel et al., 2001; Kudwa et al., 2014; W. 
J. Miller et al., 2004; Oyola et al., 2012) and other types of behavior such as social recognition and 
extinction recall, which is learning not to fear.(Choleris et al., 2003; Choleris et al., 2006; Zeidan et 
al., 2011) The use of ERβ knockout animal models and adapted behavioral tests were particularly 
useful in determining its functional role. Three studies in this review demonstrated that anxiety-like 
behavior was enhanced, while serotonin levels decreased, with the absence of functional ERβ. These 
effects may be region-specific to the stria terminalis, preoptic area, hippocampus, and possibly the 
dorsal raphe nucleus. The reduction of other monoamines such dopamine and dihydroxyphenyl-
acetate may also be associated with increased anxiety in the absence of ERβ. Similarly, the addition 
of ERβ specific agonist DPN was found to attenuate the levels of stress-induced CORT and ACTH; 
which may contribute to decrease anxiety-like behaviors in different test settings. Furthermore, ERβ 
may reduce not only anxiety but also depression-like behavior, which may be mediated by genomic 
effects of ERβ in 5-hydroxytryptamine (5-HT) neurons of the dorsal raphe nucleus.(Benmansour et 
al., 2014) This effect was described after undergoing tests such as the open field, elevated plus maze, 
and the forced swim test. ERβ activation may increase expression of TPH and thereby induce slowing 
of 5-HT clearance.(Benmansour et al., 2014) Consequently, 5-HT in the inter-synaptic spaces would 
be present in higher concentrations and would have more time to exert its antidepressant effect; 
further suggesting that ERβ likely promotes an antidepressant-like effect. 
To our knowledge, this is the first systematic review on the subject that critically appraised the 
literature following an a priori designed protocol with clearly defined inclusion and exclusion criteria. 
Using a systemic search in medical databases, few reviews evaluating the role of ERβ in the brain were 
found. They were all narrative reviews (not performed systematically) mainly focused on estrogen 
signaling and not specifically on ERβ.(H. J. Kim & Casadesus, 2010; Lokuge, Frey, Foster, Soares, & 
Steiner, 2010; Sugiyama et al., 2010; Weiser et al., 2008) In contrast to systematic reviews, narrative 
reviews do not involve a systemic search, and they are often focused on a subset of studies in the 
chosen area based on availability of the author selection. Therefore, they are more likely to suffer 
from selection bias(Garg, Hackam, & Tonelli, 2008; Uman, 2011). Additionally, the identified narra-
tive reviews, contrary to our study, covered only specific-limited areas of the function of ERβ in the 
brain. A number of limitations, however, need to be considered. We included studies that were highly 
heterogeneous in the input parameters, assumptions, and study design, and therefore, performing a 
quantitative pooling of the existing data was unfeasible. Also, all the included studies used animal 
tissue and so caution should be taken when extrapolating the results of this review to human subjects. 
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Finally, publication bias may be a concern, as with all systematic reviews. However, we tried to mini-
mize the impact of publication bias by employing a thorough search strategy in six databases in which 
no restrictions were applied on language or time of publication, checking reference lists of identified 
studies and contacting experts in the field 
Overall, the results of the current systematic review, including only animal studies, show abundant 
functions of ERβ in the female brain and support the notion that future therapies targeting ERβ 
could constitute a novel preventive strategy and treatment for neurological diseases in females. ERβ 
agonists can mimic the actions of 17β-estradiol in the brain without causing other physiological re-
sponses mediated by other estrogen receptors. In view of the high burden of depressive disorders and 
neurodegenerative disease and despite advances in their prevention and treatment, transfer of these 
novel therapeutic venues on the field of neurological diseases could constitute a suitable alternative in 
the future. However, to establish potential therapeutic and preventive strategies targeting ERβ, future 
studies should be conducted in humans to further our understanding of the importance of ERβ in 
women’s mental health.
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AbSTrACT
Alcohol affects the female body differently than it affects males, caused by females’ lower levels of 
dehydrogenase enzymes, the enzyme that breaks down alcohol, coupled with the higher ratio of fat 
to water. Both of these factors cause alcohol levels to rise more quickly in women than in men. Sex 
differences in the metabolism of alcohol make women are more vulnerable to alcohol’s harmful ef-
fects, and women tend to develop alcohol-related diseases and other consequences of drinking earlier 
in life than do men. As women age and go through menopause, there is an age-related decline in the 
dehydrogenase enzyme, and women experience changes in body composition and life changes like 
retirement or loss of a loved one. In this period, alcohol problems and dependence also become more 
prevalent among women (Epstein, Fischer-Elber, & Al-Otaiba, 2007). Furthermore, aging women 
may experience additional stress and depression caused by the perception that their youth has ended 
(by virtue of losing the ability to bear children) and ‘empty nest’ syndrome. Under these conditions, 
alcohol may seem like an acceptable remedy. There are many consequences of alcohol abuse on the 
addicts’ quality of life and the positive effects of moderate alcohol intake are miniscule in comparison 
to the adverse effects caused by its abuse. Further, due to social stigmas, women tend to have more 
difficulty gaining access to treatment and recovering from alcohol dependence than do men. Cur-
rent research on interventions and treatments that aim to reduce alcohol consumption and prevent/
treat alcohol dependence in middle-aged and elderly women is limited. In this study, we provide an 
overview of prevalences of drinking patterns and alcohol dependence, risk factors, health impacts 
and treatment challenges for women as they progress through middle and older age.
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iNTrODuCTiON
Neurophysiology of alcohol use disorder (AuD)
The human brain graditution (reward) pathways make alcohol a powerful drug. The involuntary as-
sociation between the positive effects of alcohol like its relaxing, and sociability-enhancing properties 
“rewires” the brain chemistry such that individuals who consume it wish to have more of it. Alcohol 
affects several neurological pathways, including the dopaminergic pathway, serotoninergic, gamma-
amino butyric acid (Rubin et al., 1996; Solfrizzi et al., 2011) and glutamate pathways, which cause 
significant changes in the brain. Due to its anxiolytic effect as a facilitator of sociability, alcohol is 
culturally accepted worldwide, and is the most widely used recreational drug. 
Aging process
Alcohol consumption declines with age for most adults, but some begin to experience alcohol 
dependence-related problems at or after ages 55 or 60 (Hajema, Knibbe, & Drop, 1997). Older age 
introduces multiple changes in health, lifestyle , family obligations, work roles and sources of support 
(Singh & Misra, 2009) . Also it is highly likely that older age is accompanied with physical pain (Patel, 
Guralnik, Dansie, & Turk, 2013), stress (Jeon & Dunkle, 2009) , loneliness (Singh & Misra, 2009) and 
loss of mobility (Manini, 2013) . All these reasons can trigger or worsen previously existing Alcohol 
use disorders (AUD) in elderly. In this review we focus on AUD in menopausal and postmenopausal 
women. With age, the impact of AUD related injuries becomes more severe, falls are more frequent 
which is especially harmful for menopausal and postmenopausal women due to onset and conse-
quences of osteoporosis that is more severe than in men in the same age groups (Cawthon, 2011).The 
risk of harmful medication interactions is very high, as self-medication is one of the most important 
health concerns, especially in women in menopause and the postmenopausal period (Afshary et al., 
2014) . The general physical effects of AUD are more debilitating (Alomar, 2014). 
Epidemiological data
In the past 30 years, studies have shown that the prevalence of alcohol abuse and drinking problems 
among elderly adults ranges from 1% to 16% (Ahlström S, 2008; Moore et al., 1999; Substance Abuse 
and Mental Health Services Administration, 2004).
Due to increased life expectancy and the gender gap in longevity, women make up a significantly 
larger share of the older population. Although prevalence of drinking, binge drinking and volumes 
of alcohol consumption are higher in men compared to women (Grenard, Dent, & Stacy, 2013; 
Makela, Tigerstedt, & Mustonen, 2012), the prevalence, health and social impact of women’s AUD 
is expected to increase in the near future. Aging of the baby boom and younger generations, and 
reduced disparity in levels of alcohol consumption between men and women at younger ages are 
likely to occur (Sanjuan & Langenbucher, 1999). This gap is closing in younger cohorts (Delker, 
Brown, & Hasin, 2016; Kraus, Piontek, Atzendorf, & Matos, 2016) During the past decades, alcoholic 
drinks have become more readily available, more advertised and worldwide cultural acceptance of 
women’s consumption of alcohol has significantly increased (Grenard et al., 2013; Österberg, 2002; 
Slade et al., 2016; Sudhinaraset, Wigglesworth, & Takeuchi, 2016). In a study of Finnish women aged 
59 to 79 from the mid-1980s to the early 2000s, the prevalence of consuming at least 5 units of alcohol 
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per week increased in all age groups (Sulander, Martelin, Rahkonen, Nissinen, & Uutela, 2005). A 
previous study indicates that the frequency of alcohol consumption among women is higher aft er 
menopause (Petri et al., 2004). Th is study included 13,074 Danish women combined from 6 popula-
tion cohorts, aged 20 to 91 years. Women were followed for present or prospectively diagnosed breast 
cancer. Participants reported current drinking of alcohol in the following manner: light drinking (less 
than one drink per week) was present in 9% of premenopausal women were, 25% of postmenopausal 
women below 70 years of age and 20% women above 70 years of age. 20%. Low-moderate drinking 
(<7 drinks per week) was present in 22% of the premenopausal women, 33% of postmenopausal 
women below 70 years of age and 14% of the women above 70%years of age. Sensible drinking limit 
(from 7 - 13 drinks per week) was present in 7% of premenopausal women, 11 %of postmenopausal 
women under 70 years of age and in 14% of the women above 70 years of age. Moderate to severe 
drinking (categories of 14 to 27 drinks per week and over 27 drinks per week combined) was present 
in 4% of premenopausal women , 7% of postmenopausal women below 70 years of age and in 3% 
of women above 70 years of age (Petri et al., 2004). Generally, previous studies show a considerably 
higher prevalence of alcohol consumption within postmenopausal women, having in mind that this 
topic is still understudied. A Dutch population cohort study (age >55) (Vliegenthart et al., 2002) 
explored eff ects of moderate alcohol consumption on cardiovascular disease risk reduction. Data 
showed that among 2,486 females with a mean age of 67 years of age, 75 percentage reported current 
drinking of alcohol. Out of 75 % , 51,6% were light drinkers (≤10g per day), 12, 7% were moderate 
drinkers (>10 - ≤ 20 g per day) and 10.4% were severe drinkers (>20g per day), 25.3% were nondrink-
ers and considered abstainers (Vliegenthart et al., 2002).
•	 Adverse	cardiometabolic	health	(blood	lipids,	
diabetes and heart disease)
•	 Deteriorates	bone	health
•	 Increases	risk	of	cancer
•	 Deteriorates	neurocognitive	function
•	 Improves	cardiometabolic	health	(blood	lipids,	
diabetes and heart disease)
•	 Improve	one	health
•	 Increases	risk	of	cancer
•	 Nerocognitive	functions/Neurodegenerative	diseases2
•	 Improves	cardiometabolic	health	(blood	lipids,	
diabetes and heart disease)
•	 Improve	one	health
•	 Increases	risk	of	cancer
•	 Nerocognitive	functions/Neurodegenerative	diseases2
figure 1. Dosage dependent risk factors and benefi ts of moderate intake 
1. For women, low-risk drinking is defi ned as no more than 3 drinks on any single day and no more than 
7 drinks per week. Moderate drinking: up to up to 1 drink per; Severe drinking: 4 alcoholic drinks per 
day for women on 5 or more days in the past month.
 One unit of alcohol is defi ned as 10ml (8g) of pure alcohol.
2. Current Evidence is not persuasive for a benefi cial eﬀ ect of low/moderate alcohol consumption on 
cognitive functions and/or risk of developing neurodegenerative diseases
Source of the classifi cation: Th e National Institute on Alcohol Abuse & Alcoholism (NIAAA). (2015). 
Drinking Levels Defi ned. Retrieved from US: https://www.niaaa.nih.gov/alcohol-health/overview-
alcohol-consumption/moderate-binge-drinking
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psychological aspects
The menopausal transition can also be associated with social impairment, depression, anxiety, stress, 
fatigue, embarrassment due to end of reproductive period, diminished libido, disturbed sleep, and 
changes in cognitive function and processing speed, all factors that can trigger or worsen existing 
AUD (Lewis Alexander, LaRosa, Bder, & Garfield, 2009; Maki et al., 2010; H. D. Nelson, 2008; Reed, 
Newton, LaCroix, Grothaus, & Ehrlich, 2007) . Among elderly females, death of a loved one, par-
ticularly a spouse (Rozenzweig, Prigerson, Miller, & Reynolds, 1997), is generally accepted to be a 
common and traumatic life event (Rozenzweig et al., 1997) that can cause late onset of AUD (Rigler, 
2000). Depression (along with suicide), anxiety, substance abuse, and symptoms of “complicated” 
grief are among the more important psychiatric sequelae of spousal bereavement and the challenges 
of adapting widowhood (Rozenzweig et al., 1997) . 
Socioecomic determinants and risks of developing AuD
Also, socioecomic determinants and risks of developing AUD in women exist. Previous studies 
show that effect is larger effect on when lower socioeconomic status is present (Lewer, Meier, Beard, 
Boniface, & Kaner, 2016). As already mentioned, menopausal women seem to be especially at risk of 
experience, divorce and departure of children from the home.(Allan & Cooke, 1985). Furthermore, in 
postmenopausal age, women may be more prone to AUD due to retirement (Hurt, Finlayson, Morse, 
& Davis, 1988). Published evidence show sociocultural factors influencing the initiation and contin-
ued use of alcohol and risky drinking behaviors being more common among women who are past 
or current smokers (Powers, Anderson, Byles, Mishra, & Loxton, 2015) We present Biopsychosocial 
model of female AUD - Risk factors in Figure 2.
figure 2. Biopsychosocial model of female AUD - Risk factors
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Why is AuD in women understudied?
There is a noticeable lack of studies about gender differences in AUD. This lack may be due to lack of 
resources and awareness and stigma or taboo about women’s substance use (Lal, Deb, & Kedia, 2015; 
Stone, 2015). AUD among men has been the predominant focus of the research (W. J. Lynch, Roth, 
& Carroll, 2002). The United Nations Global Illicit Drug Trends report from 2002 discusses gender 
differences with respect to substance abuse (United Nations publication SNEX, 2002) . It indicates 
that women represent an estimated 10% of substance abusers in some traditional Asian societies, 
20% in countries of the former USSR and Latin America and about 40% in North America and some 
European countries, a finding that calls for more studies that focus on alcohol and substance abuse 
in women. 
Vulnerability of females to AuD – a major public health concern
The vulnerability of females to alcohol-related harm is a major public health concern because as 
social norms have shifted away from traditional gender roles, young women start to exhibit higher 
frequency, higher volume, and more binge drinking, leading to a closing of the gender gap not only in 
consumption but also in terms of health consequences, with more pronounced health outcomes at the 
same level of consumption for all-cause mortality, cancers, gastrointestinal diseases, and cardiovascu-
lar disease (WHO, 2014). Alcohol-attributable cardiovascular disease and diabetes are more common 
in females than men (33.6% vs. 10.6% of the global disease burden, respectively 3). In line with these 
observations, alcohol-attributable morbidity has increased more steeply among women than among 
men during the past two decades (Erol & Karpyak, 2015). Therefore in the current overview we try to 
address all aforementioned issues.
METhODS
In this review we performed a narrative synthesis using 2 electronic database relevant to our topic 
(PubMed and Cochrane). In order to identify published work within the medical and psychological 
literature on AUD in in women in menopause and the postmenopausal period we selected key words, 
defined inclusion criteria and justified publication restrictions (we excluded economic analysis or 
clinical practice guideline development). The scoping review considered all study designs including 
qualitative and quantitative methodologies. We decided to select the studies published within the 
approximate 40-years period: 1977–2018. We choose our Keywords following PICO criteria and fil-
tered our search accordingly. We used the following keywords in order to define population : Female, 
Women, Menopause, Menopause transition, Postmenopausa, Psychological aspects, Neurobiological 
aspects, Elderly; in order to define intervention: Psychiatric treatment, Psychotherapy treatment, 
Pharmaco-treatment ; in order to have a comparator group : Male AUD, Gender differences in 
AUD, Elderly men, Geriatric male drinking; in order to define outcome: AUD, Alcohol addiction, 
Alcohol consumption, Heavy drinking. Identifying the themes that emerge from the set of studies, 
we synthetized published evidence and we draw our conclusion with all authors agreeing on which 
studies to include in the review. We used the experience of each of the lead authors in the area of 
alcohol consumption, cardiometabolic diseases, menopause and women’s health, addictology and 
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psychotherapy, to synthetize all the main insights on drinking patterns and alcohol dependence, risk 
factors, health impacts and treatment challenges for women as they progress through middle and 
older ages. Moreover, each author was encouraged to discuss theory and context to provoke thought 
and possible controversy by presenting philosophical perspectives in a balanced manner regarding 
clash between subjective perspective and published material. Identifying the themes that emerged 
from the set of studies, we synthetized published evidence and we draw our conclusion by identifying 
potential interventions to support the female patients with AUD, as well as their family members or 
surrounding environment in this process.
rESuLTS AND DiSCuSSiON
Current definitions of alcohol consumption
This review touches on a wide spectrum of different patterns of alcohol consumption . ICD-10 
distinguishes “harmful use” from “dependence”, whereas DSM-5 combines the two into “alcohol use 
disorder-AUD” Under DSM–5, anyone meeting any two of the 11 criteria during the same 12-month 
period would receive a diagnosis of AUD. The severity of AUD—mild, moderate, or severe—is based 
on the number of criteria met (National Institute on alcohol Abuse and Alcoholism, 2016) (Supple-
mentary table 1). Also, there is an extensive literature on safe drinking levels/patterns, international 
comparison on guidelines, government panels documents (Alcohol Guidelines development group, 
2016; Kalinowski & Humphreys, 2016; UK Chief Medical Officers, 2016) that take sex differences 
into account. 
There are several ways to define drinking at low risk of developing Alcohol Use Disorder (AUD). 
Firstly, we can refer to new DSM V definition (supplementary table 1). Next, we can refer to the US 
National Institute on Alcohol Abuse & Alcoholism (NIAAA): low drinking is considered to be one or 
less than one alcoholic drink for men and women in any single day; and a maximum of 7 drinks for 
men or 3 drinks for women per week. Moderate drinking is up to four alcoholic drinks for men and 
three for women in any single day, and a maximum of 14 drinks for men and 7 drinks for women per 
week. Severe drinking is four alcoholic drinks for men and three for women in any single day, and a 
maximum of over 14 drinks for men and over 7 drinks for women per week (The National Institute 
on Alcohol Abuse & Alcoholism (NIAAA, 2015). Since definition on units is not consistent and dif-
fers from country to country, to have more clear understanding, The National Health Service (The 
National Health Service (NHS)), UK, states that: one unit of alcohol is defined as 10 mL (8 g) of pure 
alcohol (NIAAA, 1999). However, variation in the number of grams of alcohol in a standard drinks 
between countries are wide. The lowest number of grams of alcohol is in the UK unit at 8 grams and 
the highest in Austria at 20 grams. Eleven European countries have 10 grams of alcohol in a standard 
drink and five have 12 grams in a standard drink (Mongan D & Long J, 2015). Further, due to the 
metabolic differences between men and women, as explained below in details, a woman will absorb 
about 30% more alcohol into her bloodstream than a man of the same weight who has consumed an 
equal amount. Thus, alcohol recommendations are sex specific (Lewis Alexander et al., 2009).
Though some health benefits of alcohol consumption have been demonstrated, alcohol consump-
tion can result in physical and mental health problems if consumed irresponsibly and excessively. 
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We can divide this health problems in 2 groups: a) Chronic diseases and conditions that are alcohol 
attributed by definition (Table 1) and b) Chronic diseases and conditions for which alcohol is a 
component cause (Table 2) .
Table 1. Chronic diseases and conditions: alcohol attributed by definition (Listing from ICD-
10)
iCD-10 Code Disease
F10 Mental and behavioral disorders attributed to the use of alcohol
F10.0 Acute intoxication
F10.1 Harmful use
F10.2 Dependence syndrome
F10.3 Withdrawal state
F10.4 Withdrawal state with delirium
F10.5 Psychotic disorder
F10.6 Amnesic syndrome
F10.7 Residual and late-onset psychotic disorder
F10.8 Other mental and behavioral disorders
F10.9 Unspecified mental and behavioral disorders
G31.2 Degeneration of nervous system attributed to alcohol
G62.1 Alcoholic polyneuropathy
G72.1 Alcoholic myopathy
I42.6 Alcoholic cardiomyopathy
K29.2 Alcoholic gastritis
K70 Alcoholic liver disease
K70.0 Alcoholic fatty liver
K70.1 Alcoholic hepatitis
K70.2 Alcoholic fibrosis and sclerosis of liver
K70.3 Alcoholic cirrhosis of liver
K70.4 Alcoholic hepatic failure
K70.9 Alcohol liver disease, unspecified
K85.2 Alcohol-induced acute pancreatitis
K86.0 Alcohol-induced chronic pancreatitis
P04.3 Fetus and newborn affected by maternal use of alcohol
Q86.0 Fetal alcohol syndrome (dysmorphic)
* Table 1 does not contain: “Chronic Diseases and Conditions for Which Alcohol Is a Component Cause” 
(Alcohol is a component cause for more than 200 other diseases and conditions and they are all listed in: 
“2005 Global Burden of Disease (GBD)(Rehm et al., 2009) ”) 
Source: Shield, K. D., Parry, C., & Rehm, J. (2014). Chronic Diseases and Conditions Related to Alcohol 
Use. Alcohol Research : Current Reviews, 35(2), 155-171. (Kevin D. Shield, Parry, & Rehm, 2014)
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physiological processes that make women more vulnerable to the effects of 
alcohol
Between the genders, alcohol has a different effect based on physiological processes and functioning 
(Lieber, 1997; Mumenthaler, Taylor, O’Hara, & Yesavage, 1999; Nolen-Hoeksema, 2004; Plant, 2002; 
Wilsnack RW, 1997). Women are more susceptible to long-term negative effects of alcohol on health, 
develop alcohol-related medical problems after shorter duration and lower levels of consumption 
compared to men (Erol & Karpyak, 2015) Subsequent to same dose of alcohol intake , women have 
higher blood ethanol levels than do men (Cederbaum, 2012; Nolen-Hoeksema, 2004) . Firstly, there 
are differences between men and women in the enzymatic processes that break down ethanol and 
eliminate it from the body. Women generally have lower levels of alcohol dehydrogenase enzyme, 
which makes them more susceptible to the effects of alcohol (Lieber, 1997; Nolen-Hoeksema, 2004). 
Secondly, the difference in the effect of alcohol between the sexes is due in part to the fact that women 
generally weigh less than men and that their bodies contain a lower proportion of water and a higher 
proportion of fat, causing the concentration of ethanol to rise more quickly in the blood (Ceder-
baum, 2012). Because alcohol is water-soluble, this sex difference in body composition means that, 
for a given dose of alcohol, the concentration of alcohol in the blood system is greater in women 
than in men (Cederbaum, 2012). A previous study states that the risk of liver cirrhosis, a disease 
predominantly attributable to alcohol, has been shown to be greater for women than men in relation 
to alcohol consumption (Parrish, Higuchi, & Dufour, 1991). Possible mechanisms that underlie the 
gender difference in blood-alcohol level comprise gender differences in the metabolism of alcohol 
(Baraona et al., 2001), the interaction of alcohol dehydrogenase (ADH) with female sex hormones 
and a decreased first pass effect (also known as first-pass metabolism or pre-systemic metabolism) 
(Baraona et al., 2001; Parlesak, Billinger, Bode, & Bode, 2002). First-pass metabolism is a phenom-
enon of drug metabolism whereby the concentration of a drug is greatly reduced before it reaches the 
systemic circulation . In women this phenomenon occurs because of lower levels of gastric ADH, and 
more rapid metabolism of alcohol in the liver (Baraona et al., 2001; Cederbaum, 2012; Parlesak et 
al., 2002; Thomasson, 1995). However, the only biological difference consistently related to increased 
blood-alcohol level that is easy to measure is body water (Graham, Wilsnack, Dawson, & Vogeltanz, 
1998). The lower volume of body water in women gives less volume for distribution of alcohol than 
men, which may explain their higher blood-alcohol level at comparable quantities of alcohol con-
sumed. In general this factor has been used to explain gender differences in AUD (Cederbaum, 2012; 
Ely, Hardy, Longford, & Wadsworth, 1999). Thirdly, the human body further differentiates with aging. 
Age-related changes in body composition are important factors in the study of ethanol metabolism 
and its effects. Lean body mass and total volume of distribution of the ethanol is negatively correlated 
with age (Vestal et al., 1977). The smaller volume of distribution, in association with the decreased 
lean body mass, could possibly be the reason that the higher peak ethanol concentration is found in 
the blood after intake of same alcohol dose in the old as compared with the younger (Vestal et al., 
1977). As Lean body mass decreases with age, in women - body fat increases after menopause, and 
total body water content also decreases Thus, sex differences in the effect of alcohol become even 
more prominent. Therefore, especially in women the amount of alcohol that may previously have had 
little effect can cause intoxication in women after menopause (Vestal et al., 1977). 
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Having in mind all the aforementioned physiological factors that are positively associated with 
age, postmenopausal women are more vulnerable to AUD-related medical problems at lower levels 
of consumption than men or premenopausal women (Bradley, Badrinath, Bush, Boyd-Wickizer, & 
Anawalt, 1998; Erol & Karpyak, 2015). These findings strongly suggest that male/female differences 
in alcohol-related harm is likely to be heavily influenced by physiological (biological) aspects and 
further enhanced or controlled by psycho-social factors (Erol & Karpyak, 2015).The need for addi-
tional research on women is heightened by the fact that female physiology is more complex than male 
physiology. Research has shown that, although there are no gender differences in the development of 
addiction behaviors following first administration, women typically become dependent on substances 
more quickly than do men. (W. J. Lynch et al., 2002; Reynolds, 2003; The National Institute on Alcohol 
Abuse and Alcoholism, 1999; The National Institute on Drug Abuse (NIDA), 2000; Westermeyer & 
Boedicker, 2000). 
We can clearly comprehend that physiological processes that make women more vulnerable to 
the adverse effects of alcohol intake represent a main focus of potential predisposition of developing 
AUD.
Finally, factors modifying the alcohol elimination rate which significantly influences metabolism 
of alcohol absorption, vary in humans because of various genetic and environmental factors (Ceder-
baum, 2012). Some of those are: race, food, exercise, AUD (especially severe AUD), circadian rhythm, 
and usage of other medications or drugs (Cederbaum, 2012).
health consequences 
The fact that the sex differences in the adverse effects of alcohol largely result from hormone physiol-
ogy adds to the overall discussion of cardio-protective effects of moderate consumption (Roerecke 
& Rehm, 2014) and the effect on hormone-related cancers (Rehm, 2015) . Namely, moderate alcohol 
consumption has been inversely associated with the risk of cardiovascular disease , serum cholesterol 
levels (Koppes, Twisk, Snel, Van Mechelen, & Kemper, 2000; Sillanaukee, Koivula, Jokela, Pitkajarvi, 
& Seppa, 2000), diabetes (de Vegt et al., 2002; Kao, Brancati, Boland, Watson, & Puddey, 1998; Knott, 
Bell, & Britton, 2015; Wannamethee, Camargo, Manson, Willett, & Rimm, 2003), and mortality 
(Kendler, Ohlsson, Sundquist, & Sundquist, 2016; Knott et al., 2015; Roerecke & Rehm, 2014) while 
reversely associated with hormone-related cancers (Rehm, 2015). The potential benefits of moderate 
alcohol need to be weighed against the health risks, and cancer is of particular concern, because 
alcohol causes a large number of neoplasms, even at low levels of consumption (Bagnardi et al., 2015). 
In some drinking patterns it creates the opposite effect: binge drinking substantially raises the risk of 
cardiovascular disease and liver disease (Roerecke & Rehm, 2014). While some evidence suggests that 
women experience stronger cardio-protective associations but also quicker upturn to a detrimental 
effect at lower levels of average alcohol consumption compared to men, other studies (C. Wang et al., 
2014; Zheng et al., 2015) indicated that women with moderate to heavy alcohol intake had a greater 
risk of total mortality and coronary heart disease than men. Among women, greater risk of AUD and 
total mortality is predominantly seen in postmenopausal women due to drop of estrogen. Specially, 
because of biological differences, women tend to become severely intoxicated more quickly than 
men (even when consuming less) and are at greater risk for developing a number of health problems 
including liver cancer, breast cancer, and accelerated brain atrophy (Wilsnack, Wilsnack, & Kantor, 
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2014). A systematic review and meta-analysis with studies enrolling both men and women showed 
that moderate alcohol consumption was associated immediately upon consumption with a higher 
risk of cardiovascular event, though the risk was attenuated after 24 hours, even showing protective 
effects against myocardial infarction and hemorrhagic stroke (≈2–4 drinks: relative risk=30% lower 
risk) and ischemic stroke within 1 week (≈6 drinks: 19% lower risk) (Mostofsky, Chahal, Mukamal, 
Rimm, & Mittleman, 2016).
For postmenopausal women, although not conclusive and debatable, moderate consumption of 
alcohol may be beneficial regarding the progression of osteoporosis and the severity of bone fracture 
(Charles P, 1999; Felson, Zhang, Hannan, Kannel, & Kiel, 1995; Naves Diaz, O’Neill, & Silman, 1997; 
Rapuri, Gallagher, Balhorn, & Ryschon, 2000; Smeets-Goevaers et al., 1998; Williams, Cherkas, Spec-
tor, & MacGregor, 2005). Osteoporosis is very common among postmenopausal and older women, 
and compared with abstainers, women who consume between 0.5 and 1.0 alcoholic drink per day 
were found to have a 20% lower risk of hip fracture (Berg et al., 2008). Furthermore, although the 
evidence is not consistent, light-to-moderate alcohol use may be associated with a reduced risk of 
incident dementia and Alzheimer’s disease (Letenneur, 2004). Current evidence also suggests that 
moderate alcohol consumption may be protective from cognitive decline and pre-dementia syn-
dromes (Solfrizzi et al., 2011). 
Available evidence suggests a favorable effect of low and moderate alcohol consumption on cardio-
metabolic health, bone density, and neuropsychiatric health, but a precise range of beneficial alcohol 
consumption cannot be determined. Several observational studies report a J-shaped relationship 
between alcohol consumption and cardio-metabolic and bone health outcomes (Berg et al., 2008). 
Emerging evidence indicates that the amount of alcohol associated with cardiovascular benefits is 
lower among women than it is among men, meaning that the threshold where drinking becomes 
harmful is lower in females than males (Mostofsky et al., 2016). For example, a Danish study showed 
that 14 drinks per week was associated with the lowest risk of diabetes among men, for women, the 
lowest risk of diabetes was observed at 9 drinks/week (Holst, Becker, Jorgensen, Gronbaek, & Tol-
strup, 2017). Given that different preference for alcoholic beverages exist between men and women, 
differential associations between alcohol consumption and disease risk might exist for different type 
of alcohol beverage in female drinking. For example, women are likelier to have a preference for 
wine while men may prefer to drink beer (Sluik et al., 2016). Wine contains polyphenols such as 
resveratrol and various studies have suggested that resveratrol may foster beneficial effects on cardio-
vascular, inflammatory, neurodegenerative, and metabolic diseases as well as various forms of cancer 
(Weiskirchen & Weiskirchen, 2016; Zhou et al., 2016). Although wine has been suggested to have 
particularly protective effects in relation to cardio-metabolic outcomes in either sex, epidemiological 
studies are inconclusive when it comes to the specific effects of beer and spirits and the role of sex 
(Artero, Artero, Tarín, & Cano; Koloverou et al., 2015). More recent studies show that using data on 
both amount and frequency of alcohol consumption, alcohol intake at least 3 to 4 days per week is as-
sociated with a lower risk of myocardial infarction among menopausal and postmenopausal women, 
and HDL cholesterol, fibrinogen, and HbA1c accounted for 75% of the association (Djousse, Lee, 
Buring, & Gaziano, 2009). A range of potential health benefits for the general population associated 
with low to moderate alcohol consumption has been described, from a link between low and moder-
ate alcohol intake with reduced coronary heart disease (Baer et al., 2002; Camargo, 1999; Fuchs et al., 
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1995; Grobbee, Rimm, Keil, & Renaud, 1999) to benefits related to serum cholesterol levels (Koppes 
et al., 2000; Sillanaukee et al., 2000), and to a protective effect against type 2 diabetes (de Vegt et al., 
2002; Kao et al., 1998; Wannamethee et al., 2003). 
For postmenopausal women, although not conclusive and debatable, moderate consumption of 
alcohol may be beneficial regarding the progression of osteoporosis and the severity of bone fracture 
(Charles P, 1999; Felson et al., 1995; Naves Diaz et al., 1997; Rapuri et al., 2000; Smeets-Goevaers et 
al., 1998; Williams et al., 2005)
Emerging evidence indicates that the amount of alcohol associated with cardiovascular benefits 
is lower among women than it is among men, meaning that the threshold where drinking becomes 
harmful is lower in females than males (Mostofsky et al., 2016) . For example, a Danish study showed 
that 14 drinks per week was associated with the lowest risk of diabetes among men, for women, the 
lowest risk of diabetes was observed at 9 drinks/week (Holst et al., 2017). Given that different prefer-
ence for alcoholic beverages exist between men and women, differential associations between alcohol 
consumption and disease risk might exist for different type of alcohol beverage in female drinking. To 
demonstrate this, women are likelier to have a preference for wine while men may prefer to drink beer 
(Sluik et al., 2016). Wine contains polyphenols such as resveratrol and various studies have suggested 
that resveratrol may foster beneficial effects on cardiovascular, inflammatory, neurodegenerative, and 
metabolic diseases as well as various forms of cancer (Weiskirchen & Weiskirchen, 2016; Zhou et al., 
2016) . 
While moderate alcohol consumption has been shown to have some health benefits, severe intake 
leading to severe AUD have adverse effects on health. Severe AUD can increase risk for coronary 
heart disease, certain types of stroke, liver cirrhosis, and diabetes (National Institute on Alcohol abuse 
and Alcoholism 2015). For instance, results from several meta-analyses have shown that up to 30 g 
of alcohol consumed per day may be protective for health, including cardiovascular diseases and 
type 2 diabetes, but that alcohol consumption of more than 60 g per day may have a negative impact 
(Koppes, Dekker, Hendriks, Bouter, & Heine, 2005; Ronksley, Brien, Turner, Mukamal, & Ghali, 2011). 
Combined analysis of data from 53 studies worldwide suggests a dose-response relationship between 
alcohol consumption and increased risk of breast cancer (Schutze et al., 2011). Despite these findings, 
there is little discussion among health agencies that women specifically should limit their alcohol 
consumption to a lower reference intake level than men (Nolen-Hoeksema, 2004) since acetaldehyde, 
the first and most toxic ethanol metabolite, is considered to be carcinogenic (Seitz & Becker, 2007). 
It has been estimated that for each 10g/day increase in alcohol, there is an increased risk of 5-10% 
for incident breast cancer (Hamajima et al., 2002; Schutze et al., 2011). Alcohol is causing breast 
cancer, both in pre-menopausal and post-menopausal women , and the risk increases in a linear dose-
response manner, with risk appearing even at low consumption levels (K. D. Shield, Soerjomataram, 
& Rehm, 2016). Therefore, we can infer that dosage-dependent risk factors and benefits of moderate 
intake exist and should be considered in parallel (Figure 1). 
These results suggest that women also seem to be more sensitive than men to the alcohol-related 
causes of death (C. Wang et al., 2014; Zheng et al., 2015). A recent meta-analysis found a J-shaped 
relationship between alcohol consumption and all cause cancer; as for sex-specific dose-response 
relation, a J-shape was also found in males but not in females (Jin et al., 2013). It was suggested that 
women are at higher risk for all-cause mortality at moderate-to-light levels of consumption due to 
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increased risk of alcohol-related cancers (Jin et al., 2013). Further, among men, drinking more fre-
quently seems to have greater impact than the actual amount consumed; effects are less clear among 
women (Breslow & Mukamal, 2014). 
These biological factors have not been fully understood and include, but are not limited to the 
variability in alcohol pharmacokinetics, alcohol effects on the brain, sex hormone levels (Agabio, 
Campesi, Pisanu, Gessa, & Franconi, 2016; Erol & Karpyak, 2015) . These findings strongly suggest 
that male/female differences in alcohol-related harm is likely to be heavily influenced by biological 
rather than psycho-social factors (Erol & Karpyak, 2015). Differences in sex-specific drinking patterns 
and the resulting medical consequences have recently been outlined for future research (Breslow & 
Mukamal, 2014). The higher female vulnerability seems to be multifactorial and only partly related to 
the higher alcohol blood levels achieved by women after drinking equivalent amounts (Agabio et al., 
2016; Erol & Karpyak, 2015).
AuD challenges: identifying optimal therapeutic choice for women
Most people with an AUD benefit from using both medications and psychotherapy. This approach 
appears to give the optimum results. Also, a support group such as Alcoholics Anonymous (AA) is 
very helpful . People with severe AUD may need intensive treatment. They may go to a residential 
treatment center for rehabilitation (rehab) with highly structured. It usually includes several different 
kinds of behavioral therapies and medicines for detox (medical treatment for alcohol withdrawal) 
and/or for treating the AUD. Currently, naltrexone and disulfiram are dominantly used for treating 
AUD in the general adult population (Rogers & Wiese, 2011). Naltrexone is a competitive µ -opioid 
receptor , antagonist that blocks the effects of opiates. It also belongs to a group of “anti-craving” 
medications that reduce the craving effect of opiates and it is approved by US Federal Drag Associa-
tion. Accumulating data have suggested that men and women with alcohol or drug dependence re-
spond differently to the same pharmacological treatment, typically with men having better treatment 
outcomes than women (Garbutt et al., 2005; Hernandez-Avila et al., 2006; Nich et al., 2004; Pettinati, 
Volpicelli, Pierce, & O’Brien, 2000; Thom, 1987). Conversely, a previous study on Naltrexone has 
suggested that alcohol-dependent women (mean age 47.9 years) treated with 50 mg/day of naltrexone 
abstained from alcohol for a longer duration than men (mean age 45.6 years ) treated with the same 
dosage (Kiefer, Jahn, & Wiedemann, 2005). Additional information is necessary to defect optimal 
age and gender targeted pharmacotherapy, leading to better outcomes for postmenopausal women 
suffering from AUD . 
It is also important to point out which psychological/psycho-therapies can treat alcohol use 
disorder.
Published evidence reveals that Behavioral therapy might be a good solution for elderly suffer-
ing AUD (D. & H., 2011) . Cognitive-behavioral therapy (CBT) helps to identify the feelings and 
situations that can lead to heavy drinking. It empowers coping skills, with focus on how to how to 
manage stress and how to change the “drinking-thoughts”. Clinical intervention studies indicate that 
these treatments are effective in addressing many common problems in late life, including alcohol 
abuse and dependence (D. & H., 2011). Other helpful type psychotherapies are: Motivational and 
Family therapy (US National Library of Medicine - MedlinePlus, 2018). Motivational enhancement 
therapy helps to build the motivation to change drinking behavior. It includes couple (4 to 8) ses-
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sions in a short period of time. The therapy identifies the pros and cons of entering into treatment. 
Subsequently the therapist forms a plan for restructuring drinking patterns. Further sessions focus on 
building confidence and developing the skills necessary to stick to the plan (US National Library of 
Medicine - MedlinePlus, 2018).Also, marital and family counseling involves spouses and other family 
members as co-patients. It focuses on repairing and improving family relationships, that may help the 
person to stay away from drinking (U.S National Library of Medicine - MedklinePlus, 2018).
CONCLuSiON 
While in recent decades our understanding of gender differences in developing AUD has increased, 
several gaps remain regarding factors that can improve treatment options to address the needs of 
women. Targeted screening and preventive programs for women should be developed, trending to-
wards damage control and formation of cultures around smart drinking behaviors. In order to achieve 
optimal prevention and treatment for menopausal and postmenopausal women , we must increase 
our understanding of the drinking patterns that are beneficial and harmful to women of these age 
groups; including more information on types of alcohol, and levels and frequency of consumption. 
Moreover, future studies should be conducted to investigate factors that might contribute to increased 
consumption of alcohol in menopausal and postmenopausal women, as well as sex-specific factors 
that predict better treatment outcomes in women suffering from AUD. 
Limitations of the review
Our review has several limitations. Firstly, the nature of the method that we selected for this review is 
highly subjective (in the determination of which studies to include, the way the studies are analyzed, 
and the conclusions drawn). Secondly, we might be misled in drawing conclusions due to limited 
availability of evidence as complex interactions in interpretation of the context and dynamics of AUD 
in females, especially postmenopausal women are understudied. 
Clinical implications
We underline gender and age - relevance, as older women are more vulnerable to effects and con-
sequences of AUD. Importantly, women are highly responsive to psychotherapy and recruiting the 
female patients with any form of AUD in such treatment improves chances of preventing grief and 
correlated depressive and anxiety symptomatology. 
Overall comprehension of this problem can add knowledge and expertise to a multidisciplinary 
team of healthcare professionals to prevent development of severe AUD and its consequences. 
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SuppLEMENTArY MATEriAL
Supplementary table 1. DSM-5 criteria for establishing and classifying AUD
DSM-5
in the past year, have you:  
1 Had times when you ended up drinking more, or longer, than you intended?
2 More than once wanted to cut down or stop drinking, or tried to, but couldn’t?
3 Spent a lot of time drinking? Or being sick or getting over other aftereffects?
4 Wanted a drink so badly you couldn’t think of anything else?
 **This is new to DSM-5**
5 Found that drinking - or being sick from drinking - often interfered with taking 
care of your home or family? Or caused job troubles? Or school problems?
The presence of at least 2 of 
these symptoms indicates an 
6 Continued to drink even though it was causing trouble with your family or 
friends?
Alcohol use Disorder 
(AuD).
7 Given up or cut back on activities that were important or interesting to you, or 
gave you pleasure, in order to drink?
The severity of the AUD is 
defined as:
8 More than once gotten into situations while or after drinking that increased your 
chances of getting hurt (such as driving, swimming, using machinery, walking in 
a dangerous area, or having unsafe sex?
Mild: The presence of 2 to 3 
symptoms
9 Continued to drink even though it was making you feel depressed or anxious or 
adding to another health problem? Or after having had a memory blackout?
Moderate: The presence of 4 
to 5 symptoms
10 Had to drink much more than you once did to get the effect you want? Or 
found that your usual number of drinks had much less effect than before?
Severe: The presence of 6 or 
more symptoms
11 Found that when the effects of alcohol were wearing off, you had withdrawal 
symptoms, such as trouble sleeping, shakiness, restlessness, nausea, sweating, a 
racing heart, or a seizure? Or sensed things that were not there?
Source: National Institute of Alcohol Abuse and Alcoholism. Alcohol Use Disorder: A Comparison Between 
DSM–IV and DSM–5.20. National Institute of health (NIH) Publication No. 13–7999,Reviewed July 
2016. Available online: https://pubs.niaaa.nih.gov/publications/dsmfactsheet/dsmfact.pdf
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AbSTrACT
Objective: Few studies have focused on the effect of complicated grief - unresolved and prolonged 
grief - on the neuroendocrine systems. The present study examined the association of complicated 
grief and normal grief with the diurnal cortisol patterns in a large population-based study.
Methods: This study was set in the Rotterdam Study and comprised 2084 persons aged older than 
55 years (mean [SD] age 64.9 [5.5] years). Participants were assessed with the Complicated Grief 
Inventory and classified into no grief (n = 1922), normal grief (n = 131), or complicated grief (n = 
31) if they experienced the loss in the last 2 years. Saliva samples were collected to measure cortisol 
levels. Morning cortisol and summary measures (area under the curve and the slope) were studied 
to account for the diurnal pattern of cortisol. Persons with depressive disorders were excluded and 
analyses were additionally adjusted for depressive symptoms.
Results: Compared to normal grievers, participants with complicated grief showed lower levels of 
morning cortisol (11.26 vs 15.51 nmol/L; difference, −4.24; 95% confidence interval [CI] = −7.87 to 
−0.62; p = .022), and lower levels of overall diurnal cortisol (6.89 vs 8.98 nmol/L; difference, −2.09; 
95% CI = −3.81 to −0.37; p = .017). No difference was observed in slope between both groups. Par-
ticipants with complicated grief also showed lower levels of morning cortisol than the nongrievers 
(11.26 vs 14.71; difference, −3.46; 95% CI = −6.78 to −0.13; p = .042). In contrast, cortisol secretion 
patterns did not differ between persons with normal grief and nongrieving controls. cortisol levels 
characteristic for a chronic stress reaction.
Acronyms: RS Rotterdam Study, CG complicated grief, ICG Inventory of complicated grief, AUC 
area under the curve, CES-D Centre for epidemiologic studies of depression, BMI body mass index, 
MMSE mini mental score, SD standard deviation, HPA hypothalamic–pituitary–adrenocortical axis 
, ACTH adrenocorticotropic hormone.
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iNTrODuCTiON
Bereavement is defined as having experienced a significant loss (Shah & Meeks, 2012). Its most com-
mon reaction is grief (Rozenzweig, Prigerson, Miller, & Reynolds, 1997). Grief knows many different 
manifestations and courses, but grief itself is not a mental disorder. However, approximately 9% to 
20 % of the population experiencing bereavement show symptoms of an unresolved and prolonged 
grief, termed “complicated grief ” (Newson, Boelen, Hek, Hofman, & Tiemeier, 2011). Complicated 
grief has been referred to as “traumatic grief ”, “complicated grief disorder” and “prolonged grief ” and 
is distinctly different from “depression accounted for by bereavement”, as mentioned in the DSM-IV 
(Shear et al., 2011). Recently, complicated grief has been included within the section “conditions for 
further study” in DSM-5 Section as Persistent Complex Bereavement Disorder (American Psychiatric 
Association 2013). Complicated grief includes a set of symptoms such as persistent intense yearn-
ing for the deceased, intense feelings of loneliness, feelings of disbelief or that life is empty, being 
emotionally numb or troubling accepting the death, bitterness, intrusion and rumination of thoughts 
or images of the dead person, and hearing or seeing the deceased person, lasting for at least 6 months 
(Pasternak et al., 1991; Prigerson et al., 1999; Shear et al., 2011).The etiology of complicated grief is 
not well-established, although psychosocial risk factors have been described, such as an unexpected 
death or suicide of the deceased (Ginzburg , Geron , & Solomon, 2002; Mitchell, Kim, Prigerson, 
& Mortimer-Stephens, 2004), lack of social support, or fewer pre-loss coping resources (lower self-
perceived coping efficacy; lower religiosity) (Hansson, 2014; Ott, 2003), excessive dependence on the 
deceased (Bonanno et al., 2002), and pessimistic temperament (Robinson & Marwit, 2006).
 The death of a loved one can be one of the most stressful events a person must endure (Stroebe, 
Schut, & Stroebe, 2007). Under conditions of stress, the hypothalamic-pituitary-adrenocortical (HPA) 
axis is stimulated and activates the secretion of cortisol into the bloodstream. Acute psychosocial 
stress is typically accompanied by increased secretion of cortisol, as an adaptation to the stressor and 
then decreases to normal levels; but it is the chronic dysregulation of cortisol that is implicated in a 
host of psychological and physical health conditions (Dickerson & Kemeny, 2004). A recent meta-
analysis found that, compared to non-stressed controls, chronically stressed persons more often had a 
dysregulated pattern of cortisol secretion. This pattern was characterized by lower morning secretion 
and higher secretion across the rest of the day, yielding a flattened diurnal pattern (Miller, Chen, 
& Zhou, 2007). In depressed persons, higher levels of cortisol secretion have been reported widely, 
although in chronic depression and in community dwelling depressed persons low levels of morning 
cortisol have also been observed (Stetler & Miller, 2011). Likewise, low cortisol levels are reported in 
studies of chronic fatigue syndrome (Cleare, 2003, 2004; Roberts, Wessely, Chalder, Papadopoulos, & 
Cleare, 2004; Strickland et al., 2002; Tak et al., 2011; Ter Wolbeek, van Doornen, Coffeng, Kavelaars, 
& Heijnen, 2007) and in studies of post-traumatic stress disorder and after traumatic events (Yehuda, 
2002b, 2006; Yehuda et al., 1995). Previous studies of grief and cortisol showed that the loss of a loved 
one is associated with more dysregulated cortisol patterns and an increased mortality risk of the 
bereaved person (Miller et al., 2007; Stroebe et al., 2007). Richardson et al. studied bereaved spouses 
and the effect of a prolonged forewarning of the death (i.e., knowing at least one month before the 
death that the person is going to die in the coming months). The group of bereaved persons who 
reported a forewarning of death showed higher cortisol levels at six month than those bereaved who 
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did not experience prolonged forewarning (Richardson et al., 2015). Few studies have investigated 
the relationship between cortisol and complicated grief. One study compared 12 women with com-
plicated grief to 12 women with normal grief, showing a flatter slope across the day in those with 
complicated grief (O’Connor, Wellisch, Stanton, Olmstead, & Irwin, 2012). Another study compared 
56 depressed adults, divided in three groups of non-bereaved, bereaved without signs of complicated 
grief, and bereaved with complicated grief symptoms. Interestingly, the depressed bereaved persons 
had lower levels of log-cortisol at wake and flatter diurnal slopes compared with the depressed non 
bereaved independent of, complicated grief symptoms (Holland et al., 2014).
Against this background and given the phenotypical correlation of complicated grief and chronic 
depression and PTSD, both of which have been related to lower cortisol values, we examined the 
association between complicated grief and cortisol measures.
We focused on persons with duration of complicated grief up to two years and five years after the 
loss (Maciejewski, Zhang, Block, & Prigerson, 2007). The aim of our study was to examine the asso-
ciation of the morning cortisol and summary cortisol measures with grief and complicated grief. We 
tested two hypotheses. First, persons with complicated grief symptoms have a lower diurnal cortisol 
secretion than those without grief or with normal grief. Second, persons with normal grief have a 
similar cortisol secretion pattern as those without grief.
METhODS
Study participants
This study was set in the Rotterdam Study (RS), a large prospective population-based cohort designed 
to examine the occurrence and risk factors of chronic diseases. The study has been described in detail 
elsewhere (Hofman et al., 2011). In 1990, all residents in a district of Rotterdam who were aged 
55 years and over were invited to participate. Every four years, participants undergo an extensive 
home interview and physical examination at a research center. The Medical Ethics Committee of the 
Erasmus University of Rotterdam approved the study, and informed consent was obtained from all 
participants. The current study is based on the fourth examination of the original cohort members 
(n=7983). The examination was performed in 2002-2004 with 3550 participants (74% response rate), 
and assessed complicated grief and salivary cortisol levels.
 For the present study we excluded participants with incomplete complicated grief inventory (n = 
187), those using corticosteroids (n = 78), without salivary cortisol measures (n = 840), and persons 
with complicated grief less than six months after loss (n = 18) or grieving more than two years (n 
= 313). This resulted in 2084 elderly persons aged older than 55 years (M [SD] age 64 [5.5] years, 
55% women) for the analyses of two years after loss. Another 130 grieving persons were additionally 
included in the analyses of all persons that experienced grief in the last five years.
Assessment of complicated grief 
All participants were asked if they were currently grieving (Newson et al., 2011). If the answer was 
positive we asked whom they were grieving over (spouse, partner, child, parent, sibling, other family 
member, close friend, other, several people — including or excluding spouse) and the time elapsed 
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since the death. The participants, who answered the first question affirmatively, were assessed for 
complicated grief with the Dutch version of the Inventory of Complicated Grief (ICG). 
In the present study, we used two different cut-offs to limit the time since loss. The primary 
analyses used a 2 year cut-off since bereavement and included all participants with grief (≤ 2 years) 
and complicated grief (≥ 6 months to 2 years). The second and contrasting analyses used a 5 years 
cut off since bereavement, and included all participants with grief and complicated grief up to 5 years 
after bereavement. However, at least six month duration of symptoms was required in accordance 
with recommendations for diagnostic criteria and to exclude acute stress reaction (Prigerson et al., 
2009). The choice of the two year post loss cut-off was made to study the association with more 
recent complicated grief in line with a previous study (Newson et al., 2011) and the cut-off has also 
been used in previous analyses of the present cohort (Saavedra Perez et al., 2015). However, we also 
present analyses including all persons (N=292) with grief or complicated grief up to five years post 
loss. Complicated grief was diagnosed with the Dutch version of the Inventory of Complicated Grief 
(ICG). Questions represent symptoms of complicated grief on the basis of the most recent proposed 
criteria. The ICG is considered the gold standard for measurement of complicated grief in older adults 
because it has high internal consistency, good convergent and criterion validity (Prigerson et al., 
1995). The inventory represents a single underlying construct of complicated grief. As described be-
fore (Newson et al., 2011), seventeen questions were asked and responses were provided on a 5-point 
scale to reflect an increase in severity (0-never, 1-seldom, 2-sometimes, 3-often, and 4-always). In 
the current setting, one item, “I feel bitter over this person’s death”, was removed from the original 
inventory as a pilot study revealed that this sentiment had a very similar meaning within the Dutch 
language as the included item: “I feel anger over this person’s death”. Two further items (relating to 
seeing and hearing the deceased) were combined into one due to their similarity and a pilot study 
indicating these symptoms were low in frequency and too often overlapped (“I hear the voice of, or 
see, the person who died”).
A summary score for the ICG was calculated by totaling each individual item score (responses 
from 0-never to 4-always) across the 17-items providing a potential score range of 0 to 68. Partici-
pants with a score of less than 22 were considered as participants with grief symptoms in line with 
previous studies (Newson et al., 2011). 
We defined complicated grief based on the severity of symptoms and did not define severity by 
duration of symptoms. Participants with a score of less than 22 were considered as participants with 
grief symptoms in line with previous studies (Newson et al., 2011). Participants with a score of 22 or 
greater and with symptoms lasting after for at least six months were considered to have complicated 
grief. This cut-off was based on the cut-off in the original version of the ICG (original cut-off of 
25 from 19-items). We classified participants into three groups; no grief (control group), persons 
with normal grief (experiencing non-complicated grief as shown by an ICG score < 22) and those 
with complicated grief (ICG score ≥22). The non-grieving control group included persons who had 
experienced bereavement in the past but were not grieving at the time of interview. Likewise persons 
mourning over someone with severe disease, but who were still alive; or a pet, were included in the 
control group.
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Salivary cortisol protocol
Saliva samples were collected on awakening (T1), 30 min after awakening (T2), at 1700 h (T3), and 
at bedtime (T4). Saliva samples were collected on awakening (T1), 30 min after awakening (T2), at 
1700 h (T3), and at bedtime (T4). Salivary cortisol concentrations were measured using a commercial 
immunoassay with chemiluminescence detection (CLIA; IBL Hamburg, Hamburg, Germany). In-
traassay and interassay coefficients of variation were less than 6 and 9%, respectively. The lower limit 
of detection was 0.4 nmol/liter. Data were screened for quality of cortisol measurements. For each 
time point, cortisol values that were above the 98th percentile in the original cortisol data set were 
excluded from the final data set to normalize the distribution of cortisol measurements and to exclude 
misclassification due to possible measurement errors. After this exclusion, cortisol levels followed 
a normal distribution (Dekker et al., 2008). The individual measures of cortisol were combined in 
summary measures to provide valid information about the diurnal pattern of cortisol. We calculated 
the area under the curve with respect to the ground (AUCg) and the slope. The AUCg summarizes 
overall diurnal cortisol exposure, and was calculated as the local area under the curve from the indi-
vidual cortisol measures on the Y-axis and the time between cortisol measures on the X-axis. It takes 
into account both sensitivity (the difference between the single measurements from each other) and 
intensity (the distance of these measures from ground) (Fekedulegn et al., 2007; Pruessner, Kirsch-
baum, Meinlschmid, & Hellhammer, 2003). In order not to include the effect of the morning rise as 
part of the AUC, we did not include T2 in the AUC calculation. Diurnal decline was assessed by a 
slope, which was calculated by fitting a linear regression line for each participant, which predicted the 
cortisol values from time since awakening. A greater decline in the daytime cortisol means that the 
slope of the regression line is steeper, whereas a lesser decline means that the slope is flatter.
Assessment of other variables
Age, sex, education level, smoking status, body mass index, cognitive status, major depression, de-
pressive symptoms and anxiety symptoms were evaluated as potential confounders on the basis of 
previous publication (Corruble, Falissard, & Gorwood, 2011; Direk, Newson, Hofman, Kirschbaum, 
& Tiemeier, 2011; Lee et al., 2007; Rosnick, Small, & Burton, 2010). The time between subsequent 
cortisol measurements within the same day was use as a covariate in the analyses of the AUC and the 
slope. Information was collected in home interviews and physical examination at baseline (Vermeer 
et al., 2003). 
Level of education was assessed during home interview and was classified into those with primary 
education only, intermediate education, and high education (university studies). Participants were 
asked about their smoking status (never, current, and former). Current smokers were asked how many 
cigarettes they smoked daily and how long they had been smoking. Former smokers were asked about 
their smoking history (Direk et al., 2011). Height and weight were measured in participants without 
shoes and heavy clothes and body mass index was calculated as kg/m2, and used as a continuous vari-
able (Visscher et al., 2001). Cognitive status was evaluated with the Mini Mental Status Examination 
(Folstein, Folstein, & McHugh, 1975) and used as a continuous variable. Depressive symptoms were 
assessed with a validated Dutch version of the Centre for Epidemiologic Studies Depression (CES-D) 
scale (range 0-60) to obtain a continuous measure of depressive symptoms (Beekman et al., 1997; 
Beekman, van Limbeek, Deeg, Wouters, & van Tilburg, 1994; Folstein et al., 1975). All participants 
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with clinically relevant depressive symptoms (i.e., those with a scores of 16 or greater on the CES-D, 
see above), were interviewed using the Present State Examination, a semi-structured psychiatric 
interview included in the Schedules for Clinical Assessment in Neuropsychiatry. All interviews were 
conducted by two experienced clinicians. Major depression was classified according to the Diagnostic 
and Statistical Manual of Mental Disorders-IV (World Health Organization - Division of Mental 
Health 1994).
Anxiety disorders were diagnosed with an adapted version of the Munich version of the Com-
posite International Diagnostic Interview (M-CIDI) to assess the following anxiety disorders: GAD, 
panic disorder with or without history of agoraphobia, agoraphobia, social phobia and specific pho-
bia. Obsessive compulsive disorder and post-traumatic stress disorder, which are part of the anxiety 
disorders in the DSM-IV, were not assessed. The M-CIDI was specifically designed to obtain DSM-IV 
diagnoses of mental disorders (Hek et al., 2011).
Assessment of Exclusion Criteria 
Participants using corticosteroid were excluded. Pharmacy records were used to collect data on 
systemic corticosteroid use (Direk et al., 2011).
Statistical Analysis
Information on demographic characteristics was compared among the groups using a χ2 test for 
categorical data and an analysis of variance for continuous variables. We investigated the association 
of complicated grief with cortisol, the single (T1 morning cortisol) and the summary measures (AUC 
and slope). The primary analyses included as cases only persons who grieved after a loss up to two 
years ago; as this cut-off was used previously (Maciejewski et al., 2007). The second analyses included 
persons who were grieving after bereavement five or less years ago. We compared cortisol measures of 
the reference population to participants with normal grief and to those with complicated grief using 
analysis of covariance. 
The analyses were adjusted for age and sex, level of education, smoking status, body mass index, 
Mini Mental State Examination, current depressive symptoms, and time between cortisol measures 
(for TI, T2, T3, and T4). Covariates were imputed using the Expectation-Maximization Algorithm. 
All covariates had less than 3% missing values. Missing values were imputed on the basis of the entire 
baseline population (n = 3550).
Although the ICG is designed as a screening measure and not to assess severity of grief, we per-
formed continuous analyses in persons grieving using the scores on the ICG to test whether there is 
a dose–response relationship between the grief symptoms score and cortisol levels independently of 
the predefined cutoff.
rESuLTS
The study population comprised 1922 persons with no grief, 131 with normal grief and 31 with com-
plicated grief of maximal two years duration. In the sensitivity of persons with up to five years after 
loss, 210 persons with normal grief, and 82 persons with complicated grief were included.
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Table 1 presents the characteristics of the study population. The sample was composed of 55 % 
females and the mean age of the participants was 64.9 years (SD=5.5). Participants with complicated 
grief were more often women and they were older than persons without grief. The main cause of 
grieving in those with complicated grief was death of the partner (61%), and in those with normal 
grief it was death of a partner (29%) or a sibling (22%). Participants with complicated grief had more 
clinical relevant depressive symptoms (18.4%), major depression (13.2%) and anxiety symptoms 
(18.4%) than persons without grief or those with normal grief. 
Table 2 shows the cortisol saliva measures (morning cortisol, area under the curve, and slope) of 
the participants with no grief, normal grievers and complicated grievers who experienced the loss 
in the last two years. Participants with complicated grief had lower levels of morning cortisol than 
normal grievers [11.26 versus 15.51 nmol/l; difference -4.24, 95% CI (-7.87, -0.62), p=0.02]. Persons 
with complicated grief also had lower overall diurnal cortisol levels (AUCg) [6.89 versus 8.98 nmol/l; 
Table 1. Baseline characteristics of the study population, N=2084
Characteristic
No Grief
N=1922
Grief
N=131
Complicated Grief
N=31
N % Mean±(SD) N % Mean±(SD) N % Mean±(SD)
Sex, (women) 1056 (55) 89 (68) 21 (68)
Age 63.5(5.6) 65.3(6.3) 65.9(4.7)
CESD score 5.1(6.1) 7.6(6.6) 13.8(9.8)
BMI (kg/m²) 27.4(3.9) 27.2(4.2) 26.1(2.4)
MMSE score 27.5(2.2) 27.4(2.5) 27.6(1.9)
Education Primary 515 (27) 37 (28) 10 (32)
Education Intermediate 1380 (72) 90 (69) 21 (68)
Education High 27 (1.4) 4 (3.1) 0 (0)
Smoking status 
Never smoked 603 (31) 49 (37) 14 (45)
Current smoker 234 (12) 12 (9) 3 (10)
Former smoker 1085 (57) 70 (53) 14 (45)
Anxiety Symtoms 144 (7.5) 12 (9) 6 (19)
Who died?
Partner - - 38 (29) 19 (61)
Child - - 7 (5) 1 (3)
Parent - - 4 (3) 0 (0)
Brother/sister - - 29 (22) 4 (13)
Others(another family member, 
good friend, several)
52 (40) 7 (23)
Participants with grief (ICG <22) from 0 months to 2 years post loss and participants with compli-
cated grief (ICG≥22) from 6 months to 2 years post loss were included. Participants using corticoids 
were excluded. Chi-square test and analysis of variance were performed.
SD: standard deviation. BMI: body mass index. MMSE: Mini Mental State Examination
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difference -2.09, 95% CI (-3.81, -0.37), p=0.017]. The difference in the slope of cortisol observed 
between both groups did not reach significance.
Consistently, participants with complicated grief were found to have lower levels of morning 
cortisol than non-grievers [11.26 versus 14.71; difference -3.46, 95% CI (-6.78, -0.13), p=0.042]. 
Neither the difference in overall cortisol levels nor the difference in cortisol slope reached statistical 
significance; although the effect estimates suggest a meaningful differrence. 
The table does not show the formal contrast between those with grief and without grief in the 
table; none of the group means between those with normal grief and those without grief reached 
significance (data not shown). However, the table clearly shows that the means of all cortisol measures 
are very similar in these two groups. 
Table 3 presents the results of our sensitivity analyses. The groups now include all persons that 
experienced grief or complicated grief up to five years ago (those experiencing grief two to five years 
were added in these analysis). No differences between the participants with grief, complicated grief 
and those without any grief, in the cortisol morning levels or the two sum measures were observed 
anymore - whatever the reference and comparison group. Consequently, we tested if the cortisol 
measures of persons with complicated grief differed depending on time since bereavement. To this 
aim we defined exclusive groups of complicated grievers less than two years and between two and 
five years since bereavement. Both the AUCg (CG 2 years: 6.84 nmol/l, CG>2-5 years: 9.23 nmol/l, 
difference: -2.393, CI (-4.21, -0.57); F-statistic: 3.33, p-value 0.01) and the morning cortisol levels (CG 
2 years: 11.85 nmol/l, CG>2-5 years: 16.44 nmol/l, difference: -4.58, CI (-8.46, -0.70); F-statistic: 2.69, 
p-value 0.021) differed in persons with complicated grief depending on the time since bereavement.
The continuous analyses in persons with grief experienced in the last five years showed that higher 
scores on the ICG were associated with lower morning cortisol (B=-0.270, 95% CI-11.94 to -0.72, 
p=0.027).
Consistently, participants with complicated grief were found to have lower levels of morning 
cortisol than non-grievers [11.26 versus 14.71; difference -3.46, 95% CI (-6.78, -0.13), p=0.042]. 
Neither the difference in overall cortisol levels nor the difference in cortisol slope reached statistical 
significance; although the effect estimates suggest a meaningful difference. 
The table does not show the formal contrast between those with grief and without grief in the 
table; none of the group means between those with normal grief and those without grief reached 
significance (data not shown). However, the table clearly shows that the means of all cortisol measures 
are very similar in these two groups. 
Table 3 presents the results of our sensitivity analyses. The groups now include all persons that 
experienced grief or complicated grief up to five years ago (those experiencing grief two to five years 
were added in these analysis). No differences between the participants with grief, complicated grief 
and those without any grief, in the cortisol morning levels or the two sum measures were observed 
anymore - whatever the reference and comparison group. Consequently, we tested if the cortisol 
measures of persons with complicated grief differed depending on time since bereavement. To this 
aim we defined exclusive groups of complicated grievers less than two years and between two and 
five years since bereavement. Both the AUCg (CG 2 years: 6.84 nmol/l, CG>2-5 years: 9.23 nmol/l, 
difference: -2.393, CI (-4.21, -0.57); F-statistic: 3.33, p-value 0.01) and the morning cortisol levels (CG 
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2 years: 11.85 nmol/l, CG>2-5 years: 16.44 nmol/l, difference: -4.58, CI (-8.46, -0.70); F-statistic: 2.69, 
p-value 0.021) differed in persons with complicated grief depending on the time since bereavement.
The continuous analyses in persons with grief experienced in the last five years showed that higher 
scores on the ICG were associated with lower morning cortisol (B=-0.270, 95% CI-11.94 to -0.72, 
p=0.027).
DiSCuSSiON
In this population-based study, we studied whether diurnal cortisol secretion of persons with com-
plicated grief or persons with normal grief differed from those not experiencing grief in the last two 
years. As hypothesized, the present study demonstrated that participants with complicated grief two 
years post loss showed lower level of morning cortisol and lower overall diurnal cortisol exposure 
than the participants with grief or without grief. In contrast, persons with grief showed similar corti-
sol secretion patterns as those without grief. 
Cortisol is frequently referred to as the “stress hormone”. Stressful life circumstances stimulate hy-
pothalamic–pituitary–adrenocortical axis HPA, activating a hormonal response system that results in 
increased blood levels of cortisol (Beekman et al., 1997). However, hypocortisolism has been observed 
in patients, who developed post-traumatic stress disorder (PTSD) (Beekman et al., 1994; Roberts et 
al., 2004; World Health Organization - Division of Mental Health 1994), and has also been reported 
in patients suffering from bodily disorders, such as burnout with physical complaints, chronic fatigue 
syndrome, fibromyalgia, and chronic pelvic pain (Cleare, 2003; Hek et al., 2011; Lovallo 2005; Miller 
et al., 2007; Stetler & Miller, 2011; Ter Wolbeek et al., 2007). Similar findings have been reported 
for healthy individuals living under conditions of chronic stress, chronic depression, as well as for 
patients with rheumatoid arthritis, and asthma (Lovallo 2005; Robinson & Marwit, 2006; Stroebe et 
al., 2007). Our observations in persons with complicated grief extend these latter findings. Whereas 
a previous study of complicated grief and diurnal cortisol showed that those with complicated grief 
have a flatter slope across the day (Yehuda, 2006), morning cortisol or area under the curve have not 
been examined in persons with complicated grief.
Several mechanisms may be involved in the development of hypocortisolism. First, reduced 
biosynthesis of cortisol as part of an adaptive down-regulation has been postulated in persons ex-
periencing severe trauma (Hek et al., 2011; Yehuda, Teicher, Trestman, Levengood, & Siever, 1996). 
Second, increased sensitivity of the HPA axis for negative feedback (Yehuda, 2002a; Yehuda & Seckl, 
2011) or corticotropin releasing factor hypersecretion from the hypothalamus, are discussed, as these 
can result in reduced ACTH and lower cortisol levels (Lovallo 2005). Third, a very different but not 
necessarily exclusive mechanism is suggested by prior work from our group. We have previously 
shown that persons with complicated grief are characterized by more brain atrophy than persons with 
grief. Neuronal loss may disrupt the microstructural integrity of the fascicles connecting prefrontal 
cortex with the subcortical areas (amygdala and hippocampus) (Maciejewski et al., 2007; Nugent et 
al., 2015), which are involved in the inhibitory regulation of the HPA axis (Heim, Ehlert, & Hellham-
mer, 2000; Meewisse, Reitsma, de Vries, Gersons, & Olff, 2007; Yehuda & Seckl, 2011). Morphological 
brain changes: have also been described in patients with PTSD, such as a reduced volume of the 
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hippocampus, which is predominantly involved in the inhibitory regulation of the HPA axis (Heim et 
al., 2000; Meewisse et al., 2007; Yehuda & Seckl, 2011). Our data, however, suggest also that any such 
mechanisms behind hypocortisolism may sometimes be reversible. In the present study, no effect of 
grief or complicated grief on cortisol secretion patterns was observed, if persons with longer periods 
since the loss were included. This suggests that with longer follow-up time the association between 
grief and cortisol may atenuatte. We can only carefully speculate about coping in this interval. Par-
ticipants with more than two years post loss may have adapted to the loss and the resulting changes, 
instead of avoiding the loss. Several studies proposed that CG reactions only persist when people 
engage in avoidance behaviors trying to impede habituation to painful memories and interfering with 
the integration of the loss (Bremner et al., 1997; Stein, Koverola, Hanna, Torchia, & McClarty, 1997; 
Yehuda, Lowy, Southwick, Shaffer, & Giller, 1991). 
In our study, we found no differences in diurnal secretion cortisol and persons with normal grief 
and the controls. These findings were not unexpected if one views grief as a normal life event, unre-
lated to pre-existing vulnerabilities. Effects on the HPA axis may be visible after several months or 
even years only if a person develops complicated grief or has risk factors for complicated grief such as 
a dependent relationship with the dead person, unexpected dead, lack of social support, and the loss 
of someone who was ambivalently loved (Maciejewski et al., 2007). Or results suggest that persons 
with normal grief may have a more healthy coping style. Alternatively, they experience less of those 
grief-related feelings and behaviors, which tend to dominate severe bereavement and may affect the 
HPA axis (Boelen, 2006).
Strengths of our study include the sample size, the population-based setting, and the multiple daily 
cortisol measurements. A large control group of non-grieving persons was provided the reference 
for participants with normal grief or complicated grief. Also, we controlled for clinically relevant 
depressive symptoms and major depression.
Some limitations of the current study should also be mentioned. First, it is not possible to evaluate 
if these associations were causal due to the cross-sectional design of the study. In particular, we do 
not have cortisol assessments prior to grief, nor in the next examination round. Thus, we cannot rule 
out that existing alterations in HPA axis activity made some persons more susceptible to develop 
complicated grief. Second, not all the participants with Inventory of complicated grief participated 
in the saliva sampling. Third, selection effects may have lead to the inclusion of more grievers with 
healthy coping style in those persons whose loss events occurred long ago. This would have diluted 
the effects. Fourth, is not possible to account for complicated grief with PTSD because in the Rot-
terdam Study this was not assessed. Fifth, we do not have longitudinal data to study the factors that 
might be involved on the reversibility of the cortisol secretion. Also, we can not rule out that existing 
alterations in HPA axis activity made some persons more susceptible to develop complicated grief. 
The importance of our study is that cortisol, which is involved in cognitive functions such as 
memory performance and executive function and regulates the the inflammatory responses is al-
tered in persons experience complicated grief (Bonanno et al., 2002; Hek et al., 2011; Lovallo 2005; 
Parkes, 1998). This implies that persons with complicated grief may be more vulnerable to develop 
cognitive problems (Maciejewski et al., 2007), depression and medical conditions than persons with 
normal grief. Follow-up studies are needed, however, to demonstrate the clinical consequences of our 
observations.
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AbSTrACT
Objective/Background: About 15% of grievers experience complicated grief. We determined cross-
sectional and longitudinal relations of grief and complicated grief with sleep duration and quality in 
the general population of elderly adults.
Participants: We included 5,421 men and women from the prospective population-based Rotterdam 
Study. 
Methods: The Inventory of Complicated Grief was used to define grief and complicated grief. We 
assessed sleep with the Pittsburgh Sleep Quality Index. 
Results: After 6 years, 3,511 (80% of survivors) underwent the follow-up interview. Complicated grief 
was cross-sectionally associated with shorter sleep duration and lower sleep quality. These associa-
tions were explained by the presence of depressive symptoms. The prospective analyses showed that 
sleep duration and sleep quality did not decline further during follow-up of persons who experienced 
grief or complicated grief.
Conclusion: In community-dwelling, middle-aged and older adults, persons with normal and 
complicated grief had both a shorter sleep duration and a lower sleep quality, mainly explained by 
depressive symptoms. However, prospective analyses showed that sleep quality and sleep duration do 
not decline further in persons with normal grief and complicated grief.
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iNTrODuCTiON
The death of a loved one is a common life event in older adults (Boelen & Hoijtink, 2009; Boelen & 
van den Bout, 2008; Shear, 2015. Very few persons make it through old age without having to cope 
with this kind of loss, once or several different times. The loss of a partner, child, parent, or close 
family member can be very distressing (Monk, Germain, & Reynolds, 2008). However, even if it is 
experienced as a traumatic event, after a delimited period of grief, the majority of people recover. An 
estimated 15% of bereaved people continue to grieve for an extended period; they experience disbelief 
and are preoccupied by the deceased (Prigerson et al., 1995). This state is known as complicated grief 
(Prigerson et al., 2009). Complicated grief is an important mental health issue for the aging popula-
tion, affecting social functioning and well-being (Newson, Boelen, Hek, Hofman, & Tiemeier, 2011). 
However, our knowledge about complicated grief is limited. Previous studies suggest that symptoms 
of complicated grief are distinct from those of depression and anxiety and have incremental validity 
predicting impairments in social and interpersonal daily functioning (Boelen, van de Schoot, van 
den Hout, de Keijser, & van den Bout, 2010; Newson et al., 2011; Prigerson & Jacobs, 2001). In addi-
tion, the severe emotional strain of the loss of a loved one can trigger profound changes in lifestyle. 
These changes often induce reductions in financial security, perceived personal safety, and freedom 
of action. All of these facets of grief could lead to changes in sleep patterns. Several studies (Hall et 
al., 1997; Kowalski & Bondmass, 2008; Monk, Begley, et al., 2008) suggest that grief is associated 
with significant sleep impairment. However, our knowledge regarding the associations of complicated 
grief with sleep is limited, as only a few studies with small sample size and a cross-sectional design 
have been conducted (Boelen & Lancee, 2013; Germain, Caroff, Buysse, & Shear, 2005; Maytal et 
al., 2007; Monk, Begley, et al., 2008; Purebl, Pilling, Konkoly, Bodizs, & Kopp, 2012; Spira, Stone, 
Beaudreau, Ancoli-Israel, & Yaffe, 2009). An exploratory study of the effects of complicated grief on 
sleep by McDermott et al. (1997) conducted analyses on 65 bereaved persons. The results showed 
mild subjective sleep impairment is associated with complicated grief, but no effect was detected 
using the electroencephalographic sleep measures. Germain et al. (2005) evaluated the severity of 
sleep disturbances in a group of 105 adults meeting criteria for complicated grief. They showed an 
association of complicated grief with an overall poor sleep quality. Comorbid depression (Adrien, 
2002; Germain et al, 2005; Hall et al., 1997; Maytal et al., 2007; Monk, Begley, et al., 2008; Nutt, 
Wilson, & Paterson, 2008; Purebl et al., 2012; Spira et al., 2009), but not posttraumatic stress disorder, 
further worsened sleep quality.
Taking into account the lack of high-powered longitudinal studies in normal populations of 
elderly adults, we aim to determine whether in adults aged 55 years and above, grief or complicated 
grief was related to sleep duration and sleep quality, cross-sectionally and longitudinally.
We hypothesized that if studied cross-sectionally, persons with grief and complicated grief have 
shorter sleep duration and a lower sleep quality than persons who did not experience grief due to the 
stress that death of the loved one brings to person’s life. Second, we hypothesized that complicated 
grief remains a risk factor for further decline of sleep duration and poor sleep quality over time due 
to coping mechanisms that may not always be successful.
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METhODS
Settings and Study population
This study was embedded in The Rotterdam Study, an ongoing prospective cohort of older adults 
designed to examine the occurrence and risk factors of chronic diseases. The study design and objec-
tives are described in Hofman et al. (2013). The Rotterdam Study comprises two cohorts, which were 
combined in the current analysis. Between 2002 and 2005, complicated grief and sleep quality were 
assessed during a home interview, referred to as baseline. The baseline interview was conducted in 
5,481 participants. Of these participants, 60 persons did not complete the grief or sleep question-
naire. This left 5,421 participants with assessment of grief and sleep characteristics for cross-sectional 
analysis. In part of the follow-up examination (2009– 2011), both components of sleep (duration and 
quality) were assessed at the research center. After an average of 6.33 years (SD = 0.42), 3,511 (80%) 
of the 4,601 surviving participants underwent the follow-up interview for sleep duration, and 3,003 
(71%) for sleep quality. The Rotterdam Study has been approved by the Medical Ethics Committee 
of the Erasmus Medical Center (Erasmus MC) and by the Ministry of Health of the Netherlands, 
implementing the Wet Bevolkingsonderzoek: ERGO (Erasmus Rotterdam Gezondheid Onderzoek; 
Population Studies Act: Rotterdam Study). All participants provided written informed consent to 
participate in the study and to obtain information from their treating physicians.
Assessment of Complicated Grief
Complicated grief was diagnosed at the baseline examination (2002 and 2005), with a Dutch version 
of the 17-item Inventory of Complicated Grief (ICG) originally constructed by Prigerson et al. (which 
contains 19 items). First, participants were asked if they were currently grieving. If a positive answer 
was received, the ICG was administered, but if not, they were categorized as nongrievers (the refer-
ence group). The ICG is the most widely used instrument to measure complicated grief. Questions 
represent symptoms of complicated grief such as those in the most recent proposed criteria for the 
condition suggested by (Prigerson et al., 2009). Some of the symptoms include intense yearning for 
the lost person, anger over the death, distrust and detachment from others as a consequence of the 
death, survivor guilt, and loneliness. The measure has high internal consistency and convergent and 
criterion validity and it is considered the gold standard for measurement of complicated grief in older 
adults. The inventory is shown to represent a single underlying construct of complicated grief (Boelen 
& Hoijtink, 2009). The Dutch version of the Inventory of Complicated Grief contains 17 items and 
has been previously validated (Boelen et al., 2003). These 17 questions were asked and responses 
were provided on a 5-point scale to reflect an increase in severity (0-never, 1-seldom, 2-sometimes, 
3-often, 4-always). In the current study one item from the original inventory, “I feel bitter over this 
person’s death,” was removed from the original ICG because a pilot study revealed that this sentiment 
had the same meaning within the Dutch language as the included item, “I feel anger over this person’s 
death.” Two further items (relating to seeing and hearing the deceased) were collapsed into one due 
to their similarity and to a pilot study indicating these symptoms were low in frequency and often 
overlapped (“I hear the voice of, or see, the person who died”). Several studies give further details 
on the interpretation of ICG (Boelen et al., 2010; Newson et al., 2011; Prigerson & Jacobs, 2001). 
We divided all interviewed participants into nongrievers (reference group), normal grievers, and 
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complicated grievers. Complicated grief symptoms were assessed as present among participants who 
scored equal or greater than 22 on the ICG score and grieved longer than 6 months (Newson et al., 
2011; Saavedra Perez et al., 2015).
Assessment of Sleep
Sleep duration and sleep quality were measured with the Pittsburgh Sleep Quality Index (PSQI), a 
self-reported questionnaire (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). The PSQI consists of 
19 self-rated questions. Questions are grouped into seven component scores, each weighted equally 
on a 0–3 scale. The seven component scores are then summed to yield a global PSQI score, which 
is used in all further analyses. This score has a range of 0–21; higher scores indicate worse sleep 
quality. The seven components are subjective sleep quality, sleep latency, sleep duration, habitual sleep 
efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. In the current 
study, we used total sleep time in hours to indicate sleep duration, and a total score of PSQI to indicate 
sleep quality. Finally, we presented a sample of PSQI (Supplement A).
Assessment of potential confounders
Age, sex, education, cognitive functioning, activities of daily living, body mass index (BMI), and de-
pressive symptoms were considered as potential confounders. Education was assessed routinely in the 
home interview and subdivided into low, intermediate, and high education. Cognitive functioning 
was measured using the Mini-Mental State Examination (Folstein, Folstein, & McHugh, 1975) during 
one of the visits to our center. The ability to perform activities of daily living was measured with 
the Stanford Health Assessment Questionnaire (Bruce & Fries, 2003; Fries, Spitz, & Young, 1982). 
Height and weight were measured without shoes and heavy clothing to calculate the BMI (kg/m2). 
Depressive symptoms were measured with the Center for Epidemiological Studies Depression scale 
(CES-D). In our baseline table, we also showed the presence of depressive symptoms among partici-
pants who scored 16 or above, suggesting clinically relevant depressive symptoms on the Center for 
Epidemiological Studies Depression scale.
Statistical Analyses
To explore the association between grief and sleep parameters we used linear regression. Model 1 
was adjusted for age and sex. Model 2 was additionally adjusted for education, cognitive function-
ing, activities of daily living, and BMI. Model 3 was further adjusted for depressive symptoms. In 
the longitudinal analyses, to examine whether grief status was prospectively associated with sleep 
duration and sleep quality, we used sleep duration and sleep quality assessed during the follow-up 
as outcomes. We selected the same covariates as in the cross-sectional analyses and adjusted for the 
respective baseline values of sleep duration or sleep quality.
We conducted a series of sensitivity analyses. First, we reran the analysis, not only for depressive 
symptoms, but to exclude all patients with major depression disorder at the baseline. We evaluated 
the presence of Major Depressive Disorder in those with a CES-D score, or above the established 
screening cutoff of 16, using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) 
interview (Wing et al., 1990). This semistructured clinical assessment was performed by trained clini-
cians to determine which participants fulfilled the DSM-IV major depressive disorder. We performed 
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this sensitivity analysis in order to minimize the depressive disorders on sleep quality. Also, in our 
study, Major Depressive Disorder (MDD) was assessed at baseline only (prevalence of 2%). Second, 
to test the effect of the more recent sleep, we performed longitudinal analysis restricted to those who 
experienced the bereavement in the years prior to baseline assessment. Third, we repeated the cross-
sectional linear regression only in those participants who had attended the follow-up assessment, 
to test whether any between–cross-sectional and longitudinal analysis reflected a selection effect. 
Adjustments for these analyses were conducted as in the main linear regressions. Fourth, since sleep 
duration component of PSQI, we performed a sensitivity analyses calculating the PSQI total without 
the component of sleep duration. Fifth, in order to explore the possibility of reverse causality, in the 
longitudinal analysis, we excluded people who had poor sleep at the baseline (defined as the total score 
of all components of PSQI greater than 5 points). Sixth, we explore whether, cross-sectionally and 
longitudinally, sleep duration and sleep quality differ between grievers (reference) and complicated 
grievers. We also explored the association between grief status and depressive symptoms (CES-D). In 
multivariable linear regression models, we examined whether baseline grief status was prospectively 
associated with CES-D at follow-up, further adjusted for the baseline value of depressive symptoms.
With respect to the remaining data, missing values were imputed using multiple imputations 
(Rubin, 2004). In the present study, for each missing value five draws were performed providing five 
substituted items of data, which in turn created five completed data sets. Analyses were performed 
separately on each completed data set and thereafter combined into one pooled estimate. The per-
centage of missing values within the population for the analyses was lower than 20% (ranging from 0 
to 18%). Age and sex had no missing values, education had 18%, cognitive score had 8%, activities of 
daily living score had 1%, BMI had 14%, and CES-D had 0.2%. Analyses were performed using SPSS 
Statistics (version 20; SPSS, Chicago, IL, USA).
rESuLTS
Of the 5,421 eligible participants, 4,378 (80%) were classified as experiencing “no grief,” 795 (15%) 
as experiencing “normal grief,” and 248 (5%) as experiencing “complicated grief ” at baseline. Table 
1 presents the characteristics of the study population. Participants classified as experiencing compli-
cated grief were older, were more likely to be female, had a lower level of education, and were more 
likely to have clinically relevant depressive symptoms. The main cause for grief was death of a partner 
(36% of those with normal grief and 56% of those with complicated grief), or a child (10% of those 
with normal grief and 22% of those with complicated grief). 
Table 2 shows the cross-sectional associations of grief with sleep duration and sleep quality. In the 
age-and-gender adjusted analysis, we found a consistent association pattern of grief and complicated 
grief with sleep duration as well as with sleep quality. Further, adjustment for education level, activi-
ties of daily living, cognitive functioning, and body mass index did not change these associations. 
However, the association between grief and sleep indicators was explained by depressive symptoms 
(model 3).
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Table 1. Baseline characteristics of study participants 2002-2005 (n=5421)
Characteristics Non-grievers
N=4378 (80%)
Normal grievers
N=795 (15%)
Complicated grievers
N=248 (5%)
Age, years (S.D.) 72.4 (7.7) 73.4 (8.1)a 74.7 (7.5)b
Women, (%) 55 73a 72 b
Education a.b
Primary (%) 19 22 30
Intermediate (%) 67 66 63
High (%) 14 12 7
Cognitive functioning, score (S.D.) 27.41 (2.58) 27.39 (2.52) 26.99  (3.04)b,c
Depressive symptoms, score (S.D.) 5.42 (6.67) 8.62 (8.49)a 14.12 (11.35)b,c
Clinically relevant depressive symptoms,(%) 4 8a, 25 b,c
Who died?, 
 Partner, (%) - - 36 56
 Child, (%) - - 10 22
 Parent, (%) - - 12 6
 Brother/sister, (%) - - 17 7 
 Others, (%) - - 25 9
Activities of daily living, score (SD) 0.51 (0.57) 0.59 (0.57)a 0.66 (0.60)b
Body mass index (kg/m2), (SD) 27.56 (4.03) 27.67 (4.34) 27.75 (4.38)
Sleep quality, score (SD) 3.37 (2.91) 4.28 (3.20) a 5.08 (3.67)b,c
Sleep duration (hours), (SD) 6.91 (1.30) 6.69 (1.36)a 6.44 (1.50)b,c
Group comparisons were performed with χ2 (categorical variables) or T-test (continuous variables) for 
independent-samples.
aComparison of non-grieving participants with grieving participants (p<0.05). 
bComparison of non-grieving participants with complicated-grief participants (p<0.05).
cComparison of grief participants with complicated-grief participants (p<0.05).
Table 2. Cross-sectional associations of grief and complicated grief with sleep
Sleep Duration (hours)
Model I Model II Model III
N B 95% CI p B 95% CI p B 95% CI p
Grieving status 
Non-Grievers (ref.) 4378 - - - - - - - - - - - -
Grievers 795 -0.15 -0.25 0.05  0.003 -0.15 -0.25 -0.05 0.004 -0.05 -0.15 0.05 0.30
Complicated Grievers 248 -0.41 -0.57 -0.24 ≤0.0001 -0.40 -0.57 -0.24 ≤0.0001 -0.12 -0.30 0.05 0.16
pSQi (hours)
Model I Model II Model III
N B 95% CI p B 95% CI p B 95% CI p
Grieving status 
Non-Grievers (ref.) 4378 - - - - - - - - - - - -
Grievers 795 0.64 0.39 0.90 ≤0.0001 0.63 0.38 0.88 ≤0.0001 0.15 -0.08 0.39 0.20
Complicated Grievers 248 1.52 1.09 1.95 ≤0.0001 1.48 1.06 1.90 ≤0.0001 0.08 -0.33 0.48 0.71
Model I was adjusted for age and sex; Model II was adjusted for age, sex, education, activities of daily 
living, cognitive functioning, BMI and the respective baseline values of sleep duration and Pittsburgh 
Sleep Quality Index to model change; Model III was adjusted for age, sex, education, depressive symptoms, 
activities of daily living, cognitive functioning, and BMI 
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In Table 3 we present the prospective association of grief with sleep duration and sleep quality 
(both assessed at follow up exam after 6.33 years on average (SD = 0.42)). We did not find an associa-
tion of grief or complicated grief with changes in sleep duration or sleep quality, either in the age-and-
gender adjusted or in the fully adjusted analyses. Next, we performed a series of sensitivity analyses. 
First, we excluded persons with major depression from our study population and reran the analysis; 
our result remained essentially unchanged. Then we limited the cases to those who experienced the 
bereavement leading to complicated grief in the last 2 years prior to baseline assessment (Supplement 
B). Our result showed no association between more recent lost event and sleep parameters in the 
longitudinal analysis. Also, to test whether the differences between cross-sectional and longitudinal 
analysis reflect a selection effect, we reran the cross-sectional analysis in participants who attended 
the follow-up assessment. Results remained essentially unchanged; the cross-sectional associations of 
complicated grief with sleep duration and sleep quality were similar to our original cross-sectional 
findings (data shown in Supplement C). Also, the results did not change when we reran the analysis 
calculating the PSQI score without including the sleep duration component (Supplement D). Next, in 
the longitudinal analysis, exclusion of subjects who had poor sleep quality at baseline did not change 
the results (Supplement E). Furthermore, we did not find any difference in sleep duration or sleep 
quality between grievers and complicated grievers in both cross-sectional and longitudinal analysis 
(data not shown). Last, we did not find an association between baseline grief status and depressive 
symptoms at follow-up (grievers: β = –0.22, 95% CI: –1.51—1.07, p = 0.74; complicated grievers: β = 
1.00, 95% CI: –1.30—3.31, p = 0.39).
Table 3. The longitudinal associations of grief and complicated grief with sleep.
Sleep Duration (hours)
Model I Model II Model III
N B 95% CI p B 95% CI p B 95% CI p
Grieving status 
Non-Grievers (ref.) 2876 - - - - - - - - - - - -
Grievers 495 0.02 -0.10 0.14 0.71 0.02 -0.10 0.14 0.72 0.01 -0.11 0.13 0.91
Complicated Grievers 140 0.06 -0.15 0.27 0.57 0.06 -0.15 0.27 0.57 0.01 -0.20 0.23 0.91
pSQi (hours)
Model I Model II Model III
N B 95% CI p B 95% CI p B 95% CI p
Grieving status 
Non-Grievers (ref.) 2482 - - - - - - - - - - - -
Grievers 413 -0.09 -0.39 0.21 0.55 -0.09 -0.39 0.20 0.53 -0.07 -0.37 0.23 0.66
Complicated Grievers 108 0.06 -0.49 0.61 0.83 0.07 -0.49 0.62 0.82 0.15 -0.42 0.71 0.61
Model I was adjusted for age and sex; Model II was adjusted for age, sex, education, activities of daily 
living, cognitive functioning, BMI and the respective baseline values of sleep duration and Pittsburgh 
Sleep Quality Index to model change; Model III was adjusted for age, sex, education, depressive symptoms, 
activities of daily living, cognitive functioning, BMI and the respective baseline values of sleep duration 
and Pittsburgh Sleep Quality Index to model change.
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DiSCuSSiON
In this large population-based study of middle-aged and elderly persons, we investigated whether 
persons with grief or complicated grief had a different sleep duration and sleep quality than par-
ticipants without grief. Our cross-sectional findings showed that normal and complicated grief were 
associated with shorter sleep and lower sleep quality. These associations were mainly explained by the 
presence of depressive symptoms. No further changes in sleep duration and sleep quality between the 
groups were observed after an average follow-up of more than 6 years.
Complicated grief can be regarded as a bereavement situation for which sleep duration is likely 
to be affected (Monk, Germain, et al., 2008). A cross-sectional study of duration of sleep among un-
selected grievers, that is, most probably including persons with complicated grief, has been reported 
previously (Monk, Germain, et al., 2008). The authors conducted a laboratory study of sleep and 
circadian rhythm in 38 spousal bereaved seniors (≥ 60 years) observed 4 or more months after their 
loss event. On average, the bereaved seniors achieved only about 6 hr of sleep. In a large Japanese 
population-based prevalence study of 1,871 participants conducted by Doi, Minowa, Okawa, and 
Uchiyama (2000), the authors showed that being widowed or without a partner was associated with 
lower sleep quality.
There is evidence suggesting that behavioral changes associated with grief such as decreased activ-
ity levels or overall changes in social rhythm stability could lead bereavement to sleep disturbances. 
After the loss of a loved one, there are profound changes in lifestyle, often accompanied by reductions 
in financial security, perceived personal safety, and freedom of action (Monk, Germain, et al., 2008), 
all of which are likely to lead to sleep disruption. Also, the loss of a loved one is associated with 
psychological problems such as rumination or anxiety, which are shown to impair sleep (Carney, 
Edinger, Meyer, Lindman, & Istre, 2006; K. Shear et al., 2007). Sleep disturbances are particularly 
prevalent in depressed bereaved persons; even bereaved persons who fail to meet a formal diagnosis 
of depression have measurable sleep impairment (Reynolds et al., 1992). Indeed, our cross-sectional 
analysis showed that the association between grief and complicated grief with sleep indicators was 
largely explained by depressive symptoms. However, we ran multivariable linear regression models 
to see if baseline grief status was prospectively associated with CES-D at follow-up and found no as-
sociation, providing support that depressive symptoms are not a mediator in the association between 
grief and sleep parameters. Further, reversed causality should be taken into account. Since relatively 
few studies have yet examined sleep difficulties as a risk factor for post-loss psychopathology, we 
cannot rule out that existing sleep problems make individuals vulnerable to more severe or prolonged 
grief or complicated grief. Indeed, as Boelen and Lancee (2013) pointed out, poor sleep quality is a 
known risk factor for many different forms of a psychopathology, including depression and PTSD.
We did not find a prospective association between grief and sleep parameters. Different explana-
tions for these null findings are possible: First, the lack of findings can reflect the insufficient power 
to detect an association. Although fewer participants could be included in the longitudinal analyses, 
sufficient power to detect any effect similar to that observed in the cross-sectional analyses remained. 
Thus, these findings suggest that there was no further change in sleep duration and sleep quality once 
a person had reported bereavement at our baseline assessment. We carefully infer that the results 
could be explained with mechanisms of adaptive coping (S. S. Rubin, 1999; Stroebe & Schut, 1999) 
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developed by the grieving participants during prolonged exposure to grief. Possibly, persons grieving 
reached a “stable state,” that is, with no further change of sleep quality, when participating in the 
follow-up assessment on average 6 years after the event. Sleep quality might have been affected before 
the occurrence of complicated grief. Due to the lack of prebereavement sleep assessment, it is not 
possible to evaluate the directional effects in the cross-sectional analysis, that is, whether bereavement 
triggered the decline of sleep duration and quality or whether sleep impairment preceded the grief 
reaction. However, our sensitivity analysis in which we excluded participants with poor sleep quality 
provides no evidence for reverse causality. Also, grief was assessed only at baseline. Consequently, 
we cannot account for the change in grief status, whether the feelings of grief remitted, persisted, or 
worsened.
However, the majority of clinical diseases and conditions are characterized by a progression of 
symptoms and their consequences; against this background, we had hypothesized a continuous 
decline of sleep problems, having in mind that sleep duration and quality among persons with com-
plicated grief is of potential value for prognosis of grieving persons and potentially even of relevance 
for therapeutic interventions that rely on the cognitive behavioral interventions focused on sleep 
difficulties as discussed by Boelen and Lancee (2013). It suggests that the impact of grief on this 
important aspect of well-being is not accumulating over time and can potentially be overcome.
To the best of our knowledge, other longitudinal studies have not been performed previously 
in the general population. Also, our study is characterized by a long follow-up period and a large 
sample size. Furthermore, a middle-aged and elderly sample was used, which is the main vulnerable 
population for complicated grievers, as late-life loss of a loved one is among the most common life 
events. However, some limitations of the current study should be mentioned. First, in a population-
based study, it is not feasible to ascertain grief and sleep directly after a loss event. Most important, 
complicated grief cannot be diagnosed if the event occurred less than 6 months before. Therefore, we 
performed sensitivity analyses restricting the study population to those who experienced the bereave-
ment more recently (in the last 2 years before the baseline assessment). Second, we miss information 
on whether these persons are still suffering from complicated grief or MDD at follow-up. Further 
studies should be performed including this kind of prospective reassessment.
CONCLuSiON
In community-dwelling middle-aged and older adults, persons with normal and complicated grief 
had both a shorter sleep duration and a lower sleep quality, mainly explained by depressive symptoms. 
However, prospective analyses showed that sleep quality and sleep duration do not decline further in 
persons with normal grief and complicated grief.
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AbSTrACT
Background Bereavement is a common experience in the life course of every person. The death of a 
loved one leads to grief characterized by yearning and longing, decreased interest in ongoing activi-
ties, and frequent thoughts of the deceased which might hamper the quality of life (QoL). However, 
little is known whether bereavement is associated with QoL.
Methods Seven bibliographic databases were systematically searched for studies assessing the 
association between any form of grief and QoL. Reference lists and contacts with experts were also 
used to identify relevant studies. 
Results Fourteen studies (5 cross-sectional, 5 case control studies, 1 retrospective study and 3 pro-
spective studies) were included with data on 9,108 middle-aged and elderly participants. Eight studies 
investigated grief induced by spousal loss, two focused on parental bereavement, three reported on 
grief in caregivers, one study compared bereavement in subjects with anxiety disorder to those with 
no anxiety disorder. Overall, bereavement, more precise the grief severity were associated with lower 
QoL, especially in women. Nevertheless, the evidence on grief and QoL is limited and hampered by 
the suboptimal of quality of the studies on this topic. 
Conclusion Different types of bereavement and grief severity show associations  with lower QoL. 
However, this review highlights the scarcity and low quality of the available information with impor-
tant gaps including lack of large-scale prospective investigations, needed to reliably determine the 
association of grief with QoL and its domains. 
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iNTrODuCTiON
Experiencing a death of a loved one is a common event in the life course of every person (Boelen & 
Hoijtink, 2009; Monk, Germain, & Reynolds, 2008; Shear, 2015). Although it is a traumatic event, 
after a certain period of grief most people recover (Kacel, Gao, & Prigerson, 2011). However, an esti-
mated 15% of bereaved people continue to grieve for a prolonged period, imprisoned by memories, 
regrets and a sense of guilt.  This complex condition is called a Prolonged Grief Disorder (PGD), also 
referred to as ‘complicated grief ’(Prigerson et al., 2009). Grief affects many aspects of life from social 
functioning to well-being (Newson, Boelen, Hek, Hofman, & Tiemeier, 2011). Symptoms of com-
plicated grief are distinct from those of depression and anxiety and can lead to impairment in social 
and interpersonal daily functioning (Boelen, van de Schoot, van den Hout, de Keijser, & van den 
Bout, 2010). Schwartz et al. explored the response shift phenomenon- how changes in general health 
status affect quality of life (QoL) (Schwartz & Sprangers, 1999). It is based on the hypothesis that 
internal standards, values and the conceptualization of QoL can change during a life course (Schwartz 
& Sprangers, 1999). This response shift is a subjective perception where the person is assigning a 
new meaning to the QoL construct. Thus, expectations, personality traits, and cognitive, affective or 
behavioral processes determine this new meaning (Schwartz & Sprangers, 1999). Presumable, the 
aforementioned aspects are affecting coping mechanisms in grieving persons. Also, the changes in 
individual’s physical, psychological and social responses of a grieving person affect the individual’s 
level of satisfaction and sense of self-worth (Cousson-Gelie, de Chalvron, Zozaya, & Lafaye, 2013; 
Ozer, Firat, & Bektas, 2009). Consequently, the impact of grief on a person’s QoL  might  be consider-
able. However, the extent to which grief is associated with QoL and its domains remains unclear and 
the available studies examining this hypothesis are yet to be rigorously reviewed. As bereavement 
is a common event in life, understanding QoL related with bereavement and its types would allow 
health and social care providers and researchers to better understand the bereaved individuals views 
as having the greatest impact on their QoL.
In the present study, we aimed to synthesize all available evidence on various forms of grief in 
relation to QoL.
METhODS
Data Sources, Search Strategy and Eligibility Criteria
This review was conducted in accordance with the PRISMA (Moher, Liberati, Tetzlaff, Altman, & 
Group, 2009) and MOOSE (Stroup et al., 2000) guidelines (S1 and S2 Appendices). Seven electronic 
databases (Medline via Ovid, EMBASE, Cochrane Central, Web of Science, PUBMED, Psycinfo via 
Ovid and Google Scholar) were searched with the help of a medical librarian from inception until 
29th of June, 2017 (date last searched). The searches combined terms related to the exposure (eg. 
bereavement, grief, PGD or complicated grief) and outcome (eg, quality of life), without language 
restriction. Details on the search strategy are provided in S3 Appendix. Reference lists of selected 
studies and reviews identified on the topic were searched to identify additional publications. Experts 
in the field were also contacted to identify missing studies.
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Study Selection
Studies were eligible if they (i) were observational studies (cross-sectional, case-control and cohort 
studies), or randomized clinical trials; (ii) assessed any form of grief (bereavement, grief, PGD and 
complicated grief), (iii) collected endpoints for QoL; and (iv) examined the association between any 
form of grief and QoL).  Anticipatory or preparatory (pre loss) grief was not the focus of this review, 
and therefore studies that investigated these forms of grief were excluded. 
Two independent reviewers JM and BK, working in pairs, screened the titles and abstracts of 
all initially identified studies according to the selection criteria. In case of disagreement, a decision 
was reached through consensus or consultation with a third independent author TM. Full texts were 
retrieved from studies that satisfied all selection criteria.
Data Extraction
Data were extracted by two independent authors JM and BK. A predesigned data extraction form 
was used to collect relevant information. This included questions on study size; study design; baseline 
population; location; age at baseline; duration of follow-up (for prospective studies); form of grief 
(defined as bereavement, grief, PGD or complicated grief) and methods used to define grief and QoL. 
In the case of multiple publications, the most up-to-date or comprehensive information was included.
Assessing the risk of bias
Bias within each individual study was evaluated by two independent reviewers JM and OHF using the 
validated Newcastle-Ottawa Scale (NOS), a semi-quantitative scale designed to evaluate the quality of 
observational studies (Stang, 2010). Study quality was judged on the selection criteria of participants, 
and exposure and outcome assessment. The NOS assigns a maximum of four or five points for selec-
tion, one or two points for comparability and three points for outcome, depending on study design. 
Studies that received a score of eight and nine stars were judged to be of at low risk of bias; studies 
that scored six or seven stars were considered at medium risk; those that scored five or less were 
considered at high risk of bias.
Outcome Assessment and Statistical Methods
For each study, we defined whether an association was reported, and when applicable, the direction 
of effect sizes was reported. For the current study, due to the limited number of included studies and 
high heterogeneity in exposure and outcome assessment of the individual studies, meta-analysis was 
not feasible. 
rESuLTS 
In total, we identified 1,604 potentially relevant citations. Based on the title and abstracts, 45 articles 
were selected for detailed evaluation of their full texts. Of those, 1559 were excluded for reasons 
shown in Figure 1. Therefore, 14 articles, based on 14 unique studies, met our eligibility criteria and 
were included in the analysis. 
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Summary of included Studies  
Characteristics of the included studies are summarized in Table 1. Overall, data were available on 9,631 
unique participants. The mean age of the participants at baseline across the included studies ranged 
from 42 to 72 years. Seven studies included participants from Europe, three studies participants form 
Asia, three studies from USA and one study included participants from Canada. All studies had an 
observational design: 5 studies were cross-sectional 4 were longitudinal studies (3 prospective and 1 
retrospective)  and 5 case–control studies. The year of baseline survey in these studies ranged from 
1985 to 2016. Of the 14 included studies, 10 studies were judged to be at medium risk of bias and the 
4 studies were judged to be at high risk of bias, whereas no study was judged to be at low risk of bias. 
bereavement Assessment 
Eight studies investigated grief induced by spousal loss in relation to QoL, two focused on parental 
bereavement, three reported on grief in caregivers and one study compared bereavement in subjects 
with anxiety disorder to those  with no anxiety disorder  (Table 1). Bereavement assessment varied 
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Figure 1. Flowchart of studies investigating the associated between bereavement and quality of life 
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Table 1 General characteristics of the included studies in the current systematic review 
Le
ad
 a
ut
ho
r, 
pu
bl
ic
at
io
n 
D
at
e
Location/
Name of the 
study
Study Design baseline age Average follow up Total 
participants
Outcome Assessed
*QoL Instrument 
described in Table 3
Exposure
Assessed
Estimates reported
b
oe
le
n 
 e
t a
l. 
20
07
The Nether-
lands
Longitudinal Sample 1:
(recruited through mental health 
care workers):
48.0 ±14.8 years
Sample 2:
(recruited through advertisement 
on internet site)
45.9±14.5 years 
6 and 15 months after the baseline 
assessment 
(follow up n=96))
 Total n=346
(80% women )
QoL assessed by 
RAND 36-Item Health 
Survey (RAND-36) 
Grief severity in spouses
6 and 15 months post loss
Quality of life was lower and predictable  in 
participants with prolonged grief disorder 
distinct from depression and anxiety.
b
ou
ra
ss
a 
et
 a
l. 
20
16
EU/
Data used from:
Multinational, 
representative 
study of Health, 
Ageing and 
Retirement 
in Europe 
(SHARE)
Case-control Widowed 
70.0 ±9.5 years 
Non-Widowed 
61.9±8.4 years 
Time 1 
(data collected 2 and  4 years prior 
to partner’s death)
Time 2
(data collected 2 and  4 years post 
partner’s death)
Total n=3112
Widowed
n=546
(69% women)
Non-widowed
n=2566
(50% women)
QoL  and psycho 
-logical functioning  
was asessed by the  
Control, Autonomy, 
Self-Realization and 
Pleasure.Scale (CASP-
19)
Bereaved spouses
(6 to 24 months post loss)
Quality of life measured on a partner prior 
to his/her death predicted spouses’ after loss 
quality of  life(β= 0.16, 95% 0.05, 0.26, p 
= .003). 
The association between partners’ earlier 
quality of life and their spouse’s later
quality of life was not significantly different 
for widowed vs. non-widowed people.
C
he
ng
 e
t a
l.
20
00
Hong Kong/ 
China
Cross-
sectional
80% (n=56) of respondents were
≤ 50 years.
n/a Total n=70
(67% women)
QoL was assessed 
by scale evaluating 
bereavement  
adjustments (Ho’s 
Quality of Life Scale)
Bereaved spouses
(6 to 24 months after the 
loss)
No control group (non-
bereaved)
Quality of life of the bereaved spouses was 
moderately lower; impact of age and sex was 
ruled out (mean score 6.20± 1.21),
fr
y 
at
 a
l.
20
01
 
Alberta/ Canada Longitudinal Range 65  to 85 years 18 Months  after the baseline 
assessment
Total n=211
(56% women)
Qol was assessed  by 
abbreviated Health-
Related Quality of Life 
Perceptions Scale based 
on three subscales of  
SF-36: general health, 
vitality and mental 
health.
Bereaved spouses
(4 to 6 months after the loss)
No control group (non-
bereaved)
Global and Domain-Specific 
Efficacy (DSEI) (widows vs 
widowers)
Quality of life related to health was 
significantly lower (p<0.01) in widows 
(43.8±4.4) vs. widowers (37.4 ±6.1).
Self-reported quality of life:
multidimensional efficacy showed 
significantly higher quality of life in widows 
vs. widowers.
G
ri
m
by
 A
. 1
99
3
Goberborg/ 
Sweden
IVEG Study 
(Intervention 
Study of Elderly 
in Goteborg)
Case-control 71-74
(mean 72.7)
1 year  after the baseline assessment 
;
grief severity was measured 1st, 3rd 
and the 12th  month .
Total n=42
(72% women)
QoL was assessed  
by scale assessing 
the dimensions of 
self-esteem, anxiety, 
psychosomatic health 
and satisfaction 
with life (based 
on methodology 
Rubenowitz and Berg)
Recently  bereaved spouses 
(<2 weeks after loss):
(n=47)
Non recently bereaved:
-Married (n=237)
-Single (n=35)
-Divorced (n=30)
-Previously (≥2 weeks after 
loss)bereaved (n=101)
Quality of life of the recently bereaved (<2 
weeks after loss) was lower than in married, 
single (never married) and not recently 
bereaved persons of the same age (p<0.05). 
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Goberborg/ 
Sweden
IVEG Study 
(Intervention 
Study of Elderly 
in Goteborg)
Case-control 71-74
(mean 72.7)
1 year  after the baseline assessment 
;
grief severity was measured 1st, 3rd 
and the 12th  month .
Total n=42
(72% women)
QoL was assessed  
by scale assessing 
the dimensions of 
self-esteem, anxiety, 
psychosomatic health 
and satisfaction 
with life (based 
on methodology 
Rubenowitz and Berg)
Recently  bereaved spouses 
(<2 weeks after loss):
(n=47)
Non recently bereaved:
-Married (n=237)
-Single (n=35)
-Divorced (n=30)
-Previously (≥2 weeks after 
loss)bereaved (n=101)
Quality of life of the recently bereaved (<2 
weeks after loss) was lower than in married, 
single (never married) and not recently 
bereaved persons of the same age (p<0.05). 
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Table 1 General characteristics of the included studies in the current systematic review  (continued)
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at
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Location/
Name of the 
study
Study Design baseline age Average follow up Total 
participants
Outcome Assessed
*QoL Instrument 
described in Table 3
Exposure
Assessed
Estimates reported
La
nn
en
 e
t a
l. 
20
08
Sweden
Swedish 
Population 
Register
Retrospective 
population 
based
cohor
Age (%)
<30 (15%)
30-39 (52%)
≥ 40 (32%)
Not stated (1%)
4 to 9 years prior to study start 
(Parents who lost a child to cancer)
Total n=449
(56% women)
QoL was assessed 
by the Tibblin score  
evaluating physical 
and psychological 
well-being
Parental grief 
Resolved(n=333)  vs. 
un-resolved grief (n=116)
Quality of life  of parents with unresolved 
grief showed to be significantly worse than  
parents with resolved grief .
M
ar
qu
es
 a
t a
l.
20
13
USA Cross-
sectional
bereaved with no anxiety disorder
 43.0±13.6
bereaved with  anxiety disorder
41.5±13.1
n/a Total n=397
(46% women)
Bereaved 
with  anxiety 
disorder
N=242 
( 44%women)
Bereaved 
without 
anxiety 
disorder
N=155 
(51% women)
QoL assessed 
by Quality of 
life Satisfaction 
and Enjoyment 
Questionnaire - Short 
Form (Q-LES-Q)
Bereaved people with or 
without anxiety disorder 
Bereaved with  anxiety 
disorder
N=242 
( 44%women)
Bereaved without anxiety 
disorder
N=155 
(51% women)
Quality of life of bereaved with anxiety 
disorder associated with severe grief  was  
lower (β = -0.140, P = 0.023) and with 
greater impairment (β = 0.141, P = 0.035) 
compared to bereaved without anxiety 
disorder 
O
nr
us
t e
t a
l.
20
07
The 
Netherlands
Cross-
sectional
>55
(mean 68.8)
n/a Total n=216
(13% women)
Qol assessed by 
EuroQoL (EQ-5D)
Spousal bereavement
(loss event 6 to 9 months 
prior to assessment)
Quality of life
of the spousal-bereaved was reduced. The 
average quality of life of the sample
had a value of 0.79 ±0.22, whereas full health 
has a value of 1.
O
tt
  e
t a
l.
20
07
USA/
Yale 
Bereavement 
Study (YBS)
Longitudinal 60 to 91 years
(70.35±6.42)
Measurement  of grief scores are 
taken at 3 points during
bereavement
1.Wave 1 
 at  4.36
months after loss (SD = 1.97)
2.Wave 2 
 at  9.22 months after loss 
(SD=1.92)
3.Wave 3 at 18.22 months  after the 
loss (SD = 1.97)
Total n=141
(69% women)
QoL was assessed  by 
SF-12 Health Survey
Spousal bereavement: 
clusters based on grief scores:
1.common grief
2. chronic grief
(dominantly complicated 
grievers)
3. resilient grief
Quality of life was lower in the  common and 
chronic cluster 
compared to the resilient cluster. 
r
eb
ol
lo
 
et
 a
l.
20
05
Spain/
Dying
elderly in 
Catalonia
Cross-
sectional
56.40 ± 13.20 n/a Total n=130
(80% women) 
QoL  assessed by  the  
SF-36 
Recent bereavement of 
caregivers 
Quality of life scores of the caregivers’ were 
lower compared to standardized population 
scores.
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Table 1 General characteristics of the included studies in the current systematic review  (continued)
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has a value of 1.
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Measurement  of grief scores are 
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months after loss (SD = 1.97)
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QoL was assessed  by 
SF-12 Health Survey
Spousal bereavement: 
clusters based on grief scores:
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Quality of life was lower in the  common and 
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20
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Dying
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Cross-
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Quality of life scores of the caregivers’ were 
lower compared to standardized population 
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among the included studies (Table 2). Five studies evaluated grief using evaluation criteria that by 
Prigerson, Horowitz and Jacobs developed over time, or some of variation  (Boelen & Prigerson, 2007; 
Marques et al., 2013; Onrust, Cuijpers, Smit, & Bohlmeijer, 2007; Ott, Lueger, Kelber, & Prigerson, 
2007; Wiese, 2003). Parental bereavement assessed by Lannen et al, categorized patients in two groups, 
the ones who had and the ones who had not worked through their grief, asking “Do you think that 
you have worked through your grief?” (Lannen, Wolfe, Prigerson, Onelov, & Kreicbergs, 2008). Song 
Table 1 General characteristics of the included studies in the current systematic review  (continued)
Le
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Location/
Name of the 
study
Study Design baseline age Average follow up Total 
participants
Outcome Assessed
*QoL Instrument 
described in Table 3
Exposure
Assessed
Estimates reported
So
ng
 e
t a
l, 
20
10
USA/WLS:  
The Wisconsin 
longitudinal 
study
Nested  case-
control
Bereaved parents:
Males
n=64.1±3.8
Females
n=66.6±4.5
Non-bereaved parents :
Males
n=63.4±4.3
Females
n=66.3±4.8
n/a Total n=462 
couples 
(50% women)
Bereaved 
couples 
(n=233)  
Non-bereaved 
couples 
(n=229)
QoL assessed by 
Health Utilities Index 
Mark 3 (HUI-3)
Parental bereavement 
examined by 
Cause of child death and 
Marital closeness
Quality of life of the bereaved parents was 
significantly lower than of the comparison 
group of parents. 
So
ng
 e
t a
l, 
20
12
South Korea, 
Seoul/
Fourth Korean 
National Health
and Nutrition 
Examination 
Survey
Case-control 53.2±12.5 n/a Total n=501
(58% female)
Bereaved 
family 
members:
(n= 353)
Non-bereaved 
controls:
 (n=353)
QoL assessed by  
EuroQoL (EQ-5D)
Bereavement  in family 
members of patients with 
terminal cancer vs. non 
bereaved controls from 
general population
The overall quality of life as measured by 
the EQ-5D score , was significantly lower in 
bereaved family members than in controls 
(0.88±0.20 vs 0.93±0.13, p=0.002).
W
ie
se
 e
t a
l, 
20
10
Germany Cross-
sectional
Caregivers: 58 n/a Total n= 46
(70% female)
QoL was assessed 
by   SF-12’s Mentale 
Component Score 
(MCS)
Post-mortal bereavement of 
family caregivers of patients 
with terminal cancer.
Quality of life of the caregivers 
was not reduced  by complicated grief 
compared to those who showed normal 
grieving reactions
(median MCS-12: 40 vs. 43; P > 0.05).
Z
ho
u 
et
 a
l. 
20
16
China Cross-
sectional
Married elders 
67.5 ±6.0 
Widowed elders
73.5 ±8.0 
n/a Total n=2985
Married
elders  
n=1925
(43% Women)
Widowed 
elders
n=1060
(70% Women)
QoL assessed by SF-12 
(V2 in Chinese) to 
measure the health-
related QOL of elders.
Widowed elders vs. married 
counterparts;
data from a large sample 
were analyzed instead of first 
search for widowed  and 
then matched with controls 
(non-widowed)
Quality of life of widowers ws significantly 
lower than of their married
counterparts (P<0.01).  
In widows Quality of life  declined 
significantly with age: ;  differences between 
widowed
and married women did not reach statistical 
significance
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et al. coded parental bereavement status as a dichotomous variable (1 = bereaved; 0 = comparison) 
(Song, Floyd, Seltzer, Greenberg, & Hong, 2010).  Song et al used the Questionnaire from Korean 
National Health And Nutrition Examination Survey (Song  et al., 2012). The other studies developed 
novel specific questionnaires tested in pilot studies. (Bourassa, Knowles, Sbarra, & O’Connor, 2015; 
Cheng & Ma, 2000; Fry, 2001; Grimby, 1993; Rebollo et al., 2005; Zhou & Hearst, 2016)
Table 1 General characteristics of the included studies in the current systematic review  (continued)
Le
ad
 a
ut
ho
r, 
pu
bl
ic
at
io
n 
D
at
e
Location/
Name of the 
study
Study Design baseline age Average follow up Total 
participants
Outcome Assessed
*QoL Instrument 
described in Table 3
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Post-mortal bereavement of 
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compared to those who showed normal 
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n/a Total n=2985
Married
elders  
n=1925
(43% Women)
Widowed 
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n=1060
(70% Women)
QoL assessed by SF-12 
(V2 in Chinese) to 
measure the health-
related QOL of elders.
Widowed elders vs. married 
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data from a large sample 
were analyzed instead of first 
search for widowed  and 
then matched with controls 
(non-widowed)
Quality of life of widowers ws significantly 
lower than of their married
counterparts (P<0.01).  
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Assessment of Quality of Life 
Assessment of QoL was heterogeneous among included studies (Table 2). Rebollo et al. used a Spanish 
version of the SF-36 Health Survey (Rebollo et al., 2005). Fry et al. used The Health-Related Quality 
of Life Perceptions Scale- HRQOL developed by using three subscales of the SF-36 (Fry, 2001). Ott et 
al utilized the SF-12 Health Survey (Ott et al., 2007). Lannen et al. estimated QoL using The Tibblin 
Score (Lannen et al., 2008). Grimby et al. used a 23-question questionnaire revised from Rubenowitz 
and Berg. Song et al assessed health-related QoL  with the  EQ-5D , including an a summary score and 
a visual analog scale (EQ-VAS) (Song  et al., 2012). Marques et al. assessed QoL using the short form 
of Q-LES-Q, while Boelen et al. used RAND 36 (Boelen & Prigerson, 2007; Marques et al., 2013). 
Bourassa at al. (Bourassa et al., 2015) used 12 items of the CASP-19 (Cheng & Ma, 2000), a scale 
developed specifically for assessing quality of life. Cheng at al,(Cheng & Ma, 2000) used Ho’s (Con-
dliffe et al., 2014). Zhou and Hearst  used SF12 questionnaires and information about individual and 
household characteristics (Zhou & Hearst, 2016). Wiese at al. measured psychosocial and physical 
distress of the care-giving relatives in the inquiry measured through a sub-score of SF-12 to validate 
the quality of life of the relatives with the mental  component  score (MCS-12). (Wiese  et al., 2010) 
Spousal bereavement and quality of life 
Three cross-sectional studies and four prospective studies examined the association between spousal 
bereavement and QoL (Table 1). After a follow-up of one year, Grimby  et al. found that the QoL of the 
recently bereaved (<2 weeks) 42 spouses was lower than that of married single/never married and not 
recently bereaved individuals (p<0.05) of the same age (Grimby, 1993). However, QoL was not sig-
nificantly different in comparison with divorced individuals. Among 211 bereaved spouses, Fry et al. 
found that, after 18-months follow-up, comparing to bereaved women, widowers scored significantly 
Table 2. Assessment of study quality through the Newcastle-Ottawa Scale
 Author,
publication year  Selection Comparability
 
Outcome/Exposure Overall Score
Boelen at al.,2007 *** ** ** 7
Bourassa et al.,2016 *** ** ** 7
Cheng et al., 2000 ** ** * 5
Fry at al., 2001 ** ** ** 6
Grimby  at al.,1993  *** ** ** 7
Lannen et al. 2008 *** ** ** 7
Marques at al., 2013 *** ** ** 7
Onrust et al., 2007 ** ** * 5
Ott  et al., 2007 *** ** ** 7
Rebollo et al., 2005 *** * * 5
Song at al., 2010 *** ** ** 7
Song at al., 2012 ** ** ** 6
Wiese et al, 2010 * ** ** 5
Zhou et al. 2016 *** ** ** 7
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Table 3. Methods used to define exposure and outcome in each individual study included in 
the current review 
Lead Author, 
publication Date
Exposure assessment
Grief or other
Outcome assessment       
 of QoL
boelen pA et al. 
2007
Two samples of bereaved individuals were 
recruited for the research program on 
cognitive variables in grief,
Symptoms of prolonged grief disorder. Items 
to assess PGD were taken from the Inventory 
of Complicated Grief-revised (ICG-r). The 
ICG-r was developed by Prigerson and Jacobs 
(Ref ) as an extended version of the Inventory 
of Complicated Grief (Prigerson, 2001)  
It taps most criteria for PGD and other 
problematic grief reactions. Respondents rate 
the presence of symptoms in the last month 
on 5-point scales ranging from 1 (never) to 5 
(always). The 29-item Dutch ICG-r has good 
psychometric properties. 
QoL was assessed with the Rand 36-item 
Health Survey (RAND 36) (Ware, 1992). This 
questionnaire assesses subjective health status 
and functioning in eight domains: physical 
functioning (10 items), social functioning 
(2 items), role limitations due to emotional 
problems (3 items), role limitations due to 
physical problems (4 items), mental health 
(5 items), pain (2 items), energy (4 items), 
and general health perception (5 items). In 
addition, one item is included to assess the 
direction of change in health over the preceding 
year. Domain total scores are calculated such 
that higher scores reflect better functioning. 
The items of the RAND 36 are identical to 
those of the well-validated Medical Outcomes 
Survey Short Form-36 (Ware at al. , 1996). The 
instrument has yielded adequate psychometric 
properties in original (Cunningham at al, 
2006) and Dutch version ( van der Zee KI 
& Sanderman, 1993). In the current study 
the subscale physical functioning was not 
administered. The subscale pain was only 
administered at T3.
bourassa KJ et al. 
2016
This study used data from the multinational, 
representative Study of Health, Ageing and 
Retirement in Europe (SHARE).
Spousal bereavement was detected by database 
information of couple’s, in which one of the 
spouses died. Survived spouse was included in 
the study as a bereaved participant.
No severity of grief was assessed
Quality of life was assessed by the CASP-19 
(Ref ), scale developed specifically for use in 
assessing quality of life, life satisfaction, and 
wellbeing in aging populations, which shows 
concurrent validity with similar measures..
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Table 3. Methods used to define exposure and outcome in each individual study included in 
the current review  (continued)
Lead Author, 
publication Date
Exposure assessment
Grief or other
Outcome assessment       
 of QoL
Cheng at al. 2000 Bereaved participants were included  via 
clinical referral from 11 hospitals and 1 clinic 
in China.
The Stress of Bereavement Scale was used , 
this self-constructed  assessment  scale has two 
parts: measuring the stressors and  perceived 
stress of the bereaved spouses.
Each sub-scale consisted of 30 items, which 
measured different dimensions of stress 
including the physical, the psychological and 
the social domain.
The respondents were asked to respond 
to both the objective and the subjective 
measures. These measures were  the same, 
but the questions were differently stated. The 
answers to the questions  that measured the 
stressors  ranged from frequently (5), quite 
often (4), sometimes (3), seldom (2) and 
never (1), while the answers of the second part 
ranged from very stressful (5), quite stressful 
(4), somewhat stressful (3), slightly stressful 
92) and not stressful (1).
Internal consistency of Stressor and the 
perceived Stress Sub-scales was satisfactory  
with Cronbach’s alphas of 0.82 and 0.85 
respectively.
Quality of life was assessed by Ho’s (1991) 
Quality of Life Scale measuring  the adjustment 
outcome of the bereaved spouses. 
Questions 3 was changed from “your living, 
ability, movement/ action, interest” to “your 
participation in activities, cultivating interest”. 
Higher scores denoted better quality of life. The 
Cronbach’s alpha of this scale was 0.89.
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Table 3. Methods used to define exposure and outcome in each individual study included in 
the current review  (continued)
Lead Author, 
publication Date
Exposure assessment
Grief or other
Outcome assessment       
 of QoL
fry at al. 2001 
(fry, 2001)(fry, 
2001)(fry, 2001)
(fry, 2001)
Bereavement was identified in the regional 
community-support project offering social 
support to recently bereaved elderly adults (see 
Fry, 1998,2001a, 2001b). 
Eligibility criteria included spousal loss 
approximately
4 to 6 months ago.
No Instrument for grief severity was used, 
but severity of grief was assessed  through 
the reported change on self-efficacy of the 
bereaved person (pre and post loss efficacy). 
Namely, domain Specific Efficacy and Global 
Efficacy Index. 
An abbreviated measure of the Health-Related 
Quality of Life Perceptions Scale (HRQOL)  was 
developed using three subscales of the SF-36 to 
measure quality of life.
These three subscale measures are (a) the 
Subscale for General Health Perceptions, 
which evaluates current general health as well 
as whether or not the person believes his or her 
health will deteriorate (five questions), (b) the 
Vitality Subscale, which determines the degree to 
which the person feels full of energy and “pep” 
as well as how often he or she is tired or worn 
out (four questions), and (c) the Mental Health 
Subscale, which examines nervousness and 
feelings of depression, sadness, peacefulness, and 
happiness (five questions).
Responses to the 14 questions included in 
the composite measure of the three subscales 
of the HRQOL were arranged on a 5-point 
Likert type scale ranging from strongly disagree 
(1) to strongly agree (5). The higher the 
cumulative score, the more positive are the 
HRQOL perceptions. The range of scores on 
this measure is 14 to 70.  The HRQOL score 
for each individual is based on the subscale 
scores of general health perceptions, vitality, and 
mental health. Cronbach’s alphas for this survey 
were 0.75 and 0.82 for widows and widowers, 
respectively.
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Table 3. Methods used to define exposure and outcome in each individual study included in 
the current review  (continued)
Lead Author, 
publication Date
Exposure assessment
Grief or other
Outcome assessment       
 of QoL
Grimby et al. 1993 A semi structured interview of 1.5 to 2h was 
used to assess the severity of the grief.
This interview was based on 13 grief reactions 
found in research (tested in a pilot study of 15 
bereaved people).
The reactions were rated by the psychologist 
with respect to frequency (presence or 
absence) and to intensity using a 5-point scale 
from 1 (mild) to 5 (very severe).
In the statistical analysis the grief reactions 
were grouped into 3 dimensions: low 
mood (dysphoria, loneliness, crying and 
pessimism), cognitive dysfunctioning (fatigue, 
concentration problems, lack of interest, 
indecisiveness and memory problems) and 
self-reliance (anxiety, self-reproach, anger and 
lowered self-esteem). 
After 12 months follow-up grief reactions 
intensity was categorized as: significant or 
non-significant decrease.
The control group was classified as follows:  
married, single, divorced and previously 
bereaved.
Quality of life assessment was performed with 
an instrument developed by  Rubenowitz and 
Berg, measuring the dimensions of self-esteem, 
anxiety, psychosomatic health and satisfaction 
with life.
The questionnaire contained 23 questions with 
answers scored from bad to very good. The sum 
score for each of the 3 dimension was obtained 
by dividing  (100 times the sum of the score of 
each item) by the sum of the maximum for all 
items.
Lannen et al. 2008 Bereaved parents were included upon 
identification of the death of a child via  the 
national register of causes of death and the 
national register of cancers.
Severity of the bereavement was assessed 
via parental resolution of grief assessed with 
the question: “Do you think that you have 
worked through your grief?”
Possible answers: not at all, somewhat, a lot, 
or completely.
Parents who stated not at all or somewhat 
were placed in the category of those parents 
who had not worked through their grief.
The Tibblin Score was used to assess quality of 
life. 
Quality of life according to physical and 
psychological well-being was self-assessed by the 
parents with a seven point Visual Digital Scale.
Marques at al. 
2013
Bereaved participants were recruited 
through advertisement or clinical referrals. 
They reported the loss of a close relative or 
significant other.
The 19-item, self-report Inventory of 
Complicated Grief (Prigerson et al.,1995)
The 16-item self-report Quality of Life 
Satisfaction and
Enjoyment Questionnaire–Short Form [Q-LES- 
Q) (Ref ) was used to assess quality of life.
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Table 3. Methods used to define exposure and outcome in each individual study included in 
the current review  (continued)
Lead Author, 
publication Date
Exposure assessment
Grief or other
Outcome assessment       
 of QoL
Onrust et al. 2007 Older widowed individuals were identified via 
the registers of birth , death and marriages in 
18 Dutch municipalities.
Traumatic or complicated grief was measured 
using the Inventory of Complicated Grief-
revised (ICG-r) (Prigerson et al., 1995), a 
self-report use  questionnaire  of Psychological 
adjustment after bereavement  with good 
psychometric properties (Boelen et al., 2003). 
The ICG-r consists of 29 items referring to 
cognitions, emotions and behaviours that 
define traumatic or complicated grief, such as 
preoccupation with thoughts of the deceased, 
yearning and searching for the deceased and 
feeling stunned by the death. Respondents 
were asked to indicate how often they had 
experienced each symptom during the past 
month, using the response categories “never,” 
“hardly ever,” “sometimes,” “regularly,” or 
“always.” The corresponding scores sum to a 
total score ranging from 29 to 145.
Quality of life was assessed with the EuroQol 
(EQ-5D) (Brooks and EuroQol Group, 
1996) The EuroQol is made up of five 
dimensions: mobility, self-care, usual activities, 
pain/discomfort, and, anxiety/depression. 
Respondents were
asked to indicate for each dimension whether 
they experienced “no problems,” “some 
problems,” or “extreme problems.” The separate 
scores were combined into the EQ-5D Index, 
a health status index, which is used to evaluate 
health status (QALY).
Ott  et al. 2007 The bereaved participants were derived from 
the Yale bereavement study.
Severity of the grief was assessed by a 
structured interview using the Inventory of 
Complicated Grief-Revised (ICG-R; Prigerson 
et al., 1995b; Silverman et al., 2000)
Severity  of grief was measured using the sum 
of the responses from nine questions from 
the ICG-R proposed for the DSM diagnostic 
criteria.
Quality of life was assessed at all three waves of 
data collection with the SF-12 Health Survey 
(Ware et al., 1996). 
The SF-12 is a well validated short form (12 
items) of the SF-36 Health Survey
rebollo et al. 2005 Bereaved individuals in this study were 
identified via a dataset derived from a 
project, ‘Dying elderly in Catalonia’, whose 
objective was to describe the place and the 
circumstances of the death of elderly persons 
(Ramon et al., submitted for publication)). 
The study surveyed the caregivers or  ‘the 
person, family member or otherwise, mainly
responsible for delivering care to the deceased 
in the months directly prior to death; that 
is, the person most familiar with the state of 
health and care needs of the deceased.
Quality of life was assessed via two components 
of the  Spanish version of the SF-36 Health 
Survey:
Physical Component Summary (PCS) and 
Mental Component Summary (MCS) scores of 
the SF-36 
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Table 3. Methods used to define exposure and outcome in each individual study included in 
the current review  (continued)
Lead Author, 
publication Date
Exposure assessment
Grief or other
Outcome assessment       
 of QoL
Song, et al. 2010 Bereaved parents were included from the 
Wisconsin longitudinal study.
Parental bereavement status was coded as 
a dichotomous variable (1 = bereaved; 0 
= comparison).
Cause of child death was taken into account 
as indicator of more severe grief .
Marital closeness was assessed as a mitigator  
of negative effects of bereavement (reducing 
grief severity). 
Quality of Life  was measured by the Health 
Utilities Index Mark 3 (HUI-3). This is a 
multidimensional self-report measure of overall 
health status (Ref ).
The measure evaluates eight attributes: vision, 
hearing, speech, ambulation, dexterity, emotion, 
cognition, and pain. Each attribute is assessed by 
five or six levels of health status or functionality. 
Song Ji et al. 2012 Bereaved participants  in this study were 
identified through a data set gathered via a 
national initiative to evaluate the quality of 
palliative care services
The severity of bereavement was not assessed .
Bereavement in family members of patients 
with terminal cancer vs. non-bereaved 
controls from general population
Quality of life was assessed by EQ-5D to 
evaluate health-related quality of life , including 
a summary score and a visual analog scale (EQ-
VAS) (Ref ).
Wiese Ch et al. 
2010
Bereaved participants were recruited via 
mental health institutions.
Evaluation of bereavement used the validated 
criteria of Horowitz and Prigerson, together 
with the definition of complicated grief 
according to ICD-10.
Quality of life was assessed by sub-scores of 
SF-12:
1.Psychosocial and physical distress of the 
care-giving relatives in the inquiry was measured 
through a sub-score of SF-12® to validate the 
quality of life of the relatives (MCS-12).
2.Retrospective evaluation of the subjective 
psychosocial distress of family caregivers during 
specialized PCT care.
3.Correspondence of the results with reference 
to indications of complicated bereavement
Zhou Jf et al. 
2016
Bereaved elderly  spouses in a rural part of the 
china, were identified via  a  local household 
registration information system in each town.
For the duration of the bereavement the 
question was asked to give the year in which 
the spouse had died; (exact date was not asked 
because a pre-test indicated that widows often 
could not remember this)
Severity of the bereavement was not assessed.
This study used SF-12 (V2 in Chinese) to 
measure the health-related QOL of elderly 
persons (Ref ). 
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lower in the self-report measures of multidimensional efficacy (Fry, 2001). Widows also scored higher 
in the overall health-related QoL perceptions (widows = 43.8±4.4; widowers = 37.4±6.1, P<0.01). A 
prospective cohort study by Ott et al. compared three clusters of 141 spousal mourners, based on 
grieving scores (common, chronic and resilient) (Ott et al., 2007). The resilient cluster experienced 
the lowest levels of grief and depression, and the highest quality of life. While, the majority of subjects 
in the chronic cluster met the criteria for a diagnosis of complicated grief, and experienced the highest 
levels of grief and depression, were more prone to sudden deaths, had the lowest self-esteem, and the 
highest marital dependency (Ott et al., 2007). In a case-control study among 546 widowed and 2 566 
non-widowed men and women, Bourassa at al. tested whether deceased spouses’ characteristics were 
associated with their widowed partners’ later quality of life using couples drawn from a multinational 
sample of aging adults. Independent subsamples were assessed before and after a spouse’s death. 
Quality of life before the death of deceased partner’s predicted their spouses’ later quality of life after 
their passing (β= 0.16, 95% 0.05, 0.26, p = 0.003). In additon,  as compared to people who remained 
married, widowed subjects had lower absolute levels of quality of life—both before (β=-0.23, 95% CI 
-0.33,-0.13,p<0.001) and after their partners’ death (β=-0.24;95% CI -0.34;-0.13,p<0.001). Finally, the 
strength of independence in couples’ quality of life was not significantly different between widowed 
and non-widowed subjects (β = −0.01, 95% CI −0.19, 0.17, p > 0.250) (Bourassa et al., 2015). Zhou 
and Hearst performed a  study that comprised 3053 elders aged 60 and above in rural China. The 
SF12 questionnaire was administered and individual and household characteristics were obtained. 
Health related QoL was compared between 1 925 married and 1 060 widowed persons. Physical 
component summary (PCS) and mental component summary (MCS) scores between married el-
ders and widowed elders in a bivariate model stratifying by gender and age group and in a general 
factorial ANOVA multivariate analysis were performed. Overall, widowed elderly Chinese people 
from rural areas had lower physical and mental quality of life than their married counterparts. Also, 
widowed men had lower PCS and MCS scores than married men after controlling for age. Although 
in widowed and married women QoL declined significantly with age, and overall PCS was lower 
in widowed women, the differencee in MCS scores between widowed and married women was not 
statistically significant (Zhou & Hearst, 2016). 
Finally, we found two studies that examined the quality of life of spousal bereavement but with no 
comparison group.  Onrust et al.(Onrust et al., 2007) demonstrated a reduced QoL among widows 
(widows had quality of life score of 0.79 ±0.22 whereas full health has a value of 1) in a cross-sectional 
study among 216 bereaved spouses.  Cheng at al. (Cheng & Ma, 2000) conducted research on spouses 
six months to two years into bereavement. This study comprised 70 respondents (provided by eleven 
hospitals and one clinic). The mean scores of the respondents on the quality of life ranged from 3 to 
8.78 (mean 6.20, SD 1.21). Overall, quality of life of the respondents was moderately good and age, 
gender and the other demographic characteristics of included participants did no alter their quality 
of life.
bereavement in caregivers and quality of life. 
There were three observational studies that evaluated the association between bereavement in 
caregivers and health related QoL (Table 1). Song at al. compared QoL of 353 bereaved family 
members of patients with terminal cancer with 353 non-bereaved controls from the general popula-
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tion (Song  et al., 2012). Quality of life in bereaved family members was significantly lower than in 
controls (0.88±0.20 vs 0.93±0.13, p=0.002). Also, a negative correlation with health-related QOL was 
observed with female gender, spousal relationship, lower income, and longer duration of survival 
after palliative care referral. Similarly, Wiese at al. studied 46 care-giving relatives of deceased patients 
with terminal cancer 2  to 24 months after the patient had died. The MCS-12, a subscore of SF-12, 
showed that the psychological strain in the caregivers was higher than that in the general population 
(range 46–60; median 52). Based on Prigerson criteria 30% of care-giving relatives had criteria for the 
diagnosis of complicated grief, while using the definition of ICD-10 only 13% fulfilled the criteria for 
this diagnosis. Further, the caregivers who experienced complicated grief did not present significantly 
higher psychosocial distress and limitations of their quality of life than those who showed normal 
grieving reactions (median MCS-12: 40 vs. 43; P > 0.05) Subjective evaluation of psychosocial distress 
that caregivers suffered at the time of the interview revealed increased values of MCS-12. Caregiv-
ers with decreased MCS-12 values and,  consequently, increased psychosocial distress considered 
themselves to be more stressed (Wiese  et al., 2010)- Rebollo. et al. compared recent (median of 139 
days) bereavement of 130 mainly female caregivers of a deceased elderly relative compared to stan-
dardized population scores (Rebollo et al., 2005). Caregivers’ SF-36 scores were lower than expected 
in the general population for mental health, role emotional and social functioning. The recent death, 
first-degree family relationship and younger age of deceased were found to be important factors to 
influence the health of caregivers. 
parental bereavement and quality of life
One retrospective cohort and one cross-sectional study examined the association between parental 
bereavement and QoL (Table 1). Lannen et al. investigated the QoL among 449 parents who lost a 
child due to cancer before the age of 25 (Lannen et al., 2008). Parents with unresolved grief (26%) 
were compared with parents who had worked through their grief. They were more likely to report 
poorer QoL 4 to 9 years after child loss; relative risks of Tibblin score <10 % were 2.7 (95% CI 1.2-
6.1) and 4.4 (95% CI 1.7-11.5) among mothers and fathers respectively. Fathers had higher risk of 
sleep difficulties (crude RR 2.6, 95%CI 1.3-5.1) while mothers reported increased visits to physicians 
due to anxiety/depression (adjusted RR 2.1, 95% CI 1.1-3.9) and greater likelihood of taking sick 
leave (crude RR 2.1, 95% CI 1.2-3.5) when they had not worked through their grief. Also, while the 
number of fathers with unresolved grief was significantly decreased 4 to 9 years after loss (p<0.02) this 
was not seen among mothers. A longitudinal study by Song et al, compared 233 bereaved couples with 
229 non-bereaved couples to investigate the long-term effects of child loss (that occurred on average 
two decades earlier) on parent’s health related QoL using the Health Utilities Index Mark 3 (HUI-
3) (Song et al., 2010). After controlling for demographic factors, bereaved parents had significantly 
worse health related QoL than non-bereaved parents. The age of the child or time since child’s loss did 
not significantly predict health outcomes. Also, bereaved parents whose child died in violent circum-
stances had particularly low levels of QoL. Furthermore, marital closeness was a positive predictor, 
while having experienced a depressive episode was a negative predictor of QoL.
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Severity of bereavement and QOL 
Two studies, one cross-sectional and one longitudinal, reported on severity of bereavement and 
QoL. In a cross-sectional study Marques et al. compared 155 bereaved subjects with primary anxiety 
disorder and 242 bereaved subjects without anxiety disorder (Table 1) (Marques et al., 2013). After 
adjustment for age, sex, education level, comorbidity and major depressive disorder, complicated grief 
was associated with lower quality of life (β = -0.140, P = 0.023) and greater impairment (β = 0.141, 
P = 0.035) among individuals with anxiety disorder. Boelen et al. conducted a longitudinal study to 
investigate the association of grief severity and QoL 6 and 15 months post loss among 346 subjects 
(Table 1) (Boelen & Prigerson, 2007). Results showed that prolonged grief disorder, independently of 
depression and anxiety, is predictive of reduced QoL and mental health. 
DiSCuSSiON
This is the first study to systematically review the evidence on the association between grief status and 
QoL. Overall, we found that bereaved persons and grief severity show associations  with lower QoL. 
Also, our findings suggest that women experience changes in grief related QoL in a different way 
than men. After the loss of a child, females suffer from lower QoL then men. Also, females have more 
difficulties recovering from grief; this prolongs the grieving process and consequentially might lower 
life quality. Nevertheless, the evidence on grief and QoL is limited and hampered by the scarcity and 
suboptimal quality of the studies on the topic, and therefore no firm conclusion can still be drawn.
interpretation of findings
Despite increasing efforts in bereavement research, little research has focused on QoL related to 
bereavement. Nevertheless, the current evidence, as supported by our findings, suggests that different 
types of bereavement and bereavement severity hamper the QoL in people reporting the loss of a 
loved one. Bereavement after losing a partner or a child shows associations with lower QoL. Also, 
subjects with complicated grief, a disorder characterized by persistent high levels of bereavement, 
experience persistent deficits in QoL. 
Even a century ago, grief was officially regarded as a cause of death (Parkes, 1964). Currently  QoL 
remains an important predictor of mortality. QOL is a broad concept that comprises a range of life 
domains of the individual, such as social relationships, role functioning, physical abilities and engage-
ment in daily activities, and mental health functioning (Brown , Thompson , Zack , Arnold , & Barile 
2015). The severity one grieves with after the death of a loved one may differ. Likewise, expression of 
the grief also differs depending on the social relations or how grieving is culturally/socially justified 
or expected.  Loss of a loved one results in long-term changes in one’s social situations and relation-
ships, since grieving individuals have lack of clarity of their role in society contributing to a sense of 
social isolation (Wiese, 2003). Coping strategies after a loss help resolve the isolation in case  of less 
severity and shorter duration of grief, which further prevents lower QoL. Another important aspect 
of the human stress response is the tendency to seek support and protection when feeling threatened 
(Aple, 2011). The hormone oxytocin motivates individuals to connect with others, but it has also 
been found to dampen the fight-or-flight response, which could be one explanation of why social 
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support is beneficial in the face of stress (Saavedra Perez et al., 2016). Many people experiencing 
grief might also suffer from more severe or triggered disability (d’Epinay, Cavalli, & Guillet, 2009). 
This is somewhat expected and can be explained through isolation processes or lifestyle changes 
(Cornwell & Waite, 2009). Lack of willingness to interact and retrieving to loneliness also triggers 
higher disability. Previous studies have shown bereavement is associated with a decline in functional 
impairment (d’Epinay et al., 2009). The majority of people experiencing a loss of a dear one can also 
experience a different mental health comorbidity such as, anxiety, anger, depressive symptoms or 
suicidal thoughts (Kristensen, Weisaeth, & Heir, 2012; Parkes, 1964). Although health-related factors, 
both physical and mental, have been hypothesized to influence the duration and severity of grieving, 
there is no clear explanation of mechanisms that can lead to this scenario (Feinson, 1982; Kristensen 
et al., 2012). On the other hand, recent evidence suggests that grief affects the same brain area as 
general pain mechanisms, which could explain the physical pain experienced by those who lose a 
loved one (Bratt, 2016).
Our findings suggest that bereavement may be associated with QoL in a gender-specific manner, 
with female grievers having lower QoL. These gender differences might be explained by multiple 
adaptive mechanisms as well as relation or compliance, and differences in male/female social support/
network (Trofimova, 2013). Stroebe, reports gender differences in the needs and benefits of bereaved 
men compared with bereaved women., for example, widowers benefit more from emotion-focused 
interventions while widows from problem-focused interventions (Stroebe 2001). Also, in elderly 
populations, a certain life style is present with women leading the household and taking care about 
the stability of daily rhythm, while men providing financial and logistic means. By the death of 
the woman, man would be left alone with difficulties in learning to suddenly take over control of 
household, self-care and overall setting and lifestyle (Stroebe 1998; Umberson, Wortman, & Kessler, 
1992). By the death of the man traditionally women will experience difficulties learning to manage 
financial issues. This difference will probably disappear over time, due to changing marital roles. 
In both male and female spousal bereavement, persons have lower physical and mental quality of 
life than their married counterparts. Consequent to loss event, support from children is associated 
with better QOL. Namely, these elders rely on their children for care, and a supportive family is 
associated with better QOL and, seems to mitigate negative effects of widowhood (Song et al., 2010). 
Further in the palliative care setting, the findings suggest that care from a specialized palliative-care 
team providing psychological and social support may reduce the risk of complicated grief (Wiese  et 
al., 2010). Careful exploration of possible risk factors for complicated grief is important for optimal 
care. Healthcare providers play an important role in helping family caregivers to manage the multiple 
burdens and the grieving reaction. Family-focused grief therapy may prevent complicated grieving 
reactions (Wiese  et al., 2010).
Methodological Concerns and future recommendations 
The magnitude of the effect size on the association between bereavement and QoL is currently 
difficult to assess because of the scarcity of the evidence. The available studies suffer from large het-
erogeneity in bereavement assessment and QoL instruments, study design and quality.. Factors that 
might hamper the quality of recording grieving states need consideration. These include the potential 
effect of recall bias and the challenges of objective interpretation of emotional status as it is generally 
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under-reported or not realistic if not checked or re-assessed by healthcare professionals. Beyond the 
caution needed in interpretation of grief length and severity, future studies must also consider other 
aspects associated with grieving. For instance, most of the studies define the state of grief as present or 
absent after the loss event, not taking into account the severity of grief and its duration (complicated 
grief or prolonged grief disorder). Only few of the included studies acknowledged grief severity and 
in a different manner (Boelen & Prigerson, 2007; Marques et al., 2013). Therefore, the continua-
tion/persistence of all degrees of severity in the bereavement process needs more research effort in 
the future, in order to harmonize the definitions and distinct different bereavement status. Most 
studies lack appropriate adjustment for confounding factors since they did not consider important 
determinants of grief and QoL such as socioeconomic factors, social support, depressive symptoms 
and treatment. The majority of studies used small samples (ranging from 42 to 501) and there were 
methodological concerns related to the selection of participants, compromising generalization of the 
findings. Moreover, studies used different methods to assess QoL and in some studies the instrument 
used was not validated. In the future, it is necessary to harmonize bereavement and QoL assessment, 
as well as design better studies that adjust for a broad range of confounders and select a representative 
sample. Of special importance, prospective studies will be needed before any level of causality can 
be inferred from the existing findings, and residual confounding could be considered as an explana-
tion for the associations observed. Future research, by taking into account all these methodological 
considerations, would provide a more reliable assessment of the association between bereavement 
and QoL, which might have numerous benefits. Understanding QoL related with bereavement and 
its types would allow health and social care providers and researchers to better understand what 
aspects of the bereavement and treatment/intervention the bereaved individuals views as having the 
greatest impact on their QoL. It may also give insights on whether specific interventions to enhance 
adaptation to bereavement, or treat health consequences related to bereavement might outweigh its 
potential benefits. QoL effects of bereavement may impact individuals sustaining health and social 
care activities and care providers decision-making. Understanding QoL related to bereavement may 
also be useful in shaping better interventions in individuals experiencing bereavement and improve 
outcomes related to bereavement. Also, if our findings on an association between bereavement and 
QoL are confirmed with further studies we could carefully infer that QoL could be assessed as an 
additional intervention/treatment bereavement outcome.   
Strengths and limitations of the review
Previous studies have evaluated the effect of bereavement on some of the aspects or overall quality of 
life, but our study is the first attempt to systematically review and critically appraise the literature on 
the subject, and put together the different existing studies that evaluated the associations of bereave-
ment and it’s severity with overall QoL. On the other side, a meaningful quantitative pooling of the 
existing data was unfeasible due to different types of bereavements examined by individual studies, 
different methods used to define QoL, heterogeneity in the study designs and because the estimates 
were not reported in some of the studies. Furthermore, the findings reported in the current study do 
not carry any implications on causality because all included studies are observational.
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CONCLuSiONS
Different types of bereavement and bereavement severity show associations with lower QoL. Re-
searchers and providers evaluating bereavement care interventions might consider including QoL 
outcome measures in their projects. However, future large prospective studies are warranted to 
confirm our findings and to examine specific domains of QoL affected by bereavement, as well as 
assessing sex-specific effects of bereavement on QoL. 
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SuppLEMENTArY MATEriAL
Included in the online Supplementary Material:
AppENDix 1. PRISMA 2009 CHECK-LIST
Section/topic # Checklist item 
reported 
on page # 
TiTLE 
Title 1 Identify the report as a systematic review, meta-analysis, or both. 1
AbSTrACT 
Structured 
summary 
2 Provide a structured summary including, as applicable: background; objectives; 
data sources; study eligibility criteria, participants, and interventions; 
study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number. 
2
iNTrODuCTiON 
Rationale 3 Describe the rationale for the review in the context of what is already known. 3-4
Objectives 4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS). 
3
METhODS 
Protocol and 
registration 
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number. 
4
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as 
criteria for eligibility, giving rationale. 
4-5
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact 
with study authors to identify additional studies) in the search and date last 
searched. 
4
Search 8 Present full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated. 
Appendix 
3
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis). 
4-5
Data collection 
process 
10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming 
data from investigators. 
5
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made. 
5
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how 
this information is to be used in any data synthesis. 
5
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). -
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I2) for each meta-analysis. 
-
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Section/topic # Checklist item 
reported 
on page # 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence 
(e.g., publication bias, selective reporting within studies). 
5
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, 
meta-regression), if done, indicating which were pre-specified. 
-
rESuLTS 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram. 
5-6; 
Figure 1
Study 
characteristics 
18 For each study, present characteristics for which data were extracted (e.g., study 
size, PICOS, follow-up period) and provide the citations. 
6-12; 
Table 1
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12). 
-
Results of 
individual studies 
20 For all outcomes considered (benefits or harms), present, for each study: (a) 
simple summary data for each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot. 
6-12; 
Table1 
& 3
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency. 
-
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see Item 15). -
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, 
meta-regression [see Item 16]). 
-
DiSCuSSiON 
Summary of 
evidence 
24 Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, 
users, and policy makers). 
12-15
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-
level (e.g., incomplete retrieval of identified research, reporting bias). 
17
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, 
and implications for future research. 
17
fuNDiNG 
Funding 27 Describe sources of funding for the systematic review and other support (e.g., 
supply of data); role of funders for the systematic review. 
18
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AppENDix 2. MOOSE CHECKLIST
Criteria brief description of how the criteria were handled in the meta-
analysis
reporting of background should include
✓ Problem definition It remains unclear if bereavement effects quality of life of the 
person losing a loved one.
✓ Hypothesis statement Bereavement effects on of the person losing a loved one 
✓ Description of study outcomes Quality of life
✓ Type of exposure or intervention used Bereavement, bereavement counseling, grief, mourn, loss of loved 
one
✓ Type of study designs used Studies were eligible if they (i) were observational studies (cross-
sectional, case-control and cohort studies), or randomized clinical 
trials; (ii) assessed any form of grief (bereavement, grief, PGD 
and complicated grief ), (iii) collected endpoints for QoL; and (iv) 
examined the association between any form of grief and QoL)
✓ Study population Bereaved family members or caregivers
reporting of search strategy should include
✓ Qualifications of searchers The credentials of the investigators are indicated in the authors list.
✓ Search strategy, including time period included 
in the synthesis and keywords
Search strategy and time periods are detailed in page 5 of the 
manuscript and in the Appendix 3. 
✓ Databases and registries searched Medline, EMBASE, Web of Science, PubMed, Cochrane and 
Google Scholar
✓ Search software used, name and version, 
including special features
We did not employ any search software. 
✓ Use of hand searching We did not hand searched studies given that we used a thorough 
search strategy.
✓ List of citations located and those excluded, 
including justifications
Details of the literature search process are outlined in the flow 
chart. The citation list for excluded studies is available upon 
request.
✓ Method of addressing articles published in 
languages other than English
We placed no restrictions on language. All identified studies were 
in English.
✓ Method of handling abstracts and unpublished 
studies
No unpublished studies were identified
✓ Description of any contact with authors None
reporting of methods should include
✓ Description of relevance or appropriateness of 
studies assembled for assessing the hypothesis 
to be tested
Detailed inclusion and exclusion criteria are described in the 
Methods section. 
✓ Rationale for the selection and coding of data Data extracted from each of the included studies were relevant 
to the population characteristics, study design, exposure, and 
outcome.
✓ Assessment of confounding Confounding was assessed for each of the included study and if 
found described in Table 1 in “covariates adjusted” column. 
✓ Assessment of study quality, including blinding 
of quality assessors; stratification or regression 
on possible predictors of study results
Assessed for each included study by New-castle Ottawa scale 
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Criteria brief description of how the criteria were handled in the meta-
analysis
✓ Assessment of heterogeneity Due to limited number of included studies and high heterogeneity 
in exposure and outcome assessment by the individual studies, we 
concluded that meta-analysis was not feasible
✓ Description of statistical methods in sufficient 
detail to be replicated
Not applicable.
✓ Provision of appropriate tables and graphics We included 1 main figure, 3main tables and 3 supplementary 
tables
reporting of results should include
✓ Graph summarizing individual study estimates 
and overall estimate
Figures 1
✓ Table giving descriptive information for each 
study included
Tables 1, 2 and 3
✓ Results of sensitivity testing Not applicable
✓ Indication of statistical uncertainty of findings Not applicable 
reporting of discussion should include
✓ Quantitative assessment of bias Not applicable 
✓ Justification for exclusion We excluded, conference abstracts and studies with inappropriate 
exposure or outcome 
✓ Assessment of quality of included studies Assessed for each included study by New-castle Ottawa scale
reporting of conclusions should include
✓ Consideration of alternative explanations for 
observed results
In discussion of the review we elaborate our observation.
✓ Generalization of the conclusions Our findings apply to middle age and elderly people who lost their 
loved ones . However, most of the studies were performed among 
western and Caucasian populations and generalization of findings 
to other populations and ethnicities is somewhat limited.
✓ Guidelines for future research Most studies lack appropriate adjustment for confounding factors 
since they did not consider important determinants of grief and 
QoL such as socioeconomic factors, social support, depressive 
symptoms and treatment. The majority of studies used small 
samples (ranging from 42 to 501) and there were methodological 
concerns related to the selection of participants, compromising 
generalization of the findings. Moreover, studies used different 
methods to assess QoL and in some studies the instrument used 
was not validated. In the future, it is necessary to harmonize 
bereavement and QoL assessment, as well as design better 
studies that adjust for a broad range of confounders and select a 
representative sample. Of special importance, prospective studies 
will be needed before any level of causality can be inferred from the 
existing findings, and residual confounding could be considered as 
an explanation for the associations observed.
✓ Disclosure of funding source Funding was disclosed on page 20.
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AppENDix 3. LITERATURE SEARCH STRATEGY
Embase.com
(grief/exp OR bereavement/de OR ‘bereavement counseling’/exp OR (grief OR grieve* OR mourn* 
OR sorrow* OR bereave* OR ((loss OR lose OR lost) NEAR/3 (spous* OR husband OR wife OR 
partner* OR sibling* OR partner* OR brother* OR sister*)) ):ab,ti) AND (‘quality of life’/exp OR 
((qualit* NEAR/3 life)):ab,ti) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim OR 
[Editorial]/lim) AND [english]/lim
Medline ovid
(exp bereavement/ OR (grief OR grieve* OR mourn* OR sorrow* OR bereave* OR ((loss OR lose 
OR lost) ADJ3 (spous* OR husband OR wife OR partner* OR sibling* OR partner* OR brother* OR 
sister*))).ab,ti,kf.) AND (“quality of life”/ OR ((qualit* ADJ3 life)).ab,ti,kf.) NOT ((letter OR news OR 
comment OR editorial OR congresses OR abstracts).pt.) AND english.la.
psycinfo ovid
(exp bereavement/ OR (grief OR grieve* OR mourn* OR sorrow* OR bereave* OR ((loss OR lose 
OR lost) ADJ3 (spous* OR husband OR wife OR partner* OR sibling* OR partner* OR brother* OR 
sister*)) ).ab,ti.) AND (“quality of life”/ OR ((qualit* ADJ3 life)).ab,ti.) NOT ((letter OR news OR 
comment OR editorial OR congresses OR abstracts OR books).pt.) AND english.la.
Cochrane
((grief OR grieve* OR mourn* OR sorrow* OR bereave* OR ((loss OR lose OR lost) NEAR/3 (spous* 
OR husband OR wife OR partner* OR sibling* OR partner* OR brother* OR sister*)) ):ab,ti) AND 
(((qualit* NEAR/3 life)):ab,ti) 
Web-of-science 
TS=(((grief OR grieve* OR mourn* OR sorrow* OR bereave* OR ((loss OR lose OR lost) NEAR/2 
(spous* OR husband OR wife OR partner* OR sibling* OR partner* OR brother* OR sister*)) )) AND 
(((qualit* NEAR/2 life) )) ) AND DT=(article) AND LA=(english)
Google scholar
grief|bereavement “quality * life”|wellbeing|”well-being”|hopelessness|loneliness
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AbSTrACT
Objective: We aimed to explore correlates and predictors of bereavement severity and persistence 
(triggered by “loss of a loved one”; referent group partner loss) in the Rotterdam cohort. Method: 
We used linear regression to examine factors associated with grief severity using a cross-sectional 
analysis and logistic regression to determine prospective associations. Results: Cross-sectionaly, 
females, child-lost, higher depressive symptoms, lower education, and difficulties in daily activities 
were independently associated with a higher bereavement severity. Prospectively (6 years; response 
rate 71%), the baseline value of the grief severity was the single predictor significantly associated with 
grief persistence. Discussion: Our results suggest that only grief severity is independently associated 
with grief persistence. Further studies are needed to confirm our findings.
Determinants and Predictors of Grief Severity and Persistence
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iNTrODuCTiON
Bereavement has been cited as one of the most traumatic life events (Clark & Georgellis, 2013). 
Death of a loved one is associated with severe stress and increased risk of occurrence of depressive 
symptoms, major depressive episodes, anxiety-related disorders (Alexopoulos, 2005; Kreicbergs, 
Valdimarsdottir, Onelov, Henter, & Steineck, 2004; Mendes de Leon, Kasl, & Jacobs, 1994; Prigerson 
et al., 1997), impaired immune function (Zisook et al., 1994), lower quality of life (Grimby, 1993), 
suicide, and increased risk of mortality (Kaprio, Koskenvuo, & Rita, 1987). After 6 to 12 months, 
most bereaved persons will adapt to the loss with a reduction in grief intensity and a return to a 
different but meaningful and satisfying life without the deceased (Bonanno et al., 2002; Prigerson 
et al., 2009). However, for some bereaved individuals, the adaptation might be complicated, slowed, 
or halted, leading to persistence of grief (Boelen & van den Bout, 2008; Shear et al., 2007). Persistent 
grief is associated with functional impairment, sleep disturbances, high-risk behaviors, and increased 
risk of cancer and cardiovascular disease (Simon et al., 2005; Simon et al., 2007). It is therefore 
important to identify the factors associated with persistent grief to identify the population at risk 
of developing prolonged or complicated grief in need of support and adequate treatment. Several 
factors have been suggested to influence the duration and severity of grief. First, the effects of grief 
on morbidity and mortality are greater for the widowers in the acute grieving period because women 
benefit more from social support (Stroebe, 2001). Likewise, with respect to gender differences in 
coping styles, women are more confronted and expressive of their emotions than men. That can be 
a predisposition for their better recovery (Stroebe & Stroebe, 1983). Second, due to life experience, 
people develop better coping strategies. Tempestuous emotions tend to be damped down, and it is 
less common for people to respond excitable to worries. The previous study showed that restless-
ness symptom was significantly higher in young widows and the irritability symptom showed an 
interaction effect—high for young (sudden death) and middle-aged (prolonged grief) widows (Ball, 
1977). Thirdly, race influenced the grief severity. Previous study (Fitzpatrick & Tran, 2002) revealed 
that bereavement was a significant factor affecting the health of White Americans, particularly in 
the youngest and oldest age groups. However, no bereavement effects were observed among African 
Americans within any of the age groups. These findings raise questions as to the differential effects 
of bereavement between different races. Fourth, in the acute grieving phase, lower educated people 
had worse coping skills, while in prolonged grief, education level was no longer significant (Boelen, 
van den Bout, & de Keijser, 2003). This might be due to lack of intellectual capability to work on 
a coping system or lack of possibilities to seek comfort in spiritual and intellectual aspects of life 
and social networks. Fifth, employment might play a role in younger or middle-aged adults, but in 
elderly, it helps dominantly as an additional source for seeking peers for social networking after a loss 
event. Also, working people might experience difficulties going back to work while suffering severe 
grief due to fear of underperforming. Sixth, spousal bereavement increases the grief severity. The 
previous study shows that elderly participants who lost their spouse had a higher risk of developing 
complicated grief when compared with participants losing someone else (Fujisawa et al., 2010). Next, 
bereaved spouses with prolonged grief had difficulty accessing positive memories of the deceased, 
and higher recalled marital adjustment. (Mancini, Sinan, & Bonanno, 2015). Mood-incongruency 
effects are due to a mood-regulatory process in which people retrieve memories to repair moods. :: 
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The fact that one is not able to retrieve negative but only positive memories, increases the severity 
of grief. The same phenomenon is present in the more positive recalled marital adjustment when 
people tend to forget or repress the negative memories. Rumination keeps refocusing the griever on 
the thought of the deceased. Equally important for grief severity, experiential avoidance of situations 
that serve as reminders of the loss is also common. All of the above have been implicated as predictors 
of prolonged grief (Morina, 2011). Also, studies report severe depressive symptoms to be associated 
with prolonged grief, but findings have not been consistent (Tsai et al., 2016; Tsuboya et al., 2016). 
Most of the studies examine factors associated with grief severity and persistence solely on the basis 
of spousal bereavement, while other types of loss events have not been explored. Although health-
related factors, both physical and mental (Onrust, Cuijpers, Smit, & Bohlmeijer, 2007), have been 
hypothesized to influence duration and severity of grieving, few longitudinal studies have examined 
their role in grief persistence among older adults. Grieving has been reported to differ by age, given 
the differential circumstances and mechanisms of adaptation that might occur within individuals at 
different stages of mental maturation. Mortality risk increases with age. Consequently, the probability 
of losing a spouse or partner also increases. Loss of a spouse or partner, might result in transferring 
dependency to others in the family or to the social surrounding .Elderly bereaved often lacks the 
necessary social support. This desolation further aggravates the grief process. Previous longitudinal 
studies on this topic had short follow-up (up to 24 months) and did not explore the determinants of 
grief related to long-term bereavement and different kind of loss (Bonanno et al., 2002; Prigerson et 
al., 2009; Tsai et al., 2016; Zisook, Paulus, Shuchter, & Judd, 1997; Zisook & Shuchter, 1991; Zisook et 
al., 1994). Therefore, our aim was to examine cross-sectionally factors associated with grief severity 
in adults aged 55 years and older taking into account all kind of kinship and also loved ones (not 
family related). Furthermore, we aimed to determine whether these factors were associated with grief 
persistence using a longitudinal data.
METhOD
Settings and Study population
The study was performed within the framework of the Rotterdam Study, a population-based cohort, 
among persons 55 years and older living in the Ommoord district of Rotterdam, the Netherlands. The 
rationale and design of the Rotterdam Study is described elsewhere (Hofman et al., 2013). In brief, in 
1990 all inhabitants of a well-defined district of Rotterdam were invited (RSI) and in 2000 an addi-
tional 3011 participants were enrolled (RSII), consisting of all persons living in the study district who 
had become 55 years of age. There were no eligibility criteria to enter the Rotterdam Study cohorts 
except the minimum age and residential area based on ZIP codes. The Rotterdam Study has been 
approved by the medical ethics committee according to the Population Screening Act: Rotterdam 
Study, executed by the Ministry of Health, Welfare and Sports of the Netherlands. All participants in 
the present analysis provided written informed consent to participate and to obtain information from 
their treating. Baseline measurements were performed in the fourth visit of the first cohort (RSI-4 
year 2002-2004, n = 3,554) and the first visit of the second cohort (RSII-2 year 2004-2005; n = 2,468). 
Overall, there were 6,018 eligible participants (Figure 1). Of these participants, 597 persons did not 
Determinants and Predictors of Grief Severity and Persistence
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answer whether they had experienced a death that they were still grieving (consequently, they did not 
undergo an Inventory of Complicated Grief [ICG] interview). Additionally 1,146 participants were 
excluded because of cognitive impairment defined as a score ≤26 on the Mini-Mental State Examina-
tion (MMSE; Folstein, Folstein, & McHugh, 1975). Of the remaining 4,275 participants, 3,469 were 
classified as nongrievers: participants who replied negative to the question, “In the past years, have 
you lost someone who you still grieve over?” or they did not answer sufficiently the ICG interview 
(less than 75% of the answers was present), leaving 771 (468 from RSI-5 and 303 from RSII-3) persons 
who constituted the study population. Furthermore, 73 participants died during the follow-up period 
and out of 698 eligible, 223 persons did not complete the grief questionnaire (lost to follow-up), 
leaving 475 persons who constituted the follow-up study population. Follow-up measurements were 
performed in the fifth visit of the first cohort (RSI-5, year 2009-2011) and the second visit of the 
second cohort (RSII-3 year 2011-2012). The same grief questionnaire was administered at baseline 
and a follow-up exam with average time of 6.3 years between baseline and follow-up assessment.201 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Figure 1. Flowchart of the study population  
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Assessment of Grief–interview of Complicated Grief (iCG)
Complicated grief was diagnosed with a Dutch version of the 19-item ICG (Prigerson et al., 1995). 
Participants underwent face-to-face interviews. They were first asked whether in the past years they 
had lost someone whom they were still grieving over. If yes, these participants were classified as griev-
ers and were further assessed with the ICG to measure grief severity. Complicated grief symptoms 
were assessed as present among participants who scored equal or greater than 22 on the ICG score 
and grieved longer than 6 months (Newson, Boelen, Hek, Hofman, & Tiemeier, 2011; Saavedra Perez 
et al., 2015). ICG is composed to represent symptoms of complicated grief such as those in the most 
recent proposed criteria for the condition (Newson et al., 2011; Prigerson et al., 2009; Shear et al., 
2011). Among the described symptoms are yearning for the lost person, anger over the death, distrust 
and detachment from others as a consequence of a death, survivor guilt, and loneliness. The measure 
has a high internal consistency and convergent and criterion validity, and it is the gold standard for 
measurement of complicated grief in older adults (Boelen, Van Den Bout, De Keijser, & Hoijtink, 
2003). The inventory represents a single underlying construct of complicated grief (Boelen & Hoij-
tink, 2009). The original ICG consisted of 19 questions. Responses were provided on a 5-point scale to 
reflect an increase in severity (0 = never, 1 = seldom, 2 = sometimes, 3 = often, 4 = always; Prigerson 
et al., 1995). In this study, one item from the original inventory, “I feel bitter over this person’s death,” 
was removed from the original ICG as a pilot study revealed that this sentiment had the same mean-
ing within the Dutch language as the included item, “I feel anger over this person’s death” (Boelen 
et al., 2003) Two further items (relating to seeing and hearing the deceased) were collapsed into one 
due to their similarity after a pilot study indicated these symptoms were low in frequency and often 
overlapped (“I hear the voice of, or see, the person who died”; Boelen et al., 2003). Furthermore, at 
the baseline we collect the date of the loss event to identify complicated grievers (complicated grief 
defined as grieving longer than 6 months from the time of the death). No limit for the time since loss 
was set. : In our pilot study we found that adults may grieve over the loss of a dear one even more than 
20 years. This provides the time frame for experienced loss. Information about the deceased person 
was obtained with question, “Who is the dear one you have lost?” Answers were subdivided into “Loss 
of the spouse (reference group),” “Loss of the child,” “Loss of the others” (defined as one of the parents, 
a brother/a sister (Fujisawa et al., 2010), another family member, good friend, another dear person 
(not described relation-wise so far), multiple deaths (including a spouse and/or child or not including 
a spouse and/or child; Table 1).
Assessment of potential factors Associated With Grief
Age, sex, education, cognitive functioning, activities of daily living, body mass index (BMI), use of 
psycholeptics, and the presence of comorbidities and depressive symptoms were considered as po-
tential confounders and assessed at the baseline examination. Education was defined as low (primary 
education, lower vocational education and/or lower/intermediate general education), intermediate 
(intermediate vocational education and/or higher general education), or high (higher vocational 
education or university). Information about the deceased person was obtained with the question: 
“Who is the dear one you have lost?” Answers were subdivided into loss of a partner, loss of a child, 
or other. Social support was assessed with social support interview, a self-reported questionnaire 
(Meltzer, Gill, Pettricrew, & Hinds, 1995). The social support interview consists of five self-rated 
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questions; answers scored equally for each question, on a 3-point scale (0 = not true, 1 = partly true, 
2 = certainly true) to yield a global score of maximum 10 points. A higher score indicates the better 
level of social support. Depressive symptoms were assessed with a valid Dutch version of the Centre 
for Epidemiological Studies Depression (CES-D) scale (range = 0-60) where people score over 16 
points (cutoff defined as score ≥ 16 points) identified persons with the clinically relevant depressive 
symptom (Beekman, 1997). The ability to perform activities of daily living was measured with the 
Stanford Health Assessment Questionnaire (Bruce & Fries, 2003; Fries, Spitz, & Young, 1982) that 
measures disability in eight fields (dressing and grooming, rising, reach, hygiene, eating, walking, 
grip, and activity). A Disability Index (DI) from 0.50 to 1.00 was considered as mild disability, while 
a DI of 1.00 or higher was regarded as a severe disability (Odding, Valkenburg, Stam, & Hofman, 
2001). Psycholeptic drug use data were obtained from the Rotterdam Study pharmacies network 
at the baseline. This information was later on verified by a physician/cabinet check. Psycholeptics 
included benzodiazepines, antidepressants, neuroleptics, and anticonvulsants (Hofman et al., 2013; 
Stricker & Stijnen, 2010). Cognitive functioning was measured using the MMSE, during the baseline 
visits (Folstein et al., 1975). Participants with an MMSE score < 26 were excluded from the study. All 
comorbidities were assessed at the baseline by medical history, home inter- view, or by a clinician, and 
later on validated by relevant clinical test (if necessary). Comorbidities were categorized as present 
or absent and included one or more of the prevalence of diabetes mellitus, heart failure, stroke, myo-
cardial infarction, chronic obstructive pulmonary disease (COPD), and joint problems that include 
osteoarthritis, rheumatoid arthritis gout, back pain, and ankylosing spondylitis. Diabetes mellitus 
was defined as a fasting glucose level of ≥7.0 mmol/L or use of blood glucose–lowering medica-
tion. Prevalent heart failure at baseline was measured using a validated score that was based on the 
heart failure definition of the European Society of Cardiology. A history of stroke was determined by 
interview or proxy informant interview. Confirmation of stroke diagnosis by a treating physician was 
required. A previous myocardial infarction was determined using an electrocardiogram.Diagnosis of 
COPD was confirmed by spirometry. Joint problems were obtained from home interview and a physi-
cian also measured the participants for joint complaints. Radiographic assessment for the diagnosis 
of osteoarthritis and rheumatoid arthritis were made at the research center. The presence of major 
depressive disorder (MDD) was assessed usingSchedules for Clinical Assessment in Neuropsychiatry 
(SCAN) interview. The SCAN is a set of tools created by World Health Organization aimeddiagnosing 
and measuring mental illness that occur in adult life (Wing et1990). This semistructured clinical 
interview was performed by trained clinician to determine which participants fulfilled the Diagnostic 
and Statistical Manual of Mental Disorders (4th ed.; DSM-IV; American Psychiatric Association, 
1994), criteria for MDD.
Statistical Analyses
Continuous variables were reported as mean ± SD unless stated otherwise, and categorical variables 
were presented as percentages. Multivariable linear regression models were used to determine the 
cross-sectional association between potential determinants and ICG score. In our cross-sectional and 
longitudinal analyses, each potential factor was first analyzed in models adjusted for age and gender 
(basic adjusted model), followed by analyses that were additionally adjusted for all potential factors 
(fully adjusted model). For the longitudinal association on potential predictors of grief persistence, 
226
Chapter 5.1
logistic regression models were used (the outcome was dichotomized: complicated grief at follow-up 
and griever but not-complicated grief at follow-up, the last being the reference group) because stan-
dard transformations did not achieve a near normal distribution (more than70% had an ICG score 
of 0 at follow-up). No multicollinearity was observed in any of our analysis as assessed by variance 
inflation factor (all values were <1 and cannot inflate Type I error). To examine whether the pres-
ence of a depressive disorder could influence the results, we re-ran all analyses excluding individuals 
with MDD at baseline. We also examined potential interaction terms before running fully adjusted 
models. To examine the potential selection bias, we perform sensitivity analysis testing whether there 
was any significant difference in characteristics between responders and nonresponders at follow-up 
examination. Furthermore, we explored for potential outliers and whether there was any violation of 
assumptions, but we did not find any issue related to these two aspects of the analysis. Also, to test 
the association between more severe bereavement and potential factors, we repeated the prospective 
logistic regression analyses including only those participants who had complicated grief at baseline 
(persistence vs. cessation as a reference group). To adjust for the potential bias associated with miss-
ing data, we used multiple imputation procedures (n = 5 imputations). Rubin’s method was used for 
the pooled regression coefficients (β) and 95% Confidence Intervals. The percentage of missing values 
within the population for the analyses was lower than 3% (ranging from 0% to 2%). The percentage 
of missing values within our study population was lower than 3% (ranging from 0% to 2%). Age, sex, 
cognitive score, MDD, CES-D, and comorbidities had no missing values; activities of the daily living 
score had 0.4%; psycholeptics drugs had 0.5%; and education had 2%. Analyses were performed using 
SPSS Statistics (version 20; SPSS, Chicago, IL, USA).
rESuLTS
Table 1 presents the characteristics of the study population for cross-sectional and longitudinal analy-
ses. Mean age of study participants was 72.7 years. Half of study participants had lost their partner 
(50%), 11% lost a child, and 39% lost someone else (parent, sibling, cousin, friend, or someone else 
participants felt close to). MDD was present in 4% participants. The majority of the study participants 
had depressive symptoms with the value of below 16 points and mild problems in activities of daily 
living (Table 1). Table 2 shows the results of the cross-sectional association between potential cor-
relates and ICG score In our fully adjusted models, female sex (β = 1.94, 95% CI: [0.35, 3.52]), loss 
of the child (β = 4.24, 95% CI: [1.91, 6.58]) or of the other dear person (β = −3.56, 95% CI: [−5.07, 
−2.04]), higher depressive symptoms score (β = 0.46, 95% CI: [0.37, 0.55]), middle (β = 3.14, 95% 
CI: [1.04, 5.23]) and primary education level (β = 4.81, 95% CI: [1.89, 7.73]), were associated with 
higher ICG score. More difficulties in activities of daily living were associated with lower levels of 
ICG score (β = −2.20, 95% CI: [−3.69, −0.71]). After 6 years of follow-up, 475 (71%) of the 698 
surviving participants underwent the ICG interview and were, therefore, included in our longitudinal 
analysis. Out of those, 334 participants reported complete cessation of grief and 141 still grieved. Out 
of grieving participants, 100 experienced normal grief and 41 complicated grief (Figure 1). In Table 
3, we present the results of the prospective association of the correlates of grief severity with grief 
persistence (cessation as reference). In the age and gender-adjusted analyses, CES-D (OR = 1.04, 
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95% CI: [1.02, 1.07]) and the baseline value of ICG score were associated with grief persistence (OR 
= 1.06, 95% CI: [1.04, 1.08]); other correlates were not associated with grief persistence. In the fully 
adjusted analyses, baseline value of ICG score was associated with grief persistence (OR = 1.05, 95% 
CI: [1.03, 1.08]), while no association was observed for the other factors examined (Table 3).Next, 
we performed a series of sensitivity analyses. First, we excluded persons with major depression from 
our study population and reran the analysis (Supplement Table A).; our result remained essentially 
unchanged. Then we limited the cases to those who experienced continuous complicated grief (non 
grievers as the reference group) and reran the longitudinal analyses(data not shown). Again, our 
result remained essentially unchanged. Last, to test for selection bias, we tested whether there was 
any significant difference in characteristics of the population between responders and nonresponders 
to follow-up exam. Compared with responders, nonresponders were more likely to be men, older 
age, and lower education; have more depressive symptoms, higher comorbidities, lower activities of 
daily living score, lower cognitive score, higher ICG score; and reported more use of psycholeptic 
medications (Supplement Table B). 
Table 1. Characteristics of study participants; for cross-sectional and longitudinal analyses 
Cross-sectional analysis Longitudinal analysis
Grievers
 (N = 771)
Cessation of grief
(N = 334)
Continuous grief
(N = 141)
Age, years (S.D.) 72.6 (7.6) 70.0 (6.6) 70.0 (6.4)
Gender (female), (%) 73 73 81
Education 
Primary (%)  11 6 11
Intermediate (%)  76 79 73
High (%)  13 15 16
Depressive symptoms score, (S.D.) 8.8 (8.6) 7.1 (7.2) 10.5 (10.9)
Activities of daily living problems score, (S.D.) 0.5 (0.5) 0.4 (0.4) 0.5 (0.5)
Social support score,(S.D.) 9.2 (1.4) 9.3 (1.5) 9.3 (1.3)
Diagnosed MDD, (%) 4 2 8
Who died?  
Partner (reference), % 50 56 45
Child, % 11 9 14
Other,% 39 36 41
Psycholeptics* use, yes (%) 20 14 24
Values are presented as means, standard deviation (S.D) or percentages (%)
Psycholeptics includes: benzodiazepines, antidepressants, neuroleptics and anticonvulsants
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Table 2. Potential determinants of grief persistence; cross-sectional analysis Grief severity at the 
baseline – ICG score
Model 1* Model 2† 
potential determinants N=771 N=771
B 95% CI p B 95% CI p
Gender (female) 0.35 -1.30 2.00 0.68 1.94 0.35 3.52 0.02
Age, years 0.07 -0.02 0.17 0.13 -0.06 -0.16 0.04 0.24
Social support, score -0.70 -1.23 -0.18 0.009  -0.28 -0.72 0.26 0.36
Who died?
Partner (reference), % ref. - - - ref.  -  - -
Child, % 2.44 -0.01 4.90 0.05 4.24 1.91 6.58 ≤0.0001
Other, % -5.32 -6.88 -3.76 ≤0.0001  -3.56 -5.07 -2.04 ≤0.0001
 
Depressive symptoms , per 1 point of score 0.48 0.40 0.56 ≤0.0001 0.46 0.37  0.55 ≤0.0001
Education 
High (reference) ,% ref. - - - ref. - - -
Middle,% 3.21 0.91 5.50 0.006 3.14 1.04  5.23 0.003
Primary,% 5.07 1.89 8.26 0.002 4.81 1.89  7.73 0.001
Activities of daily living problems, score 0.19 -1.34 1.73 0.80 - 2.20 -3.69 -0.71 0.004
Psycholeptics‡ use, yes (%) -3.70 -5.58 -1.81 ≤0.0001 0.83 -0.96 2.63 0.36
Comorbidities§, yes (%) 0.49 -1.03 2.00 0.53 0.02 -1.40 1.44 0.98
Cognitive functioning, MMSE‖, - score -0.66 -1.27 -0.06 0.03 -0.30 -0.86 0.26 0.30
*Model 1 was adjusted for gender and age for each covariate 
†Model 2 was adjusted for all listed covariates 
‡Psycholeptics includes: benzodiazepines, antidepressants, neuroleptics and anticonvulsants
§Comorbidities includes: the prevalence of MI, heart failure, stroke, joint problems that include 
osteoarthritis, rheumatoid arthritis gout, back pain and ankylosing spondylitis, COPD and Diabetes 
mellitus 
‖MMSE - The Mini–mental state examination (MMSE) test for cognitive impermanent 
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Table 3. Determinants of grief persistence; a six year longitudinal analysis Persistence of grief
Model 1*  Model 2† 
Covariates/determinants N=141/475 N=141/475
OR 95% CI p OR 95% CI p
Gender (female) 0.64 0.39 1.06 0.08  0.67 0.39 1.20 0.18
Age, years 0.99 0.96 1.02 0.62 0.98 0.95 1.02 0.39
Social support, score 1.12 0.94 1.34 0.20 1.19 0.98 1.44 0.08
Who died?
Partner (reference), % ref. - - - ref. - - -
Child, % 1.22 0.61 2.42 0.57  1.40 0.67 2.92 0.65
Other, % 1.00 0.61 1.63 0.99 1.13 0.67 1.92 0.37
Depressive symptoms‡ , per 1 point of score 1.02 0.99 1.04 0.17  1.02 0.99 1.06 0.13
Education 
High (reference) ,% ref. - - - ref.  - - -
Middle,% 0.67 0.36 1.23 0.20 0.72 0.38 1.36 0.31
Primary,% 1.23 0.49 3.08 0.66 1.47 0.56 3.88 0.44
Activities of daily living problems, score 1.11 0.69 1.81 0.66 0.90 0.52 1.56 0.70
Psycholeptics‡ use, yes (%) 0.73 0.42 1.24 0.24 1.25 0.69 2.28 0.46
Comorbidities§, yes (%) 1.41 0.92 2.16 0.11 1.45 0.91 2.29 0.12
Cognitive functioning, MMSE‖, - score 1.08 0.90 1.28 0.41 1.08 0.90 1.30 0.41
Baseline value of ICG, score 1.06 1.04 1.08 ≤0.0001 1.05 1.03 1.08 ≤0.0001
Note: Grief persisted In 141 of 475 participants, 334 persons reported no grief at follow up (refer-
ence category)
*Model1 was adjusted for gender and age per covariant
†Model 2 was adjusted for all listed covariates 
‡Psycholeptics includes: benzodiazepines, antidepressants, neuroleptics and anticonvulsants
§Comorbidities includes: the prevalence of MI, heart failure, stroke, joint problems that include 
osteoarthritis, rheumatoid arthritis gout, back pain and ankylosing spondylitis, COPD and Diabetes 
mellitus 
‖MMSE - The Mini–mental state examination (MMSE) test for cognitive impermanent
DiSCuSSiON
In this population-based study of middle-aged and elderly persons, we investigated the factors related 
to grief severity in cross-sectional analyses and the determinants of grief persistence in longitudinal 
analyses. Our cross-sectional findings showed that grief severity was associated with female sex, hav-
ing low to intermediate education level, the presence of depressive symptoms, and loss of a partner or 
a child, while more difficulties in daily living activities were associated with less grief severity. In this 
study of elderly individuals, several factors are associated with grief severity in our cross sectional 
analyses. These gender differences are based on the fact that females have better compliance and re-
sponse to the social support/network (Trofimova, 2013).Stroebe et al. (2001) reports gender differ-
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ences in the efficacy of different types of counseling, showing systematically gender differences in the 
needs and benefits of bereaved men compared with bereaved women: Widowers benefit more from 
emotion-focused interventions, while widows benefit more from problem-focused interventions. 
However, the only determinant of grief persistence after an average follow-up of more than 6 years 
was a lower severity of baseline grief. Similar to our results, previous studies have reported that 
women grieve more frequently and in a more complicated way than men (Ofstedal, Reidy, & Knodel, 
2004). Beneria and Permanyer (2010) conducted an in-depth analysis of 43 participants (21 males 
and 22 female) at a Monrovia college fair. Findings revealed that men would rather not talk about 
grief because talking about the deceased would not help the situation while women thought other-
wise. Women considered interiorizing the loss was a bad thing and consider being extroverted about 
grief a positive way of dealing with it. Moreover, any emotional expressions about a loss were recog-
nized as weakness in men but not in women (Beneria & Permanyer, 2010). Other studies reported a 
higher level of bereavement among elderly women (Ofstedal et al., 2004). Second, we observed an 
association between kinship (who died) and grief severity. The spousal bereavement is reported as 
one of the most stressful events that anyone might experience, although its impact might diminish 
later in life than when it occurs during young adulthood or middle age (Holmes & Rahe, 1967; Moss, 
Moss, & Hanson, 2001). Two previous studies reported that even older bereaved spouses have higher 
rates of mortality and morbidity, impaired immune system, more depressive symptoms, more 
chronic conditions, and functional disabilities (Buckley et al., 2012; Fiske, Wetherell, & Gatz, 2009; 
Shahar, Schultz, Shahar, & Wing, 2001). Bonanno et al. (2002) stated that almost everyone experi-
ences an initial increase in grief symptoms, but for most people, these symptoms subside 18 months 
after the loss. Resilient widows and widowers generally are more accepting of death, more extraverted, 
more emotionally stable, and less dependent on spouses than their nonresilient peers (Spahni, Mor-
selli, Perrig-Chiello, & Benn ett, 2015). As about 50% of our participants experienced loss of the 
partner, we defined spousal bereavement as the reference group when studying the association be-
tween kinship and severity of grief. In the current study, loss of the partner is negatively associated 
with severity of grief, but we did not find a longitudinal association between kinship and grief persis-
tence. Third, we found that difficulties in activities of daily living were associated with less grief sever-
ity. Current literature in the field suggests that the more a person is active prior to spousal death, the 
easier the adjustment process may be (Utz, Carr, Nesse, & Wortman, 2002). Documenting the effects 
of widowhood on physical function and activity of older adults is important because significant de-
clines may place individuals at risk for compromised health (Utz et al., 2002). It is important to note 
that persistent strains prior to spousal loss (caregiving responsibilities) affect the well-being of wid-
owed elders (Schulz et al., 2001) and likely affect their willingness and ability to engage in the activity 
(Utz et al., 2002). Differences between our findings and those available in the literature might be due 
to the timing of measurement of disabilities and grief as the directionality of the presence of both 
cannot be disentangled adequately at baseline. Furthermore, our results were only observed once we 
adjusted for depressive symptoms. Thus, our findings must be interpreted as the direct effect of ac-
tivities of daily living on grief severity once the indirect effect via depressive symptoms is controlled 
for. Also, there might be other factors explaining these associations that were not collected during 
baseline exami- nation (e.g., environmental, social capital, networks) and that could add residual 
confounding to our analyses and results. It is important to note that persistent strains prior to spousal 
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loss (caregiving responsibilities) affect the well-being of widowed elders (Schulz et al., 2001) and 
likely affect their willingness and ability to engage in activity (Utz et al., 2002). However, more longi-
tudinal studies are needed to examine the levels of physical function and activity prior to spousal 
death as well as after spousal death in relation to grief severity and persistence. Furthermore, we 
would like to tackle with several points to raise awareness of the further possibility for research ques-
tions. Namely, we would like to point out several possibly relevant predictors of the grief that are not 
assessed in the current study: coping style, relationship with deceased (not kinship but closeness to 
the observed/interviewed person), and do on. Also, we noticed that predictors vary by group, that 
there is interaction triggered by whom you lost, as well as gender. Unfortunately, we have no power to 
detect mentioned interaction. Furthermore, grief severity captures many aspects and includes infor-
mation on potential predictors such as depression which opens a “chicken or egg” dilemma—what 
comes first. Further studies are necessary to assess predictors before bereavement, in particular, 
complicated grief. In the current study, reverse causality obscures relation that could otherwise have 
been observed (given the data set availability). In the longitudinal analysis, we observed that the 
baseline value of ICG score was independently related to grief persistence, whereas no independent 
associations were observed between CES-D and other correlates with grief persistence. Contrary to 
the CES-D questionnaire that assesses overall feelings of sadness and melancholy, the ICG question-
naire assesses specific coping abilities to loss of the loved one. We hypothesize that the baseline sever-
ity of grief captures psychological features that predict grief cessation such as poor coping, anger, and 
detachment from others. Bereaved individuals with good coping abilities might change their lifestyle 
leading to empowerment of self and present relationships, creating new ones, while preserving health 
and well-being (Neimeyer, 2006). However, further studies are needed to investigate whether differ-
ent coping mechanisms are related to grief severity and duration.Our prospective findings imply that 
complicated grief is a dynamic condition/state that changes over time. Though the previous study 
stated that up to 40% of grievers never recover and stay in complicated grief, for the rest of the griev-
ers it is expected that the symptoms get less severe (ICG < 22) or that they even completely stop 
feeling the grief (Goldsmith, Morrison, Vanderwerker, & Prigerson, 2008; Ott, Lueger, Kelber, & 
Prigerson, 2007; Piper, Ogrodniczuk, Azim, & Weideman, 2001; Prigerson et al., 1995). Our findings 
indicate that 7 out of 10 participants did not report any symptoms of complicated grief at follow-up 
which is in line with previous studies (Goldsmith et al., 2008; Ott et al., 2007; Piper et al., 2001; 
Prigerson et al., 1995). The major strengths of this study are prospective design and the population-
based setting. To the best of our knowledge, this is the study with the longest follow-up to explore the 
determinants of grief and complicated grief in a population-based study of older adults. Furthermore, 
this study did not restrict the relationship of the person who died to the participant. We took in an 
account all kinds of kinship and also loved ones (not family related). We took in an account all kinds 
of relationships wit dear persons (both familly and not-family). Period after the loss event triggering 
grief , varies greatly among our participants (oldest date of loss event: was July 15 th, 1947, while the 
date of the most recent lost event was December 15th, 2011). Within this interval, we have people 
who grieve over 60 years. This long postdeath period is also a strength of our study because it reflects 
the variation of the time frame of grief in the general population and there is no evidence for an opti-
mal cutoff to define maximum duration. Also, restriction of our analysis among participants, who 
scored lower than 26 points on MMSE, limited the possibility of misclassification of grieving status 
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and/or recall bias. Furthermore, the interview was conducted face to face in the privacy of the par-
ticipant’s own home by trained health care professionals and researchers, thus enhancing the reli-
ability and validity of complicated grief measurement. There are also some limitations to our study 
that need to be considered. First, the screening question which determined who undertook the ICG 
allowed participants the opportunity to identify themselves as grievers, which may inadvertently re-
sult in an over- or underestimation of the number of grievers. However, in a pilot study, we found that 
nongrievers cannot meaningfully reply to the questions. We found differences in the group of par-
ticipants grieving at the follow-up and the one that did not grieve anymore. Our nonresponse analysis 
showed that older persons and less healthy participants were more likely to be lost to follow-up. We 
might carefully infer that unhealthy persons were less likely to participate in the follow-up study, 
compared with the more healthy agers. Therefore, as inherent to all cohort studies, the possibility of 
health selection bias cannot be ruled out. This selection effect may bias our results and can impact 
generalizability to older and more frailer populations. Moreover, nearly all participants were of Cau-
casian descent. Therefore, the generalizability of our findings may be hampered. Another limitation 
of the current study might be the imprecise definition of grieving (asked within a time frame covering 
previous years which varies between participants) that did not consider individuals who experience 
someone’s death but did not feel that they were still grieving (emotional detachment from self as a 
modus of defend), and therefore selection bias might have been introduced. Also, while in the current 
study we have defined very precisely the state of complicated grief and persistent grief, there are 
challenges in operationalizing and distinguishing these conditions. Previous attempts have been taken 
to tackle this issue and different terms have been suggested, but a consensus has not been achieved yet 
(Boelen & Hoijtink, 2009). The continuation/persistence of all degrees of severity in grieving process 
needs more research effort in the future, in order to harmonize the definitions and distinctions be-
tween different grief status. In conclusion, among elderly, grieving is a life event often experienced. 
Female sex, lower education, depressive symptoms, and loss of a partner orchild were associated with 
grief severity. Among those grieving approximately 25% had persistent grief after 6 years, which was 
associated with the severity of bereavement. Further longitudinal studies are needed to confirm and 
further explore our findings and to identify whether more potential predictors of grief severity and 
duration exist. 
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The WHO reports show that 20% of adults aged 60 years and over suffer from a mental and/or neuro-
logical disorder that accounts for 6.6% of all disability (disability adjusted life years-DALYs) and account 
for 17.4% of Years Lived with Disability (YLDs) (WHO, 2016) among elderly adults. The most common 
neuropsychiatric disorders are dementia and depression (WHO 2016). As the population tends toward 
longer life, populations will get older and the negative impact of depression and the burden of age-
related neurodegerative diseases such as AD and PD will increase (Dorsey, George, Leff, & Willis, 2013; 
McGovern Institute for Brain Research, 2014). Obtaining care for these type of disorders is becoming 
more important as the population ages (Dorsey et al., 2013). Therefore, identifying risk factors and 
pathways that contribute to the development of neuropsychiatric diseases could shed more light into the 
complex pathophysiology of these diseases and would facilitate the development of preventive strategies 
to reduce the burden of these diseases. Numerous genes, molecular pathways and environmental factors 
have already been identified that partly explain the complex pathophysiology underlying neurodegen-
erative diseases. The role of epigenetic determinants, such as DNA methylation and histone modifica-
tions, is increasingly being recognized as a potential link between environmental exposure and disease 
risk. Thus, epigenetic determinants may be a benchmark to capture the influences of environmental 
exposure and risk of developing neurodegenerative diseases. Knowledge of epigenetic influences on 
development of neurodegenerative diseases may help further our understanding of the mechanisms of 
AD and PD. 
Sex is also increasingly being recognized as an important determinant of neuropsychiatric dis-
eases. Mental health problems such as depression and AD are more common in women than in men, 
and other neurological disorders such as stroke present more severely in women. Estrogen signaling 
and hormonal changes during menopause may play a role in the increased risk that women face 
regarding neuropsychiatric disorders, including alcohol misuse and dependence (Wen et al., 2016). 
Many elderly people experience the death of a loved one (Boelen & Hoijtink, 2009; Monk, Ger-
main, et al., 2008; Shear, 2015). Grieving, defined as the emotional process of coping with a loss, 
can lead to health problems including depression, chronic stress, and impaired daily functioning 
(Newson et al., 2011). Grief can also affect the neuroendocrine system, immune function, and sleep 
patterns. Consequentially, grief can worsen quality of life and reduce life expectancy. An estimated 
10-20% of elderly adults will suffer chronic and severe grief reactions, but the factors that contribute 
to serious symptoms of grief for prolonged periods of time are not understood. Understanding the 
determinants and predictors of grief cessation will help us to understand the most influential aspects 
of grief on everyday life, as well as identifying people at risk of severe or prolonged grief who may 
benefit from preventive strategies.
In this chapter I present an overview of the main findings of the studies in the thesis. I also provide 
suggestions for future research and the practical implications of the research. Furthermore, I discuss 
the methodological issues of the thesis.
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The role of DNA Methylation and histone Modifications in 
Neurodegenerative Diseases
Epigenetic mechanisms may account for the missing heritability determinants of complex diseases 
such AD and PD. Taking an epigenetic perspective in AD and PD research may provide new informa-
tion in the etiology and treatment of these neurodegenerative diseases. In general, epigenetic studies 
focus on global methylation, gene-specific DNA methylation and histone modifications. Global 
methylation refers to the overall level of methylcytosine in the genome, expressed as percentage of 
total cytosine. 
Global levels of DNA methylation increase in the first years of life and then decrease beginning in 
late adulthood. The fluctuation of levels of DNA methylation suggests that global methylation plays a 
role in healthy aging and age-related diseases (Jones, Goodman, & Kobor, 2015). In chapter 2.1, how-
ever, I found inconsistent associations between global DNA methylation pattern in blood and brain 
tissue and presence of AD and PD. Nevertheless, in brain tissue and/or peripheral blood, we found 
that epigenetic regulation of 31 genes involved in cell communication, apoptosis, and neurogenesis 
to be differentially methylated in individuals with AD and/or PD. Of those 31 genes, methylation 
at the genes brain derived neurotrophic factor (BDNF), Sorbin and SH3 Domain Containing 3 
(SORBS3), and Amyloid precursor protein (APP) were the most consistently associated with AD. In 
both peripheral blood cells and brain tissue, methylation of α-synuclein gene (SNCA) was also found 
to be consistently associated with PD. In our review, seven studies reported histone protein alterations 
in AD and PD, underscoring a gap in the literature concerning the role of histone modifications in 
neurodegenerative diseases. 
I identified several methodological concerns of the studies reviewed. The majority of the stud-
ies included in the review were cross-sectional assessments, making it difficult to draw conclusions 
regarding causality. Also, studies that investigate epigenetic dysregulation in AD and PD often suffer 
from small sample size, which may result in lack of statistical power and increased false discovery 
rates. In addition, the majority of studies were classified as low quality due to lack of proper adjust-
ments. The studies included in the review lacked adjustment for basic covariates including lifestyle and 
environmental factors, such as smoking and alcohol consumption, which are important risk factors 
for neurodegenerative disorders and can alter epigenetic mechanisms. Furthermore, the studies used 
a variety of techniques to assess epigenetic modifications that may produce heterogeneous results.
The functions of Estrogen receptor beta in the female brain
In chapter 3.1 estrogen loss associated with menopause may contribute to the development of neu-
ropsychiatric diseases (Dalal & Agarwal, 2015; Wend, Wend, & Krum, 2012). Emerging evidence 
indicates that estrogen provides important benefits in the female brain, including its role in learning, 
memory, mood, and neurodevelopmental and neurodegenerative processes (Gillies & McArthur, 
2010). All of the actions of estrogen in the human body are mediated by its two main receptors, alpha 
and beta (ERβ) (Deroo & Korach, 2006; Lee, Kim, & Choi, 2012; Paterni, Granchi, Katzenellenbogen, 
& Minutolo, 2014). The newly discovered ERβ is widely distributed in the female brain and may offer 
a new opportunity for pharmacological interventions to prevent and treat neuropsychiatric diseases 
General Discussion
241
Ch
ap
te
r 6
in women (Gogos et al., 2015; Nilsson et al., 2000; Peri & Serio, 2008; Warner & Gustafsson, 2015). In 
summarizing the evidence from 49 studies, we found that ERβ phosphorylated and activated intracel-
lular second messenger proteins and regulated protein expression of the genes that are involved in 
neurological functions. It also promotes neurogenesis, modulates the neuroendocrine regulation of 
stress response, confers neuroprotection against ischemia and inflammation, and reduces anxiety- 
and depression-like behaviors. Also, ERβ may induce a significant reduction of hippocampal Apoli-
poprotein E, and may help to maintain hippocampal function, suggesting a protective effect of ERβ 
in AD. Further, ERβ may be a target for treatment of memory impairment conditions. (Figure 1.)
ApoE mRNA: 
•	 Alzheimer’s	disease
75 
 
Figure 2 Potential pathways for ERβ function in the female brain. 
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figure 1. Potential pathways for ERβ function in the female brain.
Legend: mRNA, Apolipoprotein E messenger RNA; HPA, hypothalamus-pituitary-adrenal; IDE, insulin-
degrading enzyme; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; NMDA, N-Methyl-
D-aspartic acid; Akt, Protein kinase B; MAPK, Mitogen-activated protein kinase; ERK, extracellular 
signal-regulated kinases; CREB, c-AMP response-element binding protein.
Overall, the data we reviewed showed that targeting ERβ may be a novel treatment for menopausal 
symptoms including anxiety, depression, and neurological diseases. However, since all studies have 
been based on animal models, these findings contribute to hypothesis generation. Caution should be 
taken when extrapolating the results of this review to human subjects. Studies in humans may confirm 
whether isoform-selective ERβ-ligands could be a therapeutic target for prevention and treatment of 
neuropsychiatric diseases. We did not find any studies that examined whether ERβ signaling may differ 
by age or menopausal status. Studies in tissues other than the brain, such as in the cardiovascular system 
have shown that age and menopause status may play a role in ERβ signaling (Muka et al., 2016). 
242
Chapter 6
Menopause, Ageing and Alcohol use Disorders in Women 
In chapter 3.2 I provide an overview of the prevalence of drinking patterns and dependence, risk fac-
tors, health impacts and treatment challenges for women as they progress through middle and older 
age. Moderate drinking frequency and alcohol intoxication is higher in younger women, compared 
to older women. As the disparity between men’s and women’s rates of alcohol consumption decreases 
and as women’s life expectancy increases, we may see a higher number of female drinkers and a 
greater impact of alcohol problems and dependence in women (Geels et al., 2012). The prevalence 
and impact of older female drinkers is expected to increase as members of the Baby Boomer genera-
tion reach older age and younger generations move toward older adulthood. Younger generations 
have greater parity in alcohol consumption between the genders and women’s alcohol consumption 
is also increasing for other reasons (Sanjuan & Langenbucher, 1999., Wilsnack, & Wilsnack, 1994). 
Moderate drinking frequency and alcohol intoxication has increased in both genders over time, but 
the increase has been greater among women. (Makela, Tigerstedt & Mustonen, 2012)
There are also differences between men and women in the metabolism of alcohol. As a result, it 
generally takes less alcohol to cause somatic and psychological harm in women than it does in men. 
Thus, women are more vulnerable to alcohol’s harmful effects, and tend to develop alcohol-related 
diseases and other consequences of drinking sooner than men, and after drinking smaller cumulative 
amounts of alcohol. Additionally, as women age and go through menopause, they face new health 
and societal challenges such as menopause, retirement, and illness, all of which make them more 
susceptible to the effects of alcohol misuse. Lean body mass decreases with age and women experi-
ence an increase in body fat after menopause, so total body water also decreases. For this reason, 
after menopause the same amount of alcohol that previously had little effect on a woman can cause 
intoxication (Vestal et al., 1977). 
Several observational studies have reported a J-shaped association between alcohol consumption 
and various health outcomes (e.g. cardiovascular disease), while other studies have shown a clear 
dose-response relationship between alcohol consumption and other health outcomes (e.g. for cancer) 
(Figure 2). 
Probably due to the pro-estrogenic effect of alcohol, low levels of alcohol can delay menopause onset 
and reduce the risk of menopause-related diseases such as osteoporosis, diabetes and cardiovascu-
lar disease. Alternatively, consumption of high amounts of alcohol can reverse these benefits. The 
current research does not establish causality between alcohol consumption and health impacts, nor 
does it distinguish between the effects of different types of alcoholic beverages (e.g. beer, wine) on 
health. Despite the potential favorable effects of alcohol, even low-risk drinking (e.g. one standard 
drink per day) can lead toward alcohol dependence. Due to stigma and social inequalities women 
may have more difficulty gaining access to treatment for alcohol dependence. Current research on 
women-specific interventions and for prevention and treatment aimed at reducing alcohol consump-
tion and alcohol dependence in middle-aged and elderly women is limited. Future research should 
aim to identify female-specific treatment options that take into account the challenges associated 
with woman’s life stage and circumstances related to alcohol consumption. Clinical trials should 
be designed and implemented in which women of different ages and with different socioeconomic 
background are represented. Another avenue of future research could be the potential interactions of 
alcohol consumption and pharmacological medications or other drugs. . 
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•	 Improve	one	health
•	 Increases	risk	of	cancer
•	 Nerocognitive	functions/Neurodegenerative	diseases2
figure 2. Dosage dependent risk factors and benefi ts of moderate intake 
1. Low drinking: less than 1 alcoholic drink for men and women in any single day, and a maximum of 7 
drinks for men or 3 drinks for women per week; Moderate drinking: up to 4 alcoholic drinks for men 
and 3 for women in any single day, and a maximum of 14 drinks for men and 7 drinks for women 
per week; Severe drinking: 4 alcoholic drinks for men and 3 for women in any single day, and a maxi-
mum of over 14 drinks for men and over 7 drinks for women per week. One unit of alcohol is defi ned 
as 10ml (8g) of pure alcohol.
2. Current Evidence is not persuasive for a benefi cial eﬀ ect of low/moderate alcohol consumption on 
cognitive functions and/or risk of developing neurodegeneratie diseases
Th e impact of Complicated Grief on Diurnal Cortisol Levels 
In chapter 4.1 by using data from a population-based study I investigated whether diurnal cortisol se-
cretion diff ered in persons with normal grief, complicated grief, and those who have not experienced 
grief in the past 2 years. As hypothesized, participants who had complicated grief two years aft er their 
initial loss showed lower levels of morning cortisol and lower overall diurnal cortisol exposure than 
did the participants with normal grief or without grief. Persons with normal grief showed similar 
cortisol secretion patterns as those without grief. A previous study of complicated grief and diurnal 
cortisol showed that those with complicated grief have less oscillation in cortisol levels across the day 
(Yehuda, 2006). However, neither morning cortisol nor AUC had been examined in persons with 
complicated grief. Moreover, no eff ect of grief or complicated grief on cortisol secretion patterns 
was observed. Since higher levels of cortisol are known to appear in acute stress phase, it may be 
presumed that a person with more severe grief had a more acute/severe reaction at the moment of 
loss, while, over time, the cortisol secretion may normalize. Th is suggests that with a longer period of 
grieving, the association between grief and cortisol may attenuate. We might argue, then, that a cop-
ing mechanism helps to resolve the most severe grief consequences over time and even complicated 
grief is no longer an acute stressor. We can only carefully speculate about mechanisms of coping 
with grief, as has already been suggested in previous studies (Bremner et al., 1997; Stein et al., 1997; 
Yehuda et al., 1991; Boelen et al., 2006). Eff ects on the HPA axis may be visible aft er several months 
or even years only if a person develops complicated grief or has risk factors for complicated grief, 
such as a dependent relationship with the dead person, unexpected death, lack of social support, and 
the loss of someone who was ambivalently loved (Maciejewski et al., 2007). Th e signifi cance of the 
study I performed is that it revealed that cortisol, which is involved in cognitive functions such as 
memory performance and executive function and regulates the infl ammatory responses, is altered in 
244
Chapter 6
persons experiencing complicated grief (Bonanno et al., 2002; Hek et al., 2011; Lovallo 2005; Parkes, 
1998).The finding implies that persons with complicated grief may be more vulnerable to developing 
cognitive problems (Maciejewski et al., 2007) depression, and medical conditions than are persons 
with normal grief. Follow-up studies are needed, however, to demonstrate the clinical consequences 
of these observations.
Grief and Sleep Quality in Older Adults
In chapter 4.2, I explored the cross-sectional and longitudinal associations of grief and complicated 
grief with sleep quality in older adults. Cross-sectional findings showed that normal and complicated 
grief were associated with shorter sleep duration and lower sleep quality. Complicated grief can be 
regarded as a bereavement situation in which sleep duration is likely to be affected (Doi, Minowa, 
Okawa, & Uchiyama, 2000; Monk, Germain, et al., 2008). Sleep disturbances are particularly preva-
lent in depressed bereaved persons; even bereaved persons who fail to meet a formal diagnosis of 
depression have measurable sleep impairment (Reynolds et al., 1992). Indeed, the cross-sectional 
analysis showed that the association between grief and complicated grief with sleep indicators was 
largely explained by depressive symptoms. Prospectively, however, I did not find an association be-
tween grief and sleep parameters. The results may be explained by the mechanisms of adaptive coping 
(Stroebe & Schut, 1999), which the grieving participants develop during prolonged exposure to grief. 
Participants who were evaluated in a follow-up assessment around six years after their initial loss 
demonstrated that grieving persons may reach a “stable state” in which they experience no further 
change in sleep quality. Also, another explanation for these findings may be that sleep quality had 
deteriorated before the onset of complicated grief. We did not conduct pre-bereavement sleep assess-
ment in this study, so it was not possible to evaluate the bi-directional effects in the cross-sectional 
analysis, i.e., whether bereavement triggered the decline of sleep duration and quality or whether 
sleep impairment preceded the grief reaction. Further studies should be performed applying a bi-
directional analysis to distinguish whether causal effects are presents. 
bereavement and Quality of Life 
In chapter 4.3 we explored the association between bereavement and QoL. The death of a loved one 
leads to grief characterized by yearning and longing, decreased interest in ongoing activities, and 
frequent thoughts of the deceased which can hamper the quality of life (QoL). Therefore, I aimed to 
synthesize all available evidence on various forms of grief in relation to QoL. Overall, I found that 
different types of bereavement and bereavement severity are associated with lower QoL. Subjects with 
complicated grief, a disorder characterized by persistently high levels of bereavement, experience per-
sistent deficits in QoL. Additionally, these findings suggest that bereavement may be associated with 
QoL in a gender-specific manner, with female grievers having lower QoL. These gender differences 
might also be explained by multiple adaptive mechanisms, relation or compliance, and differences in 
male/female social support/network, (Caetano, Silva, & Vettore, 2013) each of which merits further 
investigation. Also, our study indicated that QoL in bereaved family members was significantly lower 
than in controls. Our study is the first attempt to systematically review and critically appraise the 
literature on the subject and pool the existing studies that evaluated the associations of bereavement 
with overall QoL, but the evidence is limited and hampered by the scarcity and suboptimal quality of 
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the studies in the topic. Therefore no firm conclusion can be drawn and the findings we reported do 
not carry any implications on causality because all the included studies are observational.
Determinants and predictors of Grief Severity and persistence
After 6 to 12 months, most bereaved persons adapt to the loss. The demonstrate a reduction in grief 
intensity and a return to a different but meaningful and satisfying life without the deceased (Bonanno 
et al., 2002). However, for some bereaved individuals, the adaptation might be complicated, slowed, 
or halted, leading to persistence of grief (Boelen & van den Bout, 2008; Shear et al., 2007). Persistent 
grief is associated with lower QoL and increased risk of chronic disease, including cardiovascular 
disease and cancer (Zisook & Shear, 2009). It is important to identify factors associated with persis-
tent grief in order to identify the population at risk of developing prolonged or complicated grief to 
provide them with support and adequate treatment. In chapter 5.1, I investigated the factors related 
to grief severity in cross-sectional analyses. I also investigated the determinants of grief cessation 
in longitudinal analyses, within a population-based study of middle-aged and elderly persons. Our 
cross-sectional results show that female sex, loss of a child, lower education, higher depressive 
symptoms, and difficulties in daily activities were associated with grief severity. However, in the lon-
gitudinal analysis, grief severity was the only predictor significantly associated with grief persistence. 
We hypothesize that the baseline severity of grief captures psychological features that predict timing 
of grief cessation, such as poor coping, anger and detachment from others. Bereaved individuals with 
good coping abilities might change their lifestyle leading to empowerment of self, focusing on exist-
ing and new relationships, while preserving their health and well-being (Neimeyer, 2006). Further 
longitudinal studies are needed to confirm and further explore these findings and to identify whether 
more potential predictors of grief severity and duration exist. 
METhODOLOGiCAL CONSiDErATiONS
Assessment of Grief Severity within Limitations of the Current instruments 
and Terminology
Considering the nature of complicated grief and its impact on health, concerns about the definition 
of complicated grief and how it should be defined have been raised in several studies and by different 
authors (Beroud, Ferry, Henzen, & Sentissi, 2014; Lombardo et al., 2014; Maciejewski, Maercker, 
Boelen, & Prigerson, 2016). In the literature, there is a range of terms used to describe variations 
in normal grief, as well as operationalizing and distinguishing complicated grief. Uncertainties in 
terminology and conceptual confusion make it difficult for researchers and health care providers to 
interpret the data on grief and implement new clinical findings into practice. Healthcare profession-
als use a vast spectrum of terms to describe complicated grief, including prolonged grief disorder, 
persistent complex bereavement disorder, complicated grief disorder (CGD), pathological grief, 
traumatic grief, atypical grief, and delayed grief. All these terms are synonymous and introduce dif-
ficulties in interpreting the results across studies. However, in recent years there has been an increase 
in consistency in defining the condition of complicated grief and identifying consistent measures to 
assess the condition (Lobb et al., 2010). 
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In the studies presented in this thesis, I have defined the state of complicated grief and how it 
differs from normal and persistent grief with precision (Chapter 4). We diagnosed complicated grief 
based on a modified Dutch version of the 19-item Inventory of Complicated Grief (ICG) (Prigerson 
et al., 1995). To be diagnosed with complicated grief, participants underwent face-to-face interviews. 
They were asked if in the past two years they had lost someone over whom they were still grieving. If 
yes, these participants were classified as grievers and were further assessed with the ICG to measure 
grief severity. Complicated grief symptoms were assessed as present amongst participants who scored 
equal to or greater than 22 on the ICG score and who grieved for longer than 6 months (Newson et 
al, 2011; Saavedra Perez et al, 2015). The use of a slightly modified version of the original ICG might 
have introduced some issues in defining complicated grief and its validity. However, in a pilot study, 
we found that the measure has high internal consistency and convergent and criterion validity, dem-
onstrating that this tool can be widely used in a population-based and observational setting as ours 
(Newson et al., 2011). The screening/preliminary question that determined which participants would 
take the ICG, functionally allowing participants to identify themselves as grievers, may have resulted 
in an over- or underestimation of the number of grievers. However, the opportunity to self-define a 
griever should not affect the number of cases diagnosed with complicated grief. On the other hand, a 
limitation of our study was the lack of tool to assess grieving status in a normal manner. Moreover, as 
with any questionnaire, and considering the time that measurements were undertaken and the use of 
self-report data, recall bias, measurement error and possibly non-differential misclassification in grief 
status might be present. However, this is likely to bias results towards the null.
Limitations of Sleep Assessment 
In the study presented in Chapter 4 I investigated the association between grief status and sleep 
parameters. I did not have available objective measures of sleep duration nor of overall sleep quality. 
Sleep duration was self-reported and assessed by the following question: “During the past month, 
on average, how many hours of actual sleep did you get at night?” This question is extracted from 
the PSQI interview, while the subjective sleep quality was assessed using the whole Pittsburgh 
Sleep Quality Index (PSQI). The PSQI is a self-rating questionnaire that measures sleep quality and 
disturbance retrospectively over a 1-month period, resulting in a global score between 0 and 21. 
Higher values of the PSQI score indicate poorer sleep quality. These data were gathered based on 
the patients’ recall of how many times they woke up or how long they slept during the night, which 
could have introduced recall bias and misclassification of sleep outcomes. While questionnaires are 
easy to perform and are not costly, the optimal methodology to assess sleep would be to use poly-
somnographic measurements of sleep. However, polysomnographic measurements for more than 
one night are hardly feasible in large studies. Unfortunately, polysomnographic measurements in the 
Rotterdam Study were not performed at the time of our research, and now they are available only on 
a limited number of participants (N=1000), who do not overlap with assessments of the Rotterdam 
Study we used for our analysis (Luik, Zuurbier, Whitmore, Hofman, & Tiemeier, 2015). Alternatively, 
despite the fact that it does not measure sleep quality, we could have used actigraphy to obtain objec-
tive sleep duration. Actigraphy is a method that infers wakefulness and sleep from the presence or 
absence of limb movement. It estimates sleep duration more accurately than do sleep diaries and 
agrees reasonably with polysomnography((NIAAA), 2006). In a pilot study using Rotterdam Study 
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data, we found substantial discrepancies between self-reported and actigraphic sleep duration. We 
found that the differences between the two assessment types are not random, and, rather, depend 
on age, sex, depressive symptoms, cognitive function and functional disability (Van den Berg et al., 
2008). As these determinants are likely to be associated with grief status as we show in this thesis, this 
phenomenon may bias the results. Therefore, in our study on grief and sleep presented in Chapter 
4, the subjective measurements we used to assess sleep duration and quality might be the reason for 
the spurious associations we found cross-sectionally. Alternatively, the subjective measurements may 
have obscured the true associations that we did not find in the longitudinal assessment. Therefore, use 
of multiple measures of sleep duration and quality can help to examine the consistency of the results 
over assessment methods.
residual Confounding
A confounder is a factor (variable) that influences both the dependent variable and independent 
variable, and is not an intermediate in the causal pathway between the exposure and outcome. In 
observational studies, when a confounding factor is not taken into account, biased estimates may be 
obtained. In order to rule out possible confounding bias, in all our analyses we adjusted for multiple 
potential confounders, which were selected based upon previous studies. Nevertheless, since our 
studies are observational, the problem of residual confounding might still be present. Some of the 
confounders that were not considered in the studies based on original data and presented in Chapter 
3 and 4 might be some psychiatric diagnoses (such as Generalised Anxiety Disorder, Post Traumatic 
Stress Disorder or Panic Attacks), somatic diagnosis as cancer, physical activity, and frailty index at 
the time when grief status was assessed. Therefore, the results in these studies might be explained by 
residual confounding. Residual confounding, depending on how the unmeasured factor related to 
exposure and outcome can lead either to overestimation or underestimation of the observed effect 
estimate. 
Analysis of Longitudinal Data
power 
Sample size and statistical power estimate are fundamental for designing and conducting a study 
because they determine the strength of the association between the exposure and outcome of interest. 
As in most observational studies, we do not have access to the entire population of interest, so it is 
difficult to obtain optimal sample size and statistical power. To have more robust estimates of the 
outcomes in question, a large sample size is needed so that sampling error will be reasonably small. 
Studies characterized by small sample size will result in effect estimates that are too imprecise to be 
of much use outside the very specific sample. In longitudinal studies, power analysis is more chal-
lenging and complex because several factors such as number of repeated measurements and levels of 
missing data can affect the estimates of the required sample size. In this thesis, the studies presented 
in Chapters 4 and 5 have a smaller sample size compared to our cross-sectional analysis due to low 
response rate or loss of follow-up. Therefore, the studies in Chapters 4 and 5 may have limited power 
to detect an association. However, based on our power analysis, we had sufficient power to show 
consistent longitudinal effects. Including more participants with grief and complicated grief in the 
study presented in Chapter 5 might have strengthened the findings. 
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reverse Causality 
Longitudinal analysis, in contrast to cross-sectional design, reduces the risk of reverse causality. 
Reverse causality happens when the outcome causes changes in exposure. In our studies, for example, 
we cannot rule out that existing sleep problems or alterations in hypothalamic–pituitary–adreno-
cortical axis activity and cortisol levels make individuals vulnerable to more severe or prolonged 
grief or complicated grief. Indeed, as Boelen and Lancee (Boelen & Lancee, 2013) have pointed out, 
poor sleep quality is a known risk factor for many different forms of a psychopathology, including 
depression and PTSD. However, we performed sensitivity analyses in our studies to examine whether 
reverse causality could influence our results. For instance, in the longitudinal analysis investigat-
ing the association between grief and sleep parameters we excluded people who had poor sleep at 
baseline in order to explore the possibility of reverse causality. This sensitivity analyses provided no 
evidence of reverse causality. 
Missing Data and Selection bias 
Issues stemming from missing data in observational studies are unavoidable, particularly in prospec-
tive studies. Data may be missing due to loss to follow-up, low response rate, or because participants 
were not invited to follow-up assessments. In the studies presented in chapters 4 and 5, we identified 
some missing data on exposure and/or outcomes, which might have introduced selection bias and 
might have influenced the validity of our results. The participation rate in all of our original studies 
was not 100%, but was always satisfactory. However, in the longitudinal analysis on grief and sleep 
selection bias is unlikely because (non) participation was neither associated with the self-reported 
grief status, nor with sleep duration/quality. In our longitudinal analysis on determinants of grief 
cessation, the non-response analysis showed that older persons and less healthy participants were 
more likely to be lost to follow-up. We might carefully infer that unhealthy persons were less likely to 
participate in the follow-up study, compared to the healthier individuals. Selection effects may have 
led to the inclusion of more grievers with healthy coping style whose loss events occurred long ago. 
It has been shown that using a selected source population for a cohort study usually leads to bias 
towards the null, but may affect the generalizability of our results to older and frailer populations 
(Brunner, Stallone, Juneja, Bingham, & Marmot, 2001).
bias and heterogeneity in Systematic reviews 
Bias might be present in all studies, and systematic reviews are subject to the same biases as those pres-
ent in the original studies included in the review, as well as all biases related to the systematic review-
ing process. Biases included publication bias, language bias, and biases that arise from poorly defined 
methodology can be present when performing a systematic review. However, in the systematic review 
included in this thesis, we followed an a priori protocol with clearly defined inclusion and exclusion 
criteria. Further, we tried to minimize the impact of publication bias by employing a thorough search 
strategy in six databases in which no language or date restrictions were applied, with the help of an 
experienced librarian. Also, we checked reference lists of identified studies and contacted experts in 
the field. An unavoidable problem in systematic reviews is the heterogeneity of the included studies. 
Study heterogeneity can arise when performing a systematic review and can limit the opportunity to 
undertake a meta-analysis. It is unavoidable that a systematic review of studies will include heteroge-
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neous studies, comprised of different design, interventions, population characteristics, and exposure 
and outcome definitions. Study heterogeneity must be considered, evaluated and reported in studies 
that summarize the evidence. In the reviews included in this thesis, it is possible that effect estimates 
from individual studies cannot be combined, due to the high identified heterogeneity. Heterogeneity 
in the input parameters (e.g. exposure and outcome assessments) made pooling of the existing data 
unfeasible. Further, the generally small number of studies limited our opportunity to obtain summary 
estimates or to use subgroup analysis involving various study-level characteristics (ethnicity, age, etc.) 
to extensively explore the potential sources of heterogeneity that could be observed when pooling 
results from different studies. Lastly, the results inferred in the systematic reviews we performed 
should be interpreted with caution since they are limited by the quality of the individual published 
studies included in the review.
fuTurE rESEArCh
The role of DNA Methylation and histone Modifications in 
Neurodegenerative Diseases
Our systematic review reported epigenetic regulation of 31 genes (including cell communication, 
apoptosis, and neurogenesis genes in blood and brain tissue) and their relationship to AD and PD. 
Although there have been some promising results in the fields of epigenetics and neurodegenerative 
diseases, challenges related to study design, harmonized methodology of assessment, tissue hetero-
geneity and others are still present. Due to the mostly cross-sectional design of the included studies, 
inadequate adjustment for relevant confounders, and lack of replication in the case of new findings, 
many questions remain about the temporal relationship between epigenetic modifications and neu-
rological diseases, as well as the significance of the findings in disease pathology. Therefore, studies 
in larger cohorts with longitudinal design and repeated measurements of epigenetic marks, includ-
ing proper adjustment for multiple confounders may help to identify epigenetic changes that have 
clinical significance and could lead to strategies for intervening in neurological diseases. Further, to 
establish a causal direction between epigenetic marks and disease, Mendelian Randomization (MR) 
methods can be helpful. MR is considered to be a ‘natural’ randomized control trial since it uses 
common genetic polymorphisms as instrumental variables for the exposure of interest. Additionally, 
the distribution of genetic variation is thought to be unrelated to confounders, which are a common 
source of false positives in epidemiological studies. Currently, varied methods are being used to assess 
epigenetic marks. The use of similar methylation assessment methods in future studies is important 
so different studies’ results can be compared effectively. Combination with eQTL mapping may also 
have a more precise overview on which epigenetic marks determine differential expression and thus 
disorder symptoms. Finally, future studies should explore further areas of epigenetic regulatory 
mechanisms beyond DNA methylation, including histone modifications, which remain very poorly 
characterized in the context of neurodegenerative diseases.
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The functions of Estrogen receptor beta in the female brain
Our research showed that ERβ has multiple functions in the female brain. Nevertheless, because the 
current evidence on this topic comes from animal studies, one should be cautious in extrapolating 
those findings to humans. To establish potential therapeutic and preventive strategies targeting ERβ 
and to further our understanding of the importance of ERβ in women’s mental health, future studies 
should be conducted in humans. Longitudinal studies in humans should examine whether levels 
of ERβ in blood relate to improved mental health in women, including lower levels of depression, 
anxiety, and sleep disorders, all of which are common symptoms in women during the menopausal 
transition. Also, clinical trials should be designed and implemented to investigate whether ERβ 
ligands can confer the neuroprotective effects of estradiol in postmenopausal women, avoiding its 
specific adverse effects on other tissues such as those of uterus and breast, as well as on risk of diabetes 
and cardiovascular disease.
Menopausal Transition and Alcohol use Disorders 
I aimed to evaluate whether women have an increased risk of alcohol abuse during the menopausal 
transition and postmenopausal period (chapter 3 .2). However, there is a lack of studies that inves-
tigate women-specific treatment strategies, so further studies about gender differences in alcohol 
intake are necessary. Clinical studies should focus more on identifying and confirming some pre-
dictors of treatment retention in women. Some known predictors are pre-treatment characteristics, 
such as referral source, psychological functioning, personal stability, and number of children. These 
pre-treatment characteristics may be important predictors of length of stay or treatment completion. 
Future research should also aim to provide more insight into Naltrexone (Vivitrol) based treatments 
and explore the role of a “polypragmatic” approach in pharmacotherapy by identifying additional 
harm or benefits from sedatives and SSSRI medications. 
The impact of Complicated Grief on diurnal cortisol levels, sleep quality and 
overall quality of life
During the lifespan, people are likely to experience the loss of a close person. Evidence suggests 
that several factors that are associated with bereavement can cause poor health, including adverse 
cardiometabolic health and increased risk of mortality. Losing a dear person can be very stressful, so 
the first stages of bereavement are often accompanied by an acute stress-type response. Thus, we were 
interested to see how grief status is related to levels of the stress hormone cortisol. In our study, we 
did not find an association between grief and cortisol levels. However, cortisol findings were based 
on saliva samples, so we suggest that future research might further explore how grief status relates 
to serum levels of cortisol that were not available in this study. Additionally, future research in this 
area might be more informative if they use repeated measurements of cortisol levels, in order to in-
vestigate longitudinal effects of grief process on cortisol. Cortisol, which is balanced by the hormone 
dehydroepiandrosterone (DHEA), weakens the immune system as it has stimulatory effect on the 
immune function (Khorram, Vu, & Yen, 1997). Levels of DHEA sharply decrease around the age of 
30, and thus leave the immune system more vulnerable to cortisol’s influence in times of stress. Future 
studies should also investigate the association between DHEA and cortisol, as well as how grief could 
impact their respective levels. It may also be interesting to examine whether DHEA and cortisol 
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play a role in the severity of grief and grief cessation. Similarly, research on grief and sleep should 
use more accurate and objective measures of sleep duration and quality, such as polysomnographic 
measurements, as well as repeated measurements of sleep parameters. These changes in study design 
would help to determine the longitudinal and directional effects: whether bereavement triggered the 
change in hormone levels, or vice versa. 
Our review on bereavement and QoL shows that different types of bereavement and bereavement 
severity are associated with QoL, and that women might experience lower QoL than men. However, 
the magnitude of the effect on the association between bereavement and QoL is difficult to assess 
because of the scarcity of evidence, the low quality of the studies available, and the large heterogeneity 
in bereavement assessment, type of bereavement and QoL measures used, study design and quality. 
Factors such as recall bias and the challenges of objective interpretation of emotional status might 
hamper the quality of recording grieving states and require consideration in future study design. 
Objective interpretation of emotional status in particular is difficult because severe bereavement may 
be under-reported and should be assessed and re-assessed by healthcare professionals. 
Beyond the caution needed in interpretation of grief length and severity, future studies should also 
consider other social, emotional, and health-related factors associated with grief. For instance, most 
studies define the state of grief as “present” or “absent” after the loss event, not taking into account 
the severity of grief and its duration (complicated grief or prolonged grief disorder). The continuation 
or persistence of degrees of severity in bereavement need more research in order to harmonize the 
definitions and distinct different bereavement status. Moreover, it is necessary to harmonize bereave-
ment and QoL assessment, and to design better studies that adjust for a broad range of confounders 
and select a representative sample. Prospective studies are required before any level of causality can be 
inferred from the existing findings, and residual confounding may explain the associations observed. 
Taking into account all these methodological considerations, future research may provide a more 
reliable assessment of the association between bereavement and QoL.
Determinants and predictors of Grief Severity and persistence
Our cross-sectional results show that female sex, loss of a child, lower education, higher depressive 
symptoms, and difficulties in completing daily activities were associated with grief severity. However, 
in the longitudinal analysis, only grief severity predicted grief persistence (chapter 5.1). Therefore, 
analysis in future studies might include more potential predictors such as physical activity, frailty 
index, nutrition, socio-economic status, ethnicity and other comorbidities (e.g.CA, GAD and panic 
attacks), as well as hormone levels and different biomarkers. Moreover, larger cohort and longitudinal 
studies with sufficient power are necessary to identify other potential predictors of grief severity and 
persistence.
iMpLiCATiONS fOr TrEATMENT AND prEVENTiON 
We reported that several epigenetic marks in brain and blood tissue were associated with AD and PD. 
Methylation profiling in peripheral blood has great potential to identify neurological disorders-related 
methylated regions. Methylation profiling has potential clinical utility since it may allow clinicians to 
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identify high-risk individuals who may benefit from preventive and therapeutic interventions. Also, 
increasing our knowledge of environmental-related epigenetic marks may be used for early detection 
and primary prevention of the global burden of neurodegenerative diseases. Implementing reliable 
tools to track lifetime exposure at both population and individual levels will allow scientists to dissect 
and understand epigenetic variations and how they may affect the risk of neurodegenerative disease 
and treatment efficacy. Epigenetic modifications, unlike genetic changes, are usually reversible. 
Therefore, they may represent an important target for therapeutic intervention in neurodegenerative 
diseases. 
Overall, our results on ERβ show abundant functions of ERβ in the female brain and support the 
notion that future therapies targeting ERβ could constitute a novel preventive strategy and treatment 
for neurological diseases in females. ERβ agonists might mimic the actions of 17β-estradiol in the 
brain without causing other physiological responses mediated by other estrogen receptors. In view 
of the high burden of depressive disorders and neurodegenerative disease, and despite advances in 
their prevention and treatment, transfer of these novel therapies into the field of neurological diseases 
could constitute a suitable alternative in the future. 
So far, achievements in alcohol abuse treatments are based on the outdated and debunked “alco-
holism” model that observes alcoholism as a singular disease, without variation related to age, gender 
or setting. Women who are perimenopausal, menopausal, and postmenopausal alcohol users have a 
higher risk of severe comorbidities and alcohol abuse. As every subpopulation has its own specificities 
in overall health status and behavioral/cultural patterns in alcohol consumption, future behavioral 
and pharmaceutical treatment should be gender and age-targeted. Specific treatment programming 
may enhance treatment retention among certain subgroups of women. 
Finally, as aging populations might be increasingly exposed to the loss of a dear person, clinical 
settings should target the early diagnosis of complicated grief. Even more important, behavioral and 
pharmaceutical prevention treatments should be based on initial severity of grief. In line with this 
theory, our results on the determinants of grief indicate that targeting patients with an ICG score over 
22 in acute grief phase (latest at 6 months after a loss) may prevent the development of complicated 
grief and reduced quality of life. Also, if our findings on the association between bereavement and QoL 
are replicated in future studies, it may imply that QoL and bereavement are two different constructs, 
and thus QoL could be assessed as an additional intervention/treatment outcome. For example, 
researchers and providers evaluating bereavement care interventions might consider including QoL 
outcome measures in their projects.
General Discussion
253
Ch
ap
te
r 6
rEfErENCES 
 1. National Institute on Alcohol Abuse and Alcoholism (NIAAA). (2006). Alcohol Alert - National 
Epidemiologic Survey on Alcohol and Related Conditions. Retrieved from https://pubs.niaaa.nih.gov/
publications/AA70/AA70.htm.
 2. Beroud, J., Ferry, M., Henzen, A., Sentissi, O. (2014). [Grief, evolution of new definitions].Deuil, evolu-
tion conceptuelle et nouvelles definitions. Rev Med Suisse, 10(420), 565-568.
 3. Boelen, P. A., Van den Hout, M. A., Van den Bout, J. (2006). A cognitive-behavioural conceptualization 
of complicated grief. Clin Psychol Sci Prac, 13, 109–128.
 4. Boelen, P. A., Hoijtink, H. (2009). An item response theory analysis of a measure of complicated grief. 
Death Stud, 33(2), 101-129. 
 5. Boelen, P. A., Lancee, J. (2013). Sleep Difficulties Are Correlated with Emotional Problems following 
Loss and Residual Symptoms of Effective Prolonged Grief Disorder Treatment. Depress Res Treat, 739-
804.
 6. Boelen, P. A., van den Bout, J. (2008). Complicated grief and uncomplicated grief are distinguishable 
constructs. Psychiatry Res, 157(1-3), 311-314. 
 7. Bonanno, G. A., Wortman, C. B., Lehman, D. R., Tweed, R. G., Haring, M., Sonnega, J.,Nesse, R. M. 
(2002). Resilience to loss and chronic grief: a prospective study from preloss to 18-months postloss. J 
Pers Soc Psychol, 83(5), 1150-1164.
 8. Bremner, J. D., Randall, P., Vermetten, E., Staib, L., Bronen, R. A., Mazure, C., Capelli, S., McCarthy, G., 
Innis, R. B., Charney, D. S. (1997). Magnetic resonance imaging-based measurement of hippocampal 
volume in posttraumatic stress disorder related to childhood physical and sexual abuse--a preliminary 
report. Biol Psychiatry. 41, 23-32.
 9. Brunner, E., Stallone, D., Juneja, M., Bingham, S., Marmot, M. (2001). Dietary assessment in Whitehall 
II: comparison of 7 d diet diary and food-frequency questionnaire and validity against biomarkers. Br J 
Nutr, 86(3), 405-414. 
 10. Caetano, S. C., Silva, C. M. F. P., Vettore, M. V. (2013). Gender differences in the association of perceived 
social support and social network with self-rated health status among older adults: a population-based 
study in Brazil. BMC Geriatrics, 13(1), 122. 
 11. Dalal, P. K., Agarwal, M. (2015). Postmenopausal syndrome. Indian J Psychiatry, 57(Suppl 2), S222-
S232. 
 12. Deroo, B. J., Korach, K. S. (2006). Estrogen receptors and human disease. J Clin Invest, 116(3), 561-570.
 13. Doi, Y., Minowa, M., Okawa, M., Uchiyama, M. (2000). Prevalence of sleep disturbance and hypnotic 
medication use in relation to sociodemographic factors in the general Japanese adult population. J 
Epidemiol, 10(2), 79-86. 
 14. Dorsey, E. R., George, B. P., Leff, B., Willis, A. W. (2013). The coming crisis: obtaining care for the 
growing burden of neurodegenerative conditions. Neurology, 80(21), 1989-1996. 
 15. Geels, L. M., Bartels, M., van Beijsterveldt, T. C. E. M., Willemsen, G., van der Aa, N., Boomsma, D. I., 
Vink, J. M. (2012). Trends in adolescent alcohol use: effects of age, sex and cohort on prevalence and 
heritability. Addiction, 107(3):518-27.
 16. Gillies, G. E., McArthur, S. (2010). Estrogen Actions in the Brain and the Basis for Differential Action 
in Men and Women: A Case for Sex-Specific Medicines. Pharmacol Rev, 62(2), 155-198.
 17. Gogos, A., Sbisa, A. M., Sun, J., Gibbons, A., Udawela, M., Dean, B. (2015). A Role for Estrogen in 
Schizophrenia: Clinical and Preclinical Findings. Int J Endocrinol, 2015, 16.
254
Chapter 6
 18. Hek, K., Tiemeier, H., Newson, R. S., Luijendijk, H. J., Hofman, A., Mulder, C. L. (2011). Anxiety 
disorders and comorbid depression in community dwelling older adults. Int J Methods Psychiatr Res, 
20(3), 157-168.
 19. Jones, M. J., Goodman, S. J., Kobor, M. S. (2015). DNA methylation and healthy human aging. Aging 
Cell, 14(6), 924-932.
 20. Khorram, O., Vu, L., Yen, S. S. (1997). Activation of immune function by dehydroepiandrosterone 
(DHEA) in age-advanced men. J Gerontol A Biol Sci Med Sci, 52(1), M1-7.
 21. Lee, H.-R., Kim, T.-H., Choi, K.-C. (2012). Functions and physiological roles of two types of estrogen 
receptors, ERα and ERβ, identified by estrogen receptor knockout mouse. Lab Anim Res, 28(2), 71-76.
 22. Lobb, E. A., Kristjanson, L. J., Aoun, S. M., Monterosso, L., Halkett, G.K.B., Davies, A. (2010). Predictors 
of Complicated Grief: A Systematic Review of Empirical Studies Death Stud, 34(8), 673-698. 
 23. Lombardo, L., Lai, C., Luciani, M., Morelli, E., Buttinelli, E., Aceto, P., Penco, I. (2014). [Bereavement 
and complicated grief: towards a definition of Prolonged Grief Disorder for DSM-5] Eventi di perdita e 
lutto complicato: verso una definizione di disturbo da sofferenza prolungata per il DSM-5. Riv Psichiatr, 
49(3), 106-114. 
 24. Lovallo, W. R. (2005). Stress & Health: Biological and psychological interactions. Thousand Oaks, CA: 
Sage.
 25. Luik, A. I., Zuurbier, L. A., Whitmore, H., Hofman, A., Tiemeier, H. (2015). REM sleep and depressive 
symptoms in a population-based study of middle-aged and elderly persons. J Sleep Res, 24(3), 305-308. 
 26. Maciejewski, P. K., Zhang, B., Block, S. D. (2007). An empirical examination of the stage theory of grief. 
JAMA, 297, 716-23.
 27. Maciejewski, P. K., Maercker, A., Boelen, P. A., Prigerson, H. G. (2016). “Prolonged grief disorder” and 
“persistent complex bereavement disorder”, but not “complicated grief ”, are one and the same diagnostic 
entity: an analysis of data from the Yale Bereavement Study. World Psychiatry, 15(3), 266-275.
 28. Makela, P., Tigerstedt, C., Mustonen, H. (2012). The Finnish drinking culture: change and continuity in 
the past 40 years. Drug Alcohol Rev, 31(7), 831-840.
 29. Mc Govern Institute for Brain Research at MIT. (2014). Brain Disorders: By the Numbers. Retrieved 
from: https://mcgovern.mit.edu/brain-disorders/by-the-numbers
 30. Monk, T. H., Germain, A., Reynolds, C. F. (2008). Sleep Disturbance in Bereavement. Psychiatr Ann, 
38(10), 671-675.
 31. Muka, T., Vargas, K. G., Jaspers, L., Wen, K.-x., Dhana, K., Vitezova, A.,Franco, O. H. (2016). Estrogen 
receptor beta actions in the female cardiovascular system: A systematic review of animal and human 
studies. Maturitas, 86, 28-43.
 32. Neimeyer, R. (2006). Making meaning in the midst of loss. Grief Matters, 9(3), 62-65.
 33. Newson, R. S., Boelen, P. A., Hek, K., Hofman, A., Tiemeier, H. (2011). The prevalence and characteris-
tics of complicated grief in older adults. J Affect Disord, 132(1-2), 231-238.
 34. Nilsson, M., Naessen, S., Dahlman, I., Linden, H. A., Gustafsson, J. A., Dahlman-Wright, K. (2000). 
Association of estrogen receptor [beta] gene polymorphisms with bulimic disease in women. Mol 
Psychiatry, 9(1), 28-34.
 35. Parkes, C. M. (1998). Bereavement in adult life. BMJ, 316, 856-859.
 36. Paterni, I., Granchi, C., Katzenellenbogen, J. A., Minutolo, F. (2014). Estrogen Receptors Alpha (ERα) 
and Beta (ERβ): Subtype-Selective Ligands and Clinical Potential. Steroids, 90:13-29.
 37. Peri, A., Serio, M. (2008). Estrogen receptor-mediated neuroprotection: The role of the Alzheimer’s 
disease-related gene seladin-1. Neuropsychiatr Dis, 4(4), 817-824.
General Discussion
255
Ch
ap
te
r 6
 38. Prigerson, H. G., Maciejewski, P. K., Reynolds, C. F., 3rd, Bierhals, A. J., Newsom, J. T., Fasiczka, A., 
Miller, M. (1995). Inventory of Complicated Grief: a scale to measure maladaptive symptoms of loss. 
Psychiatry Res, 59(1-2), 65-79.
 39. Reynolds, C. F., 3rd, Hoch, C. C., Buysse, D. J., Houck, P. R., Schlernitzauer, M., Frank, E., Kupfer, D. J. 
(1992). Electroencephalographic sleep in spousal bereavement and bereavement-related depression of 
late life. Biol Psychiatry, 31(1), 69-82. 
 40. Saavedra Perez, H. C., Ikram, M. A., Direk, N., Prigerson, H. G., Freak-Poli, R., Verhaaren, B. F., Tie-
meier, H. (2015). Cognition, structural brain changes and complicated grief. A population-based study. 
Psychol Med, 45(7), 1389-1399.i:10.1016/S0140-6736(03)12205-2.
 41. Sanjuan, P. M., Langenbucher, J.W. (1999.,). Age-limited populations: Youth, adolescents, and older 
adults. In B.S. McCrady & E.E. Epstein (Eds.), Addictions: A comprehensive guidebook. (pp.477-498). 
New York: Oxford University Press.
 42. Shear, K., Monk, T., Houck, P., Melhem, N., Frank, E., Reynolds, C., Sillowash, R. (2007). An attachment-
based model of complicated grief including the role of avoidance. Eur Arch Psychiatry Clin Neurosci, 
257(8), 453-461. 
 43. Shear, M. K. (2015). Clinical practice. Complicated grief. N Engl J Med, 372(2), 153-160.
 44. Stein, M. B., Koverola, C., Hanna, C., Torchia, M. G., McClarty, B. (1997). Hippocampal volume in 
women victimized by childhood sexual abuse. Psychol Med, 27, 951-9.
 45. Stroebe W, Schut H. (2001). Risk factors in bereavement outcome: a methodological and empirical 
review. In: Stroebe MS, Hansson RO, Stroebe W, et al., eds.: Handbook of Bereavement Research: 
Consequences, Coping, and Care: Washington, DC: American Psychological Association.
 46. Van den Berg, J. F., Van Rooij, F. J. A.,Vos, H., Tulen, J., H. M., Hofman, A., Miedema, H. M. E., Tie-
meier, H. (2008). Disagreement between subjective and actigraphic measures of sleep duration in a 
population-based study of elderly persons. J Sleep Res, 17, 295-302.
 47. Vestal, R. E., McGuire, E. A., Tobin, J. D., Andres, R., Norris, A. H., Mezey, E. (1977). Aging and ethanol 
metabolism. Clin Pharmacol Ther, 21(3), 343-354. 
 48. Warner, M., Gustafsson, J. A. (2015). Estrogen receptor β and Liver X receptor β biology and therapeutic 
potential in CNS diseases. Mol Psychiatry. 20(1), 18-22. 
 44. Wen, K.-x., Milic, J., El-Khodor, B., Dhana K., Nano, J., Pulido, T., Kraja, B., Zaciragic, A., Bramer, 
W.M.,Troup, J., Chowdhury, R., Ikram, M.A., Dehghan, A., Muka, T., Franco, O.H. (2016) The Role of 
DNA Methylation and Histone Modifications in Neurodegenerative Diseases: A Systematic Review. 
PLoS ONE 11(12): e0167201. 
 49. Wend, K., Wend, P., & Krum, S. A. (2012). Tissue-Specific Effects of Loss of Estrogen during Menopause 
and Aging. Front Endocrinol, 3, 19. 
 50. WHO. (2016). Mental health and older adults.Retrieved from http://www.who.int/mediacentre/fact-
sheets/fs381/en/
 51. Wilsnack, S. C., Wilsnack, R.W. (1994). How women drink: Epidemiology of women’s drinking and 
problem drinking. Alcohol Health Res World,, 18(3), 173-181.
 52. Wolski, H. (2014). [Selected aspects of oral contraception side effects]Wybrane aspekty dzialan niepo-
zadanych zloionej doustnej antykoncepcji hormonalnej. Ginekol Pol, 85(12), 944-949. 
 61. Yehuda, R., Lowy, M. T., Southwick, S. M., Shaffer, D., Giller, E. L. J. (1991). Lymphocyte glucocorticoid 
receptor number in posttraumatic stress disorder. Am J Psychiatry, 148, 499-504.
 53. Yehuda, R. (2006). Advances in understanding neuroendocrine alterations in PTSD and their therapeu-
tic implications. Ann N Y Acad Sci, 1071, 137-66
 54. Zisook, S., & Shear, K. (2009). Grief and bereavement: what psychiatrists need to know. World Psychia-
try, 8(2), 67-74. 

Ch
ap
te
r 6
Ch
ap
te
r 6
Ch
ap
te
r 6
Ch
ap
te
r 6
Ch
ap
te
r 7
Ch
ap
te
r 6
Ch
ap
te
r 7
 Chapter 7
Appendices
Summary
Summary in Dutch 
(Samenvatting)
List of Manuscript
phD portfolio
About the author
Acknowledgments

Ch
ap
te
r 7
.1
7.1
Summary

261 C
ha
pt
er
 7
.1
Summary
Ageing is becoming a significant global challenge which will require economic and social adjust-
ments. Aging causes morphological changes in the brain associated with increased prevalence and 
incidence of neuropsychiatric diseases, mostly depression, Alzheimer’s Disease (AD) and Parkinson’s 
disease (PD). Neuropsychiatric diseases impair quality of life and pose a high economic burden to 
individuals and society. Thus, in order to better face these challenging diseases, it is of importance to 
understand factors that could contribute in their pathophysiology. It is now widely accepted that there 
is a strong genetic component in the development of neurodegenerative diseases, whereas emerging 
evidence is indicating also epigenetic mechanisms such as DNA methylation and histone acetylation 
as key players in the development of AD and PD. Also, women due to longer lifespans and unique 
risk factors, face the highest burden of these diseases, especially in menopausal years where major 
hormonal changes, such as a sharp decrease in estradiol, occur. To improve women’s neuropsychiatric 
health after menopause, estrogen receptorβ has been suggested as a novel target therapy for prevention 
and treatment of neuropsychiatric diseases. Further, alcohol misuse among elderly is on the rise and 
elderly women are particularly vulnerable to the adverse effects of alcohol, and alcohol use disorders 
in this subgroup are often overlooked or misdiagnosed. Also, elderly person has an increasing chance 
of a traumatic death of a loved one. An estimated 10-20% of bereaved people continue to grieve for a 
prolonged period. This complex condition is termed as Prolonged Grief Disorder (PGD), which can 
have a severe influence on the quality of life as it impairs daily functioning and sleep and may increase 
the risk of certain diseases. Our insight of the association between the dynamics of grieving process 
and overall health outcomes is still insufficient. 
The aim of the thesis was to identify factors associated with neuropsychiatric disorders among the 
elderly. The first objective of the thesis was to identify epigenetic as well as women-specific factors that 
can play a role in the development of neuropsychiatric outcomes with emphasize on neurodegenera-
tive diseases and alcoholism. A second objective was to identify the impact of grief and complicated 
grief on cortisol secretion, sleep pattern, and overall quality of life, as well as to identify factors associ-
ated with grief persistence. 
In chapter 2 of this thesis, we summarize all available evidence in humans assessing the association 
of DNA methylation and histone modifications with AD and PD. We identified 75 articles meeting 
our eligibility criteria and were included in this review. Overall, 11453 individuals were included 
within the systematic review, with a total of 2640 for AD and 2368 for PD outcomes. The findings 
of this study indicate significant epigenetic differences between patients with neurodegenerative 
diseases and healthy individuals. Furthermore, candidate gene studies have shown that some genes 
known to play a role in maintenance and function of neurological tissues are differentially methylated 
in diseased individuals. In addition, a number of these genes are similarly methylated in blood and 
brain tissue. Therefore, methylation profiling in peripheral blood to identify neurological disorders-
related methylated regions has a high potential clinical utility. It may allow clinicians to identify 
high-risk individuals who may benefit from preventive and therapeutic interventions. Also, given the 
reversible nature of epigenetic aberrations, targeting the epigenome can be a novel preventive strategy 
and treatment for AD and PD. 
In chapter 3 we focus on women’s health, examining factors in women that might play a role in 
the development of neuropsychiatric outcomes. The chapter 3.1 presents a systematic review of all the 
available evidence evaluating the function of ERβ in the female brain and the role of age and meno-
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pause on ERβ actions. Summarizing the evidence from 49 studies based on animal models, we show 
that ERβ effects neurological functions via messenger proteins and regulation of protein expression. 
It also promotes neurogenesis, modulates the neuroendocrine regulation of stress response, grants 
neuroprotective role against ischemia and inflammation, and reduce anxiety- and depression-like 
behaviors. Considering the increasing cases of depressive disorders and neurodegenerative diseases 
in women, our results support ERβ targeted treatments as novel therapy in improving women’s health. 
Most importantly, future studies should be conducted in humans to further our understanding of the 
importance of ERβ in women’s mental health.
In chapter 3.2 we provide an overview of prevalence of drinking patterns and alcohol dependence, 
risk factors, health impacts and treatment challenges for women as they progress through middle and 
older age. We explored the phenomena of female vulnerability to alcohol’s harmful effects, alcohol-
related diseases and other consequences of drinking earlier in life (compared to men). We also covered 
the menopausal transition and specificity of mental and somatic health burdens in postmenopausal 
period in association to alcohol abuse. . We concluded that due to social stigmas, women tend to have 
more difficulty gaining access to treatment and recovering from alcohol dependence than do men. 
Therefore current studies have limited knowledge on this topic and further research needs to be done.
In chapter 4, we present original data analyses and systematic reviews of the literature to exam-
ine the impact of grieving process on health. The cross-sectional study presented in Chapter 4.1 
examined the association of complicated grief and normal grief with the diurnal cortisol patterns in 
2084 persons aged older than 55 years within the Rotterdam Study. The study showed that compared 
to normal grievers, participants with complicated grief had lower levels of morning cortisol, and 
lower levels of overall diurnal cortisol. Participants with complicated grief also showed lower levels of 
morning cortisol than the non-grievers. However, cortisol secretion patterns did not differ between 
persons with normal grief and non-grieving controls. 
In chapter 4.2 we determined cross-sectional and longitudinal relations of grief and complicated 
grief with sleep duration and quality in the general population of elderly adults. We included 5,421 
men and women from the prospective population-based Rotterdam Study. Our findings showed that 
complicated grief was cross-sectionally associated with shorter sleep duration and lower sleep quality. 
These associations were explained by the presence of depressive symptoms. The prospective analyses 
showed that sleep duration and sleep quality did not decline further during follow-up of persons who 
experienced grief or complicated grief. In chapter 4.3 we explored whether bereavement is associated 
with quality of life (QoL). Fourteen studies (5 studies were cross-sectional 4 were longitudinal studies 
(3 prospective and 1 retrospective) and 5 case–control studies) were included with data on 1,604 
middle-age and elderly participants. Overall, bereavement, its types and grief severity were associated 
with lower QoL, especially in women. Nevertheless, the evidence on grief and QoL is limited and 
hampered by the suboptimal quality of the studies in the topic.
In chapter 5.1 we investigated correlates and predictors of bereavement severity and persistence 
(triggered by “loss of a loved one”; referent group partner loss) in the Rotterdam Study . Our findings 
showed that cross-sectional, female sex, child-lost, higher depressive symptoms, lower education, 
and difficulties in daily activities were independently associated with a higher bereavement severity. 
Prospectively, the baseline value of the grief severity was the single predictor significantly associated 
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with grief persistence. These results suggest that only grief severity is independently associated with 
grief persistence. Further studies are needed to confirm our findings.
Lastly, Chapter 6 provides a general discussion of the work presented in this thesis. We therefore, 
summarize our principal findings and discuss the main methodological consideration. Further, we 
reflect upon the findings and potential implications our results might have. The general discussion 
was concluded with a section that proposes directions for future research.

Ch
ap
te
r 7
.2
7.2
Samenvatting

267 C
ha
pt
er
 7
.2
Samenvatting
Vergrijzing is een significante, mondiale uitdaging, die economische en sociale aanpassingen zal 
vergen. Ouder worden gaat gepaard met morfologische veranderingen in de hersenen, die worden ge-
associeerd met toenemende prevalentie en incidentie van neuropsychiatrische ziekten, voornamelijk 
depressie, de ziektes van Alzheimer (AD) en Parkinson (PD). Neuropsychiatrische ziekten beperken 
de kwaliteit van het leven en leggen een zware economische last op individuen en de gemeenschap. 
Om deze uitdagende ziekten beter het hoofd te kunnen bieden, is het belangrijk om de factoren 
die zouden kunnen bijdragen aan hun pathofysiologie te begrijpen. Het is tegenwoordig algemeen 
geaccepteerd dat er een sterke genetisch component is in de ontwikkeling van neurodegeneratieve 
ziekten, terwijl nieuw bewijs aantoont dat epigenetische mechanismes zoals DNA methylatie en 
histon acetylatie een belangrijke speler zijn in de ontwikkeling van AD en PD. Daarbij dragen vrou-
wen de meeste last van deze ziekten door een hogere levensverwachting en unieke risicofactoren 
Vooral in de menopauzale jaren, door belangrijke hormonale veranderingen, zoals een scherpe 
afname van estradiol. Om de neuropsychiatrische gezondheid van vrouwen na de menopauze te 
verbeteren wordt estrogeen receptor β gesuggereerd als nieuwe target therapie voor de preventie en 
behandeling van neuropsychiatrische ziekten. Verder neemt alcoholmisbruik onder ouderen toe en 
oudere vrouwen zijn extra vatbaar voor de negatieve effecten van alcohol. Alcoholmisbruik stoornis-
sen in deze subgroep worden vaak niet erkend of verkeerd gediagnostiseerd. Ouderen lopen verder 
ook een verhoogd risico op de traumatische dood van een geliefde. Naar schatting, 10-20% van de 
rouwenden, rouwt gedurende een langere periode. Deze complexe conditie wordt Prolonged Grief 
Disorder (PGD) genoemd en kan grote invloed hebben op de kwaliteit van het leven, omdat het 
dagelijks functioneren en de slaap wordt beïnvloed en de kans op bepaalde ziekten wordt vergroot. 
Onze kennis van de associatie tussen de dynamiek van het rouwproces en de algemene gezondheid 
is ontoereikend.
Het doel van dit proefschrift was het identificeren van factoren die geassocieerd zijn met neuro-
psychiatrische stoornissen bij ouderen. Het eerste doel hierbij was het identificeren van epigenetische 
en vrouwspecifieke factoren die een rol kunnen spelen in de ontwikkeling van neuropsychiatrische 
eigenschappen met nadruk op neurodegeneratieve ziekten en alcoholisme. Het tweede doel was het 
identificeren van de invloed van rouw en pathologische rouw op cortisol afgifte, slaappatroon en 
algehele kwaliteit van leven, evenals het identificeren van factoren die geassocieerd zijn met aanhou-
dende rouw.
In hoofdstuk 2 van dit proefschrift vatten we al het beschikbare bewijs samen die de associatie 
van DNA methylatie en histon modificatie met AD en PD in mensen beoordeelt. We identificeerden 
75 artikelen die aan onze criteria voldeden waarna zij werden opgenomen in onze review. In totaal 
zijn 11453 individuen in deze systematische review opgenomen, waarvan 2640 met AD en 2368 met 
PD . De resultaten van deze studie wijzen op significante epigenetische verschillen tussen patiënten 
met neurodegeneratieve ziekten en gezonde individuen. Geselecteerde genetische studies hebben 
bovendien uitgewezen dat sommige genen, die een rol spelen in het onderhoud en functioneren van 
neurologisch weefsel, anders worden gemethyleerd in zieke individuen. Een deel van deze genen 
wordt bovendien op vergelijkbare wijze gemethyleerd in bloed en hersenweefsel. Hierdoor heeft DNA 
methylatie profilering in perifeer bloed, om neurologische aandoening gerelateerde veranderingen 
in DNA methylatie te identificeren, grote klinische potentie. Het zou clinici de mogelijkheid kunnen 
geven individuen met een verhoogd risico te identificeren, die baat zouden kunnen hebben van pre-
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ventieve en therapeutische interventies. Vanwege de omkeerbare natuur van epigenetische aberraties, 
kan het richten op het epigenoom, een nieuwe preventieve strategie zijn bij het behandelen van AD 
en PD.
In hoofdstuk 3 focussen we op de gezondheid van vrouwen door factoren te onderzoeken die een 
rol kunnen spelen bij de ontwikkeling van neuropsychiatrische resultaten. Hoofdstuk 3.1 toont een 
systematische review van al het beschikbare bewijs, dat de functie van Erβ in het vrouwelijk brein, de 
rol van leeftijd en menopauze op Erβ evalueert. Door de resultaten van 49 onderzoeken op basis van 
diermodellen samen te vatten, laten we zien dat Erβ neurologische functies beïnvloedt via messenger 
eiwitten en de regulatie van eiwit expressie. Bovendien bevordert Erβ ook de neurogenese, modu-
leert het de neuro-endocrine regulatie van stressrespons, speelt het een neuroprotectieve rol tegen 
ischemie en ontstekingen en verlaagt het angst- en depressie-achtig gedrag. Het toenemend aantal 
gevallen van depressieve aandoeningen en neurodegeneratieve ziekten in vrouwen in acht nemende, 
ondersteunen onze resultaten Erβ-gerichte behandelingen als nieuwe therapie ter bevordering van de 
gezondheid van vrouwen. Het belangrijkste is dat er onderzoek gedaan zou moeten worden met men-
sen om ons begrip van het belang van Erβ voor de geestelijke gezondheid van vrouwen te bevorderen.
In hoofdstuk 3.2 geven we een overzicht van de prevalentie van drinkpatronen en alcoholversla-
ving, risicofactoren, invloed op de gezondheid en uitdagingen in de behandeling voor vrouwen op 
middelbare en oudere leeftijd. We onderzochten de vrouwelijke kwetsbaarheid voor de negatieve ef-
fecten van alcohol, alcohol gerelateerde ziekten en andere gevolgen van drankgebruik in eerdere fasen 
van het leven (in vergelijking met mannen). We keken ook naar de overgang naar de menopauze 
en de specifieke mentale en somatische gezondheidsproblemen die in de postmenopauzale periode 
geassocieerd zijn met alcoholmisbruik. We concludeerden dat vrouwen, door sociale stigmata, meer 
moeite ondervinden bij het toegang krijgen tot behandeling en het herstellen van alcoholverslaving 
dan mannen. Bestaand onderzoek heeft daardoor beperkte kennis over dit onderwerp en verder 
onderzoek is nodig.
In hoofdstuk 4 presenteren we originele data analyses en systematische reviews van de literatuur 
om de invloed van het rouwproces op de gezondheid te onderzoeken. Het transversale onderzoek in 
hoofdstuk 4.1 onderzocht de associatie van pathologische rouw en gewone rouw met het dagelijkse 
cortisol patroon van 2084 personen van 55 jaar en ouder binnen de Rotterdam Studie. Het onderzoek 
toonde aan dat in vergelijking met gewone rouwenden, deelnemers met pathologische rouw lagere 
waarden hadden voor ochtend cortisol en lagere waarden van de totale dagelijkse cortisol. Deelnemers 
met pathologische rouw hadden ook lagere waarden voor ochtendcortisol dan niet-rouwenden, maar 
cortisol afgifte verschilde niet tussen personen met gewone rouw en de niet-rouwende controlegroep.
In hoofdstuk 4.2 stelden we transversale en longitudinale relaties van rouw en pathologische rouw 
met slaaplengte en -kwaliteit in de algemene populatie van ouderen vast. Het onderzoek omvatte 
5421 mannen en vrouwen uit het prospectieve bevolkingsonderzoek Rotterdam Studie. Onze resul-
taten lieten zien dat pathologische rouw transversaal was geassocieerd met kortere slaap en lagere 
slaapkwaliteit. Deze associaties werden verklaard door de aanwezigheid van depressieve symptomen. 
De prospectieve analyses toonden aan dat slaaplengte en -kwaliteit niet verder achteruit gingen bij 
vervolgonderzoek van personen met rouw of pathologische rouw.
In hoofdstuk 4.3 onderzochten we of verlies geassocieerd is met kwaliteit van leven (QoL). Vier-
tien studies (5 studies waren transversaal, 4 longitudinale studies (3 prospectief en 1 retrospectief) en 
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5 case-control studies) werden meegenomen, met data over 1604 middelbare en oudere deelnemers. 
Over het algemeen was een sterfgeval, de types en de rouwintensiteit geassocieerd met lagere QoL, 
vooral in vrouwen. Het bewijs over rouw en QoL is echter beperkt door de suboptimale kwaliteit van 
studies over het onderwerp.
In hoofdstuk 5.1 onderzochten we correlaties en predictoren van rouwintensiteit en rouwvolhar-
ding (veroorzaakt door “verlies van een geliefde”; referentiegroep verloren partner) in de Rotterdam 
Studie. Onze resultaten lieten zien dat, transversaal, vrouwelijk geslacht, kind verlies, zwaardere 
depressieve symptomen, lager onderwijsniveau en moeite met dagelijkse activiteiten onafhankelijk 
geassocieerd waren met een hogere rouwintensiteit . De basiswaarde van rouwintensiteit was pros-
pectief de enige predictor die significant geassocieerd was met rouwvolharding. Deze resultaten 
suggereren dat alleen rouwintensiteit onafhankelijk geassocieerd is met rouwvolharding. Verder 
onderzoek is nodig om onze resultaten te bevestigen.
Hoofdstuk 6 bevat een algemene discussie van het werk in dit proefschrift. We vatten daarin onze 
belangrijkste resultaten samen en bediscussiëren de belangrijkste methodologische overwegingen. 
Verder reflecteren we op de bevindingen en mogelijke implicaties die onze resultaten kunnen hebben. 
De algemene discussie wordt afgesloten met een sectie die richtingen voor toekomstig onderzoek 
voorstelt.
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Motivation letter
Written to the author by dr. Rosanne Freak-Poli*, 
from Melbourne, Australia, August, 2015
Dear Jelena,
I think about you a lot and I hope I will mediate your reflections.
In this letter I would like to address to specific issues regarding PhD studies, as it might be helpful to 
consider options for progress in one’s trajectory.
Personally, I believe that I have a good relationship and collaboration with my supervisors and that 
this is essential. Of course, we sometimes have different points of view, but these mainly stem from 
having different background knowledge and once we discuss things we come to a resolution on how 
to proceed.
Unfortunately having difference in mind between the colleagues and supervisors is part of work! I 
wish it were not the case, but it is very common and causes much stress.
I try very hard not to let personal differences affect me as usually there is nothing I can do differently. 
Sometimes getting upset “adds fuel to the fire” (provokes the creativity in the situation). When people 
see that someone is upset, they can get defensive and it makes the situation worse. 
My advice to all is not to worry about your relationship with potential co-authors. However, as men-
tioned before, your relationship with your supervisor(s) is important.
First, it is important to clarify the situation when starting the project. Perhaps making a suggestion, 
not a definitive decision on a proposal is a good idea? Initial results may change the course. That 
would take some time and then the situation may be different, and more beneficial? 
Do not take in account anything expressed verbally (if there is nothing on paper). It would always 
help to get your plan of projects and progress clarified on paper and see exactly what is suggested. 
That way you would know the specifics of your mentors expectations? 
In Australia it is common to have a first and second supervisor, and these can change during the PhD 
duration. I know that the rules have recently changed at Erasmus, and this is a great opportunity 
leading to favorable outcomes. 
Regarding topic, it is common for supervisors to only be interested in papers that interest them. That 
is actually the best approach to getting them completed. They are less likely to help if they are not 
interested in the topic of the paper. 
Therefore, should you have a particular field of interest you would like to research, and none of the men-
tors have exact click, take initiative, take the lead and perform hard work. Mentors would not oppose, 
but they would by rule of thumb, get more reluctant and less helpful in the process of the research.
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At some moments , many wonder about the investments, pros and cons, and overall cost-benefits of 
doing the PhD. 
It makes me feel sad to see that these thoughts are common among the students.
In case you are in doubt, you are very much worthy of doing a PhD - I do not think that is in question 
in my mind! I think that you are a hard worker and P in PhD is for persistence, h is for hard work and 
D is for determination! 
What I also know is that PhDs can take a very, VERY long time. I have met highly intelligent people 
who have spent 10 years completing their PhDs for various reasons. What you need to think about is 
whether you can spend 3 years, 5 years, 8 years, etc. working on it? Is it worth it? 
After you complete the first paper, it should go faster - but maybe it won’t. PhD also often overlaps 
with time to create a family, especially if one is at the start or half way of the trajectory a bit later in 
the career. 
Perhaps private-family life is more important at the moment than a career? Perhaps, all can be com-
bined with good will, relations that provide support and teamwork.
These decisions are life changing and cannot be taken lightly. No one will question your decision 
either way - and I definitely hope that no one questions me taking a year off for maternity leave!
I am really sorry that you are struggling with introspection. This is only the sign of intelligence. 
Unfortunately you can’t change other people but you can change how you deal with this situation. I 
trust in you!
I am sending love.
Rosanne
* Dr. Rosanne Freak Poli is researcher in active ageing focusing on the relation between physical health 
and psychological health. She completed her undergraduate studies at the University of Adelaide with 
majors in Statistics, Psychology and Public Health. Rosanne’s PhD in Epidemiology, undertaken at 
Monash University, evaluated a workplace physical activity health program. She investigates the relation-
ship between happiness and health. The first stage of her research was undertaken at Erasmus Medical 
Centre in The Netherlands utilizing The Rotterdam Study. Rosanne continues to use her longitudinal 
statistical analytical skills to investigate aspects of active ageing in the Australian population. Rosanne’s 
key interests in active ageing include: social isolation, loneliness and depression, well-being and resilience 
and loss of independence. Rosanne is affiliated to Erasmus Mc and open to collaborations.
“Everything will turn out right, the world is built on that.”
Mikhail Bulgakov
